(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 25 September 2003 (25.09.2003)

(10) International Publication Number WO 03/078662 A1

C12Q 1/68, (51) International Patent Classification7: G01N 33/53

PCT/US03/07713 (21) International Application Number:

(22) International Filing Date: 12 March 2003 (12.03.2003)

(25) Filing Language:

Ènglish

(26) Publication Language:

English

(30) Priority Data: 13 March 2002 (13.03.2002) 60/364,890 18 September 2002 (18.09.2002) 60/412,049

(71) Applicant (for all designated States except US): GE-NOMIC HEALTH [US/US]; 301 Penobscot Drive, Redwood City, CA 94063 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BAKER, Joffre, B. [US/US]; P.O. Box 371212, Montara, CA 94937 (US). CRONIN, Maureen, T. [US/US]; 771 Anderson Drive, Los Altos, CA 94024 (US). KIEFER, Michael, C. [US/US]; 401 Wright Court, Clayton, CA 94517 (US) SHAK, Steve [US/US]; 1133 Cambridge Road, Burlingame, CA 94010 (US). WALKER, Michael, G. [US/US]; 1475 Flamingo Way, Sunnyvale, CA 94087 (US).

Agent: DREGER, Ginger, R.; Heller Ehrman White & McAuliffe, 275 Middlefield Road, Menlo Park, CA 94025-3506 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES

(57) Abstract: The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. Th invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies.

BEST AVAILABLE COPY

BNSDOCID: <WO_

_03078662A1_I_>

GENE EXPRESSION PROFILING IN BIOPSIED TUMOR TISSUES

Background of the Invention

Cross-Reference

5

10

15

20

25

30

This application claims the benefit under 35 U.S.C. 119(h) of provisional applications serial nos. 60/412,049, filed September 18, 2002 and 60/364,890, filed March 13, 2002, the entire disclosures which are herby incorporated by reference.

Field of the Invention

The present invention relates to gene expression profiling in biopsied tumor tissues. In particular, the present invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. In addition, the invention provides a set of genes the expression of which is important in the diagnosis and treatment of breast cancer.

Oncologists have a number of treatment options available to them, including different combinations of chemotherapeutic drugs that are characterized as "standard of care," and a number of drugs that do not carry a label claim for a particular cancer, but for which there is evidence of efficacy in that cancer. Best likelihood of good treatment outcome requires that patients be assigned to optimal available cancer treatment, and that this assignment be made as quickly as possible following diagnosis.

Currently, diagnostic tests used in clinical practice are single analyte, and therefore do not capture the potential value of knowing relationships between dozens of different markers. Moreover, diagnostic tests are frequently not quantitative, relying on immunohistochemistry. This method often yields different results in different laboratories, in part because the reagents are not standardized, and in part because the interpretations are subjective and cannot be easily quantified. RNA-based tests have not often been used because of the problem of RNA degradation over time and the fact that it is difficult to obtain fresh tissue samples from patients for analysis. Fixed paraffin-embedded tissue is more readily available and methods have been established to detect RNA in fixed tissue. However, these methods typically do not allow for the study of large numbers of genes (DNA or RNA) from small amounts of material. Thus, traditionally fixed tissue has been rarely used other than for immunohistochemistry detection of proteins.

Recently, several groups have published studies concerning the classification of various cancer types by microarray gene expression analysis (see, e.g. Golub et al., Science 286:531-537

SUBSTITUTE SHEET (RULE 26)

(1999); Bhattacharjae et al., Proc. Natl. Acad. Sci. USA 98:13790-13795 (2001); Chen-Hsiang et al., Bioinformatics 17 (Suppl. 1):S316-S322 (2001); Ramaswamy et al., Proc. Natl. Acad. Sci. USA 98:15149-15154 (2001)). Certain classifications of human breast cancers based on gene expression patterns have also been reported (Martin et al., Cancer Res. 60:2232-2238 (2000); West et al., Proc. Natl. Acad. Sci. USA 98:11462-11467 (2001); Sorlie et al., Proc. Natl. Acad. Sci. USA 98:10869-10874 (2001); Yan et al., Cancer Res. 61:8375-8380 (2001)). However, these studies mostly focus on improving and refining the already established classification of various types of cancer, including breast cancer, and generally do not provide new insights into the relationships of the differentially expressed genes, and do not link the findings to treatment strategies in order to improve the clinical outcome of cancer therapy.

Although modern molecular biology and biochemistry have revealed more than 100 genes whose activities influence the behavior of tumor cells, state of their differentiation, and their sensitivity or resistance to certain therapeutic drugs, with a few exceptions, the status of these genes has not been exploited for the purpose of routinely making clinical decisions about drug treatments. One notable exception is the use of estrogen receptor (ER) protein expression in breast carcinomas to select patients to treatment with anti-estrogen drugs, such as tamoxifen. Another exceptional example is the use of ErbB2 (Her2) protein expression in breast carcinomas to select patients with the Her2 antagonist drug Herceptin® (Genentech, Inc., South San Francisco, CA).

Despite recent advances, the challenge of cancer treatment remains to target specific treatment regimens to pathogenically distinct tumor types, and ultimately personalize tumor treatment in order to maximize outcome. Hence, a need exists for tests that simultaneously provide predictive information about patient responses to the variety of treatment options. This is particularly true for breast cancer, the biology of which is poorly understood. It is clear that the classification of breast cancer into a few subgroups, such as ErbB2⁺ subgroup, and subgroups characterized by low to absent gene expression of the estrogen receptor (ER) and a few additional transcriptional factors (Perou et al., Nature 406:747-752 (2000)) does not reflect the cellular and molecular heterogeneity of breast cancer, and does not allow the design of treatment strategies maximizing patient response.

30

10

15

20

25

Summary of the Invention

The present invention provides (1) sensitive methods to measure mRNA levels in biopsied tumor tissue, (2) a set of approximately 190 genes, the expression of which is important in the diagnosis of breast cancer, and (3) the significance of abnormally low or high expression

tor the genes identified and included in the gene set, through activation or disruption of biochemical regulatory pathways that influence patient response to particular drugs used or potentially useful in the treatment of breast cancer. These results permit assessment of genomic evidence of the efficacy of more than a dozen relevant drugs.

The present invention accommodates the use of archived paraffin-embedded biopsy material for assay of all markers in the set, and therefore is compatible with the most widely available type of biopsy material. The invention presents an efficient method for extraction of RNA from wax-embedded, fixed tissues, which reduces cost of mass production process for acquisition of this information without sacrificing quality of the analysis. In addition, the invention describes a novel highly effective method for amplifying mRNA copy number, which permits increased assay sensitivity and the ability to monitor expression of large numbers of different genes given the limited amounts of biopsy material. The invention also captures the predictive significance of relationships between expressions of certain markers in the breast cancer marker set. Finally, for each member of the gene set, the invention specifies the oligonucleotide sequences to be used in the test.

In one aspect, the invention concerns a method for predicting clinical outcome for a patient diagnosed with cancer, comprising

determining the expression level of one or more genes, or their expression products, selected from the group consisting of p53BP2, cathepsin B, cathepsin L, Ki67/MiB1, and thymidine kinase in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set,

wherein a poor outcome is predicted if:

- (a) the expression level of p53BP2 is in the lower 10th percentile; or
- (b) the expression level of either cathepsin B or cathepsin L is in the upper 10th 25 percentile; or
 - (c) the expression level of any either Ki67/MiB1 or thymidine kinase is in the upper 10^{th} percentile.

Poor clinical outcome can be measured, for example, in terms of shortened survival or increased risk of cancer recurrence, e.g. following surgical removal of the cancer.

In another embodiment, the inventor concerns a method of predicting the likelihood of the recurrence of cancer, following treatment, in a cancer patient, comprising determining the expression level of p27, or its expression product, in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference

10

15

cancer tissue set, wherein an expression level in the upper 10th percentile indicates decreased risk of recurrence following treatment.

In another aspect, the invention concerns a method for classifying cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl2, hepatocyte nuclear factor 3, ER, ErbB2, and Grb7, or their expression products, in a cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein (i) tumors expressing at least one of Bcl2, hepatocyte nuclear factor 3, and ER, or their expression products, above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following treatment; and (ii) tumors expressing elevated levels of ErbB2 and Grb7, or their expression products, at levels ten-fold or more above the mean expression level in the reference tissue set are classified as having poor prognosis of disease free and overall patient survival following treatment.

All types of cancer are included, such as, for example, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer. The foregoing methods are particularly suitable for prognosis/classification of breast cancer.

In all previous aspects, in a specific embodiment, the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample. While all techniques of gene expression profiling, as well as proteomics techniques, are suitable for use in performing the foregoing aspects of the invention, the gene expression levels are often determined by reverse transcription polymerase chain reaction (RT-PCR).

If the source of the tissue is a formalin-fixed, paraffin embedded tissue sample, the RNA is often fragmented.

The expression data can be further subjected to multivariate analysis, for example using the Cox Proportional Hazards model.

In a further aspect, the invention concerns a method for the preparation of nucleic acid from a fixed, wax-embedded tissue specimen, comprising:

- (a) incubating a section of the fixed, wax-embedded tissue specimen at a temperature of about 56 °C to 70 °C in a lysis buffer, in the presence of a protease, without prior dewaxing, to form a lysis solution;
 - (b) cooling the lysis solution to a temperature where the wax solidifies; and
 - (c) isolating the nucleic acid from the lysis solution.

SUBSTITUTE SHEET (RULE 26)

10

20

25

The lysis buffer may comprise urea, such as 4M urea.

In a particular embodiment, incubation in step (a) of the foregoing method is performed at about 65°C.

In another particular embodiment, the protease used in the foregoing method is proteinase

In another embodiment, the cooling in step (b) is performed at room temperature.

In a further embodiment, the nucleic acid is isolated after protein removal with 2.5 M NH₄OAc.

The nucleic acid can, for example, be total nucleic acid present in the fixed, waxembedded tissue specimen.

In yet another embodiment, the total nucleic acid is isolated by precipitation from the lysis solution, following protein removal, with 2.5 M NH₄OAc. The precipitation may, for example, be performed with isopropanol.

The method described above may further comprise the step of removing DNA from the total nucleic acid, for example by DNAse treatment.

The tissue specimen may, for example, be obtained from a tumor, and the RNA may be obtained from a microdissected portion of the tissue specimen enriched for tumor cells.

All types of tumor are included, such as, without limitation, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer, in particular breast cancer.

The method described above may further comprise the step of subjecting the RNA to gene expression profiling. Thus, the gene expression profile may be completed for a set of genes comprising at least two of the genes listed in Table 1.

Although all methods of gene expression profiling are contemplated, in a particular embodiment, gene expression profiling is performed by RT-PCR which may be preceded by an amplification step.

In another aspect, the invention concerns a method for preparing fragmented RNA for gene expression analysis, comprising the steps of:

- 30 (a) mixing the RNA with at least one gene-specific, single-stranded DNA scaffold under conditions such that fragments of the RNA complementary to the DNA scaffold hybridize with the DNA scaffold;
 - (b) extending the hybridized RNA fragments with a DNA polymerase to form a DNA-DNA duplex; and

5

10

15

20

(c) removing the DNA scaffold from the duplex.

In a specific embodiment, in step (b) of this method, the RNA may be mixed with a mixture of single-stranded DNA templates specific for each gene of interest.

The method can further comprise the step of heat-denaturing and reannealing the duplexed DNA to the DNA scaffold, with or without additional overlapping scaffolds, and further extending the duplexed sense strand with DNA polymerase prior to removal of the scaffold in step (c).

The DNA templates may be, but do not need to be, fully complementary to the gene of interest.

In a particular embodiment, at least one of the DNA templates is complementary to a specific segment of the gene of interest.

In another embodiment, the DNA templates include sequences complementary to polymorphic variants of the same gene.

The DNA template may include one or more dUTP or rNTP sites. In this case, iin step (c) the DNA template may be removed by fragmenting the DNA template present in the DNA-DNA duplex formed in step (b) at the dUTP or rNTP sites.

In an important embodiment, the RNA is extracted from fixed, wax-embedded tissue specimens, and purified sufficiently to act as a substrate in an enzyme assay. The RNA purification may, but does not need to, include an oligo-dT based step.

In a further aspect, the invention concerns a method for amplifying RNA fragments in a sample comprising fragmented RNA representing at least one gene of interest, comprising the steps of:

- (a) contacting the sample with a pool of single-stranded DNA scaffolds comprising an RNA polymerase promoter at the 5' end under conditions such that the RNA fragments complementary to the DNA scaffolds hybridize with the DNA scaffolds;
- (b) extending the hybridized RNA fragments with a DNA polymerase along the DNA scaffolds to form DNA-DNA duplexes;
 - (c) amplifying the gene or genes of interest by in vitro transcription; and
 - (d) removing the DNA scaffolds from the duplexes.

An exemplary promoter is the T7 RNA polymerase promoter, while an exemplary DNA polymerase is DNA polymerase I.

In step (d) the DNA scaffolds may be removed, for example, by treatment with DNase I.

In a further embodiment, the pool of single-stranded DNA scaffolds comprises partial or complete gene sequences of interest, such as a library of cDNA clones.

SUBSTITUTE SHEET (RULE 26)

15

20

In a specific embodiment, the sample represents a whole genome or a fraction thereof. In a preferred embodiment, the genome is the human genome.

In another aspect, the invention concerns a method of preparing a personalized genomics profile for a patient, comprising the steps of:

- (a) subjecting RNA extracted from a tissue obtained from the patient to gene expression analysis;
- (b) determining the expression level in such tissue of at least two genes selected from the gene set listed in Table 1, wherein the expression level is normalized against a control gene or genes, and is compared to the amount found in a cancer tissue reference set;
- (c) and creating a report summarizing the data obtained by the gene expression analysis.

The tissue obtained from the patient may, but does not have to, comprise cancer cells. Just as before, the cancer can, for example, be breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, or brain cancer, breast cancer being particularly preferred.

In a particular embodiment, the RNA is obtained from a microdissected portion of breast cancer tissue enriched for cancer cells. The control gene set may, for example, comprise S-actin, and ribosomal protein LPO.

The report prepared for the use of the patient or the patient's physician, may include the identification of at least one drug potentially beneficial in the treatment of the patient.

Step (b) of the foregoing method may comprise the step of determining the expression level of a gene specifically influencing cellular sensitivity to a drug, where the gene can, for example, be selected from the group consisting of aldehyde dehydrogenase 1A1, aldehyde dehydrogenase 1A3, amphiregulin, ARG, BRK, BCRP, CD9, CD31, CD82/KAI-1, COX2, c-abl, c-kit, c-kit L, CYP1B1, CYP2C9, DHFR, dihydropyrimidine dehydrogenase, EGF, epiregulin, ER-alpha, ErbB-1, ErbB-2, ErbB-3, ErbB-4, ER-beta, farnesyl pyrophosphate synthetase, gamma-GCS (glutamyl cysteine synthetase), GATA3, geranyl geranyl pyrophosphate synthetase, Grb7, GST-alpha, GST-pi, HB-EGF, hsp 27, human chorionic gonadotropin/CGA, IGF-1, IGF-2, IGF1R, KDR, LIV1, Lung Resistance Protein/MVP, Lot1, MDR-1, microsomal epoxide hydrolase, MMP9, MRP1, MRP2, MRP3, MRP4, PAI1, PDGF-A, PDGF-B, PDGF-C, PDGF-D, PGDFR-alpha, PDGFR-beta, PLAGa (pleiomorphic adenoma 1), PREP prolyl endopeptidase, progesterone receptor, pS2/trefoil factor 1, PTEN, PTB1b, RAR-alpha, RAR-beta2, Reduced

10:

20

Folate Carrier, SXR, TGF-alpha, thymidine phosphorylase, thymidine synthase, topoisomerase II-alpha, topoisomerase II-beta, VEGF, XIST, and YB-1.

In another embodiment, step (b) of the foregoing process includes determining the expression level of multidrug resistance factors, such as, for example, gamma-glutamyl-cysteine synthetase (GCS), GST-α, GST-π, MDR-1, MRP1-4, breast cancer resistance protein (BCRP), lung cancer resistance protein (MVP), SXR, or YB-1.

In another embodiment, step (b) of the foregoing process comprises determination of the expression level of eukaryotic translation initiation factor 4E (EIF4E).

In yet another embodiment, step (b) of the foregoing process comprises determination of the expression level of a DNA repair enzyme.

In a further embodiment, step (b) of the foregoing process comprises determination of the expression level of a cell cycle regulator, such as, for example, c-MYC, c-Src, Cyclin D1, Ha-Ras, mdm2. p14ARF, p21WAF1/CI, p16INK4a/p14, p23, p27, p53, PI3K, PKC-epsilon, or PKC-delta.

In a still further embodiment, step (b) of the foregoing process comprises determination of the expression level of a tumor suppressor or a related protein, such as, for example, APC or Ecadherin.

In another embodiment, step (b) of the foregoing method comprises determination of the expression level of a gene regulating apoptosis, such as, for example, p53, BC12, Bcl-x1, Bak, Bax, and related factors, NFk-B, CIAP1, CIAP2, survivin, and related factors, p53BP1/ASPP1, or p53BP2/ASPP2.

In yet another embodiment, step (b) of the foregoing process comprises determination of the expression level of a factor that controls cell invasion or angiogenesis, such as, for example, uPA, PAII, cathepsin B, C, and L, scatter factor (HGF), c-met, KDR, VEGF, or CD31.

In a different embodiment, step (b) of the foregoing method comprises determination of the expression level of a marker for immune or inflammatory cells or processes, such as, for example, Ig light chain λ , CD18, CD3, CD68. Fas(CD95), or Fas Ligand.

In a further embodiment, step (b) of the foregoing process comprises determination of the expression level of a cell proliferation marker, such as, for example, Ki67/MiB1, PCNA, Pin1, or thymidine kinase.

In a still further embodiment, step (b) of the foregoing process comprises determination of the expression level of a growth factor or growth factor receptor., such as, for example, IGF1, IGF2, IGFBP3, IGF1R, FGF2, CSF-1, CSF-1R/fms, SCF-1, IL6 or IL8.

8
SUBSTITUTE SHEET (RULE 26)

15

20

25

In another embodiment, step (b) of the foregoing process comprises determination of the expression level of a gene marker that defines a subclass of breast cancer, where the gene marker can, for example, be GRO1 oncogene alpha, Grb7, cytokeratins 5 and 17, retinol binding protein 4, hepatocyte nuclear factor 3, integrin subunit alpha 7, or lipoprotein lipase.

In a still further aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to 5-fluorouracil (5-FU) or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis;
- (b) determining the expression level in the tissue of thymidylate synthase mRNA, wherein the expression level is normalized against a control gene or genes, and is compared to the amount found in a reference breast cancer tissue set; and
- (c) predicting patient response based on the normalized thymidylate synthase mRNA level.

Step (d) of the foregoing method can further comprise determining the expression level of dihydropyrimidine phosphorylase.

In another embodiment, step (b) of the method can further comprise determining the expression level of thymidine phosphorylase.

In yet another embodiment, a positive response to 5-FU or an analog thereof is predicted if: (i) normalized thymidylate synthase mRNA level determined in step (b) is at or below the 15th percentile; or (ii) the sum of normalized expression levels of thymidylate synthase and dihydropyrimidine phosphorylase determined in step (b) is at or below the 25th percentile; or (iii) the sum of normalized expression levels of thymidylate synthase, dihydropyrimidine phosphorylase, plus thymidine phosphorylase determined in step (b) is at or below the 20th percentile..

In a further embodiment, in step (b) of the foregoing method the expression level of c-myc and wild-type p53 is determined. In this case, a positive response to 5-FU or an analog thereof is predicted, if the normalized expression level of c-myc relative to the normalized expression level of wild-type p53 is in the upper 15th percentile.

In a still further embodiment, in step (b) of the foregoing method, expression level of NFkB and cIAP2 is determined. In this particular embodiment, resistance to 5-FU or an analog thereof is typically predicted if the normalized expression level of NFkB and cIAP2 is at or above the 10th percentile.

10

20

25

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to methotrexate or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting decreased patient sensitivity to methotrexate or analog if (i) DHFR levels are more than tenfold higher than the average expression level of DHFR in the control gene set, or (ii) the normalized expression levels of members of the reduced folate carrier (RFC) family are below the 10th percentile.

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to an anthracycline or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting patient resistance or decreased sensitivity to the anthracycline or analog if (i) the normalized expression level of topoisomerase IIα is below the 10th percentile, or (ii) the normalized expression level of topoisomerase IIβ is below the 10th percentile, or (iii) the combined normalized topoisomerase IIα or IIβ expression levels are below the 10th percentile.

In a different aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a docetaxol, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to docetaxol if the normalized expression level of CYP1B1 is in the upper 10th percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to cyclophosphamide or an analog thereof, comprising

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to the cyclophosphamide or analog if the sum of the expression levels of aldehyde dehydrogenase 1A1 and 1A3 is more than tenfold higher than the average of their combined expression levels in the reference tissue set.

10

10

15

20

In a further aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to anti-estrogen therapy, comprising

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set that contains both specimens negative for and positive for estrogen receptor- α (ER α) and progesterone receptor- α (PR α); and
- (b) predicting patient response based upon the normalized expression levels of ERα or PRα, and at least one of microsomal epoxide hydrolase, pS2/trefoil factor 1, GATA3 and human chorionic gonadotropin.

In a specific embodiment, lack of response or decreased responsiveness is predicted if (i) the normalized expression level of microsomal epoxide hydrolase is in the upper 10^{th} percentile; or (ii) the normalized expression level of pS2/trefoil factor 1, or GATA3 or human chorionic gonaostropin is at or below the corresponding average expression level in said breast cancer tissue set, regardless of the expression level of ER α or PR α in the breast cancer tissue obtained from the patient.

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a taxane, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting reduced sensitivity to taxane if (i) no or minimal XIST expression is detected; or (ii) the normalized expression level of GST- π or propyl endopeptidase (PREP) is in the upper 10th percentile; or (iii) the normalized expression level of PLAG1 is in the upper 10th percentile.

The invention also concerns a method for predicting the response of a patient diagnosed with breast cancer to cisplatin or an analog thereof, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting resistance or reduced sensitivity if the normalized expression level of ERCC1 is in the upper 10th percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to an ErbB2 or EGFR antagonist, comprising the steps of:

20

25

(a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and

(b) predicting patient response based on the normalized expression levels of at least one of Grb7, IGF1R, IGF1 and IGF2.

In particular embodiment, a positive response is predicted if the normalized expression level of Grb7 is in the upper 10th percentile, and the expression of IGF1R, IGF1 and IGF2 is not elevated above the 90th percentile.

In a further particular embodiment, a decreased responsiveness is predicted if the expression level of at least one of IGF1R, IGF1 and IGF2 is elevated.

In another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a bis-phosphonate drug, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if the breast cancer tissue obtained from the patient expresses mutant Ha-Ras and additionally expresses farnesyl pyrophosphate synthetase or geranyl pyrophosphone synthetase at a normalized expression level at or above the 90th percentile.

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to treatment with a cyclooxygenase 2 inhibitor, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if the normalized expression level of COX2 in the breast cancer tissue obtained from the patient is at or above the 90th percentile.

The invention further concerns a method for predicting the response of a patient diagnosed with breast cancer to an EGF receptor (EGFR) antagonist, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response to an EGFR antagonist, if (i) the normalized expression level of EGFR is at or above the 10th percentile, and (ii) the normalized expression

10

15

20

level of at least one of epiregulin, TGF- α , amphiregulin, ErbB3, BRK, CD9, MMP9, CD82, and Lot1 is above the 90th percentile.

In another aspect, the invention concerns a method for monitoring the response of a patient diagnosed with breast cancer to treatment with an EGFR antagonist, comprising monitoring the expression level of a gene selected from the group consisting of epiregulin, TGF
α, amphiregulin, ErbB3, BRK, CD9, MMP9, CD82, and Lot1 in the patient during treatment, wherein reduction in the expression level is indicative of positive response to such treatment.

In yet another aspect, the invention concerns a method for predicting the response of a patient diagnosed with breast cancer to a drug targeting a tyrosine kinase selected from the group consisting of abl, c-kit, PDGFR-α, PDGFR-β and ARG, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set;
- (b) determining the normalized expression level of a tyrosine kinase selected from the group consisting of abl, c-kit, PDGFR-α, PDGFR-β and ARG, and the cognate ligand of the tyrosine kinase, and if the normalized expression level of the tyrosine kinase is in the upper 10th percentile,
- (c) determining whether the sequence of the tyrosine kinase contains any mutation, wherein a positive response is predicted if (i) the normalized expression level of the tyrosine kinase is in the upper 10th percentile, (ii) the sequence of the tyrosine kinase contains an activating mutation, or (iii) the normalized expression level of the tyrosine kinase is normal and the expression level of the ligand is in the upper 10th percentile.

Another aspect of the invention is a method for predicting the response of a patient diagnosed with breast cancer to treatment with an anti-angiogenic drug, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) predicting a positive response if (i) the normalized expression level of VEGF is in the upper 10th percentile and (ii) the normalized expression level of KDR or CD31 is in the upper 20th percentile.

A further aspect of the invention is a method for predicting the likelihood that a patient diagnosed with breast cancer develops resistance to a drug interacting with the MRP-1 gene coding for the multidrug resistance protein P-glycoprotein, comprising the steps of:

10

20

25

(a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis to determine the expression level of PTP1b, wherein the expression level is normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and

(b) concluding that the patient is likely to develop resistance to said drug if the normalized expression level of the MRP-1 gene is above the 90th percentile.

The invention further relates to a method for predicting the likelihood that a patient diagnosed with breast cancer develops resistance to a chemotherapeutic drug or toxin used in cancer treatment, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) determining the normalized expression levels of at least one of the following genes: MDR1, SGT α , GST π , SXR, BCRP YB-1, and LRP/MVP, wherein the finding of a normalized expression level in the upper 4th percentile is an indication that the patient is likely to develop resistance to the drug.

Also included herein is a method for measuring the translational efficiency of VEGF mRNA in a breast cancer tissue sample, comprising determining the expression levels of the VEGF and EIF4E mRNA in the sample, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a higher normalized EIF4E expression level for the same VEGF expression level is indicative of relatively higher translational efficiency for VEGF.

In another aspect, the invention provides a method for predicting the response of a patient diagnosed with breast cancer to a VEGF antagonist, comprising determining the expression level of VEGF and EIF4E mRNA normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a VEGF expression level above the 90th percentile and an EIF4E expression level above the 50th percentile is a predictor of good patient response.

The invention further provides a method for predicting the likelihood of the recurrence of breast cancer in a patient diagnosed with breast cancer, comprising determining the ratio of p53:p21 mRNA expression or p53:mdm2 mRNA expression in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an above normal ratio is indicative of a higher risk

10

20

25

of recurrence. Typically, a higher risk of recurrence is indicated if the ratio is in the upper 10th percentile.

In yet another aspect, the invention concerns a method for predicting the likelihood of the recurrence of breast cancer in a breast cancer patient following surgery, comprising determining the expression level of cyclin D1 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an expression level in the upper 10th percentile indicates increased risk of recurrence following surgery. In a particular embodiment of this method, the patient is subjected to adjuvant chemotherapy, if the expression level is in the upper 10th percentile.

Another aspect of the invention is a method for predicting the likelihood of the recurrence of breast cancer in a breast cancer patient following surgery, comprising determining the expression level of APC or E-cadherin in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein an expression level in the upper 5th percentile indicates high risk of recurrence following surgery, and heightened risk of shortened survival.

A further aspect of the invention is a method for predicting the response of a patient diagnosed with breast cancer to treatment with a proapoptotic drug comprising determining the expression levels of BCl2 and c-MYC in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) a BCl2 expression level in the upper 10th percentile in the absence of elevated expression of c-MYC indicates good response, and (ii) a good response is not indicated if the expression level c-MYC is elevated, regardless of the expression level of BCl2.

A still further aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising the steps of:

- (a) subjecting RNA extracted from a breast cancer tissue obtained from the patient to gene expression analysis, wherein gene expression levels are normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set; and
- (b) determining the normalized expression levels of NFkB and at least one gene selected from the group consisting of cIAP1, cIAP2, XIAP, and Survivin,

wherein a poor prognosis is indicated if the expression levels for NFkB and at least one of the genes selected from the group consisting of cIAP1, cIAP2, XIAP, and Survivin is in the upper 5th percentile.

15

20.

25.

30.

The invention further concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of p53BP1 and p53BP2 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor outcome is predicted if the expression level of either p53BP1 or p53BP2 is in the lower 10th percentile.

The invention additionally concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of uPA and PAI1 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) a poor outcome is predicted if the expression levels of uPA and PAI1 are in the upper 20th percentile, and (ii) a decreased risk of recurrence is predicted if the expression levels of uPA and PAI1 are not elevated above the mean observed in the breast cancer reference set. In a particular embodiment, poor outcome is measured in terms of shortened survival or increased risk of cancer recurrence following surgery. In another particular embodiment, uPA and PAI1 are expressed at normal levels, and the patient is subjected to adjuvant chemotherapy following surgery.

Another aspect of the invention is a method for predicting treatment outcome in a patient diagnosed with breast cancer, comprising determining the expression levels of cathepsin B and cathepsin L in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor outcome is predicted if the expression level of either cathepsin B or cathepsin L is in the upper 10th percentile. Just as before, poor treatment outcome may be measured, for example, in terms of shortened survival or increased risk of cancer recurrence.

A further aspect of the invention is a method for devising the treatment of a patient diagnosed with breast cancer, comprising the steps of

- (a) determining the expression levels of scatter factor and c-met in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, and
- (b) suggesting prompt aggressive chemotherapeutic treatment if the expression levels of scatter factor and c-met or the combination of both, are above the 90th percentile.

A still further aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of VEGF, CD31, and KDR in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein

15

20

a poor treatment outcome is predicted if the expression level of any of VEGF, CD31, and KDR is in the upper 10th percentile.

Yet another aspect of the invention is a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of Ki67/MiB1, PCNA, Pin1, and thymidine kinase in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor treatment outcome is predicted if the expression level of any of Ki67/MiB1, PCNA, Pin1, and thymidine kinase is in the upper 10th percentile.

The invention further concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression level of soluble and full length CD95 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein the presence of soluble CD95 correlates with poor patient survival.

The invention also concerns a method for predicting treatment outcome for a patient diagnosed with breast cancer, comprising determining the expression levels of IGF1, IGF1R and IGFBP3 in a breast cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein a poor treatment outcome is predicted if the sum of the expression levels of IGF1, IGF1R and IGFBP3 is in the upper 10th percentile.

The invention additionally concerns a method for classifying breast cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl12, hepatocyte nuclear factor 3, LIV1, ER, lipoprotein lipase, retinol binding protein 4, integrin α 7, cytokeratin 5, cytokeratin 17, GRO oncogen, ErbB2 and Grb7, in a breast cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference breast cancer tissue set, wherein (i) tumors expressing at least one of Bcl1, hepatocyte nuclear factor 3, LIV1, and ER above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following surgical removal; (ii) tumors characterized by elevated expression of at least one of lipoprotein lipase, retinol binding protein 4, integrin α 7 compared to the reference tissue set are classified as having intermediate prognosis of disease free and overall patient survival following surgical removal; and (iii) tumors expressing either elevated levels of cytokeratins 5 and 17, and GRO oncogen at levels four-fold or greater above the mean expression level in the reference tissue set, or ErbB2 and Grb7 at levels ten-fold or more above the mean expression level in the reference

10

20

25

PCT/US03/07713 WO 03/078662

tissue set are classified as having poor prognosis of disease free and overall patient survival following surgical removal.

Another aspect of the invention is a panel of two or more gene specific primers selected from the group consisting of the forward and reverse primers listed in Table 2.

Yet another aspect of the invention is a method for reverse transcription of a fragmented RNA population in RT-PCR amplification, comprising using a multiplicity of gene specific primers as the reverse primers in the amplification reaction. In a particular embodiment, the method uses between two and about 40,000 gene specific primers in the same amplification reaction. In another embodiment, the gene specific primers are about 18 to 24 bases, such as about 20 bases in length. In another embodiment, the Tm of the primers is about 58-60 °C. The primers can, for example, be selected from the group consisting of the forward and reverse primers listed in Table 2.

The invention also concerns a method of reverse transcriptase driven first strand cDNA synthesis, comprising using a gene specific primer of about 18 to 24 bases in length and having a Tm optimum between about 58 °C and about 60 °C. In a particular embodiment, the first strand cDNA synthesis is followed by PCR DNA amplification, and the primer serves as the reverse primer that drives the PCR amplification. In another embodiment, the method uses a plurality of gene specific primers in the same first strand cDNA synthesis reaction mixture. The number of the gene specific primers can, for example, be between 2 and about 40,000.

In a different aspect, the invention concerns a method of predicting the likelihood of long-term survival of a breast cancer patient without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising determining the expression level of one or more prognostic RNA transcripts or their product in a breast cancer tissue sample obtained from said patient, normalized against the expression level of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products, wherein the prognostic transcript is the transcript of one or more genes selected from the group consisting of: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, DIABLO, CDH1, HIF1a, IGFBP3, CTSB, and Her2, wherein overexpression of one or more of FOXM1, PRAME, STK15, Ki-67, CA9, NME1, SURV, TFRC, YB-1, RPS6KB1, Src, Chk1, CCNB1, Chk2, CDC25B, CYP3A4, EpCAM, VEGFC, hENT1, BRCA2, EGFR, TK1, VDR, EPHX1, IF1A, Contig51037, CDH1, HIF1α,

10

15

20

25

IGFBP3, CTSB, Her2, and pENT1 indicates a decreased likelihood of long-term survival without breast cancer recurrence, and the overexpression of one or more of Bcl2, CEGP1, GSTM1, PR, BBC3, GATA3, DPYD, GSTM3, ID1, EstR1, p27, XIAP, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, pS2, WISP1, HNF3A, NFKBp65, and DIABLO indicates an increased likelihood of long-term survival without breast cancer recurrence.

In a particular embodiment of this method, the expression level of at least 2, preferably at least 5, more preferably at least 10, most preferably at least 15 prognostic transcipts or their expression products is determined.

When the breast cancer is invasive breast carcinoma, including both estrogen receptor (ER) overexpressing (ER positive) and ER negative tumors, the analysis includes determination of the expression levels of the transcripts of at least two of the following genes, or their expression products: FOXM1, PRAME, Bel2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, Src, CA9, Contig51037, RPS6K1 and Her2.

When the breast cancer is ER positive invasive breast carcinoma, the analysis includes dtermination of the expression levels of the transcripts of at least two of the following genes, or their expression products: PRAME, Bcl2, FOXM1, DIABLO, EPHX1, HIF1A, VEGFC, Ki-67, IGF1R, VDR, NME1, GSTM3, Contig51037, CDC25B, CTSB, p27, CDH1, and IGFBP3.

Just as before, it is preferred to determine the expression levels of at least 5, more preferably at least 10, most preferably at least 15 genes, or their respective expression products.

In a particular embodiment, the expression level of one or more prognostic RNA transcripts is determined, where RNA may, for example, be obtained from a fixed, wax-embedded breast cancer tissue specimen of the patient. The isolation of RNA can, for example, be carried out following any of the procedures described above or throughout the application, or by any other method known in the art.

In yet another aspect, the invention concerns an array comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2, immobilized on a solid surface.

In a particular embodiment, the array comprosies polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, CDH1, HIF1α, IGFBP3, CTSB, Her2 and DIABLO.

15

20-

25

In a further aspect, the invention concerns a method of predicting the likelihood of longterm survival of a patient diagnosed with invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:

- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
- (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
- (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
- (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
- 10 (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
 - (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
 - (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- 15 (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
 - (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
 - (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
 - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - (l) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
- 25 (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
- (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1,30 VEGFC; and
 - (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS

20 SUBSTITUTE SHEET (RULE 26)

in a breast cancer tissue sample obtained from said patient, normalized against the expression levels of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products;

- (2) subjecting the data obtained in step (a) to statistical analysis; and
- (3) determining whether the likelihood of said long-term survival has increased or decreased.

In a still further aspect, the invention concerns a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-positive invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:

- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
- (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 15 (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG:
 - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
 - (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
- 25 (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
 - (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- 30 (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
 - (I) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
 - (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

21 SUBSTITUTE SHEET (RULE 26)

10:

- (n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
- (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
- 5 (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
 - (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;
 - (t) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- 10 (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
 - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
 - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
 - (x). FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 15 (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, EBXO5, CA9, CYP, KRT18; and
 - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF;
 - (2) subjecting the data obtained in step (1) to statistical analysis; and
 - (3) determining whether the likelihood of said long-term survival has increased or decreased.

In a different aspect, the invention concerns an array comprising polynucleotides hybridizing to a gene set selected from the group consisting of:

- (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
- 25 (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
 - (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
 - (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
- 30 (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
 - (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
 - (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;

(h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;

- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
- 5 (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
 - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - (I) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
 - (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
 - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
- 15 (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS,

immobilized on a solid surface.

In an additional aspect, the invention concerns an array comprising polynucleotides hybridizing to a gene set selected from the group consisting of:

- 20 (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN,CYP3A4, TIMP2, AREG;
 - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
- 30 (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
 - (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;

- (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
- (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
- (I) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
- 5 (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
 - (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- 10 (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
 - (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
 - (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;
- 15 (t) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
 - (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
 - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
 - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
- 20 (x) FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
 - (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP, KRT18; and
 - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF,
- 25 immobilized on a solid surface.

In all aspects, the polynucleotides can be cDNAs ("cDNA arrays") that are typically about 500 to 5000 bases long, although shorter or longer cDNAs can also be used and are within the scope of this invention. Alternatively, the polynucleotids can be oligonucleotides (DNA microarrays), which are typically about 20 to 80 bases long, although shorter and longer oligonucleotides are also suitable and are within the scope of the invention. The solid surface can, for example, be glass or nylon, or any other solid surface typically used in preparing arrays, such as microarrays, and is typically glass.

Brief Description of the Drawings

Figure 1 is a chart illustrating the overall workflow of the process of the invention for measurement of gene expression. In the Figure, FPET stands for "fixed paraffin-embedded tissue," and "RT-PCR" stands for "reverse transcriptase PCR." RNA concentration is determined by using the commercial RiboGreen™ RNA Quantitation Reagent and Protocol.

Figure 2 is a flow chart showing the steps of an RNA extraction method according to the invention alongside a flow chart of a representative commercial method.

Figure 3 is a scheme illustrating the steps of an improved method for preparing fragmented mRNA for expression profiling analysis.

Figure 4 illustrates methods for amplification of RNA prior to RT-PCR.

Figure 5 illustrates an alternative scheme for repair and amplification of fragmented mRNA.

Figure 6 shows the measurement of estrogen receptor mRNA levels in 40 FPE breast cancer specimens via RT-PCR. Three 10 micron sections were used for each measurement. Each data point represents the average of triplicate measurements.

Figure 7 shows the results of the measurement of progesterone receptor mRNA levels in 40 FPE breast cancer specimens via RT-PCR performed as described in the legend of Figure 6 above.

Figure 8 shows results from an IVT/RT-PCR experiment.

Figure 9 is a representation of the expression of 92 genes across 70 FPE breast cancer specimens. The y-axis shows expression as cycle threshold times. These genes are a subset of the genes listed in Table 1.

Table 1 shows a breast cancer gene list.

Table 2 sets forth amplicon and primer sequences used for amplification of fragmented mRNA.

Table 3 shows the Accession Nos. and SEQ ID NOS of the breast cance genes examined.

Detailed Description of the Preferred Embodiment

A. Definitions

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY 1994), and March, Advanced Organic Chemistry Reactions, Mechanisms

20

and Structure 4th ed., John Wiley & Sons (New York, NY 1992), provide one skilled in the art with a general guide to many of the terms used in the present application.

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. Indeed, the present invention is in no way limited to the methods and materials described. For purposes of the present invention, the following terms are defined below.

The term "microarray" refers to an ordered arrangement of hybridizable array elements, preferably polynucleotide probes, on a substrate.

The term "polynucleotide," when used in singular or plural, generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as defined herein include, without limitation, single- and double-stranded DNA, DNA including single- and double-stranded regions, single- and double-stranded RNA, and RNA including single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or include single- and double-stranded regions. In addition, the term "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. The term "polynucleotide" specifically includes DNAs and RNAs that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotides" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritiated bases, are included within the term "polynucleotides" as defined herein. In general, the term "polynucleotide" embraces all chemically, enzymatically and/or metabolically modified forms of unmodified polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells.

The term "oligonucleotide" refers to a relatively short polynucleotide, including, without limitation, single-stranded deoxyribonucleotides, single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are often synthesized by chemical methods, for example using automated oligonucleotide synthesizers that are commercially available. However, oligonucleotides can be made by a variety of other methods, including *in vitro* recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms.

10

20

25

The terms "differentially expressed gene," "differential gene expression" and their synonyms, which are used interchangeably, refer to a gene whose expression is activated to a higher or lower level in a subject suffering from a disease, specifically cancer, such as breast cancer, relative to its expression in a normal or control subject. The terms also include genes whose expression is activated to a higher or lower level at different stages of the same disease. It is also understood that a differentially expressed gene may be either activated or inhibited at the nucleic acid level or protein level, or may be subject to alternative splicing to result in a different polypeptide product. Such differences may be evidenced by a change in mRNA levels, surface expression, secretion or other partitioning of a polypeptide, for example. Differential gene expression may include a comparison of expression between two or more genes, or a comparison of the ratios of the expression between two or more genes, or even a comparison of two differently processed products of the same gene, which differ between normal subjects and subjects suffering from a disease, specifically cancer, or between various stages of the same disease. Differential expression includes both quantitative, as well as qualitative, differences in the temporal or cellular expression pattern in a gene or its expression products among, for example, normal and diseased cells, or among cells which have undergone different disease events or disease stages. For the purpose of this invention, "differential gene expression" is considered to be present when there is at least an about two-fold, preferably at least about fourfold, more preferably at least about six-fold, most preferably at least about ten-fold difference between the expression of a given gene in normal and diseased subjects, or in various stages of disease development in a diseased subject.

The phrase "gene amplification" refers to a process by which multiple copies of a gene or gene fragment are formed in a particular cell or cell line. The duplicated region (a stretch of amplified DNA) is often referred to as "amplicon." Usually, the amount of the messenger RNA (mRNA) produced, i.e., the level of gene expression, also increases in the proportion of the number of copies made of the particular gene expressed.

The term "prognosis" is used herein to refer to the prediction of the likelihood of cancerattributable death or progression, including recurrence, metastatic spread, and drug resistance, of
a neoplastic disease, such as breast cancer. The term "prediction" is used herein to refer to the
likelihood that a patient will respond either favorably or unfavorably to a drug or set of drugs,
and also the extent of those responses. The predictive methods of the present invention can be
used clinically to make treatment decisions by choosing the most appropriate treatment
modalities for any particular patient. The predictive methods of the present invention are
valuable tools in predicting if a patient is likely to respond favorably to a treatment regimen, such

15

20

25

as surgical intervention, chemotherapy with a given drug or drug combination, and/or radiation therapy.

The term "increased resistance" to a particular drug or treatment option, when used in accordance with the present invention, means decreased response to a standard dose of the drug or to a standard treatment protocol.

The term "decreased sensitivity" to a particular drug or treatment option, when used in accordance with the present invention, means decreased response to a standard dose of the drug or to a standard treatment protocol, where decreased response can be compensated for (at least partially) by increasing the dose of drug, or the intensity of treatment.

"Patient response" can be assessed using any endpoint indicating a benefit to the patient, including, without limitation, (1) inhibition, to some extent, of tumor growth, including slowing down and complete growth arrest; (2) reduction in the number of tumor cells; (3) reduction in tumor size; (4) inhibition (i.e., reduction, slowing down or complete stopping) of tumor cell infiltration into adjacent peripheral organs and/or tissues; (5) inhibition (i.e. reduction, slowing down or complete stopping) of metastasis; (6) enhancement of anti-tumor immune response, which may, but does not have to, result in the regression or rejection of the tumor; (7) relief, to some extent, of one or more symptoms associated with the tumor; (8) increase in the length of survival following treatment; and/or (9) decreased mortality at a given point of time following treatment.

The term "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented. In tumor (e.g., cancer) treatment, a therapeutic agent may directly decrease the pathology of tumor cells, or render the tumor cells more susceptible to treatment by other therapeutic agents, e.g., radiation and/or chemotherapy.

The term "tumor," as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.

The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.

10

15

20

The "pathology" of cancer includes all phenomena that compromise the well-being of the patient. This includes, without limitation, abnormal or uncontrollable cell growth, metastasis, interference with the normal functioning of neighboring cells, release of cytokines or other secretory products at abnormal levels, suppression or aggravation of inflammatory or immunological response, neoplasia, premalignancy, malignancy, invasion of surrounding or distant tissues or organs, such as lymph nodes, etc.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, typically: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent that those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium cirrate), 50 mM sodium phosphate (pH 7.6), 5 x

5

15.

20

25

Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

In the context of the present invention, reference to "at least one," "at least two," "at least five," etc. of the genes listed in any particular gene set means any one or any and all combinations of the genes listed.

The terms "splicing" and "RNA splicing" are used interchangeably and refer to RNA processing that removes introns and joins exons to produce mature mRNA with continuous coding sequence that moves into the cytoplasm of an eukaryotic cell.

In theory, the term "exon" refers to any segment of an interrupted gene that is represented in the mature RNA product (B. Lewin. <u>Genes IV</u> Cell Press, Cambridge Mass. 1990). In theory the term "intron" refers to any segment of DNA that is transcribed but removed from within the transcript by splicing together the exons on either side of it. Operationally, exon sequences occur in the mRNA sequence of a gene as defined by Ref. Seq ID numbers. Operationally, intron sequences are the intervening sequences within the genomic DNA of a gene, bracketed by exon sequences and having GT and AG splice consensus sequences at their 5' and 3' boundaries.

B. <u>Detailed Description</u>

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", 2nd edition (Sambrook et al., 1989); "Oligonucleotide Synthesis" (M.J. Gait, ed., 1984); "Animal Cell Culture" (R.I. Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Handbook of Experimental Immunology", 4th edition (D.M. Weir & C.C. Blackwell, eds., Blackwell Science Inc., 1987); "Gene Transfer Vectors for Mammalian Cells" (J.M. Miller & M.P. Calos, eds., 1987); "Current Protocols in Molecular Biology" (F.M. Ausubel et al., eds., 1987); and "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994).

1. Gene Expression Profiling

In general, methods of gene expression profiling can be divided into two large groups: methods based on hybridization analysis of polynucleotides, and methods based on sequencing of polynucleotides. The most commonly used methods known in the art for the quantification of mRNA expression in a sample include northern blotting and *in situ* hybridization (Parker & Barnes, *Methods in Molecular Biology* 106:247-283 (1999)); RNAse protection assays (Hod,

10 .

15

20

25

Biotechniques 13:852-854 (1992)); and reverse transcription polymerase chain reaction (RT-PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)). Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE), and gene expression analysis by massively parallel signature sequencing (MPSS).

2. Reverse Transcriptase PCR (RT-PCR)

Of the techniques listed above, the most sensitive and most flexible quantitative method is RT-PCR, which can be used to compare mRNA levels in different sample populations, in normal and tumor tissues, with or without drug treatment, to characterize patterns of gene expression, to discriminate between closely related mRNAs, and to analyze RNA structure.

The first step is the isolation of mRNA from a target sample. The starting material is typically total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines, respectively. Thus RNA can be isolated from a variety of primary tumors, including breast, lung, colon, prostate, brain, liver, kidney, pancreas, spleen, thymus, testis, ovary, uterus, etc., tumor, or tumor cell lines, with pooled DNA from healthy donors. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples.

General methods for mRNA extraction are well known in the art and are disclosed in standard textbooks of molecular biology, including Ausubel et al., Current Protocols of Molecular Biology, John Wiley and Sons (1997). Methods for RNA extraction from paraffin embedded tissues are disclosed, for example, in Rupp and Locker, Lab Invest. 56:A67 (1987), and De Andrés et al., BioTechniques 18:42044 (1995). In particular, RNA isolation can be performed using purification kit, buffer set and protease from commercial manufacturers, such as Qiagen, according to the manufacturer's instructions. For example, total RNA from cells in culture can be isolated using Qiagen RNeasy mini-columns. Other commercially available RNA isolation kits include MasterPure™ Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, WI), and Paraffin Block RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samples can be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumor can be isolated, for example, by cesium chloride density gradient centrifugation.

As RNA cannot serve as a template for PCR, the first step in gene expression profiling by RT-PCR is the reverse transcription of the RNA template into cDNA, followed by its exponential amplification in a PCR reaction. The two most commonly used reverse transcriptases are avilo myeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murine leukemia virus

15 %

20

25

reverse transcriptase (MMLV-RT). The reverse transcription step is typically primed using specific primers, random hexamers, or oligo-dT primers, depending on the circumstances and the goal of expression profiling. For example, extracted RNA can be reverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA), following the manufacturer's instructions. The derived cDNA can then be used as a template in the subsequent PCR reaction.

Although the PCR step can use a variety of thermostable DNA-dependent DNA polymerases, it typically employs the Taq DNA polymerase, which has a 5'-3' nuclease activity but lacks a 3'-5' proofreading endonuclease activity. Thus, TaqMan® PCR typically utilizes the 5'-nuclease activity of Taq or Tth polymerase to hydrolyze a hybridization probe bound to its target amplicon, but any enzyme with equivalent 5' nuclease activity can be used. Two oligonucleotide primers are used to generate an amplicon typical of a PCR reaction. A third oligonucleotide, or probe, is designed to detect nucleotide sequence located between the two PCR primers. The probe is non-extendible by Taq DNA polymerase enzyme, and is labeled with a reporter fluorescent dye and a quencher fluorescent dye. Any laser-induced emission from the reporter dye is quenched by the quenching dye when the two dyes are located close together as they are on the probe. During the amplification reaction, the Taq DNA polymerase enzyme cleaves the probe in a template-dependent manner. The resultant probe fragments disassociate in solution, and signal from the released reporter dye is free from the quenching effect of the second fluorophore. One molecule of reporter dye is liberated for each new molecule synthesized, and detection of the unquenched reporter dye provides the basis for quantitative interpretation of the data.

TaqMan® RT-PCR can be performed using commercially available equipment, such as, for example, ABI PRISM 7700TM Sequence Detection SystemTM (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA), or Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In a preferred embodiment, the 5' nuclease procedure is run on a real-time quantitative PCR device such as the ABI PRISM 7700TM Sequence Detection SystemTM. The system consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 96-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 96 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

5'-Nuclease assay data are initially expressed as Ct, or the threshold cycle. As discussed above, fluorescence values are recorded during every cycle and represent the amount of product

10

15

20

25

amplified to that point in the amplification reaction. The point when the fluorescent signal is first recorded as statistically significant is the threshold cycle (C_i).

To minimize errors and the effect of sample-to-sample variation, RT-PCR is usually performed using an internal standard. The ideal internal standard is expressed at a constant level among different tissues, and is unaffected by the experimental treatment. RNAs most frequently used to normalize patterns of gene expression are mRNAs for the housekeeping genes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and β-actin.

A more recent variation of the RT-PCR technique is the real time quantitative PCR, which measures PCR product accumulation through a dual-labeled fluorigenic probe (i.e., TaqMan® probe). Real time PCR is compatible both with quantitative competitive PCR, where internal competitor for each target sequence is used for normalization, and with quantitative comparative PCR using a normalization gene contained within the sample, or a housekeeping gene for RT-PCR. For further details see, e.g. Held et al., Genome Research 6:986-994 (1996).

3. Microarrays

15

20

25

30

Differential gene expression can also be identified, or confirmed using the microarray technique. Thus, the expression profile of breast cancer-associated genes can be measured in either fresh or paraffin-embedded tumor tissue, using microarray technology. In this method, polynucleotide sequences of interest are plated, or arrayed, on a microchip substrate. The arrayed sequences are then hybridized with specific DNA probes from cells or tissues of interest. Just as in the RT-PCR method, the source of mRNA typically is total RNA isolated from human tumors or tumor cell lines, and corresponding normal tissues or cell lines. Thus RNA can be isolated from a variety of primary tumors or tumor cell lines. If the source of mRNA is a primary tumor, mRNA can be extracted, for example, from frozen or archived paraffin-embedded and fixed (e.g. formalin-fixed) tissue samples, which are routinely prepared and preserved in everyday clinical practice.

In a specific embodiment of the microarray technique, PCR amplified inserts of cDNA clones are applied to a substrate in a dense array. Preferably at least 10,000 nucleotide sequences are applied to the substrate. The microarrayed genes, immobilized on the microchip at 10,000 elements each, are suitable for hybridization under stringent conditions. Fluorescently labeled cDNA probes may be generated through incorporation of fluorescent nucleotides by reverse transcription of RNA extracted from tissues of interest. Labeled cDNA probes applied to the chip hybridize with specificity to each spot of DNA on the array. After stringent washing to remove non-specifically bound probes, the chip is scanned by confocal laser microscopy or by another detection method, such as a CCD camera. Quantitation of hybridization of each arrayed

element allows for assessment of corresponding mRNA abundance. With dual color fluorescence, separately labeled cDNA probes generated from two sources of RNA are hybridized pairwise to the array. The relative abundance of the transcripts from the two sources corresponding to each specified gene is thus determined simultaneously. The miniaturized scale of the hybridization affords a convenient and rapid evaluation of the expression pattern for large numbers of genes. Such methods have been shown to have the sensitivity required to detect rare transcripts, which are expressed at a few copies per cell, and to reproducibly detect at least approximately two-fold differences in the expression levels (Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996)). Microarray analysis can be performed by commercially available equipment, following manufacturer's protocols, such as by using the Affymetrix GenChip technology, or Incyte's microarray technology.

The development of microarray methods for large-scale analysis of gene expression makes it possible to search systematically for molecular markers of cancer classification and outcome prediction in a variety of tumor types.

4. Serial Analysis of Gene Expression (SAGE)

Serial analysis of gene expression (SAGE) is a method that allows the simultaneous and quantitative analysis of a large number of gene transcripts, without the need of providing an individual hybridization probe for each transcript. First, a short sequence tag (about 10-14 bp) is generated that contains sufficient information to uniquely identify a transcript, provided that the tag is obtained from a unique position within each transcript. Then, many transcripts are linked together to form long serial molecules, that can be sequenced, revealing the identity of the multiple tags simultaneously. The expression pattern of any population of transcripts can be quantitatively evaluated by determining the abundance of individual tags, and identifying the gene corresponding to each tag. For more details see, e.g. Velculescu et al., Science 270:484-487 (1995); and Velculescu et al., Cell 88:243-51 (1997).

5. Gene Expression Analysis by Massively Parallel Signature Sequencing (MPSS)

This method, described by Brenner et al., Nature Biotechnology 18:630-634 (2000), is a sequencing approach that combines non-gel-based signature sequencing with in vitro cloning of millions of templates on separate 5 µm diameter microbeads. First, a microbead library of DNA templates is constructed by in vitro cloning. This is followed by the assembly of a planar array of the template-containing microbeads in a flow cell at a high density (typically greater than 3 x 10⁶ microbeads/cm²). The free ends of the cloned templates on each microbead are analyzed simultaneously, using a fluorescence-based signature sequencing method that does not require DNA fragment separation. This method has been shown to simultaneously and accurately

15

20

25

provide, in a single operation, hundreds of thousands of gene signature sequences from a yeast cDNA library.

6. General Description of the mRNA Isolation, Purification and Amplification Methods of the Invention

The steps of a representative protocol of the invention, including mRNA isolation, purification, primer extension and amplification are illustrated in Figure 1. As shown in Figure 1, this representative process starts with cutting about 10 µm thick sections of paraffin-embedded tumor tissue samples. The RNA is then extracted, and protein and DNA are removed, following the method of the invention described below. After analysis of the RNA concentration, RNA repair and/or amplification steps may be included, if necessary, and RNA is reverse transcribed using gene specific promoters followed by RT-PCR. Finally, the data are analyzed to identify the best treatment option(s) available to the patient on the basis of the characteristic gene expression pattern identified in the tumor sample examined. The individual steps of this protocol will be discussed in greater detail below.

7. Improved Method for Isolation of Nucleic Acid from Archived Tissue Specimens

As discussed above, in the first step of the method of the invention, total RNA is extracted from the source material of interest, including fixed, paraffin-embedded tissue specimens, and purified sufficiently to act as a substrate in an enzyme assay. Despite the availability of commercial products, and the extensive knowledge available concerning the isolation of nucleic acid, such as RNA, from tissues, isolation of nucleic acid (RNA) from fixed, paraffin-embedded tissue specimens (FPET) is not without difficulty.

In one aspect, the present invention concerns an improved method for the isolation of nucleic acid from archived, e.g. FPET tissue specimens. Measured levels of mRNA species are useful for defining the physiological or pathological status of cells and tissues. RT-PCR (which is discussed above) is one of the most sensitive, reproducible and quantitative methods for this "gene expression profiling". Paraffin-embedded, formalin-fixed tissue is the most widely available material for such studies. Several laboratories have demonstrated that it is possible to successfully use fixed-paraffin-embedded tissue (FPET) as a source of RNA for RT-PCR (Stanta et al., Biotechniques 11:304-308 (1991); Stanta et al., Methods Mol. Biol. 86:23-26 (1998); Jackson et al., Lancet 1:1391 (1989); Jackson et al., J. Clin. Pathol. 43:499-504 (1999); Finke et al., Biotechniques 14:448-453 (1993); Goldsworthy et al., Mol. Carcinog. 25:86-91 (1999); Stanta and Bonin, Biotechniques 24:271-276 (1998); Godfrey et al., J. Mol. Diagnostics 2:84 (2000); Specht et al., J. Mol. Med. 78:B27 (2000); Specht et al., Am. J. Pathol. 158:419-429 (2001)). This allows gene expression profiling to be carried out on the most commonly available

15

20

25.

source of human biopsy specimens, and therefore potentially to create new valuable diagnostic and therapeutic information.

The most widely used protocols utilize hazardous organic solvents, such as xylene, or octane (Finke et al., supra) to dewax the tissue in the paraffin blocks before nucleic acid (RNA and/or DNA) extraction. Obligatory organic solvent removal (e.g. with ethanol) and rehydration steps follow, which necessitate multiple manipulations, and addition of substantial total time to the protocol, which can take up to several days. Commercial kits and protocols for RNA extraction from FPET [MasterPureTM Complete DNA and RNA Purification Kit (EPICENTRE®, Madison, WI); Paraffin Block RNA Isolation Kit (Ambion, Inc.) and RNeasyTM Mini kit (Qiagen, Chatsworth, CA)] use xylene for deparaffinization, in procedures which typically require multiple centrifugations and ethanol buffer changes, and incubations following incubation with xylene.

The present invention provides an improved nucleic acid extraction protocol that produces nucleic acid, in particular RNA, sufficiently intact for gene expression measurements. The key step in the nucleic acid extraction protocol herein is the performance of dewaxing without the use of any organic solvent, thereby eliminating the need for multiple manipulations associated with the removal of the organic solvent, and substantially reducing the total time to the protocol. According to the invention, wax, e.g. paraffin is removed from wax-embedded tissue samples by incubation at 65-75 °C in a lysis buffer that solubilizes the tissue and hydrolyzes the protein, following by cooling to solidify the wax.

Figure 2 shows a flow chart of an RNA extraction protocol of the present invention in comparison with a representative commercial method, using xylene to remove wax. The times required for individual steps in the processes and for the overall processes are shown in the chart. As shown, the commercial process requires approximately 50% more time than the process of the invention.

The lysis buffer can be any buffer known for cell lysis. It is, however, preferred that oligo-dT-based methods of selectively purifying polyadenylated mRNA not be used to isolate RNA for the present invention, since the bulk of the mRNA molecules are expected to be fragmented and therefore will not have an intact polyadenylated tail, and will not be recovered or available for subsequent analytical assays. Otherwise, any number of standard nucleic acid purification schemes can be used. These include chaotrope and organic solvent extractions, extraction using glass beads or filters, salting out and precipitation based methods, or any of the purification methods known in the art to recover total RNA or total nucleic acids from a biological source.

10

15

20

25

Lysis buffers are commercially available, such as, for example, from Qiagen, Epicentre, or Ambion. A preferred group of lysis buffers typically contains urea, and Proteinase K or other protease. Proteinase K is very useful in the isolation of high quality, undamaged DNA or RNA, since most mammalian DNases and RNases are rapidly inactivated by this enzyme, especially in the presence of 0.5 - 1% sodium dodecyl sulfate (SDS). This is particularly important in the case of RNA, which is more susceptible to degradation than DNA. While DNases require metal ions for activity, and can therefore be easily inactivated by chelating agents, such as EDTA, there is no similar co-factor requirement for RNases.

Cooling and resultant solidification of the wax permits easy separation of the wax from the total nucleic acid, which can be conveniently precipitated, e.g. by isopropanol. Further processing depends on the intended purpose. If the proposed method of RNA analysis is subject to bias by contaminating DNA in an extract, the RNA extract can be further treated, e.g. by DNase, post purification to specifically remove DNA while preserving RNA. For example, if the goal is to isolate high quality RNA for subsequent RT-PCR amplification, nucleic acid precipitation is followed by the removal of DNA, usually by DNase treatment. However, DNA can be removed at various stages of nucleic acid isolation, by DNase or other techniques well known in the art.

While the advantages of the nucleic acid extraction protocol of the invention are most apparent for the isolation of RNA from archived, paraffin embedded tissue samples, the wax removal step of the present invention, which does not involve the use of an organic solvent, can also be included in any conventional protocol for the extraction of total nucleic acid (RNA and DNA) or DNA only. All of these aspects are specifically within the scope of the invention.

By using heat followed by cooling to remove paraffin, the process of the present invention saves valuable processing time, and eliminates a series of manipulations, thereby potentially increasing the yield of nucleic acid. Indeed, experimental evidence presented in the examples below, demonstrates that the method of the present invention does not compromise RNA yield.

8. <u>5'-multiplexed Gene Specific Priming of Reverse Transcription</u>

RT-PCR requires reverse transcription of the test RNA population as a first step. The most commonly used primer for reverse transcription is oligo-dT, which works well when RNA is intact. However, this primer will not be effective when RNA is highly fragmented as is the case in FPE tissues.

The present invention includes the use of gene specific primers, which are roughly 20 bases in length with a Tm optimum between about 58 °C and 60 °C. These primers will also serve as the reverse primers that drive PCR DNA amplification.

15

20

25

Another aspect of the invention is the inclusion of multiple gene-specific primers in the same reaction mixture. The number of such different primers can vary greatly and can be as low as two and as high as 40,000 or more. Table 2 displays examples of reverse primers that can be successfully used in carrying out the methods of the invention. Figure 9 shows expression data obtained using this multiplexed gene-specific priming strategy. Specifically, Figure 9 is a representation of the expression of 92 genes (a subset of genes listed in Table 1) across 70 FPE breast cancer specimens. The y-axis shows expression as cycle threshold times.

An alternative approach is based on the use of random hexamers as primers for cDNA synthesis. However, we have experimentally demonstrated that the method of using a multiplicity of gene-specific primers is superior over the known approach using random hexamers:

9. Preparation of Fragmented mRNA for Expression Profiling Assays

It is of interest to analyze the abundance of specific mRNA species in biological samples, since this expression profile provides an index of the physiological state of that sample. mRNA is notoriously difficult to extract and maintain in its native state, consequently, mRNA recovered from biological sources is often fragmented or somewhat degraded. This is especially true of human tissue specimen which have been chemically fixed and stored for extended periods of time.

In one aspect, the present invention provides a means of preparing the mRNA extracted from various sources, including archived tissue specimens, for expression profiling in a way that its relative abundance is preserved and the mRNA's of interest can be successfully measured. This method is useful as a means of preparing mRNA for analysis by any of the known expression profiling methods, including RT-PCR coupled with 5' exonuclease of reporter probes (TaqMan® type assays), as discussed above, flap endonuclease assays (Cleavase® and Invader® type assays), oligonucleotide hybridization arrays, cDNA hybridization arrays, oligonucleotide ligation assays, 3' single nucleotide extension assays and other assays designed to assess the abundance of specific mRNA sequences in a biological sample.

According to the method of the invention, total RNA is extracted from the source material and sufficiently purified to act as a substrate in an enzyme assay. The extraction procedure, including a new and improved way of removing the wax (e.g. paraffin) used for embedding the tissue samples, has been discussed above. It has also been noted that it is preferred that oligo-dT based methods of selectively purifying polyadenylated mRNA not be used to isolate RNA for this invention since the bulk of the mRNA is expected to be fragmented, will not be polyadenylated

15 -

20

25

and, therefore, will not be recovered and available for subsequent analytical assays if an oligo-dT based method is used.

A diagram of an improved method for repairing fragmented RNA is shown in Figure 3. The fragmented RNA purified from the tissue sample is mixed with universal or gene-specific, single-stranded, DNA templates for each mRNA species of interest. These templates may be full length DNA copies of the mRNA derived from cloned gene sources, they may be fragments of the gene representing only the segment of the gene to be assayed, they may be a series of long oligonucleotides representing either the full length gene or the specific segment(s) of interest. The template can represent either a single consensus sequence or be a mixture of polymorphic variants of the gene. This DNA template, or scaffold, will preferably include one or more dUTP or rNTP sites in its length. This will provide a means of removing the template prior to carrying out subsequent analytical steps to avoid its acting as a substrate or target in later analysis assays. This removal is accomplished by treating the sample with uracil-DNA glycosylase (UDG) and heating it to cause strand breaks where UDG has generated abasic sites. In the case of rNTP's, the sample can be heated in the presence of a basic buffer (pH ~10) to induce strand breaks where rNTP's are located in the template.

The single stranded DNA template is mixed with the purified RNA, the mixture is denatured and annealed so that the RNA fragments complementary to the DNA template effectively become primers that can be extended along the single stranded DNA templates. DNA polymerase I requires a primer for extension but will efficiently use either a DNA or an RNA primer. Therefore in the presence of DNA polymerase I and dNTP's, the fragmented RNA can be extended along the complementary DNA templates. In order to increase the efficiency of the extension, this reaction can be thermally cycled, allowing overlapping templates and extension products to hybridize and extend until the overall population of fragmented RNA becomes represented as double stranded DNA extended from RNA fragment primers.

Following the generation of this "repaired" RNA, the sample should be treated with UDG or heat-treated in a mildly based solution to fragment the DNA template (scaffold) and prevent it from participating in subsequent analytical reactions.

The product resulting from this enzyme extension can then be used as a template in a standard enzyme profiling assay that includes amplification and detectable signal generation such as fluorescent, chemiluminescent, colorimetric or other common read outs from enzyme based assays. For example, for TaqMan® type assays, this double stranded DNA product is added as the template in a standard assay; and, for array hybridization, this product acts as the cDNA

20

25

template for the cRNA labeling reaction typically used to generate single-stranded, labeled RNA for array hybridization.

This method of preparing template has the advantage of recovering information from mRNA fragments too short to effectively act as templates in standard cDNA generation schemes. In addition, this method acts to preserve the specific locations in mRNA sequences targeted by specific analysis assays. For example, TaqMan® assays rely on a single contiguous sequence in a cDNA copy of mRNA to act as a PCR amplification template targeted by a labeled reporter probe. If mRNA strand breaks occur in this sequence, the assay will not detect that template and will underestimate the quantity of that mRNA in the original sample. This target preparation method minimizes that effect from RNA fragmentation.

The extension product formed in the RNA primer extension assay can be controlled by controlling the input quantity of the single stranded DNA template and by doing limited cycling of the extension reaction. This is important in preserving the relative abundance of the mRNA sequences targeted for analysis.

This method has the added advantage of not requiring parallel preparation for each target sequence since it is easily multiplexed. It is also possible to use large pools of random sequence long oligonucleotides or full libraries of cloned sequences to extend the entire population of mRNA sequences in the sample extract for whole expressed genome analysis rather than targeted gene specific analysis.

10. Amplification of mRNA Species Prior to RT-PCR

Due to the limited amount and poor quality of mRNA that can be isolated from FPET, a new procedure that could accurately amplify mRNAs of interest would be very useful, particularly for real time quantitation of gene expression (TaqMan®) and especially for quantitatively large number (>50) of genes >50 to 10,000.

Current protocols (e.g. Eberwine, *Biotechniques* 20:584-91 (1996)) are optimized for mRNA amplification from small amount of total or poly A⁺ RNA mainly for microarray analysis. The present invention provides a protocol optimized for amplification of small amounts of fragmented total RNA (average size about 60-150 bps), utilizing gene-specific sequences as primers, as illustrated in Figure 4.

The amplification procedure of the invention uses a very large number, typically as many as 100 - 190,000 gene specific primers (GSP's) in one reverse transcription run. Each GSP contains an RNA polymerase promoter, e.g. a T7 DNA-dependent RNA polymerase promoter, at the 5' end for subsequent RNA amplification. GSP's are preferred as primers because of the small size of the RNA. Current protocols utilize dT primers, which would not adequately

SUBSTITUTE SHEET (RULE 26)

15

20

25

represent all reverse transcripts of mRNAs due to the small size of the FPET RNA. GSP's can be designed by optimizing usual parameters, such as length, Tm, etc. For example, GSP's can be designed using the Primer Express® (Applied Biosystems), or Primer 3 (MIT) software program. Typically at least 3 sets per gene are designed, and the ones giving the lowest Ct on FPET RNA (best performers) are selected.

Second strand cDNA synthesis is performed by standard procedures (see Figure 4, Method 1), or by GSP_f primers and Taq pol under PCR conditions (e.g., 95 °C, 10 min (Taq activation) then 60 °C, 45 sec). The advantages of the latter method are that the second gene specific primer, SGF_f adds additional specificity (and potentially more efficient second strand synthesis) and the option of performing several cycles of PCR, if more starting DNA is necessary for RNA amplification by T7 RNA polymerase. RNA amplification is then performed under standard conditions to generate multiple copies of cRNA, which is then used in a standard TaqMan® reaction.

Although this process is illustrated by using T7-based RNA amplification, a person skilled in the art will understand that other RNA polymerase promoters that do not require a primer, such as T3 or Sp6 can also be used, and are within the scope of the invention.

11. A method of Elongation of Fragmented RNA and Subsequent Amplification

This method, which combines and modifies the inventions described in sections 9 and 10 above, is illustrated in Figure 5. The procedure begins with elongation of fragmented mRNA. This occurs as described above except that the scaffold DNAs are tagged with the T7 RNA polymerase promoter sequence at their 5' ends, leading to double-stranded DNA extended from RNA fragments. The template sequences need to be removed after *in vitro* transcription. These templates can include dUTP or rNTP nucleotides, enabling enzymatic removal of the templates as described in section 9, or the templates can be removed by DNaseI treatment.

The template DNA can be a population representing different mRNAs of any number. A high sequence complexity source of DNA templates (scaffolds) can be generated by pooling RNA from a variety of cells or tissues. In one embodiment, these RNAs are converted into double stranded DNA and cloned into phagemids. Single stranded DNA can then be rescued by phagemid growth and single stranded DNA isolation from purified phagemids.

This invention is useful because it increases gene expression profile signals two different ways: both by increasing test mRNA polynucleotide sequence length and by *in vitro* transcription amplification. An additional advantage is that it eliminates the need to carry out reverse transcription optimization with gene specific primers tagged with the T7 RNA polymerase promoter sequence, and thus, is comparatively fast and economical.

20

25

This invention can be used with a variety of different methods to profile gene expression, e.g., RT-PCR or a variety of DNA array methods. Just as in the previous protocol, this approach is illustrated by using a T7 promoter but the invention is not so limited. A person skilled in the art will appreciate, however, that other RNA polymerase promoters, such as T3 or Sp6 can also be used.

12. <u>Breast Cancer Gene Set, Assayed Gene Subsequences, and Clinical Application of</u> Gene Expression Data

An important aspect of the present invention is to use the measured expression of certain genes by breast cancer tissue to match patients to best drugs or drug combinations, and to provide prognostic information. For this purpose it is necessary to correct for (normalize away) both differences in the amount of RNA assayed and variability in the quality of the RNA used. Therefore, the assay measures and incorporates the expression of certain normalizing genes, including well known housekeeping genes, such as GAPDH and Cypl. Alternatively, normalization can be based on the mean or median signal (Ct) of all of the assayed genes or a large subset thereof (global normalization approach). On a gene-by-gene basis, measured normalized amount of a patient tumor mRNA is compared to the amount found in a breast cancer tissue reference set. The number (N) of breast cancer tissues in this reference set should be sufficiently high to ensure that different reference sets (as a whole) behave essentially the same way. If this condition is met, the identity of the individual breast cancer tissues present in a particular set will have no significant impact on the relative amounts of the genes assayed. Usually, the breast cancer tissue reference set consists of at least about 30, preferably at least about 40 different FPE breast cancer tissue specimens. Unless noted otherwise, normalized expression levels for each mRNA/tested tumor/patient will be expressed as a percentage of the expression level measured in the reference set. More specifically, the reference set of a sufficiently high number (e.g. 40) tumors yields a distribution of normalized levels of each mRNA species. The level measured in a particular tumor sample to be analyzed falls at some percentile within this range, which can be determined by methods well known in the art. Below, unless noted otherwise, reference to expression levels of a gene assume normalized expression relative to the reference set although this is not always explicitly stated.

The breast cancer gene set is shown in Table 1. The gene Accession Numbers, and the SEQ ID NOs for the forward primer, reverse primer and amplicon sequences that can be used for gene amplification, are listed in Table 2. The basis for inclusion of markers, as well as the clinical significance of mRNA level variations with respect to the reference set, is indicated below. Genes are grouped into subsets based on the type of clinical significance indicated by

15

20

25

their expression levels: A. Prediction of patient response to drugs used in breast cancer treatment, or to drugs that are approved for other indications and could be used off-label in the treatment of breast cancer. B. Prognostic for survival or recurrence of cancer.

C. Prediction of Patient Response to Therapeutic Drugs

1. Molecules that specifically influence cellular sensitivity to drugs

Table 1 lists 74 genes (shown in italics) that specifically influence cellular sensitivity to potent drugs, which are also listed. Most of the drugs shown are approved and already used to treat breast cancer (e.g., anthracyclines; cyclophosphamide; methotrexate; 5-FU and analogues). Several of the drugs are used to treat breast cancer off-label or are in clinical development phase (e.g., bisphosphonates and anti-VEGF mAb). Several of the drugs have not been widely used to treat breast cancer but are used in other cancers in which the indicated target is expressed (e.g., Celebrex is used to treat familial colon cancer; cisplatin is used to treat ovarian and other cancers.)

Patient response to 5FU is indicated if normalized thymidylate synthase mRNA amount is at or below the 15th percentile, or the sum of expression of thymidylate synthase plus dihydropyrimidine phosphorylase is at or below the 25th percentile, or the sum of expression of these mRNAs plus thymidine phosphorylase is at or below the 20th percentile. Patients with dihydropyrimidine dehydrogenase below 5th percentile are at risk of adverse response to 5FU, or analogs such as Xeloda.

When levels of thymidylate synthase, and dihydropyrimidine dehydrogenase, are within the acceptable range as defined in the preceding paragraph, amplification of c-myc mRNA in the upper 15%, against a background of wild-type p53 [as defined below] predicts a beneficial response to 5FU (see D. Arango et al., Cancer Res. 61:4910-4915 (2001)). In the presence of normal levels of thymidylate synthase and dihydropyrimidine dehydrogenase, levels of NFkB and cIAP2 in the upper 10% indicate resistance of breast tumors to the chemotherapeutic drug 5FU.

Patient resistance to anthracyclines is indicated if the normalized mRNA level of topoisomerase II α is below the 10^{th} percentile, or if the topoisomerase II β normalized mRNA level is below the 10^{th} percentile or if the combined normalized topoisomerase II α and β signals are below the 10^{th} percentile.

Patient sensitivity to methotrexate is compromised if DHFR levels are more than tenfold higher than the average reference set level for this mRNA species, or if reduced folate carrier levels are below 10th percentile.

20

25

Patients whose tumors express CYP1B1 in the upper 10%, have reduced likelihood of responding to docetaxol.

The sum of signals for aldehyde dehydrogenase 1A1 and 1A3, when more than tenfold higher than the reference set average, indicates reduced likelihood of response to cyclophosphamide.

Currently, estrogen and progesterone receptor expression as measured by immunohistochemistry is used to select patients for anti-estrogen therapy. We have demonstrated RT-PCR assays for estrogen and progesterone receptor mRNA levels that predict levels of these proteins as determined by a standard clinical diagnostic tests, with high degree of concordance (Figures 6 and 7).

Patients whose tumors express ER α or PR mRNA in the upper 70%, are likely to respond to tamoxifen or other anti-estrogens (thus, operationally, lower levels of ER α than this are to defined ER α -negative). However, when the signal for microsomal epoxide hydrolase is in the upper 10% or when mRNAs for pS2/trefoil factor, GATA3 or human chorionic gonadotropin are at or below average levels found in ER α -negative tumors, anti-estrogen therapy will not be beneficial.

Absence of XIST signal compromises the likelihood of response to taxanes, as does elevation of the GST- π or prolyl endopeptidase [PREP] signal in the upper 10%. Elevation of PLAG1 in the upper 10% decreases sensitivity to taxanes.

Expression of ERCC1 mRNA in the upper 10% indicate significant risk of resistance to cisplatin or analogs.

An RT-PCR assay of Her2 mRNA expression predicts Her2 overexpression as measured by a standard diagnostic test, with high degree of concordance (data not shown). Patients whose tumors express Her2 (normalized to cyp.1) in the upper 10% have increased likelihood of beneficial response to treatment with Herceptin or other ErbB2 antagonists. Measurement of expression of Grb7 mRNA serves as a test for HER2 gene amplification, because the Grb7 gene is closely linked to Her2. When Her2 is expression is high as defined above in this paragraph, similarly elevated Grb7 indicates Her2 gene amplification. Overexpression of IGF1R and or IGF1 or IGF2 decreases likelihood of beneficial response to Herceptin and also to EGFR antagonists.

Patients whose tumors express mutant Ha-Ras, and also express farnesyl pyrophosphate synthetase or geranyl pyrophosphonate synthetase mRNAs at levels above the tenth percentile comprise a group that is especially likely to exhibit a beneficial response to bis-phosphonate drugs.

SUBSTITUTE SHEET (RULE 26)

10

15

20

25

Cox2 is a key control enzyme in the synthesis of prostaglandins. It is frequently expressed at elevated levels in subsets of various types of carcinomas including carcinoma of the breast. Expression of this gene is controlled at the transcriptional level, so RT-PCR serves a valid indicator of the cellular enzyme activity. Nonclinical research has shown that cox2 promotes tumor angiogenesis, suggesting that this enzyme is a promising drug target in solid tumors. Several Cox2 antagonists are marketed products for use in anti-inflammatory conditions. Treatment of familial adenomatous polyposis patients with the cox2 inhibitor Celebrex significantly decreased the number and size of neoplastic polyps. No cox2 inhibitor has yet been approved for treatment of breast cancer, but generally this class of drugs is safe and could be prescribed off-label in breast cancers in which cox2 is over-expressed. Tumors expressing COX2 at levels in the upper ten percentile have increased chance of beneficial response to Celebrex or other cyclooxygenase 2 inhibitors.

The tyrosine kinases ErbB1 [EGFR], ErbB3 [Her3] and ErbB4 [Her4]; also the ligands TGFalpha, amphiregulin, heparin-binding EGF-like growth factor, and epiregulin; also BRK, a non-receptor kinase. Several drugs in clinical development block the EGF receptor. ErbB2-4, the indicated ligands, and BRK also increase the activity of the EGFR pathway. Breast cancer patients whose tumors express high levels of EGFR or EGFR and abnormally high levels of the other indicated activators of the EGFR pathway are potential candidates for treatment with an EGFR antagonist.

Patients whose tumors express less than 10% of the average level of EGFR mRNA observed in the reference panel are relatively less likely to respond to EGFR antagonists [such as lressa, or ImClone 225]. In cases in which the EGFR is above this low range, the additional presence of epiregulin, TGFα, amphiregulin, or ErbB3, or BRK, CD9, MMP9, or Lot1 at levels above the 90th percentile predisposes to response to EGFR antagonists. Epiregulin gene expression, in particular, is a good surrogate marker for EGFR activation, and can be used to not only to predict response to EGFR antagonists, but also to monitor response to EGFR antagonists [taking fine needle biopsies to provide tumor tissue during treatment]. Levels of CD82 above the 90th percentile suggest poorer efficacy from EGFR antagonists.

The tyrosine kinases abl, c-kit, PDGFRalpha, PDGFbeta, and ARG; also, the signal transmitting ligands c-kit ligand, PDGFA, B, C and D. The listed tyrosine kinases are all targets of the drug GleevecTM (imatinib mesylate, Novartis), and the listed ligands stimulate one or more of the listed tyrosine kinases. In the two indications for which GleevecTM is approved, tyrosine kinase targets (bcr-abl and ckit) are overexpressed and also contain activating mutations. A finding that one of the GleevecTM target tyrosine kinase targets is expressed in breast cancer tissue

15

20

25.

will prompt a second stage of analysis wherein the gene will be sequenced to determine whether it is mutated. That a mutation found is an activating mutation can be proved by methods known in the art, such as, for example, by measuring kinase enzyme activity or by measuring phosphorylation status of the particular kinase, relative to the corresponding wild-type kinase. Breast cancer patients whose tumors express high levels of mRNAs encoding GleevecTM target tyrosine kinases, specifically, in the upper ten percentile, or mRNAs for GleevecTM target tyrosine kinases in the average range and mRNAs for their cognate growth stimulating ligands in the upper ten percentile, are particularly good candidates for treatment with GleevecTM.

VEGF is a potent and pathologically important angiogenic factor. (See below under Prognostic Indicators.) When VEGF mRNA levels are in the upper ten percentile, aggressive treatment is warranted. Such levels particularly suggest the value of treatment with anti-angiogenic drugs, including VEGF antagonists, such as anti-VEGF antibodies. Additionally, KDR or CD31 mRNA level in the upper 20 percentile further increases likelihood of benefit from VEGF antagonists.

Farnesyl pyrophosphatase synthetase and geranyl geranyl pyrophosphatase synthetase. These enzymes are targets of commercialized bisphosphonate drugs, which were developed originally for treatment of osteoporosis but recently have begun to prescribe them off-label in breast cancer. Elevated levels of mRNAs encoding these enzymes in breast cancer tissue, above the 90th percentile, suggest use of bisphosphonates as a treatment option.

2. Multidrug Resistance Factors

These factors include 10 Genes: gamma glutamyl cysteine synthetase [GCS]; GST-α; GST-π; MDR-1; MRP1-4; breast cancer resistance protein [BCRP]; lung resistance protein [MVP]; SXR; YB-1.

GCS and both GST- α and GST- π regulate glutathione levels, which decrease cellular sensitivity to chemotherapeutic drugs and other toxins by reductive derivatization. Glutathione is a necessary cofactor for multi-drug resistant pumps, MDR-1 and the MRPs. MDR1 and MRPs function to actively transport out of cells several important chemotherapeutic drugs used in breast cancer.

GSTs, MDR-1, and MRP-1 have all been studied extensively to determine possible have prognostic or predictive significance in human cancer. However, a great deal of disagreement exists in the literature with respect to these questions. Recently, new members of the MRP family have been identified: MRP-2, MRP-3, MRP-4, BCRP, and lung resistance protein [major vault protein]. These have substrate specificities that overlap with those of MDR-1 and MRP-1. The incorporation of all of these relevant ABC family members as well as glutathione synthetic

10.

15

20

25

enzymes into the present invention captures the contribution of this family to drug resistance, in a way that single or double analyte assays cannot.

MRP-1, the gene coding for the multidrug resistance protein.

P-glycoprotein, is not regulated primarily at the transcriptional level. However, p-glycoprotein stimulates the transcription of PTP1b. An embodiment of the present invention is the use of the level of the mRNA for the phosphatase PTP1b as a surrogate measure of MRP-1/p-glycoprotein activity.

The gene SXR is also an activator of multidrug resistance, as it stimulates transcription of certain multidrug resistance factors.

The impact of multidrug resistance factors with respect to chemotherapeutic agents used in breast cancer is as follows. Beneficial response to doxorubicin is compromised when the mRNA levels of either MDR1, GST α , GST π , SXR, BCRP YB-1, or LRP/MVP are in the upper four percentile. Beneficial response to methotrexate is inhibited if mRNA levels of any of MRP1, MRP2, MRP3, or MRP4 or gamma-glutamyl cysteine synthetase are in the upper four percentile.

3. Eukaryotic Translation Initiation Factor 4E [EIF4E]

EIF4E mRNA levels provides evidence of protein expression and so expands the capability of RT-PCR to indicate variation in gene expression. Thus, one claim of the present invention is the use of EIF4E as an added indicator of gene expression of certain genes [e.g., cyclinD1, mdm2, VEGF, and others]. For example, in two tissue specimens containing the same amount of normalized VEGF mRNA, it is likely that the tissue containing the higher normalized level of EIF4E exhibits the greater level of VEGF gene expression.

The background is as follows. A key point in the regulation of mRNA translation is selection of mRNAs by the EIF4G complex to bind to the 43S ribosomal subunit. The protein EIF4E [the m7G CAP-binding protein] is often limiting because more mRNAs than EIF4E copies exist in cells. Highly structured 5'UTRs or highly GC-rich ones are inefficiently translated, and these often code for genes that carry out functions relevant to cancer [e.g., cyclinD1, mdm2, and VEGF]. EIF4E is itself regulated at the transcriptional/ mRNA level. Thus, expression of EIF4E provides added indication of increased activity of a number of proteins.

It is also noteworthy that overexpression of EIF4E transforms cultured cells, and hence is an oncogene. Overexpression of EIF4E occurs in several different types of carcinomas but is particularly significant in breast cancer. EIF4E is typically expressed at very low levels in normal breast tissue.

10 ::

15 -

20

25

D. Prognostic Indicators

1. <u>DNA Repair Enzymes</u>

Loss of BRCA1 or BRCA2 activity via mutation represents the critical oncogenic step in the most common type[s] of familial breast cancer. The levels of mRNAs of these important enzymes are abnormal in subsets of sporadic breast cancer as well. Loss of signals from either [to within the lower ten percentile] heightens risk of short survival.

2. Cell Cycle Regulators

Cell cycle regulators include 14 genes: c-MYC; c-Src; Cyclin D1; Ha-Ras; mdm2; p14ARF; p21WAF1/CIP; p16INK4a/p14; p23; p27; p53; PI3K; PKC-epsilon; PKC-delta.

The gene for p53 [TP53] is mutated in a large fraction of breast cancers. Frequently p53 levels are elevated when loss of function mutation occurs. When the mutation is dominant-negative, it creates survival value for the cancer cell because growth is promoted and apoptosis is inhibited. Thousands of different p53 mutations have been found in human cancer, and the functional consequences of many of them are not clear. A large body of academic literature addresses the prognostic and predictive significance of mutated p53 and the results are highly conflicting. The present invention provides a functional genomic measure of p53 activity, as follows. The activated wild type p53 molecule triggers transcription of the cell cycle inhibitor p21. Thus, the ratio of p53 to p21 should be low when p53 is wild-type and activated. When p53 is detectable and the ratio of p53 to p21 is elevated in tumors relative to normal breast, it signifies nonfunctional or dominant negative p53. The cancer literature provides evidence for this as born out by poor prognosis.

Mdm2 is an important p53 regulator. Activated wildtype p53 stimulates transcription of mdm2. The mdm2 protein binds p53 and promotes its proteolytic destruction. Thus, abnormally low levels of mdm2 in the presence of normal or higher levels of p53 indicate that p53 is mutated and inactivated.

One aspect of the present invention is the use of ratios of mRNAs levels p53:p21 and p53:mdm2 to provide a picture of p53 status. Evidence for dominant negative mutation of p53 (as indicated by high p53:p21 and/or high p53:mdm2 mRNA ratios—specifically in the upper ten percentile) presages higher risk of recurrence in breast cancer and therefore weights toward a decision to use chemotherapy in node negative post surgery breast cancer.

Another important cell cycle regulator is p27, which in the activated form blocks cell cycle progression at the level of cdk4. The protein is regulated primarily via phosphorylation/dephosphorylation, rather than at the transcriptional level. However, levels of

15

20

25

p27 mRNAs do vary. Therefore a level of p27 mRNA in the upper ten percentile indicates reduced risk of recurrence of breast cancer post surgery.

Cyclin D1 is a principle positive regulator of entry into S phase of the cell cycle. The gene for cyclin D1 is amplified in about 20% of breast cancer patients, and therefore promotes tumor promotes tumor growth in those cases. One aspect of the present invention is use of cyclin D1 mRNA levels for diagnostic purposes in breast cancer. A level of cyclin D1 mRNA in the upper ten percentile suggests high risk of recurrence in breast cancer following surgery and suggests particular benefit of adjuvant chemotherapy.

3. Other tumor suppressors and related proteins

These include APC and E-cadherin. It has long been known that the tumor suppressor APC is lost in about 50% of colon cancers, with concomitant transcriptional upregulation of E-cadherin, an important cell adhesion molecule and growth suppressor. Recently, it has been found that the APC gene silenced in 15-40 % of breast cancers. Likewise, the E-cadherin gene is silenced [via CpG island methylation] in about 30% of breast cancers. An abnormally low level of APC and/or E-cadherin mRNA in the lower 5 percentile suggests high risk of recurrence in breast cancer following surgery and heightened risk of shortened survival.

4. Regulators of Apoptosis

These include BCl/BAX family members BCl2, Bcl-xl, Bak, Bax and related factors, NFk-B and related factors, and also p53BP1/ASPP1 and p53BP2/ASPP2.

Bax and Bak are pro-apoptotic and BCl2 and Bcl-xl are anti-apoptotic. Therefore, the ratios of these factors influence the resistance or sensitivity of a cell to toxic (pro-apoptotic) drugs. In breast cancer, unlike other cancers, elevated level of BCl2 (in the upper ten percentile) correlates with good outcome. This reflects the fact that BCl2 has growth inhibitory activity as well as anti-apoptotic activity, and in breast cancer the significance of the former activity outweighs the significance of the latter. The impact of BCl2 is in turn dependent on the status of the growth stimulating transcription factor c-MYC. The gene for c-MYC is amplified in about 20% of breast cancers. When c-MYC message levels are abnormally elevated relative to BCl2 (such that this ratio is in the upper ten percentile), then elevated level of BCl2 mRNA is no longer a positive indicator.

NFκ-B is another important anti-apoptotic factor. Originally, recognized as a proinflammatory transcription factor, it is now clear that it prevents programmed cell death in response to several extracellular toxic factors [such as tumor necrosis factor]. The activity of this transcription factor is regulated principally via phosphorylation/dephosphorylation events. However, levels of NFκ-B nevertheless do vary from cell to cell, and elevated levels should

10

15

20%

25

correlate with increased resistance to apoptosis. Importantly for present purposes, NFk-B, exerts its anti-apoptotic activity largely through its stimulation of transcription of mRNAs encoding certain members of the IAP [inhibitor of apoptosis] family of proteins, specifically cIAP1, cIAP2, XIAP, and Survivin. Thus, abnormally elevated levels of mRNAs for these IAPs and for NFk-B any in the upper 5 percentile] signify activation of the NFk-B anti-apoptotic pathway. This suggests high risk of recurrence in breast cancer following chemotherapy and therefore poor prognosis. One embodiment of the present invention is the inclusion in the gene set of the above apoptotic regulators, and the above-outlined use of combinations and ratios of the levels of their mRNAs for prognosis in breast cancer.

The proteins p53BP1 and 2 bind to p53 and promote transcriptional activation of proapoptotic genes. The levels of p53BP1 and 2 are suppressed in a significant fraction of breast cancers, correlating with poor prognosis. When either is expressed in the lower tenth percentile poor prognosis is indicated.

5. Factors that control cell invasion and angiogenesis

These include uPA, PAI1, cathepsinsB, G and L, scatter factor [HGF], c-met, KDR, VEGF, and CD31. The plasminogen activator uPA and its serpin regulator PAI1 promote breakdown of extracellular matrices and tumor cell invasion. Abnormally elevated levels of both mRNAs in malignant breast tumors (in the upper twenty percentile) signify an increased risk of shortened survival, increased recurrence in breast cancer patients post surgery, and increased importance of receiving adjuvant chemotherapy. On the other hand, node negative patients whose tumors do not express elevated levels of these mRNA species are less likely to have recurrence of this cancer and could more seriously consider whether the benefits of standard chemotherapy justifies the associated toxicity.

Cathepsins B or L, when expressed in the upper ten percentile, predict poor disease-free and overall survival. In particular, cathepsin L predicts short survival in node positive patients.

Scatter factor and its cognate receptor c-met promote cell motility and invasion, cell growth, and angiogenesis. In breast cancer elevated levels of mRNAs encoding these factors should prompt aggressive treatment with chemotherapeutic drugs, when expression of either, or the combination, is above the 90th percentile.

VEGF is a central positive regulator of angiogenesis, and elevated levels in solid tumors predict short survival [note many references showing that elevated level of VEGF predicts short survival]. Inhibitors of VEGF therefore slow the growth of solid tumors in animals and humans. VEGF activity is controlled at the level of transcription. VEGF mRNA levels in the upper ten percentile indicate significantly worse than average prognosis. Other markers of vascularization,

10

15

20

25

CD31 [PECAM], and KDR indicate high vessel density in tumors and that the tumor will be particularly malignant and aggressive, and hence that an aggressive therapeutic strategy is warranted.

6. Markers for Immune and Inflammatory Cells and Processes

These markers include the genes for Immunoglobulin light chain λ , CD18, CD3, CD68, Fas [CD95], and Fas Ligand.

Several lines of evidence suggest that the mechanisms of action of certain drugs used in breast cancer entail activation of the host immune/inflammatory response (For example, Herceptin®). One aspect of the present invention is the inclusion in the gene set of markers for inflammatory and immune cells, and markers that predict tumor resistance to immune surveillance. Immunoglobulin light chain lambda is a marker for immunoglobulin producing cells. CD18 is a marker for all white cells. CD3 is a marker for T-cells. CD68 is a marker for macrophages.

CD95 and Fas ligand are a receptor: ligand pair that mediate one of two major pathways by which cytotoxic T cells and NK cells kill targeted cells. Decreased expression of CD95 and increased expression of Fas Ligand indicates poor prognosis in breast cancer. Both CD95 and Fas Ligand are transmembrane proteins, and need to be membrane anchored to trigger cell death. Certain tumor cells produce a truncated soluble variant of CD95, created as a result of alternative splicing of the CD95 mRNA. This blocks NK cell and cytotoxic T cell Fas Ligand-mediated killing of the tumors cells. Presence of soluble CD95 correlates with poor survival in breast cancer. The gene set includes both soluble and full-length variants of CD95.

7. Cell proliferation markers

The gene set includes the cell proliferation markers Ki67/MiB1, PCNA, Pin1, and thymidine kinase. High levels of expression of proliferation markers associate with high histologic grade, and short survival. High levels of thymidine kinase in the upper ten percentile suggest in creased risk of short survival. Pin1 is a prolyl isomerase that stimulates cell growth, in part through the transcriptional activation of the cyclin D1 gene, and levels in the upper ten percentile contribute to a negative prognostic profile.

8. Other growth factors and receptors

This gene set includes IGF1, IGF2, IGFBP3, IGF1R, FGF2, FGFR1, CSF-1R/fms, CSF-1, IL6 and IL8. All of these proteins are expressed in breast cancer. Most stimulate tumor growth. However, expression of the growth factor FGF2 correlates with good outcome. Some have antiapoptotic activity, prominently IGF1. Activation of the IGF1 axis via elevated IGF1, IGF1R, or

20

25

IGFBP3 (as indicated by the sum of these signals in the upper ten percentile) inhibits tumor cell death and strongly contributes to a poor prognostic profile.

9. Gene expression markers that define subclasses of breast cancer

These include: GRO1 oncogene alpha, Grb7, cytokeratins 5 and 17, retinal binding protein 4, hepatocyte nuclear factor 3, integrin alpha 7, and lipoprotein lipase. These markers subset breast cancer into different cell types that are phenotypically different at the level of gene expression. Tumors expressing signals for Bcl2, hepatocyte nuclear factor 3, LIV1 and ER above the mean have the best prognosis for disease free and overall survival following surgical removal of the cancer. Another category of breast cancer tumor type, characterized by elevated expression of lipoprotein lipase, retinol binding protein 4, and integrin α7, carry intermediate prognosis. Tumors expressing either elevated levels of cytokeratins 5, and 17, GRO oncogene at levels four-fold or greater above the mean, or ErbB2 and Grb7 at levels ten-fold or more above the mean, have worst prognosis.

Although throughout the present description, including the Examples below, various aspects of the invention are explained with reference to gene expression studies, the invention can be performed in a similar manner, and similar results can be reached by applying proteomics techniques that are well known in the art. The proteome is the totality of the proteins present in a sample (e.g. tissue, organism, or cell culture) at a certain point of time. Proteomics includes, among other things, study of the global changes of protein expression in a sample (also referred to as "expression proteomics"). Proteomics typically includes the following steps: (1) separation of individual proteins in a sample by 2-D gel electrophoresis (2-D PAGE); (2) identification of the individual proteins recovered from the gel, e.g. my mass spectrometry and/or N-terminal sequencing, and (3) analysis of the data using bioinformatics. Proteomics methods are valuable supplements to other methods of gene expression profiling, and can be used, alone or in combination with other methods of the present invention, to detect the products of the gene markers of the present invention.

Further details of the invention will be described in the following non-limiting Examples.

Example 1

Isolation of RNA from formalin-fixed, paraffin-embedded (FPET) tissue specimens

A. Protocols

I. EPICENTRE® Xylene Protocol

RNA Isolation

(1) Cut 1-6 sections (each 10 μ m thick) of paraffin-embedded tissue per sample using a clean microtome blade and place into a 1.5 ml eppendorf tube.

52

15

20

25

(2) To extract paraffin, add 1 ml of xylene and invert the tubes for 10 minutes by rocking on a nutator.

- (3) Pellet the sections by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (4) Remove the xylene, leaving some in the bottom to avoid dislodging the pellet.
 - (5) Repeat steps 2-4.
 - (6) Add 1 ml of 100% ethanol and invert for 3 minutes by rocking on the nutator.
- (7) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (8) Remove the ethanol, leaving some at the bottom to avoid the pellet.
 - (9) Repeat steps 6-8 twice.
 - (10) Remove all of the remaining ethanol.
- (11) For each sample, add 2 μl of 50 μg/μl Proteinase K to 300 μl of Tissue and Cell Lysis Solution.
- (12) Add 300 µl of Tissue and Cell Lysis Solution containing the Proteinase K to each sample and mix thoroughly.
 - (13) Incubate at 65 °C for 90 minutes (vortex mixing every 5 minutes). Visually monitor the remaining tissue fragment. If still visible after 30 minutes, add an additional 2 μl of 50 μg/μl Proteinase K and continue incubating at 65 °C until fragment dissolves.
- 20 (14) Place the samples on ice for 3-5 minutes and proceed with protein removal and total nucleic acid precipitation.

Protein Removal and Precipitation of Total Nucleic Acid

- (1) Add 150 µl of MPC Protein Precipitation Reagent to each lysed sample and vortex vigorously for 10 seconds.
- 25 (2) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (3) Transfer the supernatant into clean eppendorf tubes and discard the pellet.
 - (4) Add 500 μ l of isopropanol to the recovered supernatant and thoroughly mix by rocking on the nutator for 3 minutes.
- 30 (5) Pellet the RNA/DNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (6) Remove all of the isopropanol with a pipet, being careful not to dislodge the pellet.

10

Removal of Contaminating DNA from RNA Preparations

- (1) Prepare 200 μl of DNase I solution for each sample by adding 5 μl of RNase-Free DNase I (1 U/μl) to 195 μl of 1X DNase Buffer.
- (2) Completely resuspend the pelleted RNA in 200 µl of DNase I solution by 5 vortexing.
 - (3) Incubate the samples at 37 °C for 60 minutes.
 - (4) Add 200 μ l of 2X T and C Lysis Solution to each sample and vortex for 5 seconds.
- (5) Add 200 µl of MPC Protein Precipitation Reagent, mix by vortexing for 10 seconds and place on ice for 3-5 minutes.
 - (6) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (7) Transfer the supernatant containing the RNA to clean eppendorf tubes and discard the pellet. (Be careful to avoid transferring the pellet.)
 - (8) Add 500 μ l of isopropanol to each supernatant and rock samples on the nutator for 3 minutes.
 - (9) Pellet the RNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
- (10) Remove the isopropanol, leaving some at the bottom to avoid dislodging the 20 pellet.
 - (11) Rinse twice with 1 ml of 75% ethanol. Centrifuge briefly if the RNA pellet is dislodged.
 - (12) Remove ethanol carefully.
 - (13) Set under fume hood for about 3 minutes to remove residual ethanol.
- 25 (14) Resuspend the RNA in 30 μl of TE Buffer and store at -30 °C.

II. Hot Wax/Urea Protocol of the Invention

RNA Isolation

- (1) Cut 3 sections (each 10 μm thick) of paraffin-embedded tissue using a clean microtome blade and place into a 1.5 ml eppendorf tube.
- 30 (2) Add 300 μl of lysis buffer (10 mM Tris 7.5, 0.5% sodium lauroyl sarcosine, 0.1 mM EDTA pH 7.5, 4M Urea) containing 330 μg/ml Proteinase K (added freshly from a 50 μg/μl stock solution) and vortex briefly.

(3) Incubate at 65 °C for 90 minutes (vortex mixing every 5 minutes). Visually monitor the tissue fragment. If still visible after 30 minutes, add an additional 2 μl of 50 μg/μl Proteinase K and continue incubating at 65 °C until fragment dissolves.

- (4) Centrifuge for 5 minutes at 14,000 x g and transfer upper aqueous phase to new tube, being careful not to disrupt the paraffin seal.
- (5) Place the samples on ice for 3-5 minutes and proceed with protein removal and total nucleic acid precipitation.

Protein Removal and Precipitation of Total Nucleic Acid

- (1) Add 150 μ l of 7.5M NH₄OAc to each lysed sample and vortex vigorously for 10 seconds.
 - (2) Pellet the debris by centrifugation for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (3) Transfer the supernatant into clean eppendorf tubes and discard the pellet.
 - (4) Add 500 µl of isopropanol to the recovered supernatant and thoroughly mix by rocking on the nutator for 3 minutes.
 - (5) Pellet the RNA/DNA by centrifugation at 4 °C for 10 minutes at 14,000 x g in an eppendorf microcentrifuge.
 - (6) Remove all of the isopropanol with a pipet, being careful not to dislodge the pellet.

Removal of Contaminating DNA from RNA Preparations

- Add 45 μl of 1X DNase I buffer (10 mM Tris-Cl, pH 7,5, 2.5 mM MgCl₂, 0.1 mM
 CaCl₂) and 5 μl of RNase-Free DNase I (2U/μl, Ambion) to each sample.
 - (2) Incubate the samples at 37 °C for 60 minutes. Inactivate the DNaseI by heating at 70 °C for 5 minutes.

25 B. Results

15

20

30

Experimental evidence demonstrates that the hot RNA extraction protocol of the invention does not compromise RNA yield. Using 19 FPE breast cancer specimens, extracting RNA from three adjacent sections in the same specimens, RNA yields were measured via capillary electrophoresis with fluorescence detection (Agilent Bioanalyzer). Average RNA yields in nanograms and standard deviations with the invented and commercial methods, respectively, were: 139+/-21 versus 141+/-34.

Also, it was found that the urea-containing lysis buffer of the present invention can be substituted for the EPICENTRE® T&C lysis buffer, and the 7.5 M NH₄OAc reagent used for protein precipitation in accordance with the present invention can be substituted for the

EPICENTRE® MPC protein precipitation solution with neither significant compromise of RNA yield nor TaqMan® efficiency.

Example 2

10.

15

20

25

Amplification of mRNA Species Prior to RT-PCR

The method described in section 10 above was used with RNA isolated from fixed, paraffin-embedded breast cancer tissue. TaqMan® analyses were performed with first strand cDNA generated with the T7-GSP primer (unamplified (T7-GSPr)), T7 amplified RNA (amplified (T7-GSPr)). RNA was amplified according to step 2 of Figure 4. As a control, TaqMan® was also performed with cDNA generated with an unmodified GSPr (amplified (GSPr)). An equivalent amount of initial template (1 ng/well) was used in each TaqMan® reaction.

The results are shown in Figure 8. In vitro transcription increased RT-PCR signal intensity by more than 10 fold, and for certain genes by more than 100 fold relative to controls in which the RT-PCR primers were the same primers used in method 2 for the generation of double-stranded DNA for in vitro transcription (GSP-T7, and GSP,). Also shown in Figure 8 are RT-PCR data generated when standard optimized RT-PCR primers (i.e., lacking T7 tails) were used. As shown, compared to this control, the new method yielded substantial increases in RT-PCR signal (from 4 to 64 fold in this experiment).

The new method requires that each T7-GSP sequence be optimized so that the increase in the RT-PCR signal is the same for each gene, relative to the standard optimized RT-PCR (with non-T7 tailed primers).

Example 3

A Study of Gene Expression in Premalignant and Malignant Breast Tumors

A gene expression study was designed and conducted with the primary goal to molecularly characterize gene expression in paraffin-embedded, fixed tissue samples of invasive breast ductal carcinoma, and to explore the correlation between such molecular profiles and disease-free survival. A further objective of the study was to compare the molecular profiles in tissue samples of invasive breast cancer with the molecular profiles obtained in ductal carcinoma in situ. The study was further designed to obtain data on the molecular profiles in lobular carcinoma in situ and in paraffin-embedded, fixed tissue samples of invasive lobular carcinoma.

Molecular assays were performed on paraffin-embedded, formalin-fixed primary breast tumor tissues obtained from 202 individual patients diagnosed with breast cancer. All patients underwent surgery with diagnosis of invasive ductal carcinoma of the breast, pure ductal carcinoma in situ (DCIS), lobular carcinoma of the breast, or pure lobular carcinoma in situ

(LCIS). Patients were included in the study only if histopathologic assessment, performed as described in the Materials and Methods section, indicated adequate amounts of tumor tissue and homogeneous pathology.

The individuals participating in the study were divided into the following groups:

Group 1: Pure ductal carcinoma in situ (DCIS); n=18

Group 2: Invasive ductal carcinoma n=130

Group 3: Pure lobular carcinoma in situ (LCIS); n=7

Group 4: Invasive lobular carcinoma n=16

Materials and Methods

10

20

25

30

Each representative tumor block was characterized by standard histopathology for diagnosis, semi-quantitative assessment of amount of tumor, and tumor grade. A total of 6 sections (10 microns in thickness each) were prepared and placed in two Costar Brand Microcentrifuge Tubes (Polypropylene, 1.7 mL tubes, clear; 3 sections in each tube). If the tumor constituted less than 30% of the total specimen area, the sample may have been crudely dissected by the pathologist, using gross microdissection, putting the tumor tissue directly into the Costar tube.

If more than one tumor block was obtained as part of the surgical procedure, all tumor blocks were subjected to the same characterization, as described above, and the block most representative of the pathology was used for analysis.

Gene Expression Analysis

mRNA was extracted and purified from fixed, paraffin-embedded tissue samples, and prepared for gene expression analysis as described in chapters 7-11 above.

Molecular assays of quantitative gene expression were performed by RT-PCR, using the ABI PRISM 7900TM Sequence Detection SystemTM (Perkin-Elmer-Applied Biosystems, Foster City, CA, USA). ABI PRISM 7900TM consists of a thermocycler, laser, charge-coupled device (CCD), camera and computer. The system amplifies samples in a 384-well format on a thermocycler. During amplification, laser-induced fluorescent signal is collected in real-time through fiber optics cables for all 384 wells, and detected at the CCD. The system includes software for running the instrument and for analyzing the data.

Analysis and Results

Tumor tissue was analyzed for 185 cancer-related genes and 7 reference genes. The threshold cycle (CT) values for each patient were normalized based on the median of all genes

for that particular patient. Clinical outcome data were available for all patients from a review of registry data and selected patient charts.

Outcomes were classified as:

- died due to breast cancer or to unknown cause or alive with breast cancer recurrence;
- alive without breast cancer recurrence or died due to a cause other than breast cancer

Analysis was performed by:

- 1. Analysis of the relationship between normalized gene expression and the binary outcomes of 0 or 1.
 - 2. Analysis of the relationship between normalized gene expression and the time to outcome (0 or 1 as defined above) where patients who were alive without breast cancer recurrence or who died due to a cause other than breast cancer were censored. This approach was used to evaluate the prognostic impact of individual genes and also sets of multiple genes.

Analysis of 147 patients with invasive breast carcinoma by binary approach

In the first (binary) approach, analysis was performed on all 146 patients with invasive breast carcinoma. At test was performed on the group of patients classified as 0 or 1 and the p-values for the differences between the groups for each gene were calculated.

The following Table 4 lists the 45 genes for which the p-value for the differences between the groups was <0.05.

<u>Table 4</u>

| Gene/ SEQ ID NO: | Mean CT Alive | Mean CT Deceased | t-value | Degrees of freedom | p |
|---------------------|------------------|---------------------|---------|--------------------|--------|
| FOXM1 | 33.66 | 32.52 | 3.92 | 144 | 0.0001 |
| PRAME | 35.45 | 33.84 | 3.71 | 144 | 0.0003 |
| Bcl2 | 28.52 | 29.32 | -3.53 | 144 | 0.0006 |
| STK15 | 30.82 | 30.10 | 3.49 | 144 | 0.0006 |
| CEGP1 | 29.12 | 30.86 | -3.39 | 144 | 0.0009 |
| Ki-67 | 30.57 | 29.62 | 3.34 | 144 | 0.0011 |
| GSTM1 | 30.62 | 31.63 | -3.27 | 144 | 0.0014 |
| CA9 | 34.96 | 33.54 | 3.18 | 144 | 0.0018 |
| PR | 29.56 | 31.22 | -3.16 | 144 | 0.0019 |
| BBC3 | 31.54 | 32.10 | -3.10 | 144 | 0.0023 |
| NME1 | 27.31 | 26.68 | 3.04 | 144 | 0.0028 |
| SURV | 31.64 | 30.68 | 2.92 | 144 | 0.0041 |
| GATA3 | 26.06 | 26.99 | -2.91 | 144 | 0.0042 |
| TFRC | 28.96 | 28.48 | 2.87 | 144 | 0.0047 |
| YB-1 | 26.72 | 26.41 | 2.79 | 144 | 0.0060 |
| DPYD | 28.51 | 28.84 | -2.67 | 144 | 0.0084 |
| GSTM3 | 28.21 | 29.03 | -2.63 | 144 | 0.0095 |
| RPS6KB1 | 31.18 | 30.61 | 2.61 | 144 | 0.0099 |
| Src | 27.97 | 27.69 | 2.59 | 144 | 0.0105 |
| Chkl | 32.63 | 31.99 | 2.57 | 144 | 0.0113 |
| ID1 | 28.73 | 29.13 | -2.48 | 144 | 0.0141 |
| EstR1 | 24.22 | 25.40 | -2.44 | 144 | 0.0160 |
| p27 | 27.15 | 27.51 | -2.41 | 144 | 0.0174 |
| CCNB1 | 31.63 | 30.87 | 2.40 | 144 | 0.0176 |
| XIAP | 30.27 | 30.51 | -2.40 | 144 | 0.0178 |
| Chk2 | 31.48 | 31.11 | 2.39 | 144 | 0.0179 |
| CDC25B | 29.75 | 29.39 | 2.37 | 144 | 0.0193 |
| IGF1R | 28.85 | 29.44 | -2.34 | 144 | 0.0209 |

SUBSTITUTE SHEET (RULE 26)

| | · · · · · · · · · · · · · · · · · · · | | 50 | | • |
|----------|---------------------------------------|-------|----------|----------------|--------|
| AK055699 | 33.23 | 34.11 | -2.28 | 144 | 0.0242 |
| PI3KC2A | 31.07 | 31.42 | -2.25 | 144 | 0.0257 |
| TGFB3 | 28.42 | 28.85 | -2.25 | 144 | 0.0258 |
| BAGI1 | 28.40 | 28.75 | -2.24 | 144 | 0.0269 |
| CYP3A4 | 35.70 | 35.32 | 2.17 | 144 | 0.0317 |
| EpCAM | 28.73 | 28.34 | 2.16 | 144 | 0.0321 |
| VEGFC | 32.28 | 31.82 | 2.16 | 144 | 0.0326 |
| pS2 | 28.96 | 30.60 | -2.14 | 144 | 0.0341 |
| hENT1 | 27.19 | 26.91 | 2.12 | 144 | 0.0357 |
| WISP1 | 31.20 | 31.64 | -2.10 | 144 | 0.0377 |
| HNF3A | 27.89 | 28.64 | -2.09 | 144 | 0.0384 |
| NFKBp65 | 33.22 | 33.80 | -2.08 | 144 | 0.0396 |
| BRCA2 | 33.06 | 32.62 | 2.08 | 144 | 0.0397 |
| EGFR | 30.68 | 30.13 | 2.06 | 144 | 0.0414 |
| TK1 | 32.27 | 31.72 | 2.02 | 144 | 0.0453 |
| VDR | 30.08 | 29.73 | 1.99 | 144 | 0.0488 |
| | 1 > | | <u> </u> | . | |

In the foregoing Table 4, lower (negative) t-values indicate higher expression (or lower CTs), associated with better outcomes, and, inversely, higher (positive) t-values indicate higher expression (lower CTs) associated with worse outcomes. Thus, for example, elevated expression of the FOXM1 gene (t-value = 3.92, CT mean alive> CT mean deceased) indicates a reduced likelihood of disease free survival. Similarly, elevated expression of the CEGP1 gene (t-value = -3.39; CT mean alive< CT mean deceased) indicates an increased likelihood of disease free survival.

Based on the data set forth in Table 4, the overexpression of any of the following genes in breast cancer indicates a reduced likelihood of survival without cancer recurrence following surgery: FOXM1; PRAME; SKT15, Ki-67; CA9; NME1; SURV; TFRC; YB-1; RPS6KB1; Src; Chk1; CCNB1; Chk2; CDC25B; CYP3A4; EpCAM; VEGFC; hENT1; BRCA2; EGFR; TK1; VDR.

Based on the data set forth in Table 4, the overexpression of any of the following genes in breast cancer indicates a better prognosis for survival without cancer recurrence following surgery: Blc12; CEGP1; GSTM1; PR; BBC3; GATA3; DPYD; GSTM3; ID1; EstR1; p27; XIAP; IGF1R; AK055699; P13KC2A; TGFB3; BAGI1; pS2; WISP1; HNF3A; NFKBp65.

60 SUBSTITUTE SHEET (RULE 26)

Analysis of 108 ER positive patient by binary approach

108 patients with normalized CT for estrogen receptor (ER) < 25.2 (i.e., ER positive patients) were subjected to separate analysis. A t test was performed on the groups of patients classified as 0 or 1 and the p-values for the differences between the groups for each gene were calculated. The following Table 5 lists the 12 genes where the p-value for the differences between the groups was <0.05.

Table 5

| | | | • | | |
|------------|---------|----------|---------|------------|--------|
| Gene/ | Mean CT | Mean CT | t-value | Degrees of | р |
| SEQ ID NO: | Alive | Deceased | | freedom | |
| PRAME | 35.54 | 33.88 | 3.03 | 106 | 0.0031 |
| Bcl2 | 28.24 | 28.87 | -2.70 | 106 | 0.0082 |
| FOXM1 | 33.82 | 32.85 | 2.66 | 106 | 0.089 |
| DIABLO | 30.33 | 30.71 | -2.47 | 106 | 0.0153 |
| EPHX1 | 28.62 | 28.03 | 2.44 | 106 | 0.0163 |
| HIF1A | 29.37 | 28.88 | 2.40 | 106 | 0.0180 |
| VEGFC | 32.39 | 31.69 | 2.39 | 106 | 0.0187 |
| Ki-67 | 30.73 | 29.82 | 2.38 | 106 | 0.0191 |
| IGF1R | 28.60 | 29.18 | -2.37 | 106 | 0.0194 |
| VDR | 30.14 | 29.60 | 2.17 | 106 | 0.0322 |
| NME1 | 27.34 | 26.80 | 2.03 | 106 | 0.0452 |
| GSTM3 | 28.08 | 28.92 | -2.00 | 106 | 0.0485 |

10

15

20

For each gene, a classification algorithm was utilized to identify the best threshold value (CT) for using each gene alone in predicting clinical outcome.

Based on the data set forth in Table 5, overexpression of the following genes in ER-positive cancer is indicative of a reduced likelihood of survival without cancer recurrence following surgery: PRAME; FOXM1; EPHX1; HIF1A; VEGFC; Ki-67; VDR; NME1. Some of these genes (PRAME; FOXM1; VEGFC; Ki-67; VDR; and NME1) were also identified as indicators of poor prognosis in the previous analysis, not limited to ER-positive breast cancer. The overexpression of the remaining genes (EPHX1 and HIF1A) appears to be negative indicator of disease free survival in ER-positive breast cancer only. Based on the data set forth in Table 5, overexpression of the following genes in ER-positive cancer is indicative of a better

prognosis for survival without cancer recurrence following surgery: Bcl-2; DIABLO; IGF1R; GSTM3. Of the latter genes, Bcl-2; IGFR1; and GSTM3 have also been identified as indicators of good prognosis in the previous analysis, not limited to ER-positive breast cancer. The overexpression of DIABLO appears to be positive indicator of disease free survival in ER-positive breast cancer only.

Analysis of multiple genes and indicators of outcome

Two approaches were taken in order to determine whether using multiple genes would provide better discrimination between outcomes.

First, a discrimination analysis was performed using a forward stepwise approach. Models were generated that classified outcome with greater discrimination than was obtained with any single gene alone.

According to a second approach (time-to-event approach), for each gene a Cox Proportional Hazards model (see, e.g. Cox, D. R., and Oakes, D. (1984), Analysis of Survival Data, Chapman and Hall, London, New York) was defined with time to recurrence or death as the dependent variable, and the expression level of the gene as the independent variable. The genes that have a p-value < 0.05 in the Cox model were identified. For each gene, the Cox model provides the relative risk (RR) of recurrence or death for a unit change in the expression of the gene. One can choose to partition the patients into subgroups at any threshold value of the measured expression (on the CT scale), where all patients with expression values above the threshold have higher risk, and all patients with expression values below the threshold have lower risk, or vice versa, depending on whether the gene is an indicator of good (RR>1.01) or poor (RR<1.01) prognosis. Thus, any threshold value will define subgroups of patients with respectively increased or decreased risk. The results are summarized in the following Tables 6 and 7.

25

10

15

<u>Table 6</u>

<u>Cox Model Results for 146 Patients with Invasive Breast Cancer</u>

| Gene | Relative Risk (RR) | SE Relative Risk | p value |
|-------------|--------------------|------------------|---------|
| FOXMI | 0.58 | 0.15 | 0.0002 |
| STK15 | 0.51 | 0.20 | 0.0006 |
| PRAME | 0.78 | 0.07 | 0.0007 |
| Bcl2 | 1.66 | 0.15 | 0.0009 |
| CEGP1 | 1.25 | 0.07 | 0.0014 |
| GSTM1 | 1.40 | 0.11 | 0.0014 |
| Ki67 | 0.62 | 0.15 | 0.0016 |
| PR | 1.23 | 0.07 | 0.0017 |
| Contig51037 | 0.81 | 0.07 | 0.0022 |
| NME1 | 0.64 | 0.15 | 0.0023 |
| YB-1 | 0.39 | 0.32 | 0.0033 |
| TFRC | 0.53 | 0.21 | 0.0035 |
| BBC3 | 1.72 | 0.19 | 0.0036 |
| GATA3 | 1.32 | 0.10 | 0.0039 |
| CA9 | 0.81 | 0.07 | 0.0049 |
| SURV | 0.69 | 0.13 | 0.0049 |
| DPYD | 2.58 | 0.34 | 0.0052 |
| RPS6KB1 | 0.60 | 0.18 | 0.0055 |
| GSTM3 | 1.36 | 0.12 | 0.0078 |
| Src.2 | 0.39 | 0.36 | 0.0094 |
| TGFB3 | 1.61 | 0.19 | 0.0109 |
| CDC25B | 0.54 | 0.25 | 0.0122 |
| XIAP | 3.20 | 0.47 | 0.0126 |
| CCNB1 | 0.68 | 0.16 | 0.0151 |
| IGF1R | 1.42 | 0.15 | 0.0153 |
| Chk1 | 0.68 | 0.16 | 0.0155 |
| ID1 | 1.80 | 0.25 | 0.0164 |
| p27 | 1.69 | 0.22 | 0.0168 |
| Chk2 | 0.52 | 0.27 | 0.0175 |

 63 SUBSTITUTE SHEET (RULE 26)

| EstR1 | 1.17 | 0.07 | 0.0196 |
|----------|------|------|--------|
| HNF3A | 1.21 | 0.08 | 0.206 |
| pS2 | 1.12 | 0.05 | 0.0230 |
| BAGI1 | 1.88 | 0.29 | 0.0266 |
| AK055699 | 1.24 | 0.10 | 0.0276 |
| pENT1 | 0.51 | 0.31 | 0.0293 |
| EpCAM | 0.62 | 0.22 | 0.0310 |
| WISP1 | 1.39 | 0.16 | 0.0338 |
| VEGFC | 0.62 | 0.23 | 0.0364 |
| TK1 | 0.73 | 0.15 | 0.0382 |
| NFKBp65 | 1.32 | 0.14 | 0.0384 |
| BRCA2 | 0.66 | 0.20 | 0.0404 |
| CYP3A4 | 0.60 | 0.25 | 0.0417 |
| EGFR | 0.72 | 0.16 | 0.0436 |

Table 7

Cox Model Results for 108 Patients wih ER+ Invasive Breast Cancer

| Gene | Relative Risk (RR) | SE Relative Risk | p-value |
|-------------|--------------------|------------------|---------|
| PRAME | 0.75 | 0.10 | 0.0045 |
| Contig51037 | 0.75 | 0.11 | 0.0060 |
| Blc2 | 2.11 | 0.28 | 0.0075 |
| HIF1A | 0.42 | 0.34 | 0.0117 |
| IGF1R | 1.92 | 0.26 | 0.0117 |
| FOXM1 | 0.54 | 0.24 | 0.0119 |
| EPHX1 | 0.43 | 0.33 | 0.0120 |
| Ki67 | 0.60 | 0.21 | 0.0160 |
| CDC25B | 0.41 | 0.38 | 0.0200 |
| VEGFC | 0.45 | 0.37 | 0.0288 |
| CTSB | 0.32 | 0.53 | 0.0328 |
| DIABLO | 2.91 | 0.50 | 0.0328 |
| p27 | 1.83 | 0.28 | 0.0341 |
| CDH1 | 0.57 | 0.27 | 0.0352 |
| IGFBP3 | 0.45 | 0.40 | 0.0499 |

SUBSTITUTE SHEET (RULE 26)

The binary and time-to-event analyses, with few exceptions, identified the same genes as prognostic markers. For example, comparison of Tables 4 and 6 shows that, with the exception of a single gene, the two analyses generated the same list of top 15 markers (as defined by the smallest p values). Furthermore, when both analyses identified the same gene, they were concordant with respect to the direction (positive or negative sign) of the correlation with survival/recurrence. Overall, these results strengthen the conclusion that the identified markers have significant prognostic value.

For Cox models comprising more than two genes (multivariate models), stepwise entry of each individual gene into the model is performed, where the first gene entered is pre-selected from among those genes having significant univariate p-values, and the gene selected for entry into the model at each subsequent step is the gene that best improves the fit of the model to the data. This analysis can be performed with any total number of genes. In the analysis the results of which are shown below, stepwise entry was performed for up to 10 genes.

Multivariate analysis is performed using the following equation:

In this equation, coefficients for genes that are predictors of beneficial outcome are positive numbers and coefficients for genes that are predictors of unfavorable outcome are negative numbers. The "Ct" values in the equation are Δ Cts, i.e. reflect the difference between the average normalized Ct value for a population and the normalized Ct measured for the patient in question. The convention used in the present analysis has been that Δ Cts below and above the population average have positive signs and negative signs, respectively (reflecting greater or lesser mRNA abundance). The relative risk (RR) calculated by solving this equation will indicate if the patient has an enhanced or reduced chance of long-term survival without cancer recurrence.

Multivariate gene analysis of 147 patients with invasive breast carcinoma

(a) A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for all 147 patients with invasive breast carcinoma. Genes CEGP1, FOXM1, STK15 and PRAME were excluded from this analysis. The following ten-gene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.

10

15

20

25

1. Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;

- 2. Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
- 3. GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65,

ErbB3;

- 4. PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
- 5. CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
- 10 6. TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65.
 - (b) A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for all 147 patients with invasive breast carcinoma, using an interrogation set including a reduced number of genes. The following tengene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.
 - 1. Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4 p27;
 - 2. FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- 20 3. PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
 - 4. Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1
 - 5. STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - 6. GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1,
- 25 PLAUR;
 - 7. PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - 8. CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
- TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1,
 VEGFC;
 - 10. CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS.

Multivariate analysis of patients with ER positive invasive breast carcinoma

A multivariate stepwise analysis, using the Cox Proportional Hazards Model, was performed on the gene expression data obtained for patients with ER positive invasive breast carcinoma. The following ten-gene sets have been identified by this analysis as having particularly strong predictive value of patient survival without cancer recurrence following surgical removal of primary tumor.

- 1. PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 2. Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- 3. Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
- 4. HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 5. IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
- 6. FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
- 7. EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- 8. Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- 9. CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
- 10. VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
- 11. CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
- 12. DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
- 13. p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 14. CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
- IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
 - 16. GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
 - 17. hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - 18. STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;

20

25.

19. NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;

- 20. VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- 21. EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1,

HER2;

- 22. CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
- 23. ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
- 24. FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 25. GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP,

KRT18;

26. Belx, Bel2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF.

It is noteworthy that many of the foregoing gene sets include genes that alone did not have sufficient predictive value to qualify as prognostic markers under the standards discussed above, but in combination with other genes, their presence provides valuable information about the likelihood of long-term patient survival without cancer recurrence

All references cited throughout the disclosure are hereby expressly incorporated by reference.

While the present invention has been described with reference to what are considered to be the specific embodiments, it is to be understood that the invention is not limited to such embodiments. To the contrary, the invention is intended to cover various modifications and equivalents included within the spirit and scope of the appended claims. For example, while the disclosure focuses on the identification of various breast cancer associated genes and gene sets, and on the diagnosis and treatment of breast cancer, similar genes, gene sets and methods concerning other types of cancer are specifically within the scope herein.

25

20

10

WHAT IS CLAIMED IS:

1. A method for predicting clinical outcome for a patient diagnosed with cancer, comprising

determining the expression level of one or more genes, or their expression products, selected from the group consisting of p53BP2, cathepsin B, cathepsin L, Ki67/MiB1, and thymidine kinase in a cancer tissue obtained from the patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set,

wherein a poor outcome is predicted if:

- (a) the expression level of p53BP2 is in the lower 10th percentile; or
- 10 (b) the expression level of either cathepsin B or cathepsin L is in the upper 10th percentile; or
 - (c) the expression level of any either Ki67/MiB1 or thymidine kinase is in the upper 10th percentile.
- 15 2. The method of claim 1 wherein poor clinical outcome is measured in terms of shortened survival or increased risk of cancer recurrence.
 - 3. The method of claim 2 wherein poor clinical outcome is measured in terms of shortened survival or increased risk of cancer recurrence following surgical removal of the cancer.
 - 4. The method of claim 1 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
 - 5. The method of claim 4 wherein the cancer is breast cancer.
 - 6. The method of claim 5 wherein the expression level of p53BP2 is determined.
 - 7. The method of claim 5 wherein the expression levels of cathepsin B and cathepsin L are determined.
 - 8. The method of claim 5 wherein the expression level of cathepsin L is determined.

SUBSTITUTE SHEET (RULE 26)

20

25

PCT/US03/07713

- 9. The method of claim 5 wherein the expression levels of Ki67/MiB1 and thymidine kinase are determined.
 - 10. The method of claim 5 wherein the expression level of Ki67/MiB1 is determined.
- 11. The method of claim 5 wherein the expression level of thymidine kinase is determined.
- 10 12. The method of claim 1 wherein the expression level of more than one gene, or gene product, is determined.
 - 13. The method of claim 1 wherein the expression level of more than two genes is determined.
 - 14. The method of claim 13 further comprising the step of subjecting the expression data to multivariate analysis using the Cox Proportional Hazards model.
- 15. The method of claim 1 wherein the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
 - 16. The method of claim 1 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
 - 17. The method of claim 16 wherein said RNA is fragmented.
 - 18. A method of predicting the likelihood of the recurrence of cancer following treatment in a cancer patient, comprising determining the expression level of p27, or its expression product, in a cancer tissue obtained from said patient, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein an expression level in the upper 10th percentile indicates decreased risk of recurrence following treatment.
- The method of claim 18 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer,

15

25

pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.

20. The method of claim 19 wherein the cancer is breast cancer.

5.

20

25

- 21. The method of claim 20 wherein the expression level is determined following surgical removal of cancer.
- The method of claim 20 wherein the expression level is determined using RNA
 obtained from a formalin-fixed, paraffin-embedded tissue sample.
 - 23. The method of claim 22 wherein said RNA is fragmented.
- 24. The method of claim 22 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
 - 25. A method for classifying cancer comprising, determining the expression level of two or more genes selected from the group consisting of Bcl2, hepatocyte nuclear factor 3, ER, ErbB2 and Grb7, or their expression products, in a cancer tissue, normalized against a control gene or genes, and compared to the amount found in a reference cancer tissue set, wherein (i) tumors expressing at least one of Bcl2, hepatocyte nuclear factor 3, and ER, or their expression products, above the mean expression level in the reference tissue set are classified as having a good prognosis for disease free and overall patient survival following treatment; and (ii) tumors expressing elevated levels of ErbB2 and Grb7, or their expression products, at levels ten-fold or more above the mean expression level in the reference tissue set are classified as having poor prognosis of disease free and overall patient survival following treatment.
 - 26. The method of claim 26 wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular cancer, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, and brain cancer.
 - 27. The method of claim 26 wherein the cancer is breast cancer.

WO 03/078662 PCT/US03/07713

28. The method of claim 26 wherein the expression level is determined following surgical removal of cancer.

- 29. The method of claim 26 wherein the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
 - 30. The method of claim 29 wherein said RNA is fragmented.
- 31. The method of claim 29 wherein the expression level is determined by reverse phase polymerase chain reaction (RT-PCR).
 - A method of predicting the likelihood of long-term survival of a breast cancer patient without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising determining the expression level of one or more prognostic RNA transcripts or their product in a breast cancer tissue sample obtained from said patient, normalized against the expression level of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products, wherein the prognostic transcript is the transcript of one or more genes selected from the group consisting of: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, DIABLO, CDH1, HIF1a, IGFBP3, CTSB, and Her2, wherein overexpression of one or more of FOXM1, PRAME, STK15, Ki-67, CA9, NME1, SURV, TFRC, YB-1, RPS6KB1, Src, Chk1, CCNB1, Chk2, CDC25B, CYP3A4, EpCAM, VEGFC, hENT1, BRCA2, EGFR, TK1, VDR, EPHX1, IF1A, Contig51037, CDH1, HIF1α, IGFBP3, CTSB, Her2, and pENT1 indicates a decreased likelihood of long-term survival without breast cancer recurrence, and the overexpression of one or more of Bcl2, CEGP1, GSTM1, PR, BBC3, GATA3, DPYD, GSTM3, ID1, EstR1, p27, XIAP, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, pS2, WISP1, HNF3A, NFKBp65, and DIABLO indicates an increased likelihood of long-term survival without breast cancer recurrence.
 - 33. The method of claim 32 comprising determining the expression level of at least two of said prognostic transcipts or their expression products.

15.

20

25

WO 03/078662 PCT/US03/07713

The method of claim 32 wherein the breast cancer is invasive breast carcinoma, comprising determination of the expression levels of the transcripts of the following genes, or their expression products: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2.

- 35. The method of claim 32 wherein said breast cancer is characterized by overexpression of the estrogen receptor (ER).
- 10 36. The method of claim 35 comprising determination of the expression levels of the transcripts of at least two of the following genes, or their expression products: PRAME, Bcl2, FOXM1, DIABLO, EPHX1, HIF1A, VEGFC, Ki-67, IGF1R, VDR, NME1, GSTM3, Contig51037, CDC25B, CTSB, p27, CDH1, and IGFBP3.
- The method of claim 32 wherein the expression level of one or more prognostic RNA transcripts is determined.
 - 38. The method of claim 37 wherein said RNA is isolated from a fixed, waxembedded breast cancer tissue specimen of said patient.
 - 39. An array comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, CA9, Contig51037, RPS6K1 and Her2, immobilized on a solid surface.
- 40. The array of claim 39 comprising polynucleotides hybridizing to the following genes: FOXM1, PRAME, Bcl2, STK15, CEGP1, Ki-67, GSTM1, CA9, PR, BBC3, NME1, SURV, GATA3, TFRC, YB-1, DPYD, GSTM3, RPS6KB1, Src, Chk1, ID1, EstR1, p27, CCNB1, XIAP, Chk2, CDC25B, IGF1R, AK055699, P13KC2A, TGFB3, BAGI1, CYP3A4, EpCAM, VEGFC, pS2, hENT1, WISP1, HNF3A, NFKBp65, BRCA2, EGFR, TK1, VDR, Contig51037, pENT1, EPHX1, IF1A, CDH1, HIF1α, IGFBP3, CTSB, Her2 and DIABLO, immobilized on a solid surface.

PCT/US03/07713

- 41. A method of predicting the likelihood of long-term survival of a patient diagnosed with invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:
- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
 - (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
 - (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
 - (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
- 10 (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;
 - (e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;
 - (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- 15 (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
 - (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
 - (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
 - (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
 - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - (l) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
- 25 (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
 - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
 - (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS

20

WO 03/078662 PCT/US03/07713

in a breast cancer tissue sample obtained from said patient, normalized against the expression levels of all RNA transcripts or their products in said breast cancer tissue sample, or of a reference set of RNA transcripts or their products;

- (2) subjecting the data obtained in step (a) to statistical analysis; and
- (3) determining whether the likelihood of said long-term survival has increased or decreased.
- 42. A method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor (ER)-positive invasive breast cancer, without the recurrence of breast cancer, following surgical removal of the primary tumor, comprising the steps of:
- (1) determining the expression levels of the RNA transcripts or the expression products of genes of a gene set selected from the group consisting of
 - (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
- 15 (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (e) IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, TIMP2;
 - (f) FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, cyclinG1, BAG1;
- 25 (g) EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
 - (h) Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - (i) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP;
 - (j) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1;
 - (k) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP;
 - (l) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB;
 - (m) p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

20

- (n) CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, p27;
- (o) IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF;
- (p) GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC;
- (q) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
- (r) STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1;
- (s) NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG;
- (t) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1;
- (u) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, HER2;
 - (v) CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa;
 - (w) ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP;
 - (x). FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN;
- 15 (y) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, EBXO5, CA9, CYP, KRT18; and
 - (z) Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1, HBEGF;
 - (2) subjecting the data obtained in step (1) to statistical analysis; and
 - (3) determining whether the likelihood of said long-term survival has increased or decreased.
 - 43. The method of claim 41 or claim 42 wherein said statistical analysis is performed by using the Cox Proportional Hazards model.
 - 44. An array comprising polynucleotides hybridizing to a gene set selected from the group consisting of
 - (a) Bcl2, cyclinG1, NFKBp65, NME1, EPHX1, TOP2B, DR5, TERC, Src, DIABLO;
 - (b) Ki67, XIAP, hENT1, TS, CD9, p27, cyclinG1, pS2, NFKBp65, CYP3A4;
- 30 (c) GSTM1, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, NFKBp65, ErbB3;
 - (d) PR, NME1, XIAP, upa, cyclinG1, Contig51037, TERC, EPHX1, ALDH1A3, CTSL;

76 SUBSTITUTE SHEET (RULE 26)

20

WO 03/078662 PCT/US03/07713

(e) CA9, NME1, TERC, cyclinG1, EPHX1, DPYD, Src, TOP2B, NFKBp65, VEGFC;

- (f) TFRC, XIAP, Ki67, TS, cyclinG1, p27, CYP3A4, pS2, ErbB3, NFKBp65;
- (g) Bcl2, PRAME, cyclinG1, FOXM1, NFKBp65, TS, XIAP, Ki67, CYP3A4, p27;
- (h) FOXM1, cyclinG1, XIAP, Contig51037, PRAME, TS, Ki67, PDGFRa, p27, NFKBp65;
- (i) PRAME, FOXM1, cyclinG1, XIAP, Contig51037, TS, Ki6, PDGFRa, p27, NFKBp65;
- 10 (j) Ki67, XIAP, PRAME, hENT1, contig51037, TS, CD9, p27, ErbB3, cyclinG1;
 - (k) STK15, XIAP, PRAME, PLAUR, p27, CTSL, CD18, PREP, p53, RPS6KB1;
 - (1) GSTM1, XIAP, PRAME, p27, Contig51037, ErbB3, GSTp, EREG, ID1, PLAUR;
 - (m) PR, PRAME, NME1, XIAP, PLAUR, cyclinG1, Contig51037, TERC, EPHX1, DR5;
 - (n) CA9, FOXM1, cyclinG1, XIAP, TS, Ki67, NFKBp65, CYP3A4, GSTM3, p27;
 - (o) TFRC, XIAP, PRAME, p27, Contig51037, ErbB3, DPYD, TERC, NME1, VEGFC; and
- 20 (p) CEGP1, PRAME, hENT1, XIAP, Contig51037, ErbB3, DPYD, NFKBp65, ID1, TS,

immobilized on a solid surface.

- 45. An array comprising polynucleotides hybridizing to a gene set selected from the group consisting of
 - (a) PRAME, p27, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;
 - (b) Contig51037, EPHX1, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, CYP2C8;
- 30 (c) Bcl2, hENT1, FOXM1, Contig51037, cyclinG1, Contig46653, PTEN, CYP3A4, TIMP2, AREG;
 - (d) HIF1A, PRAME, p27, IGFBP2, TIMP2, ILT2, CYP3A4, ID1, EstR1, DIABLO;

77
SUBSTITUTE SHEET (RULE 26)

IGF1R, PRAME, EPHX1, Contig51037, cyclinG1, Bcl2, NME1, PTEN, TBP, (e) TIMP2; FOXM1, Contig51037, VEGFC, TBP, HIF1A, DPYD, RAD51C, DCR3, **(f)** cyclinG1, BAG1; EPHX1, Contig51037, Ki67, TIMP2, cyclinG1, DPYD, CYP3A4, TP, AIB1, (g) CYP2C8; Ki67, VEGFC, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1; (h) CDC25B, Contig51037, hENT1, Bcl2, HLAG, TERC, NME1, upa, ID1, CYP; (i) VEGFC, Ki67, VDR, GSTM3, p27, upa, ITGA7, rhoC, TERC, Pin1; (i) CTSB, PRAME, p27, IGFBP2, EPHX1, CTSL, BAD, DR5, DCR3, XIAP; (k) DIABLO, Ki67, hENT1, TIMP2, ID1, p27, KRT19, IGFBP2, TS, PDGFB; **(l)** p27, PRAME, IGFBP2, HIF1A, TIMP2, ILT2, CYP3A4, ID1, EstR1, (m) DIABLO; CDH1; PRAME, VEGFC; HIF1A; DPYD, TIMP2, CYP3A4, EstR1, RBP4, (n) p27; 15 IGFBP3, PRAME, p27, Bcl2, XIAP, EstR1, Ki67, TS, Src, VEGF; (o) · GSTM3, PRAME, p27, IGFBP3, XIAP, FGF2, hENT1, PTEN, EstR1, APC; (p) hENT1, Bcl2, FOXM1, Contig51037, CyclinG1, Contig46653, PTEN, (q) CYP3A4, TIMP2, AREG; STK15, VEGFC, PRAME, p27, GCLC, hENT1, ID1, TIMP2, EstR1, MCP1; 20 **(r)**. NME1, PRAM, p27, IGFBP3, XIAP, PTEN, hENT1, Bcl2, CYP3A4, HLAG; (s) VDR, Bcl2, p27, hENT1, p53, PI3KC2A, EIF4E, TFRC, MCM3, ID1; - (t) EIF4E, Contig51037, EPHX1, cyclinG1, Bcl2, DR5, TBP, PTEN, NME1, (u) HER2; CCNB1, PRAME, VEGFC, HIF1A, hENT1, GCLC, TIMP2, ID1, p27, upa; (v) 25 ID1, PRAME, DIABLO, hENT1, p27, PDGFRa, NME1, BIN1, BRCA1, TP; (w) FBXO5, PRAME, IGFBP3, p27, GSTM3, hENT1, XIAP, FGF2, TS, PTEN; (x) GUS, HIA1A, VEGFC, GSTM3, DPYD, hENT1, FBXO5, CA9, CYP, (y) KRT18; and Bclx, Bcl2, hENT1, Contig51037, HLAG, CD9, ID1, BRCA1, BIN1,

immobilized on a solid surface.

HBEGF,

(2)

WO 03/078662 PCT/US03/07713

Overall FPET/RT-PCR Flow Chart






FIGURE 1




2/9
SUBSTITUTE SHEET (RULE 26)




3/9 SUBSTITUTE SHEET (RULE 26)

RT-PCR (one-step or two-step)




4/9
SUBSTITUTE SHEET (RULE 26)



WO 03/078662 PCT/US03/07713

Estrogen Receptor Comparison




- Impath Prognostic Grouping: Unfavorable
 Impath Prognostic Grouping: Favorable

FIGURE 6

WO 03/078662 PCT/US03/07713

Progesterone Receptor Comparison



- Impath Prognostic Grouping: Unfavorable Impath Prognostic Grouping: Favorable

FIGURE 7

7/9 SUBSTITUTE SHEET (RULE 26)

Gene Specific Amplication of RNA for Taqman Expression Profiling Test of Concept





Figure 8

8/9 SUBSTITUTE SHEET (RULE 26)

Ct Distribution by Gene



9/9

SEQUENCE LISTING

| <pre><110> GENOMIC HEALTH Baker, Joffre B. Cronin, Maureen T Kiefer, Michael C Shak, Steve Walker, Michael C</pre> | • | |
|--|-----------------------------|---------------------------|
| | PROFILING IN BIOPSIED TUMOR | TISSUES |
| <130> 39740-0001PCT | | |
| <140> to be assigned <141> 2003-03-12 | | |
| <150> US 60/412,049 <151> 2002-09-18 | | |
| <150> US 60/364,890 <151> 2002-03-13 | | |
| <160> 384 | | |
| <170> FastSEQ for Wind | ows Version 4.0 | |
| <210> 1 <211> 18 <212> DNA <213> Homo sapiens | | |
| <400> 1 gtcccaggag cccatcct | | 18 |
| <210> 2 <211> 19 <212> DNA <213> Homo sapiens | | |
| <400> 2 cccggctgtt gtctccata | | 19 |
| <210> 3 <211> 68 <212> DNA <213> Homo sapiens | | |
| <400> 3 gtcccaggag cccatcctgt cagccggg | ttgactgcag cattgctgag aacat | tgcct atggagacaa 60 68 |
| <210> 4 <211> 18 <212> DNA <213> Homo sapiens | | |
| <400> 4 tcatggtgcc cgtcaatg | | 18 |
| <210> 5 <211> 23 <212> DNA <213> Homo sapiens | | |
| <400> 5 cgattgtctt tgctcttcat | gtg Page 1 | 23 |

| <210> 6 <211> 79 <212> DNA <213> Homo | sapiens | | |
|--|--|---|----------|
| <400> 6 tcatggtgcc tgaagagcaa | | gtgatggcga tgaagaccaa gacgtatcag gtggcccaca | 60 79 |
| <210> 7 <211> 20 <212> DNA <213> Homo | sapiens | | |
| <400> 7 aggggatgac | ttggacacat | | 20 |
| <210> 8 <211> 20 <212> DNA <213> Homo | sapiens | | • |
| <400> 8 aaaactgcat | ggctttgtca | | 20 |
| <210> 9 <211> 65 <212> DNA <213> Homo | sapiens | | |
| <400> 9 aggggatgac gttt | ttggacacat | ctgccattcg acatgactgc aattttgaca aagccatgca | 60 65 |
| <210> 10 <211> 22 <212> DNA | | | |
| <213> Homo | sapiens | | |
| <400> 10 | sapiens gatctacttc | ct | 22 |
| <400> 10 | gatctacttc | ct | 22 |
| <400> 10 tcatcctggc <210> 11 <211> 20 <212> DNA <213> Homo <400> 11 | gatctacttc | ct | 22 |
| <400> 10 tcatcctggc <210> 11 <211> 20 <212> DNA <213> Homo <400> 11 | gatctacttc sapiens gaatcagcaa | ct | |
| <400> 10 tcatcctggc <210> 11 <211> 20 <212> DNA <213> Homo <400> 11 ccgttgagtg <210> 12 <211> 91 <212> DNA <213> Homo <400> 12 tcatcctggc | gatctacttc sapiens gaatcagcaa sapiens gatctacttc | ctctggcaga acctaggtcc ctctgtcctg gctggagtcg | 20 |
| <400> 10 tcatcctggc <210> 11 <211> 20 <212> DNA <213> Homo <400> 11 ccgttgagtg <210> 12 <211> 91 <212> DNA <213> Homo <400> 12 tcatcctggc | gatctacttc sapiens gaatcagcaa sapiens gatctacttc | ctctggcaga acctaggtcc ctctgtcctg gctggagtcg | 20 |

Page 2

| < < | 210> 1 211> 2 212> 1 213> F | 20 DNA | sapiens | | | 3, 10 0 | | | | • • • • • • • • • • • • • • • • • • • | |
|--------|---|-------------|------------------------|---------------------------------------|------------------|----------------|--------|---------|--------|---------------------------------------|-------------|
| | 400> 3 gagcco | | gagagaagat | | | | | 1. s.e. | • • • | | 20 |
| < | 210> 3 211> (212> (213> (| 66 DNA | sapiens | | | | | | | | |
| a | 400> gcgcc gctct | tgga | atctacaact | cgga | gtccag | tgtttt | ccca c | ttgtcat | ct tct | ctccagg | 60 66 |
| ` < | <pre><210></pre> <pre><211></pre> <pre><212></pre> <pre><213></pre> | 24 DNA | sapiens | · · · · · · · · · · · · · · · · · · · | | | | * | | | |
| ç | <400> gcccag | 16 agaa | ggtctatga | a ctca | | | | | · • | 0)0 | 24 |
| 4 | <210> <211> <212> <213> | 22 DNA | sapiens | | | | | | | | • • • |
| 9 | <400> gttca | 17 aagg | cttggtgga | t tt. | | | | | · | | 22 |
| | <210> <211> <212> <213> | 94 DNA | sapiens | | | | | | | | |
| | <400> gcccag cctcct | aggaa | ggtctatga tgaaatcca | a ctca c caag | tgcgag cctttg | catgtt aaac | ggca g | gtggaat | ccc tc | tgaccgg | 5 60 94 |
| | <210> <211> <212> <213> | 21 DNA | sapiens | | | | | | | | * |
| | <400> cgcag | | ctgagtato | t g | | | | | | | 21 |
| | <210> <211> <212> <213> | 21 DNA | sapiens | | | | | ·. | | | |
| | <400> tgccc | 20 agggc | tactctcac | et t | | | | | : : | | 21 |
| | <210> <211> <212> <213> | 80 DNA | sapiens | | · · · | . • | | | | • | |
| | <400> cgcag agtga | tgcag | ctgagtato gccctggg | ct gct ca | cagcagt | ctaat | caatg | gcagctt | cct gg | gtgcgaga | ia 60 80 |
| | <210> | · 22 | | | | | _ | | | • | |

Page 3

39740-0001PCT.txt <211> 21 <212> DNA <213> Homo sapiens <400> 22 21 cagcagatgt ggatcagcaa g <210> 23 <211> 18 <212> DNA <213> Homo sapiens <400> 23 18 gcatttgcgg tggacgat <210> 24 <211> 66 <212> DNA <213> Homo sapiens <400> 24 cagcagatgt ggatcagcaa gcaggagtat gacgagtccg gcccctccat cgtccaccgc 60 aaatgc <210> 25 <211> 20 <212> DNA <213> Homo sapiens <400> 25 20 cgcttctatg gcgctgagat <210> 26 <211> 20 <212> DNA <213> Homo sapiens <400> 26 20 tcccggtaca ccacgttctt <210> 27 <211> 71 <212> DNA <213> Homo sapiens <400> 27 cgcttctatg gcgctgagat tgtgtcagcc ctggactacc tgcactcgga gaagaacgtg 60 gtgtaccggg a <210> 28 <211> 25 <212> DNA <213> Homo sapiens <400> 28 25 ttgtctctgc cttggactat ctaca <210> 29 <211> 24 <212> DNA <213> Homo sapiens <400> 29 24 ccagcattag attctccaac ttga <210> 30 <211> 75

Page 4

<212> DNA

| <213> F | HOMO | sapiens | • | | | | |
|----------------------------------|---------------|----------------------------|---|---------------------------------------|--------------|-------------|------------|
| <400> : ttgtcte agaate | ctgc | cttggactat gctgg | ctacattccg | gaaagattgt | gtaccgtgat | ctcaagttgg | 60 75 |
| <210> <211> <212> <213> | 25 DNA | sapiens | | | | * | |
| <400> gaagga | 31 gata | aggaggatgt | tgaca | · · · · · · · · · · · · · · · · · · · | | | 25 |
| <210> <211> <212> <213> | 18 DNA | sapiens | | | | | • |
| <400> cgccac | | atccaatc | | | | | 18 |
| <210> <211> <212> <213> | 74 DNA | sapiens | | | | | |
| <400> gaagga ggatci | agata | aggaggatgt ggcg | tgacaaggca | gtgaaggccg | , caagacaggo | ttttcagatt | 60 74 |
| <210> <211> <212> <213> | 21 DNA | sapiens | • • <u>.</u> • | | | | ₩ S |
| <400> tggtg | | t tgtgccagga | ı t | | * | | 21 |
| <210> <211> <212> <213> | 22 DNA | o sapiens | | - | | | • |
| <400> gaagg | 35 cgat | c ttgttgatc | c ga | | | | 22 |
| <210> <211> <212> <213> | · 80 · DNA | o sapiens | | | | • | |
| <400> tggtg agato | aaca | t tgtgccagg a gatcgcctt | a ttcgggccc c | a cagtgggag | c agcaatttc | t tctcaccct | c 60 80 |
| <210><211><211><212><213> | > 20 > DNA | | | | | | |
| <400 ggaca | | g aatgtgtt | c | | | | 20 |
| <210: <211: <212: <213: | > 20 > DNA | A no sapiens | | Page | . 5 | | |

| <400> 38 acccactcga | tttgtttctg | | 20 |
|---|--------------------------|---|-------------|
| <210> 39 <211> 69 <212> DNA <213> Homo | sapiens | | |
| <400> 39 ggacagcagg cgagtgggt | aatgtgtttc | tccatacagg tcacggggag ccaatggttc agaaacaaat | 60 69 |
| <210> 40 <211> 27 <212> DNA <213> Homo | sapiens | | ÷ •. |
| <400> 40 tgtgagtgaa | atgccttcta | gtagtga | 27 |
| <210> 41 <211> 27 <212> DNA <213> Homo | sapiens | | : |
| <400> 41 ttgtggttcg | ttatcatact | cttctga | ; 27 |
| <210> 42 <211> 82 <212> DNA <213> Homo | sapiens | | • . |
| <400> 42 tgtgagtgaa agagtatgat | atgccttcta aacgaaccac | gtagtgaacc gtcctcggga gccgactatg actactcaga | 60 82 |
| <210> 43 <211> 19 <212> DNA <213> Homo | sapiens | | |
| <400> 43 gtctcgctcc | gtggcctta | * | 19 |
| <210> 44 <211> 24 <212> DNA <213> Homo | sapiens | * | |
| <400> 44 cgtgagtaaa | cctgaatctt | tgga | 24 |
| <210> 45 <211> 93 <212> DNA <213> Homo | sapiens | | |
| <400> 45 gtctcgctco ccagcgtact | gtggccttag ccaaagatto | g ctgtgctcgc gctactctct ctttctggcc tggaggctat c aggtttactc acg | 60 93 |
| <210> 46 <211> 20 <212> DNA | sapiens | | |

Page 6

39740-0001PCT.txt <400> 46 20 ccattcccac cattctacct <210> 47 <211> 20 <212> DNA <213> Homo sapiens <400> 47 gggaacatag acccaccaat <210> 48 <211> 66 <212> DNA <213> Homo sapiens <400> 48 ccattcccac cattctacct gaggccagga cgtctggggt gtggggattg gtgggtctat 60 gttccc <210> 49 <211> 18 <212> DNA <213> Homo sapiens <400> 49 18 ccgccgtgga cacagact <210> 50 <211> 21 <212> DNA <213> Homo sapiens <400> 50 21 ttgccgtcag aaaacatgtc a <210> 51 <211> 70 <212> DNA <213> Homo sapiens <400> 51 ccgccgtgga cacagactcc ccccgagagg tcttttccg agtggcagct gacatgtttt 60 ctgacggcaa <210> 52 <211> 25 <212> DNA <213> Homo sapiens <400> 52 25 cagatggacc tagtacccac tgaga <210> 53 <211> 24 <212> DNA <213> Homo sapiens <400> 53 24 cctatgattt aagggcattt ttcc <210> 54 <211> 73 <212> DNA <213> Homo sapiens <400> 54 cagatggacc tagtacccac tgagatttcc acgccgaagg_acagcgatgg gaaaaatgcc 60 Page 7

| • | • | ÷ | 39740-0001PCT.txt | |
|----------------------------------|-----------|--------------------------|--|-----------|
| cttaaa | tcat | agg | 39740-0001FCF, EXC | 73 |
| <210> <211> <212> <213> | 24 DNA | sapiens | | · · · |
| <400> cttttg | | actctatggg | aaca | 24 |
| <210> <211> <212> <213> | 19 DNA | sapiens | | • |
| <400> cagcgg | | agcgttcct | | 19 |
| <210> <211> <212> <213> | 70 Dna | sapiens | | |
| <400> cttttg tcaacc | tgga | actctatggg | aacaatgcag cagccgagag ccgaaagggc caggaacgct | 60 70 |
| <210> <211> <212> <213> | 24 DNA | sapiens | | • . |
| <400> ggatat | | gtggctctta | ttca | 24 |
| <210> <211> <212> <213> | 25 DNA | sapiens | | |
| <400> cttctc | | aggcagaaaa | atctt | .25. |
| <210> <211> <212> <213> | 86 Dna | sapiens | | |
| <400> ggatat caagat | ttcc | gtggctctta ctgccttgat | ttcaaactct ccatcaaatc ctgtaaactc cagagcaaat gagaag | 60 86 |
| <210> <211> <212> <213> | 23 DNA | sapiens | | |
| <400> gcagtt | | gacacaggaa | agt | 23 |
| <210> <211> <212> <213> | 21 DNA | sapiens | | |
| <400> tgcgtg | | tattttcaag | a | 21 |

Page 8

| <210> <211> <212> <213> | 77 DNA | sapiens | | | | | |
|----------------------------------|-----------|--------------------------|------------|------------|------------|------------|----------|
| <400> gcagtt gaaaat | ggaa | gacacaggaa ccacgca | agtatcccca | aattgcagat | ttatcaacgg | cttttatctt | 60 77 |
| <210> <211> <212> <213> | 20 DNA | sapiens | | | | | · · · . |
| <400> tgttt1 | | cccgggctta | | | | * | 20 |
| <210> <211> <212> <213> | 24 DNA | sapiens | * | | | | |
| <400> caaage | | agctctagca | aaag | | | | 24 |
| <210> <211> <212> <213> | 80 DNA | sapiens | | | | | |
| <400> tgttt tgcta | tgatt | cccgggctta gacagctttg | ccaggtgaga | agtgagggag | gaagaaggca | gtgtcccttt | 60 80 |
| <210> <211> <212> <213> | 20 DNA | sapiens | 1.00 | | | | • |
| <400> tcagg | | agaaatctgt | * | | | | 20 |
| <210> <211> <212> <213> | 20 DNA | sapiens | * | | | | |
| <400> ccatt | | tgatctgtgg | | | | | 20 |
| <210><211><211><212><213> | 65 Dna | sapiens | | | | | |
| <400> tcagg aatgg | gggct | agaaatctgt | tgctatgggc | ccttcaccaa | catgcccaca | gatcaactgg | 60 65 |
| <210> <211> <212> <213> | 20 DNA | sapiens | | · | | | |
| | gtgct | ttgcaagatg | · . | ~ | | | 20 |
| ~21 ∩ √ | . 71 | | | | · | | |

Page 9

| <211> 2 <212> D <213> H | NA . | apiens | | | | | | * | | |
|--|------------------------|----------------|-----------|---------|----------|---------|--------|---------|-------|-------------|
| <400> 7 aaggtaa | 1 gct g | ggtctgctg | | · · | | | | | 2 | 20 |
| <210> 7 <211> 7 <212> C <213> H | 70 DNA : | apiens | | | | | | | • | . · ·. |
| <400> 7 agttcgt agcttac | tgct t | tgcaagatg | gtgcagag | ct tta | tgaagca | gtgaag | aatg d | agcaga | ccc 6 | 50. 70 |
| <210> 7 <211> 7 <212> 1 <213> 1 | 21 DNA | sapiens | | | | | | : 0 | | |
| <400> gcatgt | 73 tcgt <u>c</u> | , gcctctaag | a | | | ÷ | 9 | | | 21 |
| <210> <211> <212> <213> | 22 DNA | sapiens | | | | | | | | |
| <400> cggtgt | 74 agat (| gcacagcttc | tc | | * | | | | | 22 : |
| <210> <211> <212> <213> | 69 DNA | sapiens | | | | | • | | | . : |
| <400> gcatgt tctaca | tcgt | ggcctctaag | atgaagg | aga cca | tcccct | gacgg | ccgag | aagctgt | gca . | 60 69 |
| <210> <211> <212> <213> | 20 DNA | sapiens | ÷ | | | *. | • | | | · . · . |
| <400> agatga | | gaaggcgctt | | • | | | | | : | 20 |
| <210> <211> <212> <213> | 21 [°] DNA | sapiens | | | · ·· | | | | ē | |
| <400> tgccto | | atcggcaact | t g | | | | | | • | 21 |
| <210> <211> <212> <213> | 65 DNA | sapiens | | | * | | • | | | |
| <400> agatga aggca | aagtg | gaaggcgct | t ttcacco | gegg ce | atcctgca | a ggcad | agttg | ccgatt | acag | 60 65 |
| <210> | 79 18 | • | | | | | | | | • |

| <212> DNA <213> Homo | sapiens | | | | | |
|---|--------------------|---------------------------------------|------------|------------|-------------|------------|
| <400> 79 tggttcccag | ccctgtgt | | | | | 18 |
| <210> 80 <211> 19 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 80 ctcctccacc | ctgggttgt | | | | | 19 |
| <210> 81 <211> 74 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 81 tggttcccag ccagggtgga | ccctgtgtcc ggag | acctccaagc | ccagattcag | attcgagtca | tgtacacaac | 60 74 |
| <210> 82 <211> 20 <212> DNA <213> Homo | sapiens | * | | | | |
| <400> 82 tcttgctggc | tacgcctctt | | | | | 20 |
| <210> 83 <211> 21 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 83 ctgcattgtg | gcacagttct | . | | | | 21 |
| <210> 84 <211> 71 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 84 tcttgctggc ccacaatgca | tacgcctctt g | ctgtccctgt | tagacgtcct | ccgtccatat | cagaactgt | g 60 71 |
| <210> 85 <211> 21 <212> DNA <213> Homo | o sapiens | | | 14 1 | | |
| <400> 85 tgagtgtccc | ccggtatct | c c | | - ' | 130 | 21 |
| <210> 86 <211> 21 <212> DNA <213> Home | o sapiens | | | • | | |
| <400> 86 cagccgctt | t cagattttc | a t | • | | · · · · · · | 21 |
| <210> 87 <211> 81 <212> DNA <213> Hom | o sapiens | · · · · · · · · · · · · · · · · · · · | Page | 11 | | |

| tg | 00> 8 agtg gaaa | tccc | ccggtatctt gaaagcggct | ccccgccctg ccaatcccga tgaaattgga aatttta g | ttg 60 81 |
|----------|----------------------------------|-------------|--------------------------|---|---------------|
| <2 <2 | 10> 0 11> 0 12> 0 13> 0 | 21 DNA | sapiens | | - |
| | 00> gaga | | cagggtcgaa | a | 21 |
| <2 <2 | 10> 11> 212> 213> | 22 DNA | sapiens | | |
| | 100> Jcgtt | | gtggtagaaa | tc | 22 |
| <2 <2 | 210> 211> 212> 213> | 65 DNA | sapiens | | |
| t | 100> ggaga gcc | 90 ctct | cagggtcgaa | aacggcggca gaccagcatg acagatttct accact | ccaa 60 65 |
| <, <, | 210> 211> 212> 213> | 21 DNA | sapiens | | |
| | 400> ggtgg | | cgaagagtta | a | 21 |
| < < | 210> 211> 212> 213> | 19 DNA | sapiens | | |
| < 9 | 400> gctc | 92 gcctc | ttccatgtc | | 19 |
| < | 210> 211> 212> 213> | 66 DNA | sapiens | | : |
| C | 400> ggtg gagc | gacca | ı cgaagagtta | a acccgggact tggagaagca ctgcagagac atggaa | gagg 60 66 |
| < | 210> 211> 212> 213> | 19 DNA | o sapiens | * | - |
| | :400> cgga | | cctcagaca | | 19 |
| < | | 23 DNA | o saniens | | |

Page 12

| <400> tctaa | 95 gtttc | ccgaggtttc | tca | | | | 23 |
|----------------------------------|--------------------------------------|-------------------|-------------|--------------|------------|------------|-------------|
| <210> <211> <212> <213> | 70 DNA | sapiens | | | | | * |
| <400> gcgga gaaac | aggt c | cctcagacat | ccccgattga | aagaaccaga | gaggctctga | gaaacctcgg | 60 70 |
| <210><211><212><213> | 22 DNA | sapiens | | | | | |
| <400> ccago | 97 tttgt | gcctgtcact | at | | | | 22 |
| <210> <211> <212> <213> | 20 DNA | sapiens | | | | | |
| <400> gggaa | . 98 itgtgg | tagcccaaga | | | ** | | 20 |
| <210><211><212><212><213> | > 71 > DNA | sapiens | | | | | * |
| <400 ccago accao | > 99 ctttgt cattcc | gcctgtcact c | attcctcatg | ccaccactgc | caacacctct | gtcttgggc | t 60 71 |
| <211: <212: | > 100 > 27 > DNA > Homo | sapiens | | | | | |
| <400 ttgc | > 100 tataac | taagtgctto | tccaaga | | | | 27 |
| <211 <212 | > 101 > 22 > DNA > Homo | sapiens | | | | | * |
| <400 gtgg | > 101 aatggo | agctcactg | t ag | | | * | . 22 |
| <211 <212 | > 102 > 73 > DNA > Homo | o sapiens | | | | | |
| ttqc | > 102 tataa jccatto | taagtgctt ccac | c tccaagacc | c caactgagtc | cccagcacct | gctacagt | ga 60 73 |
| <217 <217 |)> 103 L> 19 2> DNA 3> Home | o sapiens | | • | | 1 | |
| <400 | 0> 103 | | | Page 1 | 13 | • | |

| | | 39740-0001PCT.txt | |
|--|--------------------------|--|------------|
| aggacgcaag | gagggtttg | | 19 |
| <210> 104 <211> 21 <212> DNA <213> Homo | sapiens | | |
| <400> 104 gatgtccgcc | gagtccttac | | 21 |
| <210> 105 <211> 87 <212> DNA <213> Homo | sapiens | | - |
| <400> 105 aggacgcaag gtgctcagta | gagggtttgt aggactcggc | cactggcaga ctcgagactg taggcactgc catggcccct ggacatc | 60 87 |
| <210> 106 <211> 24 <212> DNA <213> Homo | sapiens | | |
| <400> 106 ctatatgcag | ccagagatgt | gaca | 24 |
| <210> 107 <211> 24 <212> DNA <213> Homo | sapiens | | |
| <400> 107 ccacgagttt | cttactgaga | atgg | 24 |
| <210> 108 <211> 82 <212> DNA <213> Homo | sapiens | | -: |
| <400> 108 ctatatgcag attctcagta | ccagagatgt agaaactcgt | gacagccacc gtggacagcc tgccactcat cacagcctcc | 60 82 |
| <210> 109 <211> 20 <212> DNA <213> Homo | sapiens | | |
| <400> 109 tgtcgatgga | cttccagaac | | 20 |
| <210> 110 <211> 19 <212> DNA <213> Homo | | | |
| <400> 110 attgggacag | cttggatca | | 19 |
| <210> 111 <211> 62 <212> DNA <213> Homo | sapiens | | • |
| <400> 111 tgtcgatgga at | cttccagaac | cacctgggca gctgccaaaa gtgtgatcca agctgtccca | a 60 62 |

| <210> 112 <211> 23 <212> DNA <213> Homo sa | piens | | | | | |
|---|------------------------|------------------|----------------|------------|-----------|----------|
| <400> 112 gatctaagat gg | cgactgtc (| gaa | | | | 23 |
| <210> 113 <211> 25 <212> DNA <213> Homo sa | piens | | | | | |
| <400> 113 ttagattccg tt | ttctcctc | ttctg | | | | 25 |
| <210> 114 <211> 82 <212> DNA <213> Homo Sa | apiens | | | | | |
| <400> 114 gatctaagat gg aagaggagaa aa | gcgactgtc acggaatct | gaaccggaaa aa | ccacccctac tcc | taatccc cc | gactacag | 60 82 |
| <210> 115 <211> 20 <212> DNA <213> Homo Sa | apiens | | | | | |
| <400> 115 cggtgtgaga a | gtgcagcaa | | | | | 20 |
| <210> 116 <211> 19 <212> DNA <213> Homo S | apiens | | | | | · · . |
| <400> 116 cctctcgcaa g | tgctccat | | | | | 19 |
| <210> 117 <211> 70 <212> DNA <213> Homo S | apiens | * | | | | |
| <400> 117 cggtgtgaga a ttgcgagagg | gtgcagcaa | gccctgtgcc | cgagtgtgct at | ggtctggg c | atggagcac | 60 70 |
| <210> 118 <211> 23 <212> DNA <213> Homo S | apiens | • | | | | |
| <400> 118 cggttatgtc a | tgccagata | cac | | * | | 23 |
| <210> 119 <211> 24 <212> DNA <213> Homo S | sapiens | | | · . | | · · · |
| <400> 119 gaactgagac (| cactgaaga | aagg | | | | 24 |
| <210> 120 | | | Page 15 | | | |

| <pre><400> 120 cggttatytc atgccagata cacacctcaa aggtactcc tcctcccggg aaggcaccct 60 tcctcagtg ggttcagtt c 210- 121 2211- 19 2212- DNA 2213- HOMO</pre> | | <211><212><213> | DNA . | sapiens | | 39740-0001PC | .i.txt | | |
|--|-------|-----------------|-----------------|--------------------------|-----------------|--------------|------------|------------|----------|
| <pre></pre> | | caatta | atgtc | atgccagata ggtctcagtt | cacacctcaa c | aggtactccc | tcctcccggg | aaggcaccct | 60 81 |
| 19 | | <211> <212> | 19 DNA | sapiens | | | | | |
| <pre></pre> | | | | ctctatgac | | | | | 19 |
| 19 | | <211><212> | 19 DNA | sapiens | | | | * | |
| <pre> <211- 68 <212> DNA <213> Homo sapiens <400> 123 cgtggtgccc ctctatgacc tgctgctgga gatgctggac gcccaccgcc tacatgcgcc 60 cactagcc <210> 124 <211> 20 <212> DNA <213> Homo sapiens <400> 124 tggtccatcg ccagttatca 20 <210> 125 <211> 20 <211> 20 <211> DNA <213> Homo sapiens <400> 125 tgttctagcg atcttgcttc aca 23 <210> DNA <213> Homo sapiens <400> 126 <211> 76 <212> DNA <213> Homo sapiens <400> 126 tggtccatcg ccagttatca catctgtatg cggaacctca aaagagtccc tggtgtgaag 60 caagatcgct agaaca 76 <210> 127 <211> 24 <211> 20 <210> 127 <211> 24 <211> DNA <213> Homo sapiens <400> 127 catcatgac aactttggta tcgt 24 <210> DNA <213> Homo sapiens <400> 127 catcatgac aactttggta tcgt 24 <210> DNA <213> Homo sapiens <400> 127 catcatgac aactttggta tcgt 24 <210> DNA <211> 21 <210> 128 <211> 21 </pre> | | | | cgcatgtag | * | | | | 19 |
| cgtggtgccc ctctatgacc tgctgctgga gatgctggac gcccaccgcc tacatgcgcc 68 <210> 124 <211> 20 <212> DNA <213> Homo sapiens <400> 124 tggtccatcg ccagttatca 20 <210> 125 <211> 23 <212> DNA <213> Homo sapiens <400> 125 tgttctagcg atcttgcttc aca 23 <210> 126 <211> 76 <212> DNA <213> Homo sapiens <400> 126 tggtccatcg ccagttatca catctgtatg cggaacctca aaagagtccc tggtgtgaag 60 caagatcgct agaaca 76 <210> 127 <211> 24 <212> DNA <213> Homo sapiens <400> 127 <211> 24 <212> DNA <213> Homo sapiens <400> 127 <211> 24 <212> DNA <213> Homo sapiens <400> 127 <211> 24 <212> DNA <213> Homo sapiens <400> 127 <211> 24 <212> DNA <213> Homo sapiens | : | <211><212> | 68 DNA | sapiens | | | * . | | |
| <pre><211> 20 <212> DNA <213> Homo sapiens </pre> <pre><400> 124 tggtccatcg ccagttatca</pre> | . 9 | cgtgg | tgccc | ctctatgacc | tgctgctgga | gatgctggac | gcccaccgcc | tacatgcgcc | 60 68 |
| <pre>tggtccatcg ccagttatca <210> 125 <211> 23 <212> DNA <213> Homo sapiens <400> 125 tgttctagcg atcttgcttc aca</pre> | : | <211><212> | 20 DNA | sapiens | | | | | |
| <pre><211> 23 <212> DNA <213> Homo sapiens <400> 125 tgttctagcg atcttgcttc aca</pre> | | | | ccagttatca | | | | | .,20 |
| tgttctagcg atcttgcttc aca <210> 126 <211> 76 <212> DNA <213> Homo sapiens <400> 126 tggtccatcg ccagttatca catctgtatg cggaacctca aaagagtccc tggtgtgaag 60 caagatcgct agaaca <210> 127 <211> 24 <212> DNA <213> Homo sapiens <400> 127 catccatgac aactttggta tcgt 24 <210> 128 <211> 21 | | <211> <212> | 23 DNA | sapiens | | | | | |
| <pre><211> 76 <212> DNA <213> Homo sapiens <400> 126 tggtccatcg ccagttatca catctgtatg cggaacctca aaagagtccc tggtgtgaag 60 caagatcgct agaaca 76 <210> 127 <211> 24 <212> DNA <213> Homo sapiens <400> 127 catccatgac aactttggta tcgt 24 <210> 128 <211> 21</pre> | | <400> tgtto | 125 tagcg | atcttgcttc | aca | | | | 23 |
| tggtccatcg ccagttatca catctgtatg cggaacctca aaagagtccc tggtgtgaag 60 caagatcgct agaaca 76 <210> 127 <211> 24 <212> DNA <213> Homo sapiens <400> 127 catccatgac aactttggta tcgt 24 <210> 128 <211> 21 | | <211><212> | - 76 - DNA | sapiens | | · · | *. | * | . · |
| <211> 24 <212> DNA <213> Homo sapiens <400> 127 catccatgac aactttggta tcgt <210> 128 <211> 21 | | tggto | catcg | ccagttatca agaaca | a catctgtate | g cggaacctca | aaagagtcco | tggtgtgaag | 60 76 |
| catccatgac aactttggta tcgt <210> 128 <211> 21 | | <211: <212: | > 24 > DNA | o sapiens | | * | | | |
| <211> 21 | | <400 catc | > 127 catgad | aactttggta | a tcgt | | | | . 24 |
| | | | | ÷ , | | Page 1 | L <u>6</u> | | |

| | 39740-0001PC1. CXC | |
|--|---|----------|
| <212> DNA <213> Homo | sapiens | |
| <400> 128 cagtcttctg | ggtggcagtg a 2 | 1 |
| <210> 129 <211> 74 <212> DNA <213> Homo | sapiens | |
| <400> 129 catccatgac cacccagaag | aactttggta tcgtggaagg actcatgacc acagtccatg ccatcactgc 6 actg | 60 '4 |
| <210> 130 <211> 23 <212> DNA <213> Homo | sapiens | · · · |
| <400> 130 caaaggagct | cactgtggtg tct | 23 |
| <210> 131 <211> 26 <212> DNA <213> Homo | sapiens | |
| <400> 131 gagtcagaat | ggcttattca cagatg | 26 |
| <210> 132 <211> 75 <212> DNA <213> Home | sapiens | |
| <400> 132 caaaggagc aagccattc | cactgtggtg tctgtgttcc aaccactgaa tctggacccc atctgtgaat gactc | 60 75 |
| <210> 133 <211> 20 <212> DNA <213> Hom | o sapiens | |
| <400> 133 ccatctgca | t ccatcttgtt | 20 |
| <210> 134 <211> 20 <212> DNA <213> Hom | o sapiens | |
| <400> 134 ggccaccag | g gtattatctg | 20 |
| <210> 135 <211> 67 <212> DNA <213> Hon | | |
| <400> 135 ccatctgca ggtggcc | t ccatcttgtt tgggctcccc acccttgaga agtgcctcag ataataccct | 60 67 |
| <210> 130 <211> 23 <212> DN | · · · | |

39740-0001PCT.txt <213> Homo sapiens <400> 136 cgaaaagatg ctgaacagtg aca <210> 137 <211> 20 <212> DNA <213> Homo sapiens <400> 137 tcaggaacag ccaccagtga <210> 138 <211> 73 <212> DNA <213> Homo sapiens <400> 138 cgaaaagatg ctgaacagtg acaaatccaa ctgaccagaa gggaggagga agctcactgg 60 tggctgttcc tga <210> 139 <211> 20 <212> DNA <213> Homo sapiens <400> 139 20 gagaccctgc tgtcccagaa <210> 140 <211> 23 <212> DNA <213> Homo sapiens <400> 140 23 ggttgtagtc agcgaaggag atc <210> 141 <211> 76 <212> DNA <213> Homo sapiens <400> 141 gagaccetge tgtcccagaa ccagggagge aagacettca ttgtgggaga ccagatetee 60 ttcgctgact acaacc <210> 142 <211> 20 <212> DNA <213> Homo sapiens -<400> 142 20 cccactcagt agccaagtca <210> 143 <211> 20 <212> DNA <213> Homo sapiens <400> 143 20 cacgcaggtg gtatcagtct <210> 144 <211> 73 <212> DNA <213> Homo sapiens

Page 18

| | | |) 3 / 40 - 000 IF C | III CAC. | • | |
|--|--------------------------|---------------------|---------------------|------------|------------|----------|
| <400> 144 cccactcagt taccacctgc | | caatgtttgg | aaaacagccc | gtttacttga | gcaagactga | 60 73 |
| <210> 145 <211> 24 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 145 catcaaatgt | cagccctgga | gttc | (40) | | | 24 |
| <210> 146 <211> 26 <212> DNA <213> Homo | sapiens | • | | • | | |
| <400> 146 ttcctgtagg | tctttacccc | gatagc | -0.0 | | | 26 |
| <210> 147 <211> 85 <212> DNA <213> Homo | sapiens | | | | * | |
| <400> 147 catcaaatgt | cagccctgga aaagacctac | gttccatgat aggaa | accacacgaa | cacagctttt | tgccttcgag | 60 85 |
| <210> 148 <211> 24 <212> DNA <213> Homo | sapiens | (4) | , e | | | • : |
| <400> 148 tccaggatgt | : taggaactgt | gaag | | | | 24 |
| <210> 149 <211> 22 <212> DNA <213> Homo | o sapiens | | • | · .· | , | |
| <400> 149 gcgtgtctg | gtagtagct <u>c</u> | , tt | | | | 22 |
| <210> 150 <211> 73 <212> DNA <213> Home | o sapiens | • | | | | • . |
| <400> 150 tccaggatg tacgcagac | t taggaactg a cgc | t gaagatggaa | ı gggcatgaaa | ccagcgactg | gaacagcta | 60 73 |
| <210> 151 <211> 23 <212> DNA <213> Home | | | | | | - |
| <400> 151 aacgactgc | t actccaagc | t caa | | • | | 23 |
| <210> 152 <211> 22 <212> DNA <213> Hom | | | | | | |
| <400> 152 | · | | Page 1 | 19 | · | |

| | | | • | 307/0_0001 b/ | ~T +v+ | | |
|----------------------------------|-----------|----------------------|------------|---------------|-------------|------------|----------|
| ggattt | ccat | cttgctcacç | | 39740-0001P0 | | | 22 |
| <210> <211> <212> <213> | 76 DNA | sapiens | - | | | | |
| | tgct | actccaagct aaatcc | caaggagctg | gtgcccagca | tecccagaa | caagaaggtg | 60 76 |
| <210> <211> <212> <213> | 21 DNA | sapiens | | | | | |
| <400> tccgga | | tgatctaagg | a , | | · · · · · · | • | 21 |
| <210> <211> <212> <213> | 20 DNA | sapiens | | | | | |
| <400> cggaca | | gagctgactt | , | | | | 20 |
| <210> <211> <212> <213> | 76 Dna | sapiens | | | | | |
| <400> tccgga cagctc | gctg | tgatctaagg tgtccg | aggctggaga | tgtattgcgc | acccctcaag | cctgccaagt | 60 76 |
| <210> <211> <212> <213> | 17 DNA | sapiens | | | | | |
| <400> acgcac | | tgtctga | | | | | 17 |
| <210> <211> <212> <213> | 24 DNA | sapiens | | | • | | |
| <400> tgccct | | tgatgatgat | tatc | • | | | 24 |
| <210> <211> <212> <213> | 68 Dna | sapiens | | | | | |
| <400> acgcac aaaggg | cggg | tgtctgatcc | caagttccac | cccctccatt | caaagataat | catcatcaag | 60 68 |
| <210> <211> <212> <213> | 22 DNA | sapiens | | · | | | |
| <400> ccattc | | tgtgtaacag | ga | Page 20 |) | | 22 |

| | | • | | | | |
|--|--------------------------|------------------------|------------|------------|------------|----------|
| <210> 161 <211> 21 <212> DNA <213> Homo S | sapiens | | | | | |
| <400> 161 ccgaccctct a | aggttaaggc | a | | | | 21 |
| <210> 162 <211> 68 <212> DNA <213> Homo S | sapiens | | | | | |
| <400> 162 ccattcaccc 1 agggtcgg | tgtgtaacag | gaccccaagg | acctgcctcc | ccggaagtgc | cttaacctag | 60 68 |
| <210> 163 <211> 20 <212> DNA <213> Homo 9 | sapiens | | | | | |
| <400> 163 cgtcaggacc | caccatgtct | | | • | 0.0 | 20 |
| <210> 164 <211> 24 <212> DNA <213> Homo 9 | sapiens | | | | | |
| <400> 164 ggttaattgg | tgacatcctc | aaga | | | | 24 |
| <210> 165 <211> 81 <212> DNA <213> Homo | sapiens | | | * | | |
| <400> 165 cgtcaggacc tgaggatgtc | | | gcggccgaga | catggcttgg | ccacagctct | 60 81 |
| <210> 166 <211> 23 <212> DNA <213> Homo | sapiens | | | | | • |
| <400> 166 caaacgctga | catgtacggt | cta | • | • | | 23 |
| <210> 167 <211> 18 <212> DNA <213> Homo | sapiens | | | · . | | . * |
| <400> 167 gctcgttggc | gcactctt | | , | * | | 18 |
| <210> 168 <211> 88 <212> DNA <213> Homo | sapiens | <i>:</i> | | | | |
| <400> 168 caaacgctga cagttggagg | catgtacggt aagagtgcgc | ctatgccatt caacgagc | cctccccgc | atcacatcca | ctggtattgg | 60 88 |

22

39740-0001PCT.txt <210> 169 <211> 25 <212> DNA <213> Homo sapiens <400> 169 gaggcaactg cttatggctt aatta <210> 170 <211> 18 <212> DNA <213> Homo sapiens <400> 170 18 ggcactcggc ttgagcat <210> 171 <2**11**> 75 <212> DNA <213> Homo sapiens <400> 171 gaggcaactg cttatggctt aattaagtca gatgcggcca tgactgtcgc tgtaaagatg 60 ctcaagccga gtgcc <210> 172 <211> 18 <212> DNA <213> Homo sapiens <400> 172 18 gtccccggga tggatgtt <210> 173 <211> 25 <212> DNA <213> Homo sapiens <400> 173 gatcagtcaa gctgtctgac aattg 25 <210> 174 <211> 79 <212> DNA <213> Homo sapiens <400> 174 gtccccggga tggatgtttt gccaagtcat tgttggataa gcgagatggt agtacaattg 60 tcagacagct tgactgatc 79 <210> 175 <211> 21 <212> DNA <213> Homo sapiens <400> 175 21 cgaggattgg ttcttcagca a <210> 176 <211> 22 <212> DNA <213> Homo sapiens <400> 176

Page 22

<210> 177 <211> 73

actctgcacc agctcactgt tg

| | • | | 39740-0001PC | ı.txt | | |
|--|----------------------------|--------------------------|--------------|------------|-------------|------------|
| <212> DNA <213> Homo | sapiens | | | | | |
| <400> 177 cgaggattgg gctggtgcag | ttcttcagca agt | agacagagga | actgaaccgc | gaggtggcca | ccaacagtga | 60 73 |
| <210> 178 <211> 20 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 178 tcagtggaga | aggagttgga | *. *. | | | | 20 |
| <210> 179 <211> 20 <212> DNA <213> Homo | sapiens | | | - | | |
| <400> 179 tgccatatcc | agaggaaaca | | | | | 20 |
| <210> 180 <211> 69 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 180 tcagtggaga gatatggca | aggagttgga | ı ccagtcaaca | tctctgttgt | cacaagcagt | gtttcctctg | 60 69 |
| <210> 181 <211> 26 <212> DNA <213> Homo | o sapiens | | | | | |
| <400> 181 gtacaagaga | a gaaccagac | t ccaatg | | | | 26 |
| <210> 182 <211> 18 <212> DNA <213> Hom | | * | | * | | 8 |
| <400> 182 gtgtagccc | g cggacact | * | · . | • | | 18 |
| <210> 183 <211> 87 <212> DNA <213> Hom | | · | | | | Y. |
| <400> 183 gtacaagag gcattacco | a gaaccagac a gtgtccgcg | t ccaatgtca g gctacac | t tgtggtgga | tggctgtca | c gggctcagg | a 60 87 |
| <210> 184 <211> 22 <212> DNA <213> Hon | • | • | | ۰ | · | |
| <400> 184 gacatttco | t ca gtcctgcag | gt ca | | | | 22 |
| <210> 18! <211> 20 <212> DN/ | • | | Page | 23 | | |

| <213> | Homo | sapiens | • . • | | | | |
|----------------------------------|------------|--------------------------|--------------------------|--------------------------|-----------------|------------|-----------|
| <400> ctccga | | acacatttgt | w. | 0 | | | 20 |
| <210> <211> <212> <213> | 86 DNA | sapiens | | | | | |
| | tcca | gtcctgcagt atgtgtgcga | caatgcctct tcggag | ctgccccacc | ctttgttcag | tgtggctggt | 60 86 |
| <210> <211> <212> <213> | 24 DNA | sapiens | | | | | |
| <400> gttttg | | aaatgtgttc | ttca | | * | | 24 |
| <210> <211> <212> <213> | 26 DNA | sapiens | | | | | |
| <400> ttctct | | cactgccgtc | ttaagg | | | | 26 |
| <210> <211> <212> <213> | 101 DNA | sapiens | | | | | |
| <400> gttttg gctctg | gagg | aaatgtgttc ccctccctta | ttcagtgcac agacggcagt | agaatgcagc gtattagaga | aaaacagcca a | tctgataaat | 60 101 |
| <210> <211> <212> <213> | 22 DNA | sapiens | ÷ | ÷ | | | |
| <400> acgaga | | gggcatctat | gt | * | | . • | 22 |
| <210> <211> <212> <213> | 22 DNA | sapiens | • | | | | . 7 |
| <400> gcatg | | gcttccaatc | ac | | | | 22 |
| <210> <211> <212> <213> | 75 DNA | sapiens | | · · · . | | | ·· |
| | aacga | gggcatctat catgc | gtgcaggatg | tcaagaccgg | aaaggtgcgc | gctgtgattg | 60 75 |
| <210><211><212><213> | 21 DNA | sapiens | | · | · | | |

| <400> 193 tccctccact cggaaggact | a | | | 2 | 21 |
|---|--------------------|------------|--------------|--------------|----------|
| <210> 194 <211> 22 <212> DNA <213> Homo sapiens | | | | | |
| <400> 194 cggttgttgc tgatctgtct | ca | | | | 22 |
| <210> 195 <211> 84 <212> DNA <213> Homo sapiens | | 7 | | | |
| <400> 195 tccctccact cggaaggact cctgagacag atcagcaaca | atcctgctgc accg | caagagggtc | aagttggaca | gtgtcagagt | 60 84 |
| <210> 196 <211> 19 <212> DNA <213> Homo sapiens | | | | | |
| <400> 196 ttgttggtgt gccctggtg | | | | | 19 |
| <210> 197 <211> 21 <212> DNA <213> Homo sapiens | | | | | |
| <400> 197 tgggttctgt ccaaacact | g g | | | | 21 |
| <210> 198 <211> 67 <212> DNA <213> Homo sapiens | 7 | | | | |
| <400> 198 ttgttggtgt gccctggtg gaaccca | c cgtggtggc | gtcactccct | t ctgctgccag | ı tgtttggaca | 60 67 |
| <210> 199 <211> 20 <212> DNA <213> Homo sapiens | . : | | * | | |
| <400> 199 actgaaggag acccttgga | ag | | | | 20 |
| <210> 200 <211> 20 <212> DNA <213> Homo sapiens | | | | | |
| <400> 200 taaataaccc tgcccaca | ca | | | | 20 |
| <210> 201 <211> 62 <212> DNA <213> Homo sapiens | | | | | |
| <400> 201 | | . Dage | 25 | | |

| | - ' | 39740-0001PCT.txt | | |
|--|-------------------------|----------------------------------|------------|------------|
| actgaaggag ta | acccttggag | cctaggggca tcggcaggag agtgtgtggg | cagggttatt | 60 62 |
| <210> 202 <211> 28 <212> DNA <213> Homo | sapiens | | | |
| <400> 202 agttactaaa | aaataccacg | aggtcctt | | 28 |
| <210> 203 <211> 21 <212> DNA <213> Homo | sapiens | | | |
| <400> 203 gtcggtgagt | gatttgtgca | a | | 21 |
| <210> 204 <211> 79 <212> DNA <213> Homo | sapiens | | | |
| <400> 204 agttactaaa gcacaaatca | aaataccacg ctcaccgac | aggtccttca gttgagacca aagaccggtg | tcaggggatt | 60 79 |
| <210> 205 <211> 20 <212> DNA <213> Homo | sapiens | | | . • |
| <400> 205 gggagtttcc | aagagatgga | | | 20 |
| <210> 206 <211> 20 <212> DNA <213> Homo | sapiens | | | · |
| <400> 206 cttcaaccac | cttcccaaac | | | 20 |
| <210> 207 <211> 72 <212> DNA <213> Homo | sapiens | | | |
| <400> 207 gggagtttcc aggtggttga | aagagatgga ag | ctagtgcttg gtcgggtctt ggggtctgga | gcgtttggga | a 60 72 |
| <210> 208 <211> 23 <212> DNA <213> Homo | sapiens | | | , |
| <400> 208 aggtgtcato | catcaacgto | tct | | 23 |
| <210> 209 <211> 20 <212> DNA <213> Homo | o sapiens | | | |
| <400> 209 tcccgatcae | aatgcacatg | Page 26 | | 20 |

| <210> 210 | | |
|--|---|----------|
| <211> 90 <212> DNA <213> Homo sapiens | | |
| <400> 210 aggtgtcatc catcaacgtc tacatcaccct catgtgcatt g | tctgtgaacg cagtgcagac tgtggtccgc cagggtgaga 6 gtgatcggga | 0 |
| <210> 211 <211> 24 <212> DNA <213> Homo sapiens | | ·, · · |
| <400> 211 agagccagtt gctgtagaac | tcaa 2 | 4 |
| <210> 212 <211> 21 <212> DNA <213> Homo sapiens | | |
| <400> 212 ctgggcctac acagtccttc | a | 21 |
| <210> 213 <211> 74 <212> DNA <213> Homo sapiens | | |
| <400> 213 agagccagtt gctgtagaac ctgtgtaggc ccag | tcaaatctct gctgggcaag gatgttctgt tcttgaagga | 60 74 |
| <210> 214 <211> 26 <212> DNA | | |
| <213> Homo sapiens | | |
| | aaaatc | 26 |
| <213> Homo sapiens | aaaatc | 26 |
| <213> Homo sapiens <400> 214 gaaatgactg catcgttgat <210> 215 <211> 19 <212> DNA | aaaatc | 26 19 |
| <213> Homo sapiens <400> 214 gaaatgactg catcgttgat <210> 215 <211> 19 <212> DNA <213> Homo sapiens <400> 215 | aaaatc | 26 19 |
| <213> Homo sapiens <400> 214 gaaatgactg catcgttgat <210> 215 <211> 19 <212> DNA <213> Homo sapiens <400> 215 tgccagcctg acagcactt <210> 216 <211> 78 <212> DNA <213> Homo sapiens | t aaaatccgca gaaaaaactg cccagcatgt cgccttagaa | 19 |
| <213> Homo sapiens <400> 214 gaaatgactg catcgttgat <210> 215 <211> 19 <212> DNA <213> Homo sapiens <400> 215 tgccagcctg acagcactt <210> 216 <211> 78 <212> DNA <213> Homo sapiens <400> 216 qaaatgactg catcgttgat | aaaatc | 19 |

39740-0001PCT.txt <210> 218 <211> 20 <212> DNA <213> Homo sapiens <400> 218 20 tgaactgtga ggccagagac <210> 219 <211> 68 <212> DNA <213> Homo sapiens <400> 219 gatcaacggc tacatccaga agatcaagtc gggagaggag gactttgagt ctctggcctc 60 acagttca <210> 220 <211> 19 <212> DNA <213> Homo sapiens <400> 220 19 gtggatgtgc cctgaagga <210> 221 <211> 20 <212> DNA <213> Homo sapiens <400> 221 20 ctgcggatcc agggtaagaa <210> 222 <211> 70 <212> DNA <213> Homo sapiens <400> 222 gtggatgtgc cctgaaggac aagccaggcg tctacacgag agtctcacac ttcttaccct 60 ggatccgcag <210> 223 <211> 27 <212> DNA <213> Homo sapiens <400> 223 27 tggacttcta gtgatgagaa agattga <210> 224 <211> 22 <212> DNA <213> Homo sapiens <400> 224 22 cactgcgaga tcaccacagg ta <210> 225 <211> 84 <212> DNA <213> Homo sapiens <400> 225 tggacttcta gtgatgagaa agattgagaa tgttcccaca ggccccaaca ataagcccaa 60 gctacctgtg gtgatctcgc agtg <210> 226 Page 28

| <211> 25 <212> DNA <213> Homo | sapiens | | 0 | | | .· · |
|--|------------------------------|-----------------|---------------------------------------|------------|------------|------------|
| <400> 226 tggctaagtg | aagatgacaa | tcatg | | | * | 25 |
| <210> 227 <211> 25 <212> DNA <213> Homo | sapiens | * | | | | |
| <400> 227 tgcacatato | attacaccag | ttcgt | | | | 25 |
| <210> 228 <211> 81 <212> DNA <213> Homo | o sapiens | | · · · · · · · · · · · · · · · · · · · | | | |
| <400> 228 tggctaagtgactggtgtaa | g aagatgacaa a tgatatgtgc | tcatgttgca a | gcaattcact g | taaagctgg | aaagggacga | 60 81 |
| <210> 229 <211> 23 <212> DNA <213> Home | o sapiens | | | | | |
| <400> 229 tctgcagag | t tggaagcact | cta | | | | 23 |
| <210> 230 <211> 21 <212> DNA <213> Hom | | | * | | | |
| <400> 230 gccgaggct | t ttctaccaga | a | | | · · · · · | 21 |
| <210> 231 <211> 79 <212> DNA <213> Hom | • | | | | | |
| <400> 231 tctgcagag ctggtagaa | t tggaagcact a agcctcggc | ctatggtgac | atcgatgctg | tggagctgta | tcctgccct | t 60 79 |
| <210> 232 <211> 24 <212> DNA <213> Hon | | T) . | · | • | • • | • |
| <400> 232 acgacacgt | ? :a tgccgtacag | , tact | | | | 24 |
| <210> 233 <211> 18 <212> DN/ <213> Hor | | | | | | ٠. |
| <400> 233 ccgggaaaa | 3 ac acgaagga | • . | | | | 18 |
| <210> 234 <211> 86 <212> DNA | | | | . | • | |
| | | | Page 29 | 7 | | • |

| <213> Homo | sapiens | | | | | - |
|--|--------------------------|----------------------|---------------|------------|------------|----------|
| <400> 234 acgacacgta acagctactc | tgccgtacag cttcgtgttt | tactcctgcc tcccgg | gcctcctgaa | cctcgatggc | acctgtgctg | 60 86 |
| <210> 235 <211> 19 <212> DNA <213> Homo | sapiens | | * | | | ·· . |
| <400> 235 ctgccgggat | ggcttctat | | | - | | 19 |
| <210> 236 <211> 22 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 236 ccaggttctg | gaaactgtgg | at | | | | 22 |
| <210> 237 <211> 68 <212> DNA <213> Homo | sapiens | | | | | ٠ ٠, |
| <400> 237 ctgccgggat gaacctgg | ggcttctatg | aggctgagct | ctgcccggac | cgctgcatcc | acagtttcca | 60 68 |
| <210> 238 <211> 20 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 238 ccacaagctg | aaggcagaca | • . | and the state | | | 20 |
| <210> 239 <211> 21 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 239 gcgtgcttcc | ttggtcttag | a | | # | * ** | 21 |
| <210> 240 <211> 85 <212> DNA <213> Homo | sapiens | • | | · | | |
| <400> 240 ccacaagctg caggtctaag | aaggcagaca accaaggaag | aggcccgcaa cacgc | gaagctcctg | gctgaccagg | ctgaggcccg | 60 85 |
| <210> 241 <211> 24 <212> DNA <213> Homo | sapiens | | | | | |
| <400> 241 ccattctatc | . atcaacgggt | acaa | | | | -24 |
| <210> 242 <211> 23 <212> DNA <213> Homo | sapiens | | Page 3 | 30 | | |

| <400> 242 tcagcaagtg ggaaggtgta at | .c 23 |
|---|---|
| <210> 243 <211> 75 <212> DNA <213> Homo sapiens | |
| <400> 243 ccattctatc atcaacgggt accttcccactt gctga | caaacgagt cctggccttg tctgtggaga cggattacac 60 75 |
| <210> 244 <211> 20 <212> DNA <213> Homo sapiens | |
| <400> 244 tatcgaggca ggtcatacca | 20 |
| <210> 245 <211> 20 <212> DNA <213> Homo sapiens | |
| <400> 245 taacgcttgg catcatcatt | 20 |
| <210> 246 <211> 74 <212> DNA <213> Homo sapiens | |
| <400> 246 tatcgaggca ggtcatacca t gatgccaagc gtta | gaccggaag tcaaaagttg acctggatag gctcaatgat 60 74 |
| <210> 247 <211> 19 <212> DNA <213> Homo sapiens | |
| <400> 247 ccgcaacgtg gttttctca | 19 |
| <210> 248 <211> 21 <212> DNA <213> Homo sapiens | |
| <400> 248 tgctgggttt ctcctcctgt | t 21 |
| <210> 249 <211> 81 <212> DNA <213> Homo sapiens | |
| <400> 249 ccgcaacgtg gttttctcac aacaggagga gaaacccagc | cctatggggt ggcctcggtg ttggccatgc tccagctgac 60 81 |
| <210> 250 <211> 25 <212> DNA <213> Homo sapiens | Page 21 |

Page 31

| <pre><400> 250 tcaagaccat catcac</pre> | tttc attgt | | | 25 |
|---|--|----------------------------------|------------|----------|
| <210> 251 <211> 27 <212> DNA <213> Homo sapien | . \$ | | | |
| <400> 251 ggatcaggaa gtacac | ggag tataact | | | 27 |
| <210> 252 <211> 96 <212> DNA <213> Homo sapier | ıs | | | |
| <400> 252 tcaagaccat catcac agcagttcca gttata | tttc attgtctcgg a ctcc gtgtacttcc t | cgtgcgggg cctgggcctc (gatcc | ccggtccgca | 60 96 |
| <210> 253 <211> 19 <212> DNA <213> Homo sapier | 15 | | | |
| <400> 253 gcccgaaacg ccgaat | rata | | | 19 |
| <210> 254 <211> 23 <212> DNA <213> Homo sapie | าร | * | | |
| <400> 254 cgtggctctc ttatc | ctcat gat | | | 23 |
| <210> 255 <211> 65 <212> DNA <213> Homo sapie | ns | | - | |
| <400> 255 gcccgaaacg ccgaa ccacg | tataa tcccaagcgg 1 | ttgctgcgg taatcatgag | gataagagag | 60 65 |
| <210> 256 <211> 19 <212> DNA <213> Homo sapie | ns | | | • |
| <400> 256 gccctcccag tgtgc | aaat | • | • | 19 |
| <210> 257 <211> 25 <212> DNA <213> Homo sapie | ns | | | |
| <400> 257 cgtcgatggt attag | gatag aagca | | | 25 |
| <210> 258 <211> 86 <212> DNA <213> Homo sapie | ens | | | |
| <400> 258 gccctcccag tgtgc | aaata agggctgctg | tttcgacgac accgttcgtg Page 32 | gggtcccctg | 60 |

| 39740-0001PCT.txt | |
|--|----------------|
| gtgcttctat cctaatacca tcgacg | 86 |
| <210> 259 <211> 27 <212> DNA <213> Homo sapiens | |
| <400> 259 caagctagat cagcattctc taacttg | 27 |
| <210> 260 <211> 25 <212> DNA <213> Homo sapiens | |
| <400> 260 cacatgactg ttatcgccat ctact | 25 |
| <210> 261 <211> 99 <212> DNA <213> Homo sapiens | |
| <400> 261 caagctagat cagcattctc taacttgttt ggtggagaac cattgtcata tacccg agcctggctc ggcaagtaga tggcgataac agtcatgtg | gttc 60 99 |
| <210> 262 <211> 22 <212> DNA <213> Homo sapiens | |
| <400> 262 cacaggaaca acagcatctt tc | 22 |
| <210> 263 <211> 20 <212> DNA <213> Homo sapiens | |
| <400> 263 agataagccc ctgggatcca | . 20 |
| <210> 264 <211> 75 <212> DNA <213> Homo sapiens | |
| <400> 264 cacaggaaca acagcatctt tcaccaagat gggtggcacc aaccttgctg ggact cccaggggct tatct | tggat 60 75 |
| <210> 265 <211> 21 <212> DNA <213> Homo sapiens | |
| <400> 265 ggattgctca acaaccatgc t | 21 |
| <210> 266 <211> 24 <212> DNA <213> Homo sapiens | |
| <400> 266 ggcattaaca cttttggacg ataa | . 24 |

```
<210> 267
<211> 91
<212> DNA
<213> Homo sapiens
<400> 267 ·
ggattgctca acaaccatgc tgggcatctg gaccctccta cctctggttc ttacgtctgt 60
tgctagatta tcgtccaaaa gtgttaatgc c
<210> 268
<211> 24
<212> DNA
<213> Homo sapiens
<400> 268
                                                                          24
gcactttggg attctttcca ttat
<210> 269
<211> 24
<212> DNA
<213> Homo sapiens
<400> 269
gcatgtaaga agaccctcac tgaa
<210> 270
 <211> 80
 <212> DNA
 <213> Homo sapiens
 gcacttiggg attctttcca ttatgattct ttgttacagg caccgagaat gttgtattca 60
 gtgagggtct tcttacatgc
 <210> 271
<211> 20
<212> DNA
 <213> Homo sapiens
 <400> 271
                                                                           20
 aatccaaggg ggagagtgat
 <210> 272
<211> 20
<212> DNA
 <213> Homo sapiens
 <400> 272
                                                                           20
 gtacagattt tgcccgagga
 <210> 273
<211> 72
 <212> DNA
  <213> Homo sapiens
  <400> 273
 aatccaaggg ggagagtgat gacttccata tggactttga ctcagctgtg gctcctcggg 60
  caaaatctgt ac
  <210> 274
  <211> 21
  <212> DNA
  <213> Homo sapiens
  <400> 274
                                                                            21
  tgtggacatc ttcccctcag a
  <210> 275
                                           Page 34
```

SUBSTITUTE SHEET (RULE 26)

| | 39740 00011 21. 222 | |
|--|---|-------------|
| <211> 18 <212> DNA <213> Homo sapiens | | · · · · · · |
| <400> 275 ctagcccgac cggttcgt | 18 | В |
| <210> 276 <211> 66 <212> DNA <213> Homo sapiens | | ·. |
| <400> 276 tgtggacatc ttcccctcag a ggctag | cttccctac tgagccacct tctctgccac gaaccggtcg 6 6 | 0 6 |
| <210> 277 <211> 20 <212> DNA <213> Homo sapiens | | |
| <400> 277 ctttgaaccc ttgcttgcaa | 2 | 20 |
| <210> 278 <211> 18 <212> DNA <213> Homo sapiens | | |
| <400> 278 cccgggacaa agcaaatg | | 18 |
| <210> 279 <211> 68 <212> DNA <213> Homo sapiens | | * |
| <400> 279 ctttgaaccc ttgcttgcaa gtcccggg | taggtgtgcg tcagaagcac ccaggacttc catttgcttt | 60 68 |
| <210> 280 <211> 18 <212> DNA <213> Homo sapiens | | |
| <400> 280 gcctcggtgt gcctttca | | 18 |
| <210> 281 <211> 19 <212> DNA <213> Homo sapiens | | |
| <400> 281 cgtgatgtgc gcaatcatg | | 19 |
| <210> 282 <211> 65 <212> DNA <213> Homo sapiens | | |
| <400> 282 gcctcggtgt gcctttcaac tcacg | atcgccagct acgccctgct cacgtacatg attgcgcaca | 60 65 |
| <210> 283 <211> 20 | Page 35 | |

```
<212> DNA
<213> Homo sapiens
<400> 283
ctgctgtctt gggtgcattg
<210> 284
<211> 18
<212> DNA
<213> Homo sapiens
<400> 284
                                                                                                                               18
gcagcctggg accacttg
<210> 285
<211> 71
<212> DNA
<213> Homo sapiens
<400> 285
ctgctgtctt gggtgcattg gagccttgcc ttgctgctct acctccacca tgccaagtgg 60
tcccaggctg c
<210> 286
<211> 1947
 <212> DNA
 <213> Homo sapiens
 <400> 286
 ttttccccag atatggggtt ctattcagcc atagataatc tagacagagg atttcagaat 60
 gaaaggaaaa atgtgtggag attagtccta gttcattctg agggccgact aagtggctca 120 gccagcttct tactccatct gcagttcata ctgccaaaga gctcccactt ccaaatcccc 180
aatatgaact gacagcagta actctgatac agaataatct aaattgcatc aaatggcctt
 aattcagagt ttgttaggct tatcagtatg ttgcttttaa ttggggtggg aaagtagagg gagagaaagc aagacatta ttaagcacct cgtatgtgcc aggcactatg ctaagcactt tacataagt aggattaatc cctgcaagaa tcctataaag aatgttacta gcatttacac
                                                                                                                                960
                                                                                                                                1080
 cctgctgttg caggatgcta tttgcatgtg tccccaggtg atgtttttc tttggggagt 1320 aggggtttgg cttcctcatt catcctctt gctaaaagag gagatagttg atgttgcatc 1380 taaagatgct ataaagacaat gaaagtttga tgttgtacat acctacaagt accatttttg 1440 tgcatgatta cactccactg acatcttcca agtactgcat gtgattgaat aagaaacaag 1500 aaagtgacca caccaaagcc tccctggctg gtgtacaggg atcaggtca cagtggtaca 1560 gattcaacca ccacccaggg agtgcttgca gactctgcat agatgttgct gcatgcgtcc 1620 catgtgcctg tcagaatggc agtgtttaat tctcttgaaa gaaagttatt tgctcactat 1680 ccccagcctc aaggagccaa ggaagagcca ttcacatgga aggtccgggt ctggtcagcc 1740 actctgactt tctaccaca ttaaattctc cattaccatgt cactattggt atggtaaagg ccatgatgtg tatattaagc cattactct tatggtccac atatttatt tagactctc 1860 cacagcattc atgccaatat gggattaat tgagtgt
  <210> 287
  <211> 1311
   <212> DNA
  <213> Homo sapiens
```

```
tagtcgggcg gggttgtgag acgccgcgct cagcttccat cgctgggcgg tcaacaagtg 60
<400> 287
cgggcctggc tcagcgcggg ggggcgcgga gaccgcgagg cgaccgggag cggctgggtt 120
cgggcctggc tcagcgcggg ggggcgcgga gaccgcgagg cgaccgggag cggctgggtt 120 cccggctgcg cgcccttcgg ccaggccggg agccgcgcca gtcggagcc ccggcccagc 180 gtggtccgcc tccctctcgg cgtccacctg cccggagtac tgccagcggg catgaccgac 240 ccaccagggg cgccgcccc ggcgctcgca ggcgcggat gaagaagaaa acccggcgcc 300 gctcgacccg gagcgaggag ttgacccgga gggaggagtt gaccctgagt gaggaagcga 360 gccaggaggt gacccgggac cagagtgagg aggcgaccca gggcgaagag atgaatcgga 420 ggcggagg gacccgggac gaggagtcga cccggagcga gggggtgacc agggaggaaa 480 gcgggagc tgggcgaaga aggagcac agggagcac agggagcac aggagagcac gaccttcatg 540 tggcggcagc tggacaga aggagaccaa ttgccaaga cctagccaa gtctcaac gcaagaaccaa ttgccaaga cctagcccaa gtcttcaaaa 600
<210> 288 <211> 582
  <212> DNA
  <213> Homo sapiens
  <211> 6030
    <212> DNA
    <213> Homo sapiens
   cacacacaca caacaattaa cagtcttcag gcaaaacgtc gaatcagcta tttactgcca 960 aagggaaata tcatttattt tttacattat taagaaaaaa agatttattt atttaagaca 1020 gtcccatcaa aactcctgtc tttggaaatc cgaccactaa ttgccaagca ccgcttcgtg 1080 gtcccatcac
     tggctccacc tggatgttct gtgcctgtaa acatagattc gctttccatg ttgttggccg 1140 gatcaccatc tgaagagcag acggatggaa aaaggacctg atcattgggg aagctggctt 1200 tctggctgct ggaggctggg gagaaggtgt tcattcactt gcatttcttt gccctggggg 1260
                                                                            Page 37
```

```
39740-0001PCT.txt
   ctgtgatatt aacagaggga gggttcctgt ggggggaagt ccatgcctcc ctggcctgaa 1320 gaagagactc tttgcatatg actcacatga tgcatacctg gtgggaggaa aagagttggg 1380
aaaaagttcc aggtgtggaa tatgggggtt atctgtacat cctggggcat taaaaaaaaa 2340 atcaatggtg gggaactata aagaagtaac aaaagaagtg acatcttcag caaataaact 2400 aggaaatttt tttttctcc agtttagaat cagccttgaa acattgatgg aataactctg 2460 tggcattatt gcattatata ccatttatct gtattaactt tggaatgtac tctgttcaat 2520 gtttaatgct gtggttgata tttcgaaagc tgctttaaaa aaatacatgc actctagcg cctatacact atttgtgagc aaaggtgatc 2640 gttttctgtt ttaattgtat ttagttatgg cctatacact atttgtgagc aaaggtgatc 2640 agccctgagt ctcagctacc taagaaaaac ctggatgtca ctggccactg aggagctttg 2760 tttcaaccaa gtcatgtgca tttccacgtc aacagaattg tttattgtga cagttatatc 2820 tgtgtccct ttgaccttgt ttcttgaagg tttcctcgtc cctgggcaat tccgcatta 2880 attcatggta ttcatggatta catgcatgtt tggttaaacc catgagattc attcagttaa 2940
     attcatggta ttcaggatta catgcatgtt tggttaaacc catgagattc attcagttaa 2940 aaatccagat ggcaaatgac cagcagattc aaaatctatgg tggtttgacc tttagagagt 3000 tgctttacgt ggcctgttc aacacagacc cacccagagc cetectgccc tccttccgcg 3060 ggggctttct catggctgtc cttcagggtc ttcctgaaat gcagtggtgc ttacgctcca 3120 ccaagaaagc aggaaacctg tggtatgaag ccagacctcc ccggcgggcc tcagggaaca 3180 gaatgatcag acctttgaat gattctaatt tttaagcaaa atattattt atgaaaggtt 3240 tacattgcaa aagggatgat aagggatga cagaacctg gctgctatcc tgccaaaatc 3300 aattctaatt aggaatgaa cagtafgat aagggatgaa gatcctccaa gctgctataa 3360
    actgtacttt taaggcagtg gctgttttta gactttctta tcacttatag ttagtaatgt 4500 acacctactc tatcagagaa aaacaggaaa ggctcgaaat acaagccatt ctaaggaaat 4560 taggaggagtca gttgaaattc tattctgatc ttattctgtg gtgtcttttg cagcccagac 4620 aaatgtggtt acacactttt taaggaaatac aattctacat tgtcaagctt atgaaggttc 4680
        aaatgtggtt acacactttt taagaaatac aattctacat tgtcaagctt atgaaggttc 4680 caatcagatc tttattgtta ttcaatttgg atctttcagg gattttttt ttaaattatt 4740 atgggacaaa ggacatttgt tggaggggtg ggagggagga acaattttta aatataaaac 4800 attcccaagt ttggatcagg gagttggaag ttttcagaat aaccagaact aagggtatga 4860 aggacctgta ttggggtcga tgtgatgcct ctgcgaagaa ccttgtgtga caaatgaggaa 4920 acattttgaa gtttgtggta cgacctttag attccagaga catcagcatg gctcaaagtg 4980 cagctccgtt tggcagtga atggtataaa tttcaagctg gatatgtcta atgggtattt 5040 aaacaataaa tgtgcagttt taactaacag gatattaata gacaaccttc tggttggtag 5100 ggacatcgt ttctaaatgt ttattatgta caatacagaa aaaaatttta taaaattaag 5160 caatgggaa ctgaatggaa cgaatggaa caatggaa caatgaa caatggaa ca
          caatgtgaaa ctgaattgga gagtgataat acaagtcctt tagtcttacc cagtgaatca 5220 ttctgttcca tgtctttgga caaccatgac cttggacaat catgaaatat gcatctcact 5280 ggatgcaaag aaaatcagat ggagcatgaa tggtactgta ccggttcatc tggactgccc 5340
                                                                                                                                                                                                                                                                      Page 38
```

```
39740-0001PCT.txt
cagaaaaata acttcaagca aacatcctat caacaacaag gttgttctgc ataccaagct 5400
gagcacagaa gatgggaaca ctggtggagg atggaaaggc tcgctcaatc aagaaaattc 5460
tgagactatt aataaataag actgtagtgt agatactgag taaatccatg cacctaaacc 5520 ttttgggaaaa tctgccgtgg gccctccaga tagctcattt cattaagttt ttccctccaa 5580
ttttggaaaa tctgccgtgg gccctccaga tagctcattt cattaagttt ttccctccaa 5580 ggtagaattt gcaagagtga cagtggattg catttcttt ggggaagctt tcttttggtg 5640 gttttgtta ttataccttc ttaagttttc aaccaaggtt tgcttttgt ttgagttact 5700 ggggttattt ttgttttaaa taaaaataag tgtacaataa gtgttttgt attgaaagct 5760 tttgttaca agatttcat acttttacct tccatggctc tttttaagat tgatactttt 5820 taaggtaggc tgatattctg caacactgta cacataaaaa atacggtaag gatactttac 5880 atggttagg aaaagtaaa ttgccattaa actttccttg tctgtctagt taatattgtg 6000 aaagaaaaata aagtacagt tgagatactg
 aagaaaaata aagtacagtg tgagatactg
```

```
<210> . 290
<211> 10987
<212> DNA
<213> Homo sapiens
```

| gaagaaacta | cttcaatttc | aaaaataact | gtcaatccag | actctgaaga | acttttctca | 2880 |
|------------|--|---|--|--|---|--|
| diciptuada | | | | | | |
| ualaalyaya | ataattttgt | cttccaaqta | gctaatgaaa | ggaataatct | tgctttagga | 2940 · |
| aatactaagg | aacttcatga | aacagacttg | acttqtgtaa | acgaacccat | tttcaagaac | 3000 |
| tctaccatgg | ttttatatag | agacacaggt | gataaacaag | caacccaagt | gtcaattaaa | 306U. |
| aaagatttgg | tttatottct | tacagaggag | aacaaaaata | gtgtaaagca | gcatataaaa | 3120 |
| atgactctag | atcaagattt | aaaatcqqac | atctccttga | atatagataa | aataccagaa | 3780 |
| aaaaataato | attacatoaa | caaatgggca | ggactcttag | gtccaatttc | aaatcacagt | 3240 |
| tttggaggta | gcttcagaac | agcttcaaat | aaggaaatca | agctctctga | acataacatt | 3300 |
| aagaagagca | aaatgttctt | caaagatatt | gaagaacaat | atcctactag | tttagcttgt | 3360 |
| gttgaaattg | taaatacctt | ggcattagat | aatcaaaaga | aactgagcaa | gcctcagtca | 3420. |
| attaatactg | tatctgcaca | tttacagagt | agtgtagttg | tttctgattg | taaaaatagt | 2540 |
| catataaccc | ctcagatgtt | attttccaag | caggatttta | attcaaacca | taatttaaca | 2600 |
| cctagccaaa | aggcagaaat | tacagaactt | tctactatat | tagaagaatt | ayyaayccay | 3660 |
| tttgaattta | ctcagtttag | aaaaccaagc | tacatattyc | agaagagtac | tactactet | 3720 |
| cctgaaaacc | agatgactat | cttaaagacc | coetagagg | aatytayaya | egetgatett | 3780 |
| catgtcataa | tgaatgcccc | attgattggt. | ctottasasa | ataactataa | casasatact | 3840 |
| acagttgaaa | ttaaacggaa | gritginge | ccyctyaaaa | actettete | toctcatooc | .3070 |
| tctggttatt | taacagatga | tanageteta | casasacta | tossectort | tantnatatt | 3960 |
| acaaaactga | atgitticac | ttctccccc | caaaaagctg | taantttato | ttcaantaaa | 4020 |
| gagaatatta | gtyayyaaac | antotttaag | atanaaaate | ataatuataa | aactotaant | 4080 |
| tgtcatgatt | ctgttgttt | adiyiliday | casastasta | ttnaaatnac | tactoncact | 4140 |
| gaaaaaaata | aldadiycca | actyatatta | anaaataata | aaaatnaana | taacaaatat | 4200 |
| tttgttgaag | adallaliya | testssetts | agaaatactg. | ncantnatto | aantaaaaat | 4260 |
| actgctgcca | grayaaarr | 202t0222C0 | gaacttgatg | ttactuatca | ocacaacata | 4320 |
| gatactgttt | glaticataa | ayatyaaaty | gacttyctat | ctcactgattaa | anaanattto | 4380 |
| tgtcttaaat | cttttttaa | acttacass | actcaadaan | catotcatoo | taatacttca | 4440 |
| tcagatttaa | cetteregya | tactasasco | geceaagaag | taaaanattt | tgagacttct | 4500 |
| aataaagaac | ttcaactyc | nactadaacy | aatattantn | tenecasans | otcatttaat | 4560 |
| gatacatti | atttctttaa | tcagagaga | naanaattne | ataacttttc | cttaaattct | 4620 |
| aaaattytaa | ctoscotoso | 222022022 | atonacatto | taanttatna | ggaaacagac | 4680 |
| gaactacact | cigacataay | naaanaaant | atcccaatta | otactooaaa | tcaactagto | 4740 |
| acayctaaac | acaaaacacc | acotoatoaa | aanatcaaan | aacctactct | attaoatttt | 4800 |
| catacageta | gacaacccga | anttaaaatt | ncaaannaat | ctttooacaa | agtgaaaaac | 4860 |
| ctttttata | aaaaananca | aggtactagt | gaaatcacca | attttaacca | tcaatogoca | 4920 |
| aanaccctaa | antacanana | nocctotaaa | gaccttgaat | tagcatgtga | gaccattgag | 4980 |
| atcacancta | ccccaaagta | taaagaaatg | cagaattctc | tcaataatga | taaaaacctt | 5040 |
| attacagety | agactatagt | accacctaaa | ctcttaaqtq | ataatttatg | tagacaaact | 5100 |
| gaaaatctca | aaacatcaaa | aagtatcttt | ttgaaagtta | aagtacatga | aaatgtagaa | 5160 |
| aaagaaacag | caaaaaatcc | tacaacttat | tacacaaatc | agtcccctta | ttcagtcatt | 5220 |
| gaaaattcag | ccttagcttt | ttacacaagt | tgtagtagaa | aaacttctgt | gagtcagact | 5280 |
| trattactto | aagcaaaaaa | atoocttaoa | gaaggaatat | ttgatggtca | accagaaaga | 5340 |
| ataaatacto | cagattatgt | aqqaaattat | ttqtatqaaa | ataattcaaa | cagtactata | 5400 |
| octoaaaato | acaaaaatca | tctctccqaa | aaacaagata | cttatttaag | taacagtagc | 5460 |
| atotctaaca | actattccta | ccattctgat | qaqqtatata | atgattcagg | atatctctca | 5520 |
| aaaaataaac | ttaattctaa | tattqaqcca | gtattgaaga | atgttgaaga | tcaaaaaaac | 2280 |
| actauttttt | ccaaagtaat | atccaatota | aaaqatqcaa | atgcataccc | acaaactgta | 5640 |
| aatgaagata | tttgcgttga | ggaacttgtg | actagctctt | caccctgcaa | aaataaaaat | 5/00 |
| ocaoccatta | aattotccat | atctaatagt | aataatttta | aggtagggcc | acctgcattt | 3/60 |
| aggatagcca | gtggtaaaat | cgtttgtgtt | tcacatgaaa | caattaaaaa | agtgaaagac | 5020 |
| atatttacag | acagtttcag | taaagtaatt | aaggaaaaca | acgagaataa | attaaaaatt | 5000 |
| tgccaaacga | aaattatggc | aggttgttac | gaggcattgg | atgattcaga | ggatattett | 6000 |
| cataactctc | tagataatga | tgaatgtagc | acgcattcac | ataaggitti | rgctyacate | 6060 |
| cagagtgaag | aaattttaca | acataaccaa | aatatgtctg | gattggagaa | tatagggaaa | 6120 |
| atatcacctt | gtgatgttag | tttggaaact | tcagatatat | gradaryray | Latayyyaay | 6180 |
| cttcataagt | cagtctcatc | tgcaaatact | tgtgggattt | ctaycacayc | tannataan | 6240 |
| tctgtccagg | tatcagatgc | ttcattacaa | aacgcaagac | aagtgtttt | ttcaacayaa | 6200 |
| gatagtacca | agcaagtctt | ttccaaagta | ttgtttaaaa | glaacyaaca | ccananage | 6360 |
| ctcacaagag | aagaaaatac | tgctatacgt | tteteteagaac | ttagtacanc | 220to02220 | 6420 |
| ttttcatata | atgtggtaaa | ttcatciget | -ciciciyyat | . claytatayt | nnaatttort | 6480 |
| caagtttcca | ttttagaaag | tetteret | teacetacet | gaytyttayd | totateaaaa | 6540 |
| τταατcagaa | ctgagcatag | CCCCCCCCCC | clacitatyt | . clayaladd | . Lytattaadd | 6600 |
| atacttcctc | gigitgataa | yayaaaccca a++a+caaa+ | yaycactyty | taaatttaya ttmaammtma | ttcttcanaa | 6660 |
| acctgcagta | aayaatttaa | | ctctctcaaty | ttcaacaag | casacaacaa | 6720 |
| aataatcact | cialtadagt | ctcacttatt | . CLCLCLCAAL | . cccaacaaya | . caaacaacay | 6780 |
| ttygtattag | gaaccaaagt | - cicacityEt | gayaacatt | . acycetyyy | tnathtter | 6840 |
| gerecaceta | addalyladd | . aalyyaaall | tactccaaacty | attcanaaaa | ctactttmaa | 6900 |
| yryaaaacaa | alalayadyt | Ligiticiaci | . cacticaday | , ucccuyaaaa In | . ctacticgaa | 0500 |
| raye 40 | | | | | | |
| | atgactctag aaaaataatg tttggaggta aagaagagca gttgaaaattg attataaccc cttgaaaaaccc cttgaaaatt ccatgattata ccatgttata acagttgaaatt gataaaaaaa ttgttgctgta tgttattaaa tctgaaaatta tgttgctgtat aataaaaaaaa tctgaaaatta tgttgctgtat taaaaaaaaaa | atgactctag aaaaataatg attacatgaa tttggaggta acgagaactg tttgaaattg taaatacctt cataataaccc catagccaaa tttgaattaa cctgaaaacc catgtcataa tacagctaaa tacagctaaaaacagaaaattgaaaattgaaaacagaaaacagaaacagaaacccaaaaaccgaaacccgaacattttgaag actgctgaaaat ttgttgaag actgctgcaa gagaatatta tgttgtgaag actgctgcaa gagaatatta tgttgtgaag actgctgcaa gagaatatta tgttgtgaag actgctgcaa gagaatatta tacagatttaa aaaaaaaaaa | atgactctag attaaaataatg attacatgaa atgagagaa aaaatgtctt attaatactg cttaaaattg attaataccc ctagccaaa atgcccaaa aggcagaaatt tttgaattta ccagttgaaa cctgctgcaaa acagttgaaa tctggtcataa acaaactga gagaatatta gagaaatata gagaaatata acaaactga acaaaactga actgctgcaa actgctgcaaa actgctgcaaa actgctgcaaa actgctgcaaa actgctgcaaa actgctgcaaa actgctgcaaa actgctgcaaa actgctgcaaa actgctgcaaaataaagaac actgctgcaa actgctgcaaaatact actttttgaa acaaaatact ccaaactgta acaaacccga acaacccga acaacccga acaacccga acaacccga acaacccga acaacacccga accccaaacccga accccaaacccga accccaaacccga accccaaacccga accccaaacccga accccaaacccga accccaaacccga accaacccga accaacacccga accaacccga accaacacccga accaacccga accaacccaacccga accaacccaacccga accaacccaacccga accaacacccga accaacccaacccga accaacacccga accaacacccga accaacacccga accaacacccga accaacacccga accaacacccga accaacacccga accaacacc | atgactctag gtcaagattt aaaatcggac atctccttga ataaatatg attacatgaa caaatgggca gaactctag tttggaggta gcttcagaac agcttcaaat aaggaaatca aaggaagagaca tactacattg tgcattaatactg tactocaca tttacagagt agtgatgtgcatatatacacc ctcagattgta attacaagac tctacatattttgaattta ctcagattga aaaaccaagc ctctagaaacc aggagactat tctacaagac tctctacatattttgaattta ctcagattga aaaaccaagc ctctctgaaga aggagactat tctaaagacc acagttgaaa ttaaacggaa gttgctggc cagtacataa taaaacgga gttgctggc cagtacataa taaaacgaa gttgctggc acagtagaa ttaaacggaa gttgctggc cagtacataa taaaacgaa aggagactat taaagaagac ctttgtggtatt taacaggaag aaatgaagg gggtttaggg aaaaacaaaac | atgactctag gtcaagattt aaaatgggac atctccttga gtccaatttc ttggaggta gcttcagaac agcttcaaat aaggaaatca agctctctag aagaaagagca aaatgttctt caaaagatatt gaagaaacaa atcaacaga attaatactg taatacctt ggcattagat aatcaaaaga aactgagcaa attaatactg taatacctt ggcattagat aatcaaaaga aactgagcaa attaatactg taatcgcca tttcaagat agtgatgtt tttctgattg catataaccc ctcagatgtt atttccaag caggatttta attcaacca cctagacaaa aggcagaaat tacaagaact tctactatat tagaagaatc cttgaaatta ctcagttag aaaaccaaga cacttctgagg catgtcataa tgaatgccca tttcaaagac acttctgagg actgtcataa tgaatgccca tctgattggi caggtagaca gcagaagca caggttgaaa ttaaacggaa gttgctggc cacagttgaaa ttaaacggaa gttgctggc acaggttgaaa ttaaacggaa gttgctggc cacagttgaaa ttaaacggaa gttgctggc cagaaactga ttgttctac tgaagcttg agaaaataa tgaaggaact tctgcaagag catgtcatat tgttgtgttc aatgtatgac ggaaaataa gtgaggaact tcttgcagag gtacaactga gaaaaaaaaaa ataaatgcca acttgtgagg ggcttgagg acttgtgag aaattactga aaattacaga gaaaatactg aaaatgaaga acttgttgag aaattactga aaattacaga gaaaatactg aaaatgaaga acttgctgcca gtagaaattc tcataacta gaatttgag aattacatt ttttgga gttatgaag aattacatt ttcagacca gtttatgaag aattacattt ctaaaacg gaagaaacaa ctcagattaa tgatactatta ctttttgga agtgaaacaa gccagaagaa actggataaa atttctttga agtgaaacaa gaaaaaaaaa aattacatt ttaaagacg agtgaaacaa gaaaaaaaaa aattacatt ttaaaacg aagaaacaaa atgaagaaca aacttttagaa gaaaatacaa gaaaataaa taaaagacta gaatacattt cgaaaacaaa aggtgaaaaaaaaaaaaa | atqactctag gtcaagattt aaaatcggac gtctcttgga chaafactagat aafaccagat tttggaggtg gtctcaagttc aaatcacagtt tttggaggtg gtctcaagtc aaatgttctt caaagatat gaggaacata agcttcttga cataacattt aagagaagaca aaatgttctt caaagatat gaggaacata atctactaag tttggttgaatttg tactgcaca tttactacagat gtgtaagttg tttctgaattg tactgcaca gaggaacata tacgaacaa aggcagaatt acagaacat ttcacagatt gttaattacct ctcagcaaa aggcagaatt atcacagat gaggatttta atcaacaca aggcagaatt acagaacat tactacacattgaattta ctcagtttag aaaaccaagc tacatattgc agaagaaca aggcagaaat tacagagaa gttgcagattt ctcagattagt caggttgaattc ctcagattagatt |

```
acagaagcag tagaaattgc atgacacaa ttctctttt atgaagagag atgaactgac aagaattggaa aagaagagga gaagccctta tcttagtggg aagaaccctca 7080 aagaccctca 7080 
                                                                                                                                                                                                      39740-0001PCT.txt
      gaagattatt ttggtaagga aagtttatgg actggaaaag gaatacagtt ggctgatggt 7980 ggatggctca taccctccaa tgatggaaag gctggaaaag aagaatttta tagggctctg 8040 tgggacactc caggtgtgga tccaaagctt attctagaa tttgggtta taatcactat 8100
   ttacaatcaa caaaatggtc atccaaactc aaacttgaga aaatatcttg ctttcaaatt 10980
                                                                                                                                                                                                                                                    Page 41
```

```
gacacta
```

10987

```
<210> 291
<211> 1552
 <212> DNA
 <213> Homo sapiens
gcccgtacac accgtgtgct gggacacccc acagtcagcc gcatggctcc cctgtgcccc 60
 <211> 1578
  <212> DNA
  <213> Homo sapiens
 <400> 292
  cctttgcact tccttcggag agcatctaag attggagagg ttgatgtcga gcaacatact 1140 ttggccaaat acctgatgga actaactatg ttggactatg acatggtgca ctttcctcct 1200 tctcaaattg cagcaggagc ttttgctta gcactgaaaa ttctggataa tggtgaatgg 1260 acaccaactc tacaacatta cctgtcatat actgaagaat ctcttctcc agttatgcag 1320
  cacctggcta agaatgtagt catggtaaat caaggactta caaagcacat gactgtcaag 1380 aacaagtatg ccacatcgaa gcatgctaag atcagcactc taccacagct gaattctgca 1440 ctagttcaag atttagccaa ggctgtggca aaggtgtaac ttgtaaactt gagttggagt 1500
                                                         Page 42
```

```
aaaaaaaaa aaaaaaaa
<210> 293
<211> 3195
<212> DNA
 <213> Homo sapiens
cagagacccagctcggcccccgacctgatgtgtctcagtcctgaccggaagatggaagtg1020gaggaagccagccccttggccctaggtcgcttctctctgacgggagatcttaaaggatgatgagtgaagtt1080ccccaggcatggaagatttgggacatcctagagagtgacttaaaaggatgatgatgagatga1200gaaaaggactcgtcatgtacagcaagtgccactggtcatccgctctcc1260gacagcgtgatccggccatcctcaaagaggctggagcggccctctgagaggacagcgagcggctgagaataagcggaggggagggtgacccctctgaggggacagcagaaggggacagcggaaggggacagcggaagggacagtgaacgccgtctctcggattggagatcttctaaaatcactgtgtcacgaccaagaaggaaggggacagcagaaggggacagaaggaaggggacagaaggaaggggacagaaggaagggacaggaaagcaccgaagagccctctaaaagaggcttgtgtcacgaccatgagagaaggggacagaagaag1380gacaggaaagcaccgaagagaccaagtacatccaagtacatccaccaagaaaccttctctaaggccttctctaaggccttctcaagaaccttctctaaggccttctcaagaaccttctctaaggccttctatgagaatgccttctcaagaaccttctcaagaatgccttctatgaagaagaag1500gacaggaaagcaccaagaacctggataagaagaagcttctcaagaaaccttctcaagaaaccttctcaagaaaccttctcaagaaaccttctcaagaaatgccttctcaagaaaccttctcaagaaatgccttctcaagaatgccttctcaagaatgccttctcaagaatgccttctaagaatgccttctatgagaatgccttcttgagaacaggacctgaaccctcaagaaccccctaagaacccccaagaagcccatcaagaagcccattcaagaaccccctaagaagcccccaa
    gcgttttgtt gagcatgaca cctgcagcag gaatatatgt gtgcctattt gtgtggacaa
     aaatatttac acttagggtt tggagctatt caagaggaaa tgtcacagaa gcagctaaac caaggactga gcaccctctg gattctgaat ctcaagatgg gggcagggct gtgcttgaag gccctgctgaag cactgagcaa gttgagaaaa
                                                                                                                                                             3060
                                                                                                                                                             3120
                                                                                                                                                             3180
                                                                                                                                                              3195
      aaaaaaaaaa aaaaa
      <210> 294
      <211> 3737
       <212> DNA
       <213> Homo sapiens
                                                                                           Page 43
```

```
<400> 294
  ggcgtccgcg cacacctccc cgcgccgccg ccgccaccgc ccgcactccg ccgcctctgc 60
 ccgcaaccgc tgagccatcc atgggggtcg cgggccgcaa ccgtcccggg gcggcctggg 120
  cggtgctgct gctgctgctg ctgctgccgc cactgctgct gctggcgggg gccgtcccgc 180
cgggtcgggg ccgtgccgc gggccgcagg aggatgtaga tgagtgtgc caagggctag 240 atgactgcca tgccgacgc ctgtgtcaga acacaccac ctcctacaag tgctcctgca 300 agcctggcta ccaaggggaa ggcaggcagt gtgaggacat cgatgaatgt ggaaatgagc 360 tcaatggagg ctgtgtccat gactgtttga atattccagg caattatcgt tgcactgtt 420 ttgatggctt catgttggct catgacggtc ataattgtc tgatgtggac gagtgcctgg 480
ttgatggctt catgttggct catgacggtc ataattgtct tgatgtggac gagtgcctgg 480 agaacaatgg cggctgcag catacctgtg tcaacgtcat ggggaggctat gagtgctgct 540 gcaaggaggg gttttcctg agtgacaatc agcacacctg cattcaccgc tcggaagagg 600 gcctgagctg catgaataag gatcacggct gtagtcacat ctgcaaggag gccccaaggg 660 gcagcgtcgc ctgtgagtgc aggcctggtt ttgagctggc caagaaccag agagactgca 720 tcttgacctg taaccatggg aacggtggt gccagcactc ctgtgacgat acacgccgatg 780 gcccagaggg cacgtcctg ccacagtaca agatgcacac agatggagga agctgccttg 840 agcgagagga cactgtcctg gaggtgacag agagcacac cacatcagtg gtggatgggg 900 ataaacgggg gaaacggcgg ctgctcatgg aaacggtggc ttgcaacaat ggaggctgtg 960 accgcacctg taaggatact tcgacaggtg tccactgcag ttgtccagt ggaggctgtg 960 tccagttgga tgggaagaca tgtaaagata ttgatgaggg ccagacccgc aatggaggtt 1080 gtgatcattt agatgagaag tcttgccaag atgtggatga gtgctctttg gataggacct 1200
  aattattaac agatgagaag tcttgccaag atgtggatga gtgctctttg gataggacct 1200 gtgaccacag ctgcatcaac caccctggca catttgcttg tgcttgcaac cgagggtaca 1260 ccctgtatgg cttcacccac tgtggagaca ccaatgagtg cagcatcaac aacggaggct 1320 gtcagcaggt ctgtgtgaac acagtgggag gctcatgag cctctgggagaca 2380
 gtcagcaggt ctgtgtgaac acagtgggca gctatgaatg ccagtgccac cctgggtaca 1380 agctccactg gaataaaaaa gactgtgtgg aagtgaaggg gctcctgccc acaagtgtgt 1440 caccccgtgt gtccctgcac tgcggtaaga gtggtggagg agacgggtgc ttcctcagat 1500 gtcactctgg cattcacctc tcttcagatg tcaccaccat caggacaagt gtaaccttta 1560 agctaaatga aggcaagtgt agtttgaaaa atgctgagct gtttcccgag ggtctgcgac 1620 cagcactacc aggaaagca agctcagtaa aagagggct ccggacca aagcacccct tcttgagagcc ctggacgagcc ctggccgac aagacaccct aaggaaatgt 1740 ttatcactgt tgagttgag cctgaaacta accaaaagga ggtgacagct tcttgtgacc 1800 tgagctgcac caggagcag tttcacctcc aagcacaccc acggacagcc caggacagc caggacaccc aagcacccc acaggagcag tttcacctcc aggaccacccc acaggacccc aagcacccc acaggacagc aaccgacaagc cagagacccc caggaccacccc acaggacagc 1920 cagaaaacca atgtgtcagt tgcagggctg ggacctatta tgatggagca cgagaacgct 2040 gcattttatg tccaaatgga accttccaaa atgaggaagg acaaatgac tgtggacca 2100
    gcăttttatg tccaăatgga accttccaaă atgaggaagg acaaatgact tgtgaaccat 2100
   gcccaagacc aggaaattct ggggccctga agaccccaga agcttggaat atgtctgaat 2160 gtggaggtct gtgtcaacct ggtgaatatt ctgcagatgg ctttgcacct tgccagctct 2220 gtgccctggg cacgttccag cctgaagctg gtcgaacttc ctgcttcccc tgtggaggag 2280 gccttgccac caaacatcag ggagctactt cctttcagga ctgtgaaacc agagttcaat 2340 gttcacctgg acatttctac aacaccaca ctcaccatg tattcgttg ccantagga 2400
   gttcacctgg acatttctac aacaccacca ctcaccgatg tattcgttgc ccagtgggaa 2400 cataccagcc tgaatttgga aaaaataatt gtgtttcttg cccaggaaat actacgactg 2460 actttgatgg ctccacaaac ataacccagt gtaaaaacag aagatgtgga ggggagctgg 2520
    gagatttcac tgggtacatt gaatccccaa actacccagg caattaccca gccaacaccg 2580 agtgtacgtg gaccatcaac ccaccccca agcgccgcat cctgatcgtg gtccctgaga 2640 tcttcctgcc catagaggac gactgtgggg actatctggt gatgcggaaa acctcttcat 2700 ccaattctgg gacaacatag gacagcctacga agcgcccaat gccttcact 2760
    ccaggtcaaa gaagctgtgg attcagttca agtccaatga agggaacagc gctagagggt 2820 tccaggtccc atacgtgaca tatgatgagg actaccagga actcattgaa gacatagttc 2880 gagatggcag gctctatgca tctgagaacc atcaggaaat acttaaggat aagaaactta 2940 tcaaggctct gtttgatgtc ccggcccatc cccaggaacta tttcaagtac acagcccagg 3000
   tcaaggctct gtttgatgtc ctggcccatc cccagaacta tttcaagtac acagcccagg 3000 agtcccgaga gatgttcca agatcgttca tccgattgct acgttccaaa gtgtccaggt 3060 ttttgagacc ttacaaatga ctcagccac gtgccactca atacaaatgt tctgctatag 3120 ggttggtggg acagagctgt cttccttctg catgtcagca cagtcgggta ttgctgcctc 3180 ccgtatcagt gactcattag agttcaattt ttatagataa tacagatatt ttggtaaatt 3240 gaacttggtt tttctttcc agcatcgtgg atgtagactg agaatggctt tgggtggcat 3360 ttggtcagcc ctgctgtggg cggatgtctt ggatagacca cgggctggct gagctggact 3360 ttggtcagca aggaggccac agaataagct ctctcggggt cttatcctc tcaaggagtc 3420 tgagtggaa aggaggccac agaataagct gcttattctg aaacttcagc ttcctcagc 3480 ccggccctct ctaagggaga cccctgcagc ctctgcact cggtggagg ctctgaccag gcagaacagg 3540 actcagttc aggtgctgg aaaaaaaaaa gcagaaagaa ttagaaataa ataaaaacta 3720
      agttctaagc agtgctcgtg aaaaaaaaaa gcagaaagaa ttagaaataa ataaaaacta
                                                                                                                                                                                                                                                                                                                    3720
      agcacttctg gagacat
```

<210> 295 <211> 2042

```
<212> DNA
 <213> Homo sapiens
<400> 295
 ggggccagtc gttcgccgga aagcatttgt ctcccacctc atcataacaa caattaattt 60
    <210> 296
<211> 2547
    <212> DNA
     <213> Homo sapiens
   ttgaggctca gcagtctcat ggcagcagtg cctgttcaca gccccatggc agcgttaccc 840 agtcccaagg ctcctcca cagtcccagg gcatatccag ctccttacc agcacgatgc 900 caaactccag ccagtcctct cactccagct ctgggacact gagctcctta gagacagtgt 960 cactcagga actctattct attcctgagg accaagaacc tgaggaccaa gaacctgagg 1020 agctacccc tgccccctgg gctcgattat aggaccaaca tgggcccttca gggatggattt gccaatcttg 1080 agcacatgct gaacaacac tgggttggaa tgacaactac tggtttgga gaacatacag caagaaacac tttcggatt 1200 aaccatggagt gggtcctaaa aactcttaca tgcatacac agaagatcac agtggcaatg 1260 cagggaagt gggtcctaaa cttttaaggaa ctttaaggaacc ccgtccttt aaccacact 1320
      gaacctttgt aaatacagag cttgtaggga aaggaaaacg ccgtcctttg aataacaatt 1320
                                                                             Page 45
```

```
39740-0001PCT.txt
 ctgaaattgc actgtcacta agcagaaata aagtttttgt cttttttgat ctgactgtag 1380
 atgatcagic agtitatect aaggeattaa gagatgaata catcatgica aaaactettg
gaagtggtgc ctgtggagag gtaaagctgg ctttcgagag gaaaacatgt aagaaagtag 1500 ccataaagat catcagcaaa aggaagtttg ctattggttc agcaagagag gcagacccag 1560 ctctcaatgt tgaaacagaa atagaaattt tgaaaaagct aaatcatcct tgcatcatca 1620
ctctcaatgt tgaaacagaa atagaaattt tgaaaaagct aaatcatcct tgcatcatca 1620 agattaaaaa cttttttgat gcagaagatt attatattgt tttggaattg atggaagggg 1680 gagagctgtt tgacaaagtg gtggggaata aacgcctgaa agaagctacc tgcaagctct 1740 atttttacca gatgctcttg gctgtgcagt accttcatga aaacggtatt atacaccgtg 1800 acttaaagcc agagaatgtt ttactgtcat ctcaagaaga ggactgtctt ataaagatta 1860 ctgattttgg gcactccaag atttgggag agacctctct catgagaacc ttatgtggaa 1920 ccccaccta cttggcgct gaagttcttg tttttatctg gactgctggg tataaccgtg 1980 ctgtggactg ctggagttat ggagttattc tttttatctg ccttagtggg tatcaccctt 2040 tcctgagca taggaccaa gtgtcactga aggaccgat caccagtgga aaatacaact 2100 tcattcctga aggactgaga gaagtctcaa aggacctct aagaaggttat 2160
 tcattcctga agtctgggca gaagtctcag agaaagctct ggaccttgtc aagaagttgt 2160 tggtagtgga tccaaaggca cgttttacga cagaagaagc cttaagacac ccgtggcttc 2220 aggatgaaga catgaagaga aagtttcaag atcttctgtc tgaggaaaat gaatccacag 2280
 ctctaccca ggttctagcc cagccttcta ctagtcgaaa gcggccccgt gaaggggaag 2340 ccgagggtgc cgagaccaca aagcgcccag ctgtgtgtgc tgctgtgttg tgaactccgt 2400 ggtttgaaca cgaaagaaat gtaccttctt tcactctgtc atctttctt tctttgagtc 2460 tgtttttta tagtttgtat tttaatag ggaataattg ctttttcaca gtcactgatg 2520
  tacaattaaa aacctgatgg aacctgg
  <210> 297 <211> 2768
  <212> DNA
  <213> Homo sapiens
   <400> 297
  cactgctgtg cagggcagga aagctccatg cacatagccc agcaaagagc aacacagagc 60 tgaaaggaag actcagagga gagagataag taaggaaagt agtgatggct ctcatcccag 120 acttggccat ggaaacctgg cttctcctgg ctgtcagcct ggtgctcctc tatctatatg 180 gaacccattc acatggactt ttaagaagc tgtgatgtc agggcccaca cctctgcctt 240
  gaacccattc acatggactt tttaagaagc ttggaattcc agggcccaca cctctgcctt 240 ttttgggaaa tattttgtcc taccataagg gcttttgtat gtttgacatg gaatgtcata 300 aaaagtatgg aaaagtgtgg ggcttttatg atggtcaaca gcctgtgctg gctatcacag 360 atcctgacat gatcaaaaca gtgctagtga aagaatgtta ttctgtcttc acaaaccgga 420 ggcaagagatt acgatcattg ctgtcccaa ccttcacacag tggaaaaactc gaagaagatg 540 tcctatcat tgcccagtat gagaatgtg ttggggaaaa tctgaggcgg gaagcagaga 600 caggcaagcc tgtcaccttg aaagacgtct ttggggccta cagcatggat gtgatcacta 660 gcacatcatt tggagtgaac atcgactct taacaaatcc acaagacccc tttgtggaaa 720 acaccaagaa gcttttaaga tttgatttt tggatcact ctttctca ataacagtct 780
    acaccaagaa gcttttaaga tttgatttt tggatccatt ctttctctca ataacagtct ttccattcct catcccaatt cttgaagtat taaatatctg tgtgtttcca agagaagtta caaattttt aagaaaatct gtaaaaagga tgaaagaaag tcgcctcgaa gatacacaaa
                                                                                                                                                                                                                                                                                                                             840
                                                                                                                                                                                                                                                                                                                            900
  cataltitit aagaaaatci gtaaaaagga tgaaagaag tcgcctcgaa gatacacaaa 900 agcaccgagt ggatticctt cagctgatga ttgactctca gaattcaaaa gaaactgagt 960 cccacaaagc tctgtccgat ctggagctcg tggcccaatc aattatcttt attittgctg 1020 gctatgaaac cacgagcagt gttctccct tcattatgta tgaactggcc actcaccctg 1080 atgtccagca gaaactgcag gaggaaattg atgcagtttt acccaataag gcaccaccca 1140 cctatgatac ttggctacag atggaggat ttgacatggt ggtgaatgaa acgctcagat 1200 tattcccaat tgctatgaga cttggagagg tctgcaaaaa agatgttgag atcaatggga 1260 tgtcattcc caaaggggtg gtggtgatga ttccaagcta tgctcttcac cgtgacccaa 1320 agtactggac agagcctgag aagttcctcc ctgaaagatt cagcaagaag aacaaggaca 1380 acatagatcc ttacatatac acaccctttu gaagtggac cagaaactoc attggcatga 1440
  agtactggac agagcctgag aagttcctc ctgaaagatt cagcaagaag aacaaggaca 1380 acatagatcc ttacatatac acaccetttg gaagtggacc cagaaactgc attggcatga 1440 ggtttgctct catgaacatg aaacttgctc taatcagagt ccttcagaac ttctccttca 1500 aacacttgtaa agaaacacag atccccctga aattaagctt aggaggactt cttcaaccag 1560 aaaaacccgt tgttctaaag gttgagtcaa gggatggcac cgtaagtgga gcctgaattt 1620 tcctaaggac ttctgctttg ctcttcaaga aatctgtgcc tgagaacacc agagacctca 1680 aattactttg tgaatagaac tctgaaatga agatgggct catccaatgg actgcataaa 1740 taaccgggga ttctgtacat gcattgagct ctctcattgt ctgtgtagag tgttatacctt 1800 gggaatataa aggaggtgac caaatcagtg tgaggaggta gatttggctc ctctgcttct 1860 cacgggacta ttccaccac ccccagttag caccattaac tcctcctgag ctctgataag 1920 agaatcaaca tttctcaata attcctcca caaattatta atgaaaataa gaattattt 1980 gatggctcta acaatgacat ttatatcaca tgttttctct ggagtatct ataaagtttta 2040 tgttaaatca ataaagacca ctttacaaaa gtattatcag atgctttcct gcacattaag 2100
     tgttaaatca ataaagacca ctttacaaaa gtattatcag atgctttcct gcacattaag 2100
    gagaaatcta tagaactgaa tgagaaccaa caagtaaata tttttggtca ttgtaatcac 2160 tgttggcgtg gggcctttgt cagaactaga atttgattat taacataggt gaaagttaat 2220 ccactgtgac tttgcccatt gtttagaaag aatattcata gtttaattat gccttttttg 2280 atcaggcaca gtggctcacg cctgtaatcc tagcagttg ggaggctgag ccgggtggat 2340 cgcctgaggt caggagttca agacaagcct ggcctacatg gttgaaaccc catctctact 2400
```

```
39740-0001PCT.txt
aaaaatacac aaattagcta ggcatggtgg actcgcctgt aatctcacta cacaggaggc 2460
daddatatat daartaytta yytatyytyy atteyttyi datteatta tacaggaggc 2400 tyaggcagga gaatcactty aacetyggag geggatytty aagtgagety agattycaec 2520 actycaete agtetyggty agagtyagae teagtettaa aaaaatatye ettittyaag 2580 cacytacatt tyataacaaa gaactyaage tettattata ttattaytti tyatttaaty 2640 titteageec ateteette atatteetyg gagacagaaa acatyttee etacacetet 2700 tyattaget
gattggtc
 <210> 298
<211> 1358
<212> DNA
 <213> Homo sapiens
<210> 299
  <211> 4407
  <212> DNA
  <213> Homo sapiens
  tttcgactcg cgctccggct gctgtcactt ggctctctgg ctggagcttg aggacgcaag 60 gagggtttgt cactggcaga ctcgagactg taggcactgc catggcccct gtgctcagta 120
  <400> 299
 ttctgccatt cctgtcccca cggaaggtta tagtaaaagg tgggagaatt gttgctatgc 1320 agtttgttcg gacagagcaa gatgaaactg gaaaatggaa tgaagatgaa gatcagatgg 1380 tccatctgaa agccgatgtg gtcatcagtg cctttggttc agttctgagt gatcctaaag 1440
                                                          Page 47
```

```
39740-0001PCT.txt
taaaagaagc cttgagccct ataaaattta acagatgggg tctcccagaa gtagatccag 1500 aaactatgca aactagtgaa gcatgggtat ttgcaggtgg tgatgtcgtt ggtttggcta 1560 acactacagt ggaatcggtg aatgatggaa agcaagcttc ttggtacatt cacaaatacg 1620 tacagtcaca atatggagct tccgtttctg ccaagcctga actacccctc ttttacactc 1680
ctattgatct ggtggacatt agtgtagaaa tggccggatt gaagtttata aatccttttg 1740 gtcttgctag cgcaactcca gccaccagca catcaatgat tcgaagagct tttgaagctg 1800 gatggggttt tgccctcacc aaaactttct ctcttgataa ggacattgtg acaaatgttt 1860 ccccagaat catccgggga accacctctg ggacatgat tggccctgga caaagctcct 1920
 ttctgaatat tgagctčatc agtgagaaaa cggctgcata ttggtgtcaa agtgtcactg 1980
aactaaaggc tgacttccca gacaacattg tgattgctag cattatgtgc agttacaata 2040 aaaatgactg gacggaactt gccaagaagt ctgaggattc tggagcagat gccctggagt 2100 taaatttatc atgtccacat ggcatggag aaagaggaat gggcctggcc tgtgggcagg 2160
taaatttatc atgtccacat ggcatgggag aaagaggaat gggcctggcc tgtgggcagg 2160 atccagagct ggtgcggaac atctgccgct gggttaggca agctgttcag attccttttt 2220 ttgccaagct gaccccaaat gtcactgata ttgtgagcat cgcaagagct gcaaaggaag 2280 gtggtgccaa tggcgttaca gccaccaaca ctgtctcagg tctgatggga ttaaaatctg 2340 atggcacacc ttggccagca gtggggattg caaagcgaac tacatatgga ggagtgtctg 2400 ggacagcaat cagacctatt gctttgagag ctgtgacctc cattgctcgt gctctgcctg 2460 gattcccat tttggctact ggtggaattg actctgca aagtggtctt cagtttctc 2520 atagtggtg ttccgtctc caggtatgca gtgccattca gaatcaggat ttcactgtga 2580 tcgaagacta ctgcactggc ctcaaagccc tgctttatct gaaaagcatt gaagaactac 2640 aagactggaa tggaaaaga ccagttccac 2700
 aagactggga tggacagagt ccagctactg tgagtcacca gaaagggaaa ccagttccac 2700
gtatagctga actcatggac aagaaactgc caagttttgg accttatctg gaacagcgca 2760 agaaaatcat agcagaaaac aagattagac tgaaagaaca aaatgtagct ttttcaccac 2820 ttaagagaag ctgtttatc cccaaaaggc ctattctac catcaaggat gtaataggaa 2880 aagcactgca gtaccttgga acatttggtg aattgagcaa cgtagagcaa gttgtgggcta 2940 gctaccaggc tataccagtt gatccagaaa cccacctgc catcactgt aatgattctg 3000 gctaccaggc tatacagttt gatccagaaa cccacctgcc caccataacc gacacttgta 3060 caggctgtac tctgtgtctc agtgtttgcc ctattgtcga ctgcatcaaa atggtttcca 3120 ggacaaacacc ttatgacca aagagagagg taccacttgta tgtgagacca ctattgagac aagagagagg taccacttgtc agtgttgcc ctattgtcga ctgcatcaaa atggtttcca 3120 ggacaacacc ttatgagaca aagagagagg taccacttatc tgtgagaca ctattgagaca 3180
 agtgāaātta agcattttga aacāaagtac īctītāacat acaagaāaat gtatccaāgg 3600
  aaacatttta tcaataaaaa ttacctttaa ttttaatgct gtttctaaga aaatgtagtt 3660 agctccataa agtacaaatg aagaaagtca aaaattattt gctatggcag gataagaaag 3720 cctaaaattg agtttgtgga ctttattaag taaaatcccc ttcgctgaaa ttgcttattt 3780
  ttggtgttgg atagaggata gggagaatat ttactaacta aataccattc actactcatg 3840 cgtgagatgg gtgtacaaac tcatcctctt ttaatggcat ttctctttaa actatgttcc 3900 taaccaaatg agatgatagg atagatcctg gttaccactc ttttactgtg cacatatggg 3960 ccccggaatt ctttaatagt caccttcatg attatagcaa ctaatgttg aacaaagctc 4020
  aaagtatgca atgcttcatt attcaagaat gaaaaatata atgttgataa tatatataa 4080 gtgtgccaaa tcagtttgac tactctctgt tttagtgttt atgtttaaaa gaaatatatt 4140 ttttgttatt attagataat attttgtat ttctctattt tcataatcag taaatagtgt 4200 catataaact catttattc ctcttcatgg catcttaata atgaatctat aagtagtaaa 4260
   tcagaaagta acaatctatg gcttatttct atgacaaatt caagagctag aaaaataaaa 4320 tgtttcatta tgcactttta gaaatgcata tttgccacaa aacctgtatt actgaataat 4380
                                                                                                                                                                                                                      4407
   atcaaataaa atatcataaa gcattit
   <211> 5532
   <212> DNA
    <213> Homo sapiens
   <400> 300
   gccgcgctgc gccggagtcc cgagctagcc ccggcgccgc cgccgcccag accggacgac 60
   aggccacctc gtcggcgtcc gcccgagtcc ccgcctcgcc gccaacgcca caaccaccgc 120 gcacggcccc ctgactccgt ccagtattga tcgggagagc cggagcgagc tcttcgggga 180 gcagcgatgc gaccctccgg gacggccggg gcagcgctcc tggcgctgct ggctgcgctc 240 tgcccggcga gtcggctct ggaggaaaag aaaggttcccaaaggcc 300
   acgcagttgg gcacttttga agatcatttt ctcagcctcc agaggatgtt caataactgt 360 gaggtggtcc ttgggaattt ggaaattacc tatgtgcaga ggaattatga tctttccttc 420 ttaaagacca tccaggaggt ggctggttat gtcctcattg ccctcaacac agtggagcga 480 attcctttgg aaaacctgca gatcatcaga ggaaatagt actacgaaaa ttcctatgcc 540 ttagcagtct tatctaacta tgatgcaaat aaaaccggac tgaaggagct gcccatggaga 600
   aatttacagg aaatcctgca tggcgccgtg cggttcagca acaaccctgc cctgtgcaac 660
                                                                                                                         Page 48
```

39740-0001PCT.txt gtggagagca tccagtggcg ggacatagtc agcagtgact ttctcagcaa catgtcgatg 720

```
39740-0001PCT.txt
ttctcgcaaa aacgtatctc ctaatttgag gctcagatga aatgcatcag gtcctttggg 4800 gcatagatca gaagactaca aaaatgaagc tgctctgaaa tctcctttag ccatcacccc 4860 aacccccaa aattagtttg tgttacttat ggaagatagt tttctccttt tacttcactt 4920 caaaagcttt ttactcaaag agtatatgtt ccctcaggt cagctgccc caaaccccct 4980 ccttacgctt tgtcacacaa aaagtgtct tgccttgagt catctattca agcacttaca 5040 gctctggca caacagaga ttttacagat cgcaataga gtaccatta ggaagatagt tgccttgagt catctattca agcacttaca 5040 gctctggca caacagaga ttttacagat gccaataga gtaccatta ggaagataga gtaccatta ggaagatga gtaccatta ggaagatga gtaccatta ggaagatga gaagatga gaaga gaagatga gaagatga gaagatga gaagatga gaagatga gaagatga gaagatga 
 gctctggcca caacagggca ttttacaggt gcgaatgaca gtagcattat gagtagtgtg 5100 aattcaggta gtaaatatga aactagggtt tgaaattgat aatgctttca caacatttgc 5160 agatgtttta gaaggaaaaa agttccttcc taaaataatt tctctacaat tggaagattg 5220
 gaagattcag ctagttagga gcccatttt tcctaatctg tgtgtgccct gtaacctgac 5280 tggttaacag cagtcctttg taaacagtgt tttaaactct cctagtcaat atccaccca 5340 tccaatttat caaggaagaa atggttcaga aaatattttc agcctacagt tatgttcagt 5400 cacacacaca tacaaaatgt tccttttgct tttaaagtaa tttttgactc ccagatcagt 5460
  cagagcccct acagcattgt taagaaagta tttgattttt gtctcaatga aaataaaact 5520
  ataticattt cc
  <210> 301
<211> 1528
   <212> DNA
   <213> Homo sapiens
   <400> 301
   cggcgagcga gcaccttcga cgcggtccgg ggaccccctc gtcgctgtcc tcccgacgcg 60
   găcccgcgtg ccccaggcct cgcgctgccc ggccggctcc tcgtgtccca ctcccggcgc 120
  acgccctccc gcgagtcccg ggcccctccc gcgcccctct tctcggcgcg cgcgcagcat 180 ggcgcccccg caggtcctcg cgttcggct tctgcttgcc gcggcgacgg cgacttttgc 240 cgcagctcag gaagaatgtg tctgtgaaaa ctacaagctg gccgtaaact gctttgtgaa 300 taataatcgt caatgccagt gtacttcagt tggtgcacaa aatactgtca tttgctcaaa 360 gctggctgcc aaatgtttgg tgatgaaggc agaaatgaat ggctcaaaac ttggggaag 420 agcagaaacct gaaggggccc tccagaacaa tgatgggctt tatgatcctg actgcgatga 480 gagcgggctc tttaaggcca agcagtgcaa cggcacctcc acgtgctggt gtgtgaacac 540 tgctgaggcc
   tgctggggtc agaagaacag acaaggacac tgaaataacc tgctctgagc gagtgagaac 600 ctactggatc atcattgaac taaaacacaa agcaagagaa aaaccttatg atagtaaaag 660 tttgcggact gcacttcaga aggagatcac aacgcgttat caactggatc caaaatttat 720 cacgagtatt ttgtatgaga ataatgtat cactattgat ctggttcaaa attcttctca 780
  cacgagitatt itgtatgaga ataaigttat caciaitgat ctggitcaaa attcttctca 780 aaaaactcag aatgatgigg acatagciga tgiggcitat tattitgaaa aagatgitaa 840 aggitgaatcc tigittcatt ctaagaaaat ggacctgaca gtaaatgggg aacaactgga 900 gcagggitca aaagctggig ttattgigt tattigiggit giggitgatag cagitgitigi 1020 tggaatigit gigciggita titccagaaa gaagagaatg gcaaagtat aggacgiga 1080 gataaaggag atgggigaga tgcataggga actcaatgca taactatata atitigaagat 1140 aaggicataga gagacctgaaa tigaaaactg tigaaactgg cittaccaaa tattigiaaa aggacacaatigi aggacacaati 1320 gtctatata tgcagacta atgaaaatc gggacataga atccaatcg taaaaatc tattigiaat tagaaaactg 1440 attigigati gaaagcigcc titctatta citgagicti gaacatacat acttittat 1500 gagctatgaa ataaaacati ttaaactg
     gagctatgaa ataaaacatt ttaaactg
     <210> 302
     <211> 1856
      <212> DNA
       <213> Homo sapiens
     ctgacttggc aggactgtgc aattgtcaga aggccgtggg gagtgggggc cagtgcctgc 60 agcctgcct gcctctca caggccctta gagcatcgcc aggtgcagag ctccacagct 120 ctcttccca aggagtaatc agagggtgag aacgtggagc ctggtggaca ggtgaaagca 180
     ctgggatctt tctgcccaga aaggggaaag ttgcacattt atatcctaga gggaagcgac 240 agcagtgctt ctccctgtgc tgaggtacag gagccatgtg gctagaaatc ctcctcactt 300 cagtgctggg ctttgccatc tactggttca tctcccggga caaagaggaa actttgccac 360 ttgaagatgg gtggtggggg ccaggcacga ggtccgcagc cagggaggac gacagcatcc 420
     gccctttcaa ggtggaaacg tcagatgagg agatccacga cttacaccag aggatcgata 480 agttccgttt cacccacct ttggaggaca gctgcttcaa ctatggcttc aactccaact 540 acctgaagaa agtcatctcc tactggcgga atgaatttga ctggaagaag caggtggaga 600
       tictcaacag ataccetcae ticaagacta agattgaagg getggacate cactteatee 660
       acgtgaagcc ccccagctg cccgcaggcc ataccccgaa gcccttgctg atggtgcacg 720
```

```
39740-0001PCT.txt
acccccaact ccgtgtggta agcaacatgg ctttgatgat aaacgacttt actcta
<210> 303
<211> 6450
<212> DNA
<213> Homo sapiens
 gagttgtgcc tggagtgatg tttaagccaa tgtcagggca aggcaacagt ccctggccgt 60
```

39740-0001PCT.txt ctgataagca ctttttaaat ggctctaaga ataagccaca gcaaagaatt taaagtggct 2580 cctttaattg gtgacttgga gaaagctagg tcaagggttt attatagcac cctcttgtat tcctatggca atgcatcctt ttatgaaagt ggtacacctt aaagctttta tatgactgta gcagagtatc tggtgattgt caattcactt ccccctatag gaatacaagg ggcacacagg ggaaggcaga tcccctagtt ggccaagact tatttaact tgatacactg cagattcaga 2700 2760 cagtcattta tgcctaaagc ctggtgatta ttcatttaaa tgaagatcac atttcatatc aacttttgta tccacagtag acaaaatagc actaatccag atgcctattg ttggatattg aatgacagac aatcttatgt agcaaagatt atgcctgaaa aggaaaatta ttcagggcag ctaattttgc ttttaccaaa atatcagtag taatatttt ggacagtagc taatgggtca 4320 gtgggttctt tttaatgttt atacttagat tttcttttaa aaaaattaaa ataaaacaaa 4560 aaaaatttct aggactagac gatgtaatac cagctaaagc caaacaatta tacagtggaa ggttttacat tattcatcca atgtgtttct attcatgtta agatactact acatttgaag 4680 tgggcagaga acatcagatg attgaaatgt tcgcccaggg gtctccagca actttggaaa 4740 tctctttgta tttttacttg aagtgccact aatggacagc agatattttc tggctgatgt 4800 tggtattggg tgtaggaaca tgatttaaaa aaaaaactct tgcctctgct ttcccccact 4860 ctgaggcaag ttaaaatgta aaagatgtga tttatctggg gggctcaggt atggtgggga 4920 agtgggatca ggaatctggg gaatggcaaa tatattaaga agagtattga aagtatttgg 4980 aggaaaaatgg ttaaattcag ggaatcca ggaatctgg gaatggcaaa tatattaaga agagtattga aagtatttgg 4980 aggaaatgg ttaattctgg gtgtgcacca aggttcagta gagtccactt ctgccctgga gaccacaaat caactagctc catttacagc catttctaaa atggcagctt cagttctaga gaagaaagaa caacatcagc agtaaagtcc atggaatagc tagtggtctg tgtttcttt 5040 5100 cgccattgcc tagcttgccg taatgattct ataatgccat catgcagcaa ttatgagagg 5220 ctaggtcatc caaagagaag accctatcaa tgtaggttgc aaaatctaac ccctaaggaa 5280 gtgcagtctt tgatttgatt tccctagtaa ccttgcagat atgtttaacc aagccatagc 5340 ccatgccttt tgagggctga acaaataagg gacttactga taatttactt ttgatcacat 5400 taaggtgttc tcaccttgaa atcttataca ctgaaatggc cattgattta ggccactggc 5460 ttagagtact ccttccctg catgacactg attacaaata ctttcctatt catacttcc 5520 aattatggaa tggactgtgg gtactgggag tgatcactaa caccatagta atgtctaata 5580 tracaagga gatctgcttg gggaagctag ttatggtaaa ggcaaataaa gtcatacagt 5640 actgcaccat tcccaagtta atcccttgga aacttactct cggaggcgtga tctagattac 5700 actgcaccat tcccaagtta atcccctgaa aacttactct caactggagc aaatgaactt 5760 tggtccaaa tatccatctt ttcagtagcg ttaattatgc tctgttcca actgcattc 5820 ctttccaatt gaattaaagt gtggcctcgt ttttagtcat ttaaaaattg tttctaagta 5880 actgcacct ctattatggc acttcaattt tgcactgtct tttgagattc aagaaaaatt 5940 cgccattgcc tagcttgccg taatgattct ataatgccat catgcagcaa ttatgagagg attgctgcct ctattatggc acticaatit tgcacigtct tttgagatic aagaaaaatt tctattcatt tttttgcatc caattgtgcc tgaactttta aaatatgtaa atgctgccat 6000 gttccaaacc catcgtcagt gtgtgtgtt agagctgtgc accctagaaa caacatactt 6060 gtcccatgag caggtgctg agacacagac ccctttgcat tcacagagag gtcattggtt 6120 atagagactt gaattaataa gtgacattat gccagtttct gttctctcac aggtgataaa 6180 caatgcttt tgtgcactac atactcttca gtgtagagct cttgtttat gggaaaaggc 6240 tcaaatgcca aattgtgtt gatggattaa tatgcccttt tgccgatgca tactattact 6300 gatgtgactc ggtttgtcg cagctttgct ttgtttaatg aaacacactt gtaaacctct 6360 tttgcacttt gaaaaagaat ccaggcgggat gctcgagcac ctgtaaacaa ttttctcaac 6420 6450 ctatttgatg ttcaaataaa gaattaaact

Page 52

```
<210> 304
<211> 3336
<212> DNA
<213> Homo sapiens
 <221> unsure
 <222> (0)...(0)
 <223> n = A, T, C or G
<400> 304
cggcggcgac tgcagtctgg agggtccaca agattcataa tgaaagctag ccccgtcgg cttcctgttc aaaatgcccc aacaggagt ctaatcaagc agaggcttcc aacaggagt ctaatcaagc agaggcttcc atcccacaaca atgctaatat tcacagcatc agtggcagta gtggaaaacg ctcttgcaag 240 ctcccacaaca atgctaatat tcacagcatc agtggcagta gtggaccaa caaattcatc ctcatcagct gtgggggac cccaactcag 420 ctccaggac tccggcctca aacccaaacc agctatgatg ccaaaaggac agaggtgacc 480 agcagaacc ttgggagacct tgggaccaa acctgcagct agcagatgga agcagaagg acccctatac 600
 <400> 304
 gccctttgcg agcagaaacg ggagacctgt gcagatggtg aggcagcagg ctgcactatc 600 aacaatagcc tatccaacat ccagtggctt cgaaagatga gttctgatgg actgggctcc 660
  cgcagcatca agcaagagat ggaggaaaag gagaattgtc acctggagca gcgacaggtt 720 aaggttgagg agccttcgag accatcagcg tcctggcaga actctgtgtc tgagcggcca 780
 tttäagacac ccattaagga aacgctgccc atctcctcca ccccgagcaa atctgtcctc 1920
   cccagaaccc ctgaatcctg gaggctcacg cccccagcca aagtaggggg actggatttc 1980 agcccagtac aaacctcca gggtgcctct gaccccttgc ctgacccct ggggctgatg 2040 gatctcagca ccattcctt gcaaagtgct ccccccttg aatcaccgca aaggctcctc 2100 agttcagaac ccttagacct catctccgtc ccctttggca actcttctc ctcagatata 2160 aggctcacca aaggctcctc 2200
   agttcagaac ccttagacct catctccgtc ccctttggca actcttctcc ctcagatata 2160 gacgtccca agccaggctc cccggagcca caggttctg gccttgcagc caatcgttct 2220 ctgacagaag gcctggtcct ggacacaatg aatgacagcc tcagcaagat cctgctggac 2280 atcagttc ctggcctgga cgaggaccca ctgggccctg acaacatcaa ctggtcccag 2340 ttattcctg agctacagta gagccctgcc cttgccctg tgctcaagct gtccaccatc 2400 gtctggcctc caaggctcag tgcacccaa gcctctgagt gaggacagca ggcagggact 2460 gtctgctcc tcatagctcc ctgctgcctg attatgcaaa agtagcagtc acaccctagc 2520 cactgctggg accttgtgt ccccaagagt atctgattcc tctgctgtcc ctgccaggag 2580 ctgaagggtg ggaacaacaa aggcaatggt gaaaagagat taggaacccc ccagcctgtt 2640 tagtataaat tctccaaatt atcctctaat tataaatgta agcttattc cttagatca 2700 tagtataaat ctgccagaag gtgggtagga tgacctgggg tttcaattga cttctqttcc 2820
    tatccagaga ctgccagaag gtgggtagga tgacctgggg tttcaattga cttctgttcc 2820 ttgcttttag ttttgataga agggaagacc tgcagtgcac ggtttcttcc aggctgaggt 2880 acctggatct tgggttcttc actgcaggga cccagacaag tggatctgct tgccagagtc 2940
      ctttttgccc ctccctgcca cctcccgtg tttccaagtc agctttcctg caagaagaaa
      tcctggttaa aaaagtcttt tgtattgggt caggagttga atttggggtg ggaggatgga
tgcaactgaa gcagagtgtg ggtgcccaga tgtgcgctat tagatgtttc tctgataatg
      tccccaatca taccagggag actggcattg acgagaactc aggtggaggc ttgagaaggc cgaaagggcc cctgacctgc ctggcttcct tagcttgcc ctcagctttg caaagagcca ccctaggccc cagctgaccg catgggtgt agccagcttg agaacactaa ctactcaata
                                                                                                                                                                                                     3180
                                                                                                                                                                                                      3240
                                                                                                                                                                                                     3300
                                                                                                                                                                                                      3336
      aaagcgaagg tggaccnaaa aaaaaaaaa aaaaaa
                                                                                                                 Page 53
```

```
<210> 305
                  2365
  <211>
  <212> DNA
  <213> Homo sapiens
<400>, 305
  tcccagcctt cccatccccc caccgaaagc aaatcattca acgacccccg accctccgac 60
    <210> 306
<211> 1117
     <212> DNA
      <213> Homo sapiens
     <400> 306
     gcaccaacca gcaccatgcc catgatactg gggtactggg acatccgcgg gctggcccac 60 gccatccgcc tgctcctgga atacacagac tcaagctatg aggaaaagaa gtacacgatg 120 ggggacgctc ctgattatga cagaagccag tggctgaatg aaaaattcaa gctgggcctg 180 gactttcca atctgccta cttgattgat ggggctcaca agatcaccca gagcaacgcc 240
    gactttccca atctgcccta cttgattgat ggggctcaca agatcaccca gagcaacgcc 240 atcttgtgct acattgcccg caagcacaac ctgtgtgggg agacagaaga ggagaagatt 300 cgtgtggaca ttttggagaa ccagaccatg gacaaccata tgcagctggg catgatctgc 360 tacaatccag aatttgagaa actgaagcca aagtacttgg aggaactccc tgaaaagcta 420 aagctctact cagagtttct ggggaagcgg ccatggttg caggaaacaa gatcactttt 480 gtagatttc tcgtctatga tgtccttgac ctccaccgta tatttgagcc caactgctg 540 ggcctacatga aggcccttcc aagtccagcc cttcctcca agacctgtt tctcaaagat ggacttctc 600 gcctacatga aggccctga aggcagagg tgggagtgag gagcccatac tcagcctgct 720 gccaagctg tgcagcgag tgcagcaga cttcatct catctattat tcccatctt actccaaga cttcattgc cctcttcact ccccctaaac 840 Page 54
                                                                                                                   Page 54
```

```
39740-0001PCT.txt
ccctgtccca tgcaggccct ttgaagcctc agctacccac tatccttcgt gaacatcccc 900 tcccatcatt acccttccct gcactaaagc cagcctgacc ttccttcctg ttagtggttg 960 tgctgcttt aaagcctgcc tggcccctcg cctgtggagc tcagcccga gctgtccccg 1020 tgttgcatga aggagcagca ttgactggtt tacaggccct gctcctgcag catggtccct 1080 tgctaggcct acctaggcat acctaggcct acctaggcc aggagcatcaggcat acctaggcct acctaggccct a
   gcctaggcct acctgatgga agtaaagcct caaccac
    <211> 1266
<212> DNA
     <213> Homo sapiens
attgat
          <210> 308
<211> 2162
<212> DNA
            <213> Homo sapiens
            gggctgcgct gtccagctgt ggctatggcc ccagccccga gatgaggagg gagagaacta 60 gggcccgca ggcctgggaa tttccgtccc ccaccaagtc cggatgctca ctccaaagtc 120
```

```
39740-0001PCT.txt
atcctgagtg gtctggcggt tttttcttct aactgacttc tgctttccac ggcgtgtgct 1680 gggcccggat ctccaggccc tggggaggga gcctctggac ggacagtggg gacattgtgg 1740 gtttggggct cagagtcgag ggacggggtg tagcctcggc atttgcttga gtttctccac 1800 tcttggctct gactgatcc tgcttgtgca ggccagtgga ggcctttggg cttgggagaac 1860 acgtgtgtct ctgtgtatgt gtctgtgtg ctgcgtccgt gtctgtcaga cttgtctgcct 1920 gtcctggggt ggctaggagc tgggtctgac cgttgtatgg tttgacctga tatactccat 1980 tctcccctgc gcctcctcct ctgtgtttt tccatgtccc cctcccaact ccccatgccc 2040 agttttacc catcatgcac cttgtacgat tgccacgtta ctgccttttt taaaaatata 2100 tttgacagaa accaggtgcc ttcagaggct ctctgattta aataaacctt tcttgtttt 2160 tt
   <210> 309
   <211> 3933.
    <212> DNA
    <213> Homo sapiens
ttacccaccg ctgaaacgcc aaagccactt cgaagtagtg ctgaccctgc actcaatcaa 1680 gaagttgcat taaaattaga accaaatcca gagtcactgg aactttcttt taccatgccc 1740 cagattcagg atcagacacc tagtccttcc gatggaagca ctagacaaag ttcactgag 1800 cctaatagtc ccagtgaata ttgttttat gtggatagtg atatggtcaa tgaattcaag 1860
      ttggaattgg tagaaaact ttttgctgaa gacacagaag caaagaaccc attttctact 1920 caggacacag atttagactt ggagatgtta gctccctata tcccaatgga tgatgacttc 1980 cagttacgtt ccttcgatca gttgtcacca ttagaaagca gttccgcaag ccctgaaagc 2040 gcaagtcctc aaagcacagt tacagtattc cagcagactc aaatacaaga acctactgct 2100
    gcăagtcctc aaagcacagt tacagtatt cagcagactc aaatacaaga acctactgct 2100 aatgccacca ctaccactgc caccactgat gaattaaaaa cagtgacaaa agaaccgtatg 2160 gaagacatta aaatattgat tgcatctcca tctcctaccc acatacataa agaaccgtatg 2220 aggaaaaggag tcatagaaca gacagaaaaa tctcatccaa gaagccctaa cgtgtttga gtcaaagaac tacagttcct gaggaagaac tacagtcct gaggaagaac tacagtcgg gaactagaa ggaattggaa cattatacaa gcagccagac gatcatgag gtcactact tcaagcagta 2460 ggaattggaa aaggatgaa acttagtgaa cagaatggaa tggagcaaaa gacaattatt 2580 aaggatgaa caggtgaa aaggatact cagagcttg aagaatgat cagagctga aagaatact cagagcttca tttggaagtt aatgctccta tacaaggcag cagaaaccta 2700 ctgcagggtg aagaattact cagagcttg gatcaagta agtctattta agaagcctgg ctacaatact ggatcaattt agaagctgg ctacaatact ggtggtcac aactacatca agtttctaattt agaagcctgg ctacaatact ggatcaattta tattttctac 2820 atttattatt agaagcctgg ctacaatact ggatcaatact ggttagttca atttttgatc 2880
       atctaatttt agaagcctgg ctacaatact gcacaaactt ggttagttca atttttgatc 2880 ccctttctac ttaatttaca ttaatgctct tttttagtat gttctttaat gctggatcac 2940 agacagctca ttttctcagt tttttggtat ttaaaccatt gcattgcagt agcatcattt 3000 taaaaaaatgc accttttat ttatttattt ttggctaggg agtttatccc tttttcgaat 3060
                                                                                                                                                                                            Page 56
```

```
39740-0001PCT.txt
 acatcttctg tggaaaaaaa aaaaaaaaaa aaa
 <210> 310
<211> 2872
 <212> DNA
  <213> Homo sapiens
ttacatgttg ggaggaggag ataagttata gggagctgga tttcaaacgg tggtccaaga 2520 ttcaaaaatc ctattgatag tggccatttt aatcattgcc atcgtgtgct tgttcatcc 2580 agtgttatgc actttccaca gttggtgtta gtatagccag agggtttcat tattattct 2640 ctttgcttc tcaatgttaa tttattgcat ggtttatct ttttctttac agctgaaatt 2700 gctttaaatg atggttaaa ttacaaatta aattggaat ttttatcaat gtgattataa 2760
   gctttaaatg atggttaaaa ttacaaatta aattgggaat ttttatcaat gtgattgtaa 2760
                                                       Page 57
```

WO 03/078662 PCT/US03/07713

```
39740-0001PCT.txt
 ttaaaaatat titgatttaa ataacaaaaa taataccaga tittaagccg cggaaaatgt 2820
tcttgatcat ttgcagttaa ggactttaaa taaatcaaat gttaacaaaa aa
 <210> 311
 <211> 926
 <212> DNA
 <213> Homo sapiens
  <400> 311
ggggcccatt ctgtttcagc cagtcgccaa gaatcatgaa agtcgccagt ggcagcaccg 60 ccaccgccgc cgcgggcccc agctgcgcg tgaaggccgg caagacagcg agcggtgcgg 120 gcgaggtggt gcgctgtctg tctgagcaga gcgtggccat ctcgcgctgc cggggcgccg 180 gggcgcgcct gcctgccctg ctggacgagc agcaggtaaa cgtgctgctc tacgacatga 240 acggctgtta ctcacgcctc aaggaggctgg tgccaccct gccccagaac ctcacgcta 360
acggctgtta ctcacgcct aaggagctgg tgcccacct gccccagaac cgcaaggtga 300 gcaaggtgga gattctccag cacgtcatcg actacatcag ggaccttcag ttggagctga 360 actcggaatc cgaagttggg acccccgggg gccgagggct gccggtccgg gctccgctca 420 gcaccctcaa cggcgagatc agcgccctga cggccgaggc ggcatgcgtt cctgcggacg 480 attcgcatctt gtgtcgctga agcgcctcc ccagggaccg gcggaccca gccatccagg 540 gggcaagagg aattacgtgc tctgtgggtc tccccaacg cgcctcgcc gaggaggg 600 agaacaagac cgatcgggg ccactggcc cttaactgca tccagcctgg ggctgaggct 660 gaggcactgg cgaggaggg cgctcctct ctgcacacct actagtcacc agagacttta 720 gggggtggga ttccactcgt gtgttctat ttttgaaaa gcagacattt taaaaaatgg 780 tcacgtttgg tgcttctcag attctgagg aaattgcttt gtattgtata ttacaatagat 840 caccgactga gaatattgtt ttacaatagt tctgtgggc tgttttttg ttattaaaca 900 aataatttag atggtgaaa aaaaaa
                                                                                                                                                                                                                                                                                  926
  aataatttag atggtgaaaa aaaaaa
  <210> 312
  <211> 4989
  <212> DNA
  <213> Homo sapiens
  <400> 312
  tttttttttt ttttgagaaa gggaatttca tcccaaataa aaggaatgaa gtctggctcc 60
 ggaggagggt ccccgacctc gctgtggggg ctcctgtttc tctccgccgc gctctcgctc 120 tggccgacga gtggagaaat ctgcgggcca ggcatcgaca tccgcaacga ctatcagcag 180 ctgaagcgcc tggagaactg cacggtgatc gagggctacc tccacatcct gctcatctc 240 aaggccgagg actaccgcag ctaccgcttc cccaagctca cggtcattac cgatacttg 360
 ctgctgttcc gagtggctgg cctcgagagc ctcggagacc tcttccccaa cctcacggtc 360 atccgcggct ggaaactctt ctacaactac gccctggtca tcttcgagat gaccaatctc 420 aaggatattg ggctttacaa cctgaggaac attactcggg gggccatcag gattgagaaa 480 aatgctgacc tctgagacc tctgagagacc 500 aatgctgacc ttgatcctgga tgcggtgtcc 540
 aataactaca ttgtggggaa taagcccca aaggaatgtg gggacctgtg tccagggacc 600 atggaccacaa accgctgca gaaaatgtgc ccaagcacgt gtgggaagcg ggcgtgcacc 720 gagaacaatg agtgctgcca ccccgagtgc ctgggcagct gcagcgccc tgacaacgac 780
 aggaacaatg agtgctgcca ccccgagtgc ctgggcagct gcagcgcgcc tgacaacgac 780 acggcctgtg tagcttgccg ccactactac tatgccggtg tctgtgtgcc tgcctgcccg 840 cccaacacct acaggtttga gggctggcgc tgtgtggacc gtgacttctg cgccaacatc 900 ctcagcgccg agagcagcga ctccgagggg tttgtgatcc acgacggcga gtgcatgcag 960 gagtgccct cgggcttcat ccgcaacggc agccagagca tgtactgcat cccttgtgaa 1020 ggtccttgcc cgaaggtctg tgaggaagaa aagaaaacaa agaccattga ttctgttact 1080 tctgctcaga tgctccaagg atgcaccatc ttcaagggca atttgctcat taacatccga 1140 cgggggaata acattgcttc agagctggag aacttcattg ggctcatcga ggtggtgaccg 1200 ggctacgtga agatccgcca ttctcatgcc tggctccct tgtccttcct acaaaacctt 1260 cgcctcatcc taggagagaga gcagctagaa gggaattact ccttctacgt cctcgacac 1320
 cgcctcatcc taggagagga gcagctagaa gggaattact ccttctacgt cctcgacaac 1320 cagaacttgc agcaactgtg ggactgggac caccgcaacc tgaccatcaa agcagggaaa 1380 atgtactttg ctttcaatcc caaattatgt gtttccgaaa tttaccgcat ggaggaagtg 1440
  acggggacta aagggcgcca aagcaaaggg gacataaaca ccaggaacaa cgggggagaga 1500 gcctcctgtg aaagtgacgt cctgcatttc acctccacca ccacgtcgaa gaatcgcatc 1560 atcataacct ggcaccggta ccggcccct gactacaggg atctcatcag cttcaccgtt 1620 tactacaagg aagcaccctt taagaatgtc acagggtatg atgggcagga tgcctgcggc 1680
 tactacaagg aagcaccctt taagaatgtc acagagtatg atgggcagga tgcctgcggc 1680 tccaacagct ggaacatggt ggacgtggac ctcccgcca acaaggacgt ggagcccggc 1740 atcttactac atgggctgaa gccctggact cagtacgccg tttacgtcaa ggctgtgacc 1800 ctcaccatgg tggagaacga ccatatccgt ggggccaaga gtgagatctt gtacattcgc 1860 accaatgctt cagttccttc cattcccttg gacgttcttt cagcatcgaa ctcctcttct 1920 cagttaatcg tgaagtggaa ccctccctct ctgcccaacg gcaacctgag ttactacatt 1980 gtgcgctggc agcggcagcc tcaggacggc tacctttacc ggcacaatta ctgctccaaa 2040 gacaaaatcc ccatcaggaa gtatgccgac ggcaccatcg acattgagga ggtcacagag 2100 aaccccaaga ctgaggtgtg tggtggggag aaagggcctt gctgcgcctg ccccaaaact 2160
                                                                                                                                                           Page 58
```

```
39740-0001PCT.txt
 gaagccgaga agcaggccga gaaggaggag gctgaatacc gcaaagtctt tgagaatttc 2220 ctgcacaact ccatcttcgt gcccagacct gaaaggaagc ggagagatgt catgcaagtg 2280 gccaacacca ccatgtccag ccgaagcagg aacaccacgg ccgcagacac ctacaacatc 2340
 accgacccgg aagagctgga gacagagtac cctttctttg agagcagagt ggataacaag 2400 gagagaactg tcatttctaa ccttcggcct ttcacattgt accgcatcga tatccacage 2460 tgcaaccacg aggctgagaa gctgggctgc agcgcctcca acttcgtctt tgcaaggact 2520 atgcccgcag aaggagcaga tgacattcct gggccagtga cctgggagcc aaggcctgaa 2580 aactccatct ttttaaagtg gccggaacct gagaatccca atggattgat tctaatgtat 2640
ggaaaaataa ttgccacaag tccagctggg aagccctttt tatcagtttg aggaagtggc 4560 tgtccctgtg gccccatcca accactgtac acacccgcct gacaccgtgg gtcattacaa 4620 aaaaacacgt ggagatggaa attttacct ttatcttca cctttctagg gacatgaaat 4680 ttacaaaggg ccatcgttca tccaaggctg ttaccattt aacgctgcct aattttgcca 4740 aaatcctgaa cttctccct catcggcccg gcgctgattc ctcgtgtccg gaggcatggg 4800 tgagcatggc agctggttgc tccatttgag agacacgctg gcgacacact ccgtccatcc 4860 gactgccct gctgtgctgc tcaaggccac aggcacacag gtctcattgc ttctgactag 4920 attattattt ggggggaactg gacacaatag gtctttctct cagtgaaggt ggggagaagc 4980 tgagccgc
                                                                                                                                                                                                        4989
     tgaaccggc
     <210> 313
    <211> 12515
     <212> DNA
     <213> Homo sapiens
     <400> 313
    ctaccgggcg gaggtgagcg cggcgccggc tcctcctgcg gcggactttg ggtgcgactt 60 gacgagcggt ggttcgacaa gtggccttgc gggccggatc gtcccagtgg aagagttgta 120 aatttgcttc tggccttccc ctacggatta tacctggcct tcccctacgg attatactca 180
    acttactgtt tagaaaatgt ggcccacgag acgcctggtt actatcaaaa ggagcggggt 240 cgacggtcc cacttccc tgagcctcag cacctgcttg tttggaaggg gtattgaatg 300 tgacatccgt atcagcttc ctgttgtgtc aaaacaacat tgcaaaattg aaatccatga 360
     gcaggaggca atattacata atttcagttc cacaaatcca acacaagtaa atgggtctgt 420
    tattgatgag cctgtacggc taaaacatgg agatgtaata actattattg atcgttcctt 480 caggtatgaa aatgaaagtc ttcagaatgg aaggaagtca actgaatttc caagaaaaat 540 acgtgaacag gagccagcac gtcgtgtctc aagatctagc ttctcttctg accctgatga 600
     gaaagctcaa gattccaagg cctattcaaa aatcactgaa ggaaaagttt caggaaatcc 660 tcaggtacat atcaagaatg tcaaagaaga cagtaccgca gatgactcaa aagacagtgt 720 tgctcaggga acaactaatg ttcattcctc agaacatgct ggacgtaatg gcagaaatgc 780
                                                                                                                   Page 59
```

39740-0001PCT.txt agctgatccc atttctgggg attttaaaga aatttccagc gttaaattag tgagccgtta 840 tggagaattg aagtctgttc ccactacaca atgtcttgac aatagcaaaa aaaatgaatc 900 tcccttttgg aagctttatg agtcagtgaa gaaagagttg gatgtaaaat cacaaaaaga 960 aaatgtccta cagtattgta gaaaatctgg attacaaact gattacgcaa cagagaaaga 1020 aagtőctgat ggíttacagg gggagaccca actgttggtc tcgcgtaagt caagaccaaa 1080 aagtgctgat ggtttacagg gggagaccca actgttggtc tcgcgtaagt caagaccaaa 1080 atctggtggg agcggccacg ctgtggcaga gcctgcttca cctgaacaag agcttgacca 1140 gaacaagggg aagggaagag acgtggagtc tgttcagact cccagcaagg ctgtgggcgc 1200 cagctttcct ctctatgagc cggctaaaat gaagacccct gtacaatatt cacagcaaca 1260 aaattctcca caaaaacata agaacaaaga cctgtatact actggtagaa gagaatctgt 1320 gaatctgggt aaaagtgaag gcttcaaggc tggtgataaa actcttactc ccaggaagct 1380 ttcaactaga aatcgaacac cagctaaagt tgaagatgca gctgactctg ccactaagcc 1440 agaaaatctc tcttccaaaa ccagaggaag tattcctaca gatgtggaag ttctgcctac 1500 gaaactgaa attcacaatg agccatttt gtcagtgg ctcactcaag ttgaggaggaa 1560 gaatccaaaag gattccctca gcaagcctga gaatcctggg ctcactcaagct gacagatgtg 1620 ctctgggtta cctggtctta gtcagttga tattcacaaca tttggtgatt ccattaatga 1680 gagtgaggga atacctttga aaagaaggcg tgtgtccttt ggtgggcacc taagacctga 1740 actatttgat gaaaacttgc ctcctaatac gcctctcaaa aggggagaag ccccaacaa 1800 aagaaagtct ctggtaatgc acactccacc tgtcctgaag aaaatcatca aggaacagcc 1860 tcaaccatca ggaaaacaag agtcaggttc agaaatccat gtgggaagtga aggcacaaag 1920 tcaaccatca ggaaaacaag agtcaggttc agaaatccat gtggaagtga aggcacaaag 1920 cttggttata agccttccag ctctagtcc taggaaaact ccagttgcca gtgatcaacg 1980 ccgtaggtcc tgcaaaacag ccctgcttc cagcagcaaa tctcagacag aggttcctaa 2040 gagaggagga gaaagagtgg caacctgcct tcaaaagaga gtgtctatca gccgaagtca 2100 acatgatatt ttacagatga tatgttccaa aagaagaagt ggtgcttcgg aagcaaatct 2160 gattgttgca aaatcatggg cagatgtagt aaaacttggt gcaaaacaaa cacaaactaa 2220 agtcataaaa catggccat aaaggtcaat gaacaaaagg caaagaagac ctgctactcc 2280 aaagaagcct gtgggcgaag ttcacagtca atttagtaca ggccacgcaa actctccttg 2340 taccataata atagggaaag ctcatactga aaaagtacat gtgcctgctc gaccctacag 2400 agtgctcaac aacttcattt ccaaccaaaa aatggacttt aaggaagatc tttcaggaat 2460 agctgaatg ttcaagacc cagtgaagga gcaaccgcag ttgacaagca catgtcacat 2520 cgctatttca aattcagaga atttgcttgg aaaacagttt caaggaactg attcaggaga 2580 agaacctctg ctccccacct cagagagttt tggaggaaat gtgttcttca gtgcacagaa 2640 tgcagcaaaa cagccatctg ataaatgctc tgcaagccct cccttaagac ggcagtgtat 2700 tagagaaaat ggaaacgta caaaacgcc taggaacacc tacaaaatga cttctctgga 2760 gacaaaaact tcagatactg agacagagcc ttcaaaaaca gtatccactg taaacaggtc aggaaggtct acagagttca ggaatataca gaagctacct gtggaaagta agagtgaaga aacaaataca gaaattgttg agtgcatcct aaaaagaggt cagaaggcaa cactactaca acaaaggaga gaaggagaga tgaaggaaat agaaagacct tttgagacat ataaggaaaa 3000 tattgaatta aaagaaaacg atgaaaagat gaaagcaatg aagagatcaa gaacttgggg 3060 gcagaaatgt gcaccaatgt ctgacctgac agacctcaag agcttgcctg atacagaact 3120 catgaaagac acggcacgtg gccagaatct cctccaaacc caagatcatg ccaaggcacc 3180 aaagagtgag aaaggcaaaa tcactaaaat gccctgccag tcattacaac cagaaccaat aaacacccca acacacacaa aacaacagtt gaaggcatcc ctggggaaag taggtgtgaa agaagagctc ctagcagtcg gcaagttcac acggacgtca ggggagacca cgcacacgca cagaagagcca gcaggagatg gcaagagcat cagaacgttt aaggagtctc caaagcagat 3300 3420 cctggacca gcagcccgtg taactggaat gaagaagtgg ccaagaacgc ctaaggaaga ggcccagtca ctagaagacc tggctggctt caaagagctc ttccagacac caggtccctc tgaggaatca atgactgatg agaaaactac caaaatagcc tgcaaatctc caccaccaga 3600 atcagtggac actccaacaa gcacaaagca atggcctaag agaagtctca ggaaagcaga tgtagaggaa gaattettag cacteaggaa actaacacca teageaggga äägeeätget tacgcccaaa ccagcaggag gtgatgagaa agacattaaa gcatttatgg gaactccagt gcagaaactg gacctggcag gaactttacc tggcagcaaa agacagctac agactcctaa ggaāaaggcc caggctctag āagacctggc tggctttaaa gāgctcttcc agactcctgg 3900 tcacaccgag gaattagtgg ctgctggtaa aaccactaaa ataccctgcg actctccaca 3960 gtcagaccca gtggacaccc caacaagcac aaagcaacga cccaagagaa gtatcaggaa 4020 agcagatgta gagggagaac tcttagcgtg caggaatcta atgccatcag caggcaaagc 4080 catgcacacg cctaaaccat cagtaggtga agagaaagac atcatcatat ttgtgggaac 4140 tccagtgcag aaactggacc tactagagaa cttaaaccag agcaagagaa 4260 tcctaaggaa gaggcccagg ctctggaaga cctgactggc tttaaagagc tcttccagac 4260 ccctggtcat actgaagaag cagtggctgc tggcaaaact actaaaatgc cctgcgaatc 4320 ttctccacca gaatcagcag acaccccaac aagcacaaga aggcagccca agacaccttt 4380 ggagaaaagg gacgtacaga aggagctctc agccctgaag aagctcacac agacatcagg 4440 ggaaaccaca cacacagata aagtaccagg aggtgaggat aaaagcatca acgcgtttag 4500 ggaaactgca aaacagaaac tggacccagc agcaagtgta actggtagca agaggcaccc 4560 aaaaactaag gaaaaggccc aacccctaga agacctggct ggctggaaag agctcttcca 4620 gacaccagta tgcactgaca agcccacgac tcacgagaaa actaccaaaa tagcctgcag 4680 accacaacca gacccagtgg acacaccaac aagctccaag cacacgaccac catcagcagg 4800 caaaagccatg gacacacca aaccaacaa aagcaccatg aaacgaacac catcagcagg 4860 caaagccatg cacacaccca aaccagcagt aagtggtgag aaaaacatct acgcatttat 4860 Page 60

```
39740-0001PCT.txt
gggaactcca gtgcagaaac tggacctgac agagaactta actggcagca agagacggct 4920
gactyatyat aadactacta aaatactty taaattatta claydactay aayacatty 8760 aacaagctca aagagacggc ccaggacacg tgcccagaaa gtagaagtga aggaggagct 8760 gttagcagtt ggcaaagctca cacaaacctc aggggagacc acgcacaccg acaaagagcc 8820 ggtaggtgag ggcaaaggca cgaaagcatt taagcaacct gcaaagcgga acgtggacgc 8880 agaagatgta attggcagca ggagacagcc aagagcacct aaggaaaagg cccaacccct 8940
                                                          Page 61
```

| | | 39740-0001PCT.txt | | | | | |
|---|-------------|-------------------|--------------|-------------|--------------|--------------|-------|
| | nnaanaccta | accaacttcc | aagagctctc | tcaaacacca | gaccacacta | aggaactggc | 9000 |
| | agatontoct | octoataget | ttacaagcgc | tccaaagcaa | acacctgaca | gtggaaaacc | 9060 |
| | +c+11222 | tecanaanan | ttcttcgagc | ccctaaagta | gaacccgtgg | gagacgtggt | 9120 |
| | 10Laaaaata | naccetataa | aatcacaaan | caaaancaác | acttccctgc | ccccactocc | 9180 |
| | adycaccaya | gaccetgeaa | aaccacaaag | catcaconna | accaagaggc | tacactacat | 9240 |
| | cttcaagagg | ggaggraggea | tagatygaay | cgccacggga | 2202200202 | ngattactcc | 9300 |
| | gccagcacca | gaggaaarrg | Lygayyayct | gccagccagc | aagaagcaga | taaaaacttc | 9360 |
| | cagggcaaga | ggcaaatcat | ccgaacccgt | ggicalcaly | aagagaagtt | ccascasasa | 9300 |
| | tgcaaaaaga | attgaacctg | cggaagagct | gaacagcaac | gacatgaaaa | ccaacaaaya | 0420 |
| | ggaacacaaa | ttacaagact | cggtccctga | aaataaggga | atatccctgc | gctccagacg | 9460 |
| | ccaagataag | actgaggcag | aacagcaaat | aactgaggtc | tttgtattag | cagaaagaat | 9540 |
| | anaaataaac | agaaatgaaa | agaagcccat | gaagacctcc | ccagagatgg | acattcagaa | 9000 |
| | tccanatgat | ggagcccgga | aacccatacc | tagagacaaa | gtcactgaga | acaaaaggtg | 9000 |
| | cttgaggtct | octagacaga | atgagagete | ccaacctaaa | gtggcagagg | agagcggagg | 9/20 |
| | deadaadadt | ocoaaoottc | tcatocaoaa | tcagaaaggg | aaaggagaag | caggaaattc | 9/80 |
| • | anactccato. | tocctoagat | caagaaagac | aaaaaqccaq | cctgcagcaa | gcactttgga | 9040 |
| | nancaaatct | otocagagag | taacocogaq | tatcaagagg | tgtgcagaaa | atccaaagaa | 9900 |
| | nactaganac | aatotototo | tcaagaaaat | aacaaccaga | agtcataggg | acagtgaaga. | 9960 |
| | tatttaacan | aaaaatcoaa | ctoooaaaaa | tataataaag | ttagttttgt | gataagttct | 10020 |
| | attecanttt | ttotcataaa | ttacaantna | attetataag | taaggctgtc | agtctgctta | 10080 |
| | agracage | actttagatt | tactanatct | naatconctt | cataaactcc | actoogagca | 10140 |
| | ayyyaayaaa | cctanactaa | daatanttaa | acacconono | ctttgtgaag | gagtctgggc | 10200 |
| • | chychygych | cctcaacttt | gaatagttga | acaccagagag | ctgtcaccac | ccacagecac | 10260 |
| | caaggtttgt | cctcagettt | grayaaryaa | acactatate | gtcgtttgtt | tocctatott | 10320 |
| | cctacagcag | ccctaactyt | gacactigce | ctcatctatc | ccaacactga | ocaoncacte | 10380 |
| | ctccagggca | cggtggcagg | dacaactacc | citytityti | ccaacactga | tetatette | 10440 |
| | ggtaaacacg | aatgaatgga | taagcgcacg | yatyaatyya | gcttacaaga | cagacagte | 10500 |
| | caatggccgg | gggcatttgg | tccccaatt | aaggctatty | gacatctgca | antonctoot | 10560 |
| | ctatttttga | tgtcctttcc | tttctgaaaa | taaagttttg | tgctttggag | acttacetta | 10620 |
| | gagcacatct | ttagggacca | agagtgactt | tetgtaagga | gtgactcgtg | teenegeere | 10020 |
| | gtctcttggg | aatacttttc | taactagggt | tgctctcacc | tgagacattc | ccacccycy | 10080 |
| | gaatctcagg | gtcccaggct | gtgggccatc | acgacctcaa | actggctcct | aatetteage | 10740 |
| | tttcctgtca | ttgaaagctt | cggaagttta | ctggctctgc | tcccgcctgt | tttctttctg | 10000 |
| | actctatctg | gcagcccgat | gccacccagt | acaggaagtg | acaccagtac | tctgtaaagc | 10000 |
| | atcatcatcc | ttagagagac | toaocactca | acaccttcaa | ccacgatttc | aggatcgctt | 10970 |
| | ccttotoacc | cactacctcc | oaaatctcct | ttaaaaccca | gacatctttc | tccagcttca | 70390 |
| | gacttgtaga | ·tataactcot | tcatcttcat | ttactttcca | ctttqcccc | tgtcctctct | 11040 |
| | ntnttcccca | aatcagagaa | taocccocca | tcccccagat | cacctqtctq | gattcctccc | TTT00 |
| | cattcaccca | ccttaccaga | tacaaataaa | aataatacac | cagacagggt | agctgtcccc | TTTOU |
| | caaaatgtgc | cctatacaaa | caatacccta | tctccacgtt | tgtttcccca | gtgtctggcg | 11750 |
| | aggagggagg | toacatcata | aatacttoct | gaatgaatgc | agaaatcagc | ggtactgact | 11280 |
| | totactatat | togctoccat | gatagggttc | tcacagcgtc | atccatgatc | gtaagggaga | 11340 |
| | atgacattct | acttaadaaa | gggaatagaa | aggacagg | aggggacatc | tgagggcttc | 11400 |
| | ·acangactac | aaaqqqtaca | aggattacac | caqqqcaqaa | caggggaggy | tytttaayya | 11400 |
| | -anantonete | ttagcagagg | cactttaaaa | aatataaaac | ataaatgctt | ccttctacgt | 11320 |
| | annecaacet | caaaactttc | aotaggaatg | τταςταταατ | . caagttgttc | Laacactitia | TTOOR |
| | nacttantan | taattatgaa | cctcacatau | aaaaatttca | ticayicala | Lyccigigga | 11040 |
| | otogaatatt | ctatttaata | · aaaaaatcct | ttagagttca | gctctaacca | gaaatcttgc | TT/00 |
| | tosantatot | cancaccttt | tctcacccto | otaaotacao | tatttcaaga | gcacgctaag | 11760 |
| | ogtagtatt | attttacann | octottoato | atgoottaaa | aatgttcatt | taaqqqctac | 11820 |
| | cccatatt | 2212021022 | caccacttct | acacaaccct | ccttggtact | gggggggga | 11880 |
| | ccccgcgccc | aatagatgaa | cattccccta | onctaactaa | atttgagaac | aaatacccac | 11940 |
| | gagattigat | catagtatag | taacttctct | gactactaga | ttccaagtga | atttccatgt | 12000 |
| | ccatticcat | tecesttass | taccidetet | ttttacttt | tcgcctccca | onacctatac | 12060 |
| | aataggacat | cccattaaa | cttaggcttt | cttacactaa | ctctatacct | accatctcct | 12120 |
| | gatctggtcc | cccayccict | *********** | acacactaa | ctctgtacct | cctacctacc | 12180 |
| | gcctccctta | ygcaggcacc | LCCAACCACC | catacacicc | tgctgttttc | ttaannnann | 12240 |
| | actttcccac | cagececace | aayattattt | calleagell | tgagctcagc | canattetta | 12300 |
| | cttcttgcct | gragaticcc | Caccccat | gccigicctc | caggetgggg | ctaaggiiiiid | 12360 |
| | gtttgcctgg | aattgttctg | tacctctttg | cagcacgtag | tgttgtgaaa | - claayclact | 12/20 |
| | aattgagttt | ctggctcccc | τοςτησησητί | gtaagttttg | ttcattcatg | ayyyccyaci | 12460 |
| | gtatttcctg | gttactgtat | cccagtgacc | agccacagga | gatgtccaat | aaaytatyty | 12515 |
| | atgaaatggt | cttaaaaaaa | aaaaaaaaa | aaaaa | • | | 12515 |
| | | | | | | | |

<210> 314 <211> 2444 <212> DNA <213> Homo sapiens

Page 62

```
<210> 315
<211> 732
            <212> DNA
             <213> Homo sapiens
            <400> 315
            tgctgcgaac cacgtgggtc ccgggcgcgt ttcgggtgct ggcggctgca gccggagttc 60 aaacctaagc agctggaagg aaccatggcc aactgtgagc gtaccttcat tgcgatcaaa 120 ccagatgggg tccagcgggg tcttgtggga gagattatca agcgttttga gcagaaagga 180 ctcgccttg ttcgaa attcatgcaa gcttccgaag attttctcaa ggaacactac 240 ctcgcctgaa aaccatgaa attcatgcaa accatgaa aaccatgaa a
            gttgacctga aggaccgtcc attctttgcc ggcctggtga aatacatgca ctcagggccg 300 gtagttgcca tggtctggga ggggctgaat gtggtaaga cgggccgagt catgctcggg 360 gagaccaacc ctgcagactc caagcctggg accatcgtg gagacttctg catacaagtt 420 ggcaggaaca ttatacatgg cagtgattct gtggagagtg cagagaagga gatcggcttg 480 tagtttcacc ctcaggact gatagattac accatgatagattac ctcagaacta gatctataga 540
             tggtttcacc ctgaggaact ggtagattac acgagctgtg ctcaggaactg gatctatgaa 540 tgacaggagg gcagaccaca ttgctttca catccattc ccctccttcc catgggcaga 660 ggaccaggct gtaggaaatc tagttatta caggaacttc atcataattt ggagggaagc 660 tcttggaggt gtgaggttctc cctgtacagt gttaccatcc ccgaccatct gattaaaatg 720 732
                cttcctccca gc
                <210> 316
                <211> 2422
                 <212> DNA
                  <213> Homo sapiens
```

Page 63

```
<400> 316
gtcagcctcc cttccaccgc catattgggc cactaaaaaa aggggggctcg tctttcggg 60 gtgttttct cccctccc tgtccccgct tgctcacggc tctgcgactc cgacgccggc 120
aaggtttgga gagcggctgg gttcgcggga cccgcgggct tgcacccgcc cagactcgga 180
tttttgagag tgcgagagag gcggtcgtgc agacccggga gaaagatgtc aaacgtgcga 480 gtgtctaacg ggagccctag cctggagcgg atggacgcca ggcaggcgga gcaccccaag 540 ccctcggcct gcaggaacct cttcggcccg gtggaccacg aagagttaac ccgggacttg 600 gagaagcact gcagagagag ggaaggcga agccagggaattt cgatttcag 600 gagaagcact gcagagagag gaaggaggag agccagggaattt cgatttcag 600
aatcacaaac ccctagaggg caagtacgag tggcaagagg tggagaaggg cagcttgccc 720 gagttctact acagacccc gcggcccccc aaaggtgcct gcaaggtgcc ggcgaggag 780 agccaggatg tcagcgggag ccgcccggcg gcgcctttaa ttggggctcc ggctaactct 840 gaggacacgc atttggtgga cccaaagact gacagacagac ggggttagcg 900
gaggaatgcg caggaataag gaaggacct gcaaccgacg attettetac tcaaaacaaa 960 agagccaaca gaacagaaga aaatgtttca gacggttcc caaatgccgg ttctgtggag 1020 cagacgcca agaagcctgg cctcagaaga cgtcaacagt aaacagctcg aattaagaat 1080 attttaaaaa tacatacgc tgacttcatg gaatggacat cctgtataag caacgaagat atacatgaaa 1140 caacaacaca ataacactaa aattttaggc actcttaaat gatctgcctc taaaagcgtt 1260 ggatgtagca ttatgcaatt aggttttcc ttatttgctt cattgtacta cctgtgtata 1320 tagtttttac cttttatgta gcacataaac ttatggaag ggaggaag atacgacag ataggacat 1320
taggatgtagca tratgcaatt aggittite trattigett cattgtacta ectgigtata 1320 tagtittac ettitatgta geacataaac titiggggaag ggagggeagg gtggggetga 1380 ggaactgacg tggaggggg tatgaagac tigettigat tracageaag tagataaata 1440 titigactige atgaaggaa geaattitig ggaagggtt gaattgitti etitaaagat 1500 gtaatgtee titeaggaa agetgatat teattaaaa aaatcacaaa aattgaaca 1500 etigetaaag ataattgeta titattita caagaagtii atteteatti gggagatetg 1620
 gtgatctcc aagctatcta aagtttgtta gatagctgca tgtgggctttt ttaaaaaagc 1680 aacagaaacc tatcctcact gccctccca gtctctctta aagttggaat ttaccagtta 1740 attactcagc agaatggtga tcactccagg tagtttgggg caaaaatccg aggtgcttgg 1800 gagtttgaa tgttaagaat tgaccatctg ctttattaa attgttgac aaaattttct 1860
 cattttcttt tcacttcggg ctgtgtaaac acagtcaaaa taattctaaa tccctcgata 1920 tttttaaaga tctgtaagta acttcacatt aaaaaaatgaa atattttta atttaaagct 1980 tactctgtcc atttatccac aggaaagtgt tatttttaaa ggaaggttca tgtagagaaa 2040
  agcacacttg taggataagt gaaatggata ctacatcttt aaacagtatt tcattgcctg 2100
 tgtatggaaa aaccatttga agtgtacctg tgtacataac tctgtaaaaa cactgaaaaa 2160 ttatactaac ttatttatgt taaaagattt ttttaatct agacaatata caagccaaag 2220 tggcatgttt tgtgcatttg taaatgctgt gttgggtaga ataggttttc ccctcttttg 2280 ttaaataata tggctatgct taaaaggttg catactgagc caagtataat tttttgtaat 2340 gtgtgaaaaa gatgccaatt attgttacac attaagtaat caataaagaa aacttccata 2400 gctaaaaaa aacaaaaaa aacaaaaaa 2222
  gctaaaaaaa aaaaaaaaaa aa
  <210> 317
  <211> 5061
   <212> DNA
   <213> Homo sapiens
  <400> 317
  atggctcaga tatttagcaa cagcggattt aaagaatgtc cattttcaca tccggaacca 60
  acaagagcaa aagatgtgga caaagaagaa gcattacaga tggaagcaga ggctttagca 120 aaactgcaaa aggatagaca agtgactgac aatcagagag gctttgagtt gtcaagcagc 180 accagaaaaa aagcacaggt ttataacaag caggattatg atctcatggt gtttcctgaa 240 tcagattccc aaaaaagagc attagatatt gatgtagaaa agctcacca agctgaactt 300
  gagaaactat tgctggatga cagtttcgag actaaaaaaa cacctgtatt accagttact 360 cctattctga gcccttcctt ttcagcacag ctctatttta gacctactat tcagagagga 420 cagtggcac ctggattacc tgggccttcc acttatgctt taccttctat ttatccttct 480 acttacagta aacaggctgc attccaaaac gaccaatctc caagaatgcc cacttttcca 540
  tctacagaac ctatatattt aagtcttccg ggacaatctc catatttctc atatcctttg 600 acacctgcca caccctttca tccacaagga agcttaccta tctatcgtcc agtagtcagt 660 actgacatgg caaaactatt tgacaaaata gctagtacat cagaattttt aaaaaatggg 720 aaagcaagga ctgatttgga ggtaacagat ttaaagctag ggtatctcca 780
  aagtctgagg atatcagtaa atttgactgg ttagacttgg atcctctaag taagcctaag 840 gtggataatg tggaggtatt agaccatgag gaagagaaaa atgtttcaag tttgctagca 900 aaggatcctt gggatgctgt tcttcttgaa gagagatcga cagcaaattg tcatcttgaa 960 agaaaggtga atggaaaatc cctttctgtg gcaactgtta caagaagcca gtctttaaat 1020 attcgaacaa ctcagcttgc aaaagcccag ggccatatat ctcagaaaga cccaaatggg 1080 accagtagtt tgccaactgg aagttctctt cttcaagaag ttgaagtaca gaatgaggag 1140
                                                                                                                             Page 64
```

| i | | | 20 | 740-0001PC | T +v+ | | |
|-----|-------------|--------------------------|--|--------------|--------------|--------------|---------|
| | • . | | cattacaaaa t | 7740-0001FC | .1.txt . | taccaatcac | 1200 |
| . ; | atoacaactt. | tttgtcgatc | cattacaaaa t | tgaayacca | aaccccaca | atocoososs. | 1260 |
| ì | rncacaaacc | caggetattt | gttaagtcca <u>G</u> | rcacagege | adayadacac | +>c++++>ca | 1320 . |
| ` | notactaata | toaaggtctc | gttaagtila <u>C</u> cattgacatt <u>G</u> | gaaggatttc | agctaccage | | 1280 |
| • | tatastatas | ottetactat | agaaatcatt a | taatgcaag | ccctttgctg | ggtacatgat | 1300 |
| | tgtgatgtga | 220ta0at0t | agaaatcatt a tggcagctat (| ittctaaaag | tttgtggtca | agaggaagtg | 1440 |
| 1 | gacttgaalc | adgragarge | tggcagctal (tggaagtcat (| jagcatattc | aaaactgtcg | aaaatgggac | 1500 |
| • | ctgcagaata | attattyctt | cttgaccttc a | atacaatat | ntcaaaatct | ggcccgaaca | 1560 |
| į | acagaaatta | gactacaact | ctigactite a | ig cycaacyc | totatcaaat | anaaaaacct | 1620 |
| , | ocagaagatg | atgaaacacc | cttgaccttc a cgtggattta a acaccctgtt | acaacacc | tagattetta | tracaaccaa | 1680 |
| | tocaaadaag | ccatgacgag | acaccctgtt (| gaagaactct | tagattetta | aattaaanct | 1740 |
| | otagaactgg | ctcttcaaat | tgaaaaccaa (| caccgagcag | tagattaagt | aattaaaget | 1800 |
| • | gtagaactgg | tctataatac | tttagatggt | gtcgagactc | ttgccattac | agaattagta | 1000 |
| | y Laayaaaaa | adadadcagt. | taatcttcca | aggagtaaaa | ctgctgatgt | gacttctttg | 1000 |
| | aagaagctaa | agagagagaga | caggagttca | actaggggct | cacttaatcc | tgaaaatcct | 1920 |
| • | tttggaggag | adyacactag | attaactgca | ncaatttato | atcttctcag | actccatgca | 1980 |
| , | gttcaagtaa | gcataaacca | attaactgca | caaantanca | agagtotcaa | ggaagcatgg | 2040 |
| | aattctggta | ggagtcctac | gtttactatt | taaagtagta | atonaatttC | aagtaattoo | 2100 |
| | actacaacag | agcagctcca | gtttactatt | tegetgete | ctcacaatoo | aaannatott | 2160 |
| | otatcaaatt | atgaaaaata | ctacttgata | tgttcacigi | . cccacaacyy | +c++>++> | 2220 |
| | tttaaaccta | ttčaatcaaa | gaaggttggc | acttacaaga | atticitica | atcacttctt | 2280 |
| | TagastasaC | taatcatttt | tcctatccag | atatcacaat | tgccattaga | accageteet | 2240 |
| | cyggatgaac | tttttnnaat | tttaaatcag | agcagtggaa | gttcccctga | ttctaataag | 2340 |
| | Caccitacic | 226629306 | tttaaattag | otttctttac | ctctttgtga | ctttagacgg | 2400 |
| | cagagaaagg | gactagaagt | acttctatat | ctttggactt | catcacatac | aaattctgtt | 2460 |
| | tttttaacat | gtggaactaa | acttctatat aggatatgtc | 2100222022 | tagtgctaca | ggttgatttt | 2520 |
| | cctggaacag | ttaccaaaaa | tatttataca | actactasa | ttgacagaag | cattatacag | 2580 |
| | ccttctcctg | catttgatat | agagaatgat | acticicaag | octtctt03 | tattetteat | 2640 |
| | caacataact | tagaaacact | agagaatgat | ataaaayyya | ++++>+000 | naaacnttat | 2700 |
| | aaagactcat | cacttogact | ttctaaagaa | gataaagctt | Littatygge | gaaacgccac | 2760 |
| | tattocttca | aacacccaaa | ttgtcttcct | aaaatattag | caagegeeee | . adactygada | 2820 |
| | tacageeee | ttoccaaaac | ttactcattg | cttcaccagt | : ggcctgcatt | gtacccacca | 2020 |
| | tygygtaate | aacttettaa | ttactcatty | octoatcago | g aagtaagato | cctagctgtg | 2000. |
| | attgcartyg | adccccttan | tgatgatgag | ctaacagato | ttcttccaca | ı gtttgtacaa | 2940 |
| | acctggatty | aggetattag | cttgaatagt | tcattagtgg | aattccttt1 | gtccagggca | 3000 |
| | gctttgaaat | atgaaatta | acacaattta | tattooctto | traaagatg | cctocatgat | 3060 |
| | ttgggaaata | tccagatagc | acacaattta cgaacatgtt | ++aggtact/ | tectateaa | aggaggaaaa | 3120 |
| | gtacagttta | gtacccgata | aaaacagacg | t tugget get | accttttan | annantanca | 3180 |
| | coacttagag | _l aagaacttct | aaaacagacg | adactigia | - ++c+cc333 | , aggagtagaa | 3240 |
| | gaaaaagtaa | ggcaggctag | tggatcagcc | agacaggtt | j ((CCCCaaa | aagtatggaa | 3300 |
| | coantacant | ccttttttca | gaaaaataaa | tgccgtctcc | cctctcaagc | aagttagtg | 3360 |
| | cgagtatagt | taaatattaa | gtcgtgttcc | ttcttcagt | t ctaatgctg | CCCCCCaaaa | 2420 |
| | gcaaaagaa | thaathctda | ccctctggga | gaagaaatta | a atgtcatgt | t taaggttyyt | 3420 |
| | greatatige | - nncaanatat | gttagcttta | cagatgata | a agattatgg | a taagatctgg | 3460 |
| | gaagatete | gycaagacac gycaagacac | gaggatggta | attttcaaa | t gictcicaa | c tggcagagat | 3540 |
| | cttaaagaag | gactagacci | tcctgcttcc | gataccctc | a ogaaaatcc | a agtggaatat | 3600 |
| | cgaggcatgg | g tggagctggt | agataaacca | cttacaaaa | t noctaagga | a atacaatcco | : 3660 |
| | ggtgtgacag | g gatcetttaa | ayataaacca | acetetate | t attectata | c tagatactat | 3720 |
| | tctgaagaag | g aatatgaaaa | catctgtgat | adtitiati | a acaatataa | t octtogaag | 3780 |
| | ataaccacc' | t atgttttagg | , catctgtgat | Cgacacaac | y acaatataa | a datutttuu | 3840 |
| | acoggacac | a tgtttcacat | tgactttgga testtttgga | aagttttig | g gacatgeac | a gatgittgg | 3900 |
| | ancttcaaa | a gaatcaga | tccttttgtg | ctgacctct | g atatyycar | a tyllallaa | 3960 |
| | ageceaaa | a ancecaccat | tccttttgtg | ttgtttgtg | g acctetget | g ccaggecta | 4020 |
| | 226440242 | a naaancana | aaaccttttt | cttaacctc | c tttcactga | t gatteette | 4020 |
| | adettgata | a sacttacaa | tattcaagat | ttgaaatac | g ttagagatg | c acttcaacc | 4000 |
| | gggctacca | 9 200000000 | tactcaagat | tttactagg | c ttattgaat | c aagtttggg | a 4140 |
| | caaactaca | g acycagaag | cttcttcatt | cacaacctt | g ctcagctto | g tttttctgg | t 4200 |
| | agcattgcc | a cadayilla | , cotcottate | ttttcacct | a aaacatact | c ctttagaca | a 4260 |
| | cttccttct | a atgatgage | catcetteatt catcettteatt t ctctgttttt | ccccacca | a anaaataca | a cccagataa | a 4320 |
| | gatggtcga | a tcaaggaag | t ctclgilli | . acacaccac | a agadaccat | c attrotett | c 4380 |
| | cattatatt | t atgtagtco | g aattttgtgg | .yaayyacay | a ctgaacta | t tccacttto | a 4440 |
| | cgaacattt | q tcgaatttc | g aattitgigg a ggaacttcac | aataayci | a graciati | na anathtanc | a 4500 |
| | · aanttacca | á actttccta | a ggaacticac a taggatggtt | : ctaggaaga | ia cacacaca | a ayatytayt | + 4560 |
| | accasasaa | a aaattoagt | t aaacagttac | : ttacagagī | t tgatgaal | je ticaacyga | + 4620 |
| | gecadagg | t otgatetto | t aaacagttac t ttgtactttc | : ttccaccc1 | tt tacttcgt | ja tyagaaagc | 4020 |
| | grayrayay | a ctanntctn | c agatgcaggt | tccttcagt | tc ctactcca | gg ccaaatagg | 4000 |
| | gaayyyata | y crayyerry | t ctcttaccga | a aatootaci | tc ttttcatc | at ggtgatgca | T 4/40 |
| | ggagctgtg | a dallalla | a agatggagci | gacccaaat | tc catatotc | aa aacatacct | a 4800 |
| | atcaaagat | c rigitacty | a ayaryyayr | ב שמכככמממי | aa tttcacoa | aa aacgaggaa | t 4860 |
| | cttccagat | a accacaaaa | L acceaacy | - acatatan | ca aanaaacc | rt aagacagc | ia 4920 |
| | ccgacatto | a atgaaatgo | t tgtatacagi | yyalalay | no anaatttt | tt cttaaataa | ia 4980 |
| | gaacttcaa | ac taagtgtac | t tgtatacagi t cagtgcagaa | a tetetgeg | gy ayaallil | to otatraort | a 5040 |
| | ntaacccto | ic ctttgaaag | a lillaacity | g agcaaaga | ya cyyrtada | cy yearcayer | รักค์วั |
| | actocooc | a catacttgt | a a | | | | 3001 |
| | ~~-5-55 | | | | | | |

Page 65

```
<210> 318
 <21:1> 3014
 <212> DNA
 <213> Homo sapiens
 <400> 318
 ctgaccagcg ccgccctcc ccgcccccga cccaggaggt ggagatccct ccggtccagc 60 cacattcaac acccacttc tcctcctct gcccctatat tcccgaaacc ccctcctct 120
gtacaaagcg gagggcgcc cgcccaagca gggcccgttc gcgccgccg cctgcaaggc 1620 gccgggcgc agcggctgc tgctccagcg ggacggcctg ccctcaacct ccgcctctgc 1680 cgccgccgcc ggggcggcc ccgcgctcta ccctgcactc ggcctcaacg ggctcccgca 1740 gctcggctac caggccggct tgctcaagga gggcctgccg caggtctacc cgccctatct 1800 caactaccag aggccggatt cagaagccag cagagccca caatacagct tcgagtcatt 1860
  acctcagaag atttgttaa tctgtgggga tgaagcatca ggctgtcatt atggtgtcct 1920 tacctgtggg agctgtaagg tcttctttaa gagggcaatg gaagggcagc acaactactt 1980 atgtgctgga agaaatgact gcatcgttga taaaatccgc agaaaaaact gcccagcatg 2040
  tcgccttaga aagtgctgtc aggctggcat ggtccttgga ggtcgaaaat ttaaaaagtt 2100 caataaagtc agagttgtga gagcactgga tgctgttgct ctcccacagc cagtgggcgt 2160 tccaaatgaa agccaagccc taagccagag attcactttt tcaccaggtc aagacataca 2220 gttgattcca ccactgatca acctgttaat gagcattgaa ccagatgtga tctatgcagg 2280
  acatgacaac acaaaacctg acacetccag ttettgetg acaagtetta atcaactagg 2340 cgagaggcaa ettetteag tagtcaagtg gtetaaatca ttgccaggtt ttegaaactt 2400 acatattgat gaccagataa eteteatca gtattettgg atgagettaa tggtgtttgg 2460
  agttgtgtcg agctcacagc gtttctatca acttacaaaa cttcttgata acttgcatga tcttgtcaaa caacttcatc tgtactgctt gaatacattt atccagtccc gggcactgag tgttgaattt ccagaaatga tgtctgaagt tattgctgca caattacca agatattggc
                                                                                                                                                 2940
   ağggātggtg aaačccctīc tctttcatāa aaagīgaātg tcatcttttt cītttaaāga
                                                                                                                                                  3000
                                                                                                                                                   3014
   attaaatttt gtgg
   <210> 319
   <211> 2148
    <212> DNA
   <213> Homo sapiens
   <400> 319
   gcttcagggt acagctccc cgcagccaga agccgggcct gcagcgcctc agcaccgctc 60 cgggacaccc cacccgcttc ccaggcgtga cctgtcaaca gcaacttcgc ggtgtggtga 120 actctctgag gaaaaaccat tttgattatt actctcagac gtgcgtggca acaagtgact 180
                                                                                    Page 66
```

```
39740-0001PCT.txt
tgttgaāaat aāagagaagc aatgtgaagc aaaaaaaaaa āaaaaaaa
<210> 320
<211> 540
<212> DNA
<213> Homo sapiens
<210> 321
<211> 2346
<211>
<212> DNA
<213> Homo sapiens
<400> 321
                Page 67
```

```
39740-0001PCT.txt
ttgcctcct acctcacaa agaagccaga gatctgctta aaaagctgct gaaaagaaat 1020 gctgcttctc gtctgggag tggtcctggg gacgctggag aagttcaagc tcatccattc 1080 tttagacaca ttaactggga agaacttctg gctgaaagg tggagcccc ctttaaacct 1140 ctgttgcaat ctgaagagga tgtaagtcag tttgattcca agttcaacg tcagacacct 1200 gtcgacagcc cagatgactc aactctcagt gaaagtgcca atcaggtctt tctgggttt 1260 acctatgtgg ctccatctgt acttgaaagt gtgaaagaaa agtttcctt tgaaccaaaa 1320 atccgatcac ctcgaagatt tattggcagc ccacgaacac ctgtcagccc agtcaaattt 1380 atcccanag atttctggg aagaaggtgct tcgacaacct 1440
tctcctgggg atttctgggg aagaggtgct tcggccagca cagcaaatcc tcagacact 1440 gtggaatacc caatggaaac aagtggcata gagcagatgg atgtgacaat gagtggggaa 1500 gcatcggcac cacttccaat acgacagccg aactctgggc catacaaaaa acaagctttt 1560 cccatgatct ccaaacggcc agagcacctg cgtatgaatc tatgacagag caatgctttt 1620 aatgaattta aggcaaaaag gtggagaggg agatgtgtga gcatcctgca aggtgaaaca 1680 agactcaaaa tgacagtttc agagagtcaa tgtcattaca tagaacactt cggacacaagg 1740 aaaaataaac gtggattta aaaaatcaat caatggtgca aaaataaact taatagacc ttatcaagg atttcatgt tgatgactcg aaactggtgca aaactgaac tattacaagg aggtgaaacaa 1800 cttatcaagg atttcatgt tgatgaccg aaagggtatcc tttcattaagg caagtacaaa 1980 ttgcctataa tacttgcaac taaggacaaa acttaccaat tgatggtca aggtggaacaa ggaaggcaaaa gacaaaagaa acttaccaat tgatgttta aggtgtca aacttttccc 2040 aggaagcaaat ggaaggcaaaa gacaaaagaa acttaccaat tgatgttta cgtgcaaaca 2100 acctgaatct ttttttata taaatatata tttttcaaat agattttga gaaagccaga 2220 caacttctgt ttgagggat tggggggac ctggggtta ttttcagtaa cccaaccag 2280 ctgtggctcg tttgagggat tggggggac ctggggttta ttttcagtaa cccaactggggtcc
  tctcctgggg atttctgggg aagaggtgct tcggccagca cagcaaatcc tcagacacct 1440
   gagcct
   <210> 322
<211> 2420
    <212> DNA
    <213> Homo sapiens
  tccgggcgg cccccggcag ccagcgcgac gttccaaaat cgaacctcag tggcggcgct 60 cggaagcgga actctgccgg ggccgcccg gctacattgt ttcctcccc cgactccctc 120 ccgcccctt ccccgcctt tcttccctcc gcgacccggg ccgtgcgtc gtcccctgc 180 ctctgcctgg cggtccctc tcccctcc ttgcacccat acctcttgt accgcaccc 240 ctggggaccc ctgcgcccct ccccccc ctgacccat agacgtcc gcaggccgct 300 gatgccgcc gcggcgaggt ggcccggacc gcagtgccc aagagagctc taatggtacc 360 aagtgacagg ttggctttac tgtgactcgg ggacgccaga gctcctgaga agatgtcagc 420 aatacaggcc gcctggccat ccggtacaga atgtattgcc aagtacaact tccacggcac 480 tgccgagag gacctgccct tctgcaaaaaa agacgtctc accattgtag ccgtcacca 540
    <400> 322
   tgccgagcag gacctgcct tctgcaaagg agacgtgctc accattgtgg ccgtcaccaa 540 ggaccccaac tggtacaaag ccaaaaacaa ggtgggccgt gagggcatca tcccagccaa 600 ctacgtccag aagcgggagg gcgtgaaggc gggtaccaaa ctcagcctaa tgccttggtt 660 ccacggcaag atcacacggg agcaggctga gcggcttctg tacccgccgg agacaggcct 720 gttcctggtg cgggaaggca ccaactaccc cggagactac acgctgtgcg tgagctgcgc 720 cggcaaggtg gagcactacc gcatcatgta ccatgccagc aagctcagca tcgacgagga 840 ggtgtacttt gagaacctca tgcagctggt ggagcactac acctcagacg cagatggact 900 ctgtacggc ctcattaaac caaaggtcat gagaagcaca atgagacca agatgaatt 960
   čťgťacgcgc čtčattaaac căaaggtčát ggagggcaca gtggcggccc aggatgagtt 960
     caagatggat gccccgacg gctgcccgcc cgcagtctat gaagtcatga agaactgctg 1680 gcacctggac gccgccatgc ggcctcctt cctacagctc cgaggacagc ttgagcacat 1740 caaaacccac gagctgcacc tgtgacggct ggcctccgcc tgggtcatgg gcctgtgggg 1800 actggaacctg gaagatcatg gacctggtgc cctgctacc tgggcccgag cctgaactga 1860
     gccccagcgg gctggcgggc cttttcctg cgtcccagcc tgcaccctc cggccccgtc 1920
                                                                                                                                                                  Page 68
```

```
39740-0001PCT.txt
tctcttggac ccacctgtgg ggcctgggga gcccactgag gggccaggga ggaaggaggc 1980 cacggagcgg gcggcagcgc cccaccacgt cgggcttccc tggcctcccg ccactcgct 2040 tcttagagtt ttattccttt cctttttga gattttttt ccgtgtgtt atttttatt 2100 atttttcaag ataaggagaa agaaagtacc cagcaaatgg gcgccctct ctagggaccc 2220 ctcgcccag cctcattccc cattcggt cccatgccc gtgtctcct ggtcgcccc 2280 tgttggccccg tgaccatgtt gcactgtttg catgccccg aggcagacgt ctgtcagggg 2340 atcgtattc gtgtgccgct gccacccgc cacccgcct gtgagatgga atcgtaataa 2400 accacgccat gaggaaaaaaa
 accacgccat gaggaaaaaa
 <210> 323
 <211> 2253
 <212> DNA
 <213> Homo sapiens
ggcttatttt títaaaaçat tggagtcata gcatgigtgt aaactttaaa tatgcaaata
   aataagtatc tatgtctaaa aaaaaaaaaa aaa
   <211> 1619
   <212> DNA
   <213> Homo sapiens
   <400> 324
   ggacagagaa agagccaaga acaaaattgc aaaggaaacc aacaataaga agaaagaatt 420
                                                      Page 69
```

```
tgaggaaact gcgaagaaag tgcgccgtgc catcgagcag ctggctgcca tggattgagg 480 cctctggccg gagctgcctg gtcccagagt ggctgcacca cttccagggt ttattccctg 540 gtgccaccag ccttcctgtg ggccccttag caatgtctta ggaaaggaaga tcaacatttt 600 caaattagat gcttcaactg tgctcctgtt ttgtcttgaa agtggcacca gaggtgcttc 660 tgcctgtgca gcgggtgctg ctggtaacag tggctgcttc tctctctct tctcttttt 720 ggggggctcat ttttgctgtt ttgattcccg ggcttaccag gtgagaagtg agggaggaag 780 aaggccatgt cccttttgct agacttgaca gctttcacag gctggcaga gccttccaca 840 ggggcccttat tgttgttgag gctgcacag tcctgagtgt ggacttggca gaatctgagc tgcaggttcc ttatctgtca cacctgtgcc tcctcagagg 960 aatggaagag aatggagaa gagtccctgg ctcctcact gtttaacaac atggcttct 1020 gaatcttgta aggcattcta agccattcta agccattcta agccattcta agccattcaggg gaacttggg gaacttggagag gaacgaatag 1200
                                                                                                       39740-0001PCT.txt
 agccattcta agtcattggg gaaacggggt gaacttcagg tggatgagga gacagaatag agtgatagga agcgtctggc agatactcct tttgccactg ctgtgtgatt agacaggccc agtgagccgc ggggcacatg ctggccgctc ctccctcaga aaaaggcagt ggcctaaatc
                                                                                                                                                                                                                  1260
 cttttaaat gacttggctc gatgctgtgg gggactggct gggctgctgc aggccgtgtg 1380 tctgtcagcc caaccttcac atctgtcacg ttctccacac gggggagaga cgcagtccgc 1440 ccaggtcccc gctttctttg gaggcagcag ctcccgcagg gctgaagtct ggcgtaagat 1500 gatggatttg atccgcctc ctcctgtca tagactgca gggggggatgg ttacagcttc 1560
  gctggaaacc tctggaggtc atctcggctg ttcctgagaa ataaaaagcc tgtcatttc
  <210> 325
<211> 5010
   <212> DNA
   <213> Homo sapiens
<400> · 325
   tgaagctcac tgtgagcaat gtgctgaaag agataaaaat tcttaacatc tttggagtta 1440 ttaaaggctt tgtagaacca gatcactatg ttgtagttgg ggcccagaga gatgcatggg 1500 gccctggagc tgcaaaatcc ggtgtaggca cagctctcct attgaaactt gcccagatgt 1560
    tctcagatat ggtcttaaaa gatgggtttc agcccagcag aagcattatc tttgccagtt 1620
   ggagtgctgg agactttgga tcggttggtg ccactgaatg gctagaggga tacctttcgt 1680 ccctgcattt aaaggcttc acttaatta atctggataa agcggttctt ggtaccagca 1740 acttcaaggt tctgccagc ccactgttgt atacgcttat tgagaaaaca atgcaaaatg 1800
   tgaagcatcc ggttactggg caattictat atcaggacag caactgggcc agcaaagttg 1860 agaaactcac tttagacaat gctgcttcc ctttccttgc atattctgga atcccagcag 1920 tttcttctg tttttgcgag gacacagatt atccttattt gggtaccacc atggacacct 1980 ataaggaact gattgagagg attcctgagt tgaacaaagt ggcacgagca gctgcagagg 2040 tcgctggtca gttcgtgatt aactaaccc atggacactt gacatagaga 2100
   ggtacaacag ccaactgctt tcatttgtga gggatctgaa ccaatacaga gcagacataa 2160 aggaaatggg cctgagttta cagtggctgt attctgctcg tggagacttc ttccgtgcta 2220 cttccagact aacaacagat ttcgggaatg ctgagaaaac agacagattt gtcatgaaga 2280
   aactcaatga tcgtgtcatg agagtggagt atcacttcct ctctccctac gtatctccaa 2340 aagagtctcc tttccgacat gtcttctggg gctccggctc tcacacgctg ccagctttac 2400 tggagaactt gaaactgcgt aaacaaaata acggtgcttt taatgaaacg ctgttcagaa 2460
                                                                                                                         Page 70
```

```
39740-0001PCT.txt
accagitigged to transport to aggragate and aggragated to transport to 
     accagttggc tctagctact tggactattc agggagctgc aaatgccctc tctggtgacg 2520
        aattatcgga agcagtgcct tccataatta tgacagttat actgtcggtt taagaaccacaca gatactggaa gttttgcatt tatggtcaac 3600 acttaagggt tttagaaacc agccgtcagc caaatgtaat tgaataaagt taagagctaag 3720 accagttggtt ttcctaaatg cagtgaattg tgaccaagtt ataccaaggtg gtactcctgc aaaatttat agctcagtt atccaaggtg ttccatata agctcgtctgt cacaatccta acacattatc gggggggcagtg gtactccata tgaacatttat agctcagttt accaaggtg ttccataa acaaggtagt ttttacctac cacaggtcg taactctaat 3840 tgaccaagtt atccaaggtg gtactctaaa 3780 accaggtagt ttttaccaa accaattatc ggggggcagtg 3900 accagtaatg acaaggtagt ttttacctac cacaggtct ggaccagg 3900 cagtgatctc catatgttac actaaggggg taagtaatta tcggggaacag attttccaa atcttcaaag cttgaagaac gttagtatct aacaatttat agcaatgac atcttcaaag cttgaagaac gttagtatct aacaatttag ggtaaattca accactgtaa aatgaaatta ctacaaaatt tggtacctt accacaggtct tttagtggttt tggtacctt atgacaagtca ttttaattta tcacattatt tgcatgttac 4200 cttgggttt tgtaccttt agcaagtca ttttaattta tcacattatt tgcatgttac 4320 ctcctaaaa cttagtggg acaagtttta accagaatt gaccttttga aagggaccttg taaggaccttg ttagaaggacgagga gagtcccctg aaggtctgac 4440 aagggaccttg taagaaggt ttggggaagga gagtcccctg aaggtctgac 4440 aagggacctttg taagaaggt ttggggaagga gagtcccctg aaggtctgac 4440
               ctcctataaa cttagtgcgg acaagttta atccagaatt gaccttttga cttaaagcag 4380 agggactttg tatagaaggt ttgggggctg tggggaagga gagtccctg aaggtctgac 4440 cgtctgct acccattcgt ggtgatcaat taaatgtagg tatgaataag ttcgaagctc 4500 ggcctcctag ggaaaagtc atagggtctc ttcaggttct tagtgtcact tacctagat 4620 accaccta cttgaatgtg tcactactca cagtctctt tatcttgga ctgacattta gcgtagctaa gcattggca ttcatctct ttatcttgga ctgacattta gcgtagctaa gcattggca tgttcatcgg 4800 atacaccata atgaatacag ggcatgcatt ttgaggaagg gagtccttc aggaaaaggt 4800 atacaccata tagggttgag ttactccta tcaagccagt acgtgctaac aggactcatt agggttgag ttactccta tcaagccagt acgtgctaac aggactcaata 4920 ggagtagggc cttttggagg taaagggtaa
```

```
39740-0001PCT.txt
agatatcctg gaaaacattc acgaggtgat ggaaatcaaa ttcaaaggcg tggacaatga 1020 ggatgaccat ggccgtggag atctggggcg cctcaagaag cagaaggatc accacaaccc 1080 tcatctaatc ctcatgatga ttccccaca ccggctcgac aacccgggcc aggggggtca 1140 gaggaagaag cgggctttgg acaccaatta ctgcttccgc aacttggagg agaactgctg 1200 tggcgcccc ctctacattg acttccgaca ggatctgggc tggaaagtggg tccatgaacc 1260
 tgtgcgccc ctctacattg acttccgaca ggatctgggc tggaagtggg tccatgaacc 1260 taagggctac tatgccaact tctgctcagg cccttgccca tacctccgca gtgcagacac 1320 aacccacagc acggtgctgg gactgtacaa cactctgaac cctgaagcat ctgcctcgcc 1380 ttgctgcgtg ccccaggacc tggagccct gaccatcctg tactatgttg ggaggacccc 1440 caaagtggag cagcttcca acatggtggt gaagtcttgt aaatgtagct gagagcccca 1560 acacaagcaa gagaggggag agagaaccac cactgcctga ctgcccgctc ctcgggaaac 1560 ggctgagatg gaggttcct tttggaacaca accttcggct ccgggcaaat 1620 ggtaaagaag gggtttcct tttggaacaca acggctgaact cttcagaaca cacagacttt 1740 ggtaaagaag ggcagagggg atggggatag aggaaaggga tggtaagttg agatgttgtg 1800 tggcaatggg attgggcta ccctaaaggg agaaggaagg gcagagaatg gctgggtcag 1860
 tggcaatggg atttgggcta ccctaaaggg agaaggaagg gcagagaatg gctgggtcag 1860 ggccagactg gaagacatt cagatctgag gttggatttg ctcattgctg taccacatct 1920 gctctaggga atctggatta tgttatacaa ggcaagcatt tttttttta aagacaggtt 1980
 gctctaggga atctggatta tgttatacaa ggcaagcatt tttttttta aagacaggtt 1980 acgaagacaa agtcccagaa ttgtatcta tactgtctgg gattaagggc aaatctatta 2040 cttttgcaaa ctgtcctca catcaattaa catcgtgggt cactacaggg agaaaatcca 2100 ggtcatgcag ttcctggcc atcaactgt ttgggccttt tggatatgct gaacgcagaa 2160 gaaagggtgg aaatcaaccc tctcctgtct gccctctggg tccctcctct cacctctccc 2220 tcgatcatat ttccccttgg acacttggtt agacgcctc caggtcagga tgccacattt tcccccatt cccctccaag 2340 accctgtgt cattggtgt tccttggaagc aggtgctaca acactgtgagg cattcgggga 2400 agctgcacat gtgccacaca gtgacttggc ccagacgca tagactgagg tataaagaca 2460 agtatgaata ttactctcaa aatctttgta taaataaata tttttggggc atcctggatg 2520 atttcatctt ctggaatat gtttcaaca cagtaaaaag ccttattcaa ggtg
atttcatctt ctggaatatt gtttctagaa cagtaaaagc cttattctaa ggtg
  <210> 327
<211> 1421
    <212> DNA
    <213> Homo sapiens
  <400> 327
   cctgcttctt cccctctgcg gctttcactg ctgagttct gttctcctg ggaagcctgt 1140 gccagcacct ttgagccttg gcccacctg aggcttaggc ctctctgct gggatgggct 1200 cccacctcc cctgaggatg gcctggattc acgccctctt gttcctttt gggctcaaag 1260 cccttcctac ctctggtgat ggtttccaca ggaaccaacc ttgctgggac ttggatcaca ggggcttatc tcttcaagtg tggagagggc 1380 aggctcaca cctctgctg aggcttataa attaactaat t
     agggtccacg ccictgcigt agcitatgaa aitaactaat t
     <210> 328
     <211> 4604
      <212> DNA
      <213> Homo sapiens
      <400> 328
     ggaacagett gtccaccege eggeeggace agaageettt gggtetgaag tgtetgtgag 60 aceteacaga agageacee tgggetecae ttacetgeee ectgeteett eagggatgga 120
     ggcaatggcg gccagcactt ccctgcctga ccctggagac tttgaccgga acgtgccccg 180
                                                                                                                                      Page 72
```

```
39740-0001PCT.txt
ttataactga aggagaaggt gccccaaaat gcaagatttt ccacaagatt cccagagaca 4320 ggaaaatcct ctggctggct aactggaagc atgtaggaga atccaagcga ggtcaacaga 4380
gaaggcagga atgtgtggca gatttagtga aagctagaga tatggcagcg aaaggatgta 4440 aacagtgcct gctgaatgat ttccaaagag aaaaaaagtt tgccagaagt ttgtcaagtc 4500 aaccaatgta gaaagctttg cttatggtaa taaaaatggc tcatacttat atagcactta 4500
 ctttgtttgc aagtactgct gtaaataaat gctttatgca aacc
<210> 329
<211> 2076
 <212> DNA
 <213> Homo sapiens
 <400> 329
cggggaaggg gagggaggag ggggacgagg gctctggcgg gtttggaggg gctgaacatc 60 gcggggtgtt ctggtgtcc ccgccccgcc tctccaaaaa gctacaccga cgcggaccgc 120 ggcggcgtcc tccctcgccc tcgcttcacc tcgcgggctc cgaatgcggg gagctcggat 180 gtccggttc ctgtgaggct tttacctgac acccgccgc tttccccggc actggctggg 240 agggcgccct gcaaagtggg gaacgcggag ccccggcacca gctcccgcg cctccggct 300
gcccaggggg ggtcgccggg aggagcccgg gggagaggga ccaggagggg cccgcggcct 360 cgcaggggcg cccgcgccc cacccctgcc cccgccagcg gaccggtccc ccacccccgg 420 tccttccacc atgcacttgc tgggcttctt ctctgtggcg tgttctctgc tcgccgctgc 480
gctgctcccg ggtcctcgcg aggcgcccgc cgccgccgcc gccttcgagt ccggactcga 540 cctctcggac gcggagcccg acgcgggcga ggccacggct tatgcaagca aagatctgga 600 ggagcagtta cggtctgtgt ccagtgtaga tgaactcatg actgtactct acccagaata 660 ttggaaaatg tacaagtgtc agctaaggaa aggaggctgg caacataaca gagaacaggc 720 caacctcaac tcaaggacag aagagactat aaaatttgct gcagcacatt ataatacaga 780
gatcttgaaa agtattgata atgagtggag aaagactcaa tgcatgccac gggaggtgtg 840 tatagatgtg gggaaggagt ttggagtcgc gacaaacacc ttctttaaac ctccatgtgt 900 gtccgtctac agatgtgggg gttgctgcaa tagtgagggg ctgcagtgca tgaacaccag 960
 cacgagetae etcageaaga egitatitga aaitacagig ecietetete aaggeeceaa 1020
accagtaaca atcagttttg ccaatcacac ttcctgccga tgcatgtcta aactggatgt 1080 ttacagacaa gttcattcca ttattagacg ttcctgcca gcaacactac cacagtgtca 1140 ggcagcgaac aagacctgcc ccaccaatta catgtggaat aatcacatct gcagatgcct 1200
 ggctcaggaa gattttatgt tttcctcgga tgctggagat gactcaacag atggattcca 1260 tgacatctgt ggaccaaaca aggagctgga tgaagagacc tgtcagtgtg tctgcagagc 1320 ggggcttcgg cctgccagct gtggacccca caaagaacta gacagaaact catgccagtg 1380
 tgtctgtaaa aacaaactct tccccagcca atgtggggcc aaccgagaat ttgatgaaaa 1440
cacatgccag tgtgtatgta aaagaacctg ccccagaaat caacccctaa atcctggaaa 1500 atgtgcctgt gaatgtacag aaagtccaca gaaatgcttg ttaaaaggaa agaagttcca 1560 ccaccaaaca tgcagctgtt acagacggcc atgtacgaac cgccagaagg cttgtgagcc 1620
aggattitca tatagtgaag aagtgtgtcg ttgtgtccct tcatattgga aaagaccaca 1680 aatgagctaa gattgtactg ttttccagtt catcgattit ctatatgga aaactgtgtt 1740 gccacagtag aactgtctgt gaacagagag acccttgtgg gtccatgcta acaaagacaa 1800 aagtctgtct ttcctgaacc atgtggataa ctttacagaa atggactgga gctcatctgc 1860 aaaaggcctc ttgtaaagac tggttttctg ccaatgacca aacagccaag attttcctct 1920 tgtgattict ttaaaagaat gactatataa tttatttcca ctaaaaatat tgtttctgca 1980 tcattttta tagcaacaagaa aatggaaaa attaattgta 2046
 caaaatatgt ttaaaataaa atgaaaattg tattat
 <210> 330
<211> 2819
 <212> DNA
 <213> Homo sapiens
 <400> 330
 ctgggcccag ctcccccgag aggtggtcgg atcctctggg ctgctcggtc gatgcctgtg 60
 ccactgacgt ccaggcatga ggtggttcct gccctggacg ctggcagcag tgacagcagc 120 agccgccagc accgtcctgg ccacggcct ctctccagc cctacgacca tggactttac 180 cccagctcca ctggaggaca cctcctcacg ccccaattc tgcaagtggc catgtgagtg 240
cccagctcca ctggaggaca cctcctcacg cccccaattc tgcaagtggc catgtgagtg 240 cccgccatcc ccaccccgct gcccgctggg ggtcagcctc atcacagatg gctgtgagtg 300 ctgtaagatg tgcgctcagc agcttgggga caactgcacg gaggctgcca tctgtgaccc 360 ccaccggggc ctctactgtg actacagcgg ggaccgcccg aggtacgcaa taggagtgtg 420 tgcacaggtg gtcggtgtgg gctgcgtcct ggatggggtg cgctacaaca acggccagtc 480 cttccagcct aactgcaagt acaactgcac gtgcatcgac ggcgcggtgg gctgcacacc 540 actgtgcccc cgagtgcgcc ccccgcgtct ctggtgcccc cacccgggc gcgtgagcat 600 acctggccac tgctgtgagc agtgggtatg tgaggacgac gccacaggag cccccggt gacacaggag ccttcgatgc tgtgggtgag gtggaggcat ggcacaggaa 720 ctgcatagcc tacacaagcc cctggagccc ttgctccacc agctgcggcc tgggggtctc 780
                                                                                                                    Page 74
```

```
39740-0001PCT.txt
 gttgagaagt tcccattatt atttctgttc ttacaaatgt gaaacggaag ctcatagagg 2640 tgagaaaact caaccagagt cacccagttg gtgactggga aagttaggat tcagatcgaa 2700 attggactgt ctttataacc catatttcc ccctgtttt agagcttcca aatgtgtcag 2760
 aataggaaaa cattgcaata aatggcttga ttttttaaaa aaaaaaaaa aaaaaaaa
 <210> 331
<211> 2540
<212> DNA
 <213> Homo sapiens
```

```
39740-0001PCT.txt
tagcatttgc taccaagtag gaaaaaaaat gtacatggca gtgttttagt tggcaatata 1680 atcttgaat ttcttgatt ttcagggtat tagctgtatt atccatttt tttactgtta 1740
tttaattgaa accatagact aagaataaga agcatcatac tataactgaa cacaatgtgt 1800 attcatagta tactgattta atttctaagt gtaagtgaat taatcatctg gattttttat 1860
tcttttcaga taggcttaac aaatggagct ttctgtatat aaatgtggag attagagtta 1920 atctccccaa tcacataatt tgttttgtgt gaaaaaggaa taaattgttc catgctggtg 1980 gaaaggataga gattgtttt agaggttggt tgttgtgttt taggattctg tccattttct 2040 tgtaaaggga taaacacgga cgtgtgcgaa atatgttgt aaagtgattt gccattgttg 2100 aaagcgtatt taatgataga atactatcga gccaacatgt actgacatgg aaagatgtca 2160
gagatatgtt aagtgtaaaa tgcaagtggc gggacactat gtatagtctg agccagatca 2220 aagtatgtat gttgttaata tgcatagaac gagagatttg gaaagatata caccaaactg 2280 ttaaatgtgg tttctcttcg gggagggggg gattgggga ggggcccag aggggttta 2340 gaggggcctt ttcactttcg actttttca ttttgttctg ttcggattt ttataagtat 2400 gtagaccccg aaggggttta tgggaactaa catcagtaac ctaacccccg tgactatcct 2460 gtgctcttcc tagggagctg tgttgttcc cacccaccac ccttccctct gaacaaatgc 2520
 ctgagtgctg gggcactttg
 <210> 332
<211> 1474
 <212> DNA
 <213> Homo sapiens
 <400> 332
 aaaaagaaat caagaatgca attttattta caatagtcac gccggaaata cctagaaata 60
 aatttaactg aggatgtaaa agacctctac aaggagagtt caatgcgtag cgggagcgga 120
 gagctgaccc cagagagccc tgggcagccc cacctccgcc gccggcctag ttaccatcac 180
 accccggaga geccgcaget gecgcagecg gecccagtea ceateacege aaccatgage 240 agegaggecg agacceagea gecgccegec gecccecege egecceege cetcagegec 300 gecgaeacea ageceggeae taceggageg gegcagggag eggtggeceg ggeggeteae 360
 ggagatggag agactgtgga gtttgatgtt gttgaaggag aaaagggtgc ggaggcagca 600 aatgttacag gtcctggtgg tgttccagtt caaggcagta aatatgcagc agaccgtaac 660 cattatagac gctatccacg tcgtaggggt cctccacgca attaccagca gtggggaaaa gaacgaggga tcggagagtg ctcccgaagc caggcccaac 780 cagccacagt attccaaccc tcctgtgcag ggagaagtga tggaggggac ctatggggg tggtgaggag aacaaggtag accagtgagg cagatatgta tcggagggtgc tgacaaccag 900 ggtgcaggag aacaaggtag accagtgagg cagatatgta tcgggggatat agaacaacag 900 cagatatatacc gagatgagac ccaaaggtcag cctagagagg acggcaatga agaagataaa 1020 gaaaatcaag gagatgagac cccagaaaac cctaaaccac aaggctggta agaacaaaa 1140 gaacacacg caataagaaa tgaacaaaa attggagct aagacctaaa qaagacataa 1260 gaaattccag caataagaaa tgaacaaaaq attggagctg aagacctaaa qtqcttqctt 1320
 gaaattccag caataagaaa tgaacaaaag attggagctg aagacctaaa gtgcttgctt 1320 tttgcccgtt gaccagataa atagaactat ctgcattatc tatgcagcat ggggttttta 1380 ttatgtttta cctaaagacg tctctttttg gtaataacaa accgtgtttt ttaaaaaagc 1440 ctggttttc tcaatacgcc tttaaaggaa ttcc 1474
  <210> 333
  <211> 4079
  <212> DNA
  <213> Homo sapiens
  <400> 333
  ggagcggcgg gcgggcggga gggctggcgg ggcgaacgtc tgggagacgt ctgaaagacc 60
  aacgagactt tggagaccag agacgcgct ggggggacct ggggcttggg gcgtgcgaga 120 tttcccttgc attcgctggg agctcgcga gggatcgtc catggccggg gctcggagcc 180 gcgacccttg gggggcctcc gggatttgct acctttttgg ctcctgctc gtcgaactgc 240 tcttctcacg ggctgtcgcc ttcaatctgg acgtgaggg gccttgcgc aaggaggggcg 300
  agccaggcag cctcttcgc ttctctgtgg ccctgcaccg gcagttgcag ccccgaccc 360 agagctggct gctggtggt gctccccagg ccctggctct tcctgggcag caggcgaatc 420 gcactggagg cctcttcgct tgcccgttga gcctggagga gactgactgc tacagagtgg 480
  acatcgacca gggagctgat atgcaaaagg aaagcaagga gaaccagtgg ttgggagtca 540
  gtgttcggag ccaggggct gggggcaaga ttgttacctg tgcacaccga tatgaggcaa 600 ggcagcgagt ggaccagatc ctggagacgc gggatatgat tggtcgctgc tttgtgctca 660 gccaggacct ggccatccgg gatgagttgg atggtgggga atggaagttc tgtgagggac 720 gccccaagg ccatgaacaa tttgggttct gccagcaggg cacagctgcc gccttctccc 780
                                                                                                         Page 76
```

```
39740-0001PCT.txt
  <210> 334
  <211> 3373
  <212> DNA
  <213> Homo sapiens
  <400> 334
  ggtggcaact tctcctctg cggccgggag cggcctgcct gcctccctgc gcacccgcag 60 cctccccgc tgcctccta gggctccct ccggccgcca gcgcccattt ttcattcct 120
  Page 77
```

```
39740-0001PCT.txt
acgccgcgc cgcggagcag ccgtgcccgc cgcccgggcc cgccgccagg gcgcacacgc 420 tcccgcccc ctacccggcc cggggag tttgcacctc tccctgcccg ggtgctcgag 480 ctgccgttgc aaagccaact ttggaaaaag tttttgggg gagacttggg ccttgaggtg 540 cccagctccg cgctttccga ttttgggggc ctttccagaa aatgttgcaa aaaagctaag 600 cccagcagca gagaaaaag cctgagagaaaag cccagcagaa aacgccaaca aaaagctaag 600
cccagctccy cycliccya titygygyc cliccayad aatyligda dadagctaag 600 ccggcgggca gaggaaaacg cctgtagccg gcgagtgaag acgaaccatc gactgccgtg 660 ttccttttcc tcttggaggt tggagtccc tgggcgccc cacacggcta gacgcctcgg 720 ctggttcgcg acgcaccac ccggccgtgg atgctgcact cgggctcggg atccgccag 780 gtagccggc tcggacccag gtcctgcgc caggtctga cctgcccca agcgacggag 840 ccggggccgg ggggggcgc tgagggca tgcgggtga ccgcggctgc agaggcctga 900 gcgcctgatc gccgcggacc tgagccgag ccaccccct ccccagccc ccaccctggc 960 ccggggcga agaggcctga tctaccagtc cagggcccca ccagccca ccaccctgc 960
  cgcgggggg gcgcgctcga tctacgcgtc cggggccccg cgggggccggg cccggagtcg 1020 gcatgaatcg ctgctgggcg ctcttcctgt ctctctgctg ctacctgcgt ctggtcagcg 1080 ccgaggggga ccccattccc gaggagcttt atgagatgct gagtgaccac tcgatcagct 1140
ccgaggggga ccccattcc gaggagcttt atgagatgct gagtgaccac tcgatccgct 1140 cctttgatga tctccaacgc ctgctgcacg gagaccccgg agaggaagat ggggccgagt 1200 tggacctgaa catgacccc tcccactctg gaggcgagct ggagagcttg gctcgtggaa 1260 gaaggagcct gggttccctg accattgctg agccggccat gatcgccgag tgcaagacgc 1320 gcaccgaggt gttcgagatc tcccggcgcc tcatagaccg caccaacgcc aacttcctgg 1380 tgtgggccgcc ctgtgtggag gtgcagcgct gctccggctg ctgcaacaac cgcaacgtgc 1440 agtgccgcc cacccaggtg cagctgcgac ctgtccaggt gagaaagatc gagattgtgc 1500 ggaagaagacc aatctttaag aaggccacgg tgacgctgga agaccacctg gcatgcaagt 1560 ggcagcagac cggcctgtga cccgaagccc gggggggttcc caggagcagc 1620 gagccaaaac gccccaaact cgggtgacca ttcggacggt gcgagtccgc cggccccca 1680 agggcaagca ccggaaattc aagcacaccc atgacaagac qqcactqaag gagacccttg 1740
  agggcaagca ccggaaattc aagcacacgc atgacaagac ggcactgaag gagacccttg 1740 gagcctaggg gcatcggcag gagagtgtg gggcagggtt atttaatatg gtattgctg 1800 tattgcccc atggggtcct tggagtgata atattgttc cctcgtccgt ctgtctcgat 1860
 tattgcccc atggggtcct tggagtgata atattgttc cctcgtcgt ctgtctcgat 1860 gcctgattcg gacggcaat ggtgcttcc ccaccctcc acgtgtcgt ccacccttcc 1920 atcagcggt ctcctccag cggcctccgg tcttgcccag cagctcaaag aagaaaaaga 1980 aggactgaac tccatcgcca tcttctccc taactccaa gaacttggga taagagtgtg 2040 aggagactg atggggtcg tctttggggg aaacgggttc cttccctgc acctggcctg 2100 ggccacacct gagcgctgtg gactgtcctg aggagccctg aggacctctc agcatagcct 2160 gcctgatccc tgaacccctg gccagctctg aggagccctg aggagcac cctccaggcc 2220 cctcggactc catggctaag accacagacg ggcacacaga ctggagaaaa cccctcccac 2280 ggtgccaaa caccagtcac ctcgtcccc tggtgcctct tgaagacgtg gactctctt ggtggagaac cctctccac 2280 gtttcgtt tgaagacgtg gactcctctt ggtgggtgtg gccagcacc caagtggctg 2400 ggtgccctct caggtgggtt agagatggag ttttgctgttg agggtggtgta gatggtgacc 2460 tgggtatcc ctgcctcctg ccaccccttc cccccatac tccactctga ttcacctct 2520 cctctggttc ctttcatctc tctacctca ccctgcatt tcctcttgtc ctggcccttc 2580 agtctgctc accaggggc tcttgaaccc 2640
   agtctgctcc accaaggggc tcttgaaccc cttattaagg ccccagatga ccccagtcac 2640 tcctctctag ggcagaagac tagaggccag ggcagcagg gacctgctca tcatattcca 2700 acccagccac gactgccatg taaggttgtg caggggtgt actgcacaag gacattgtat 2760 gcagggagca ctgttcacat catagataaa gctgattgt atatttatta tgacaatttc 2820
    tggcagatgt aggtaaagag gaaaaggatc cttttcctaa ttcacacaaa gactccttgt 2880 ggactggctg tgcccctgat gcagcctgtg gctggagtgg ccaaatagga gggagactgt 2940 ggtaggggca gggaggcaac actgctgtc acatgacctc cattcccaa agtcctctgc 3000
    tccagcaact gcccttccag gtgggtgtgg gacacctggg agaaggtctc caagggaggg 3060 tgcagcctc ttgcccgcac ccctcctgc ttgcacactt ccccatcttt gatccttctg 3120 agctccacct ctggtggctc ctcctaggaa accagctcgt gggctgggaa tgggggagag 3180 aagggaaaag atcccaaga ccccttggg tgggatctga gctccacct cccttccca 3240 ctactgcact ttccccttc ccgccttcca aaacctgctt ccttcagttt gtaaagtcgg 3300
                                                                                                                                                                                                                                                                                                           3360
      tgattātatt titgggggct ticctittat tittaāatg taaaatītat ītataītcēģ
                                                                                                                                                                                                                                                                                                           3373
      tatttaaagt tgt
      <210> 335
      <211> 2304
       <212> DNA
      <213> Homo sapiens
      <400> 335
      gtccccgcag cgccgtcgcg ccctcctgcc gcaggccacc gaggccgccg ccgtctagcg 60
      ccccgacctc gccaccatga gagccctgct ggcgcgcctg cttctctgcg tcctggtcgt 120
     gagcgactcc aaaggcagca atgaacttca tcaagttcca tcgaactgtg actgtctaaa 180 tggaggaaca tgtgtgtcca acaagtactt ctccaacatt cactggtgca actgcccaaa 240 gaaattcgga gggcagcact gtgaaataga taagtcaaaa acctgctatg aggggaatgg 300 tctctgccatttac cgaggaaagg ccagcactga caccatgggc cggccctgcc tgccctggaa 360 ctctgccatt gtccttcagc aaaggaatga tgccacaga tcttgaccat gtccttcagc
      ctctgccact gtccttcagc aaacgtacca tgcccacaga tctgatgctc ttcagctggg 420 cctggggaaa cataattact gcaggaaccc agacaaccgg aggcgaccct ggtgctatgt 480 gcaggtgggc ctaaagccgc ttgtccaaga gtgcatggtg catgactgcg cagatggaaa 540 aaagccctcc tctcctccag aagaattaaa atttcagtgt ggccaaaaga ctctgaggcc 600
                                                                                                                                                                           Page 78
```

```
39740-0001PCT.txt
  cttaccctgg atccgcagtc acaccaagga agagaatggc ctggccctct gagggtcccc 1380 agggaggaaa ccgggcaccac ccgctttctt gctggttgtc atttttgcag tagagtcatc 1440 acacaccacgg gtgaacgaca atagctttac cctcacggat aggcctgggt gagaccctct tggccaggatg gaggggtggt cctgaactcaa acagatggat ttgcctgggt gaccaggatg gaggggtggt cctgaactcaa catgttact gctgatgaag caggggtggt cctgaacgaag gaggggtggt taaaaaaggg caggcagcc attcatgaaggag tagaacgaaga taggcctgggt gaggcaact tcccccaacta aggaccttat ggaaggtaa acactaacga atagtgggag cagcggttg ggagagagaga acactaacga cttcagggca ttgaaggccc attcagggca gaggcttgat ggaggagaaga caactaacga attcatacaga ataatatatg tgtgtgtatg tttgcacact tgttgtgtgg 1920 ataagtgtgag taaagagctgg tgtctgatg ttaaagtctaa atattcctt 1980 ccacacagag tggtctttct ggaggggtta taggtcact ctgcagcatg 1920 ataactggtgg gacctggatg taagagctgg tgtctgattg ttaaagtctaa atattcctt 1980 ccacacagag tggtctttct ggaggggtta taggtcact ctgcagcatg 2100 cactgtgacc agcactgct tttaacataaa tgtgatttt tttaatattt tgtaatttta tttatatttt tgtaatttta actatttta tttatatttt tgtaatttta actatttta tttatatttt tgtaatttta 2304
       atcaataaaa tgtgattttt ctga
        <210> 336
        <211> 1876
        <212> DNA
        <213> Homo sapiens
        cgcggccgcg gttcgctgtg gcgggcgcct gggccgccgg ctgtttaact tcgcttccgc 60 tggcccatag tgatctttgc agtgacccag cagcatcact gtttcttggc gtgtgaagat 120 tagccaagga attgaggaag ttgctgagaa gagtgtgctg gagatgctct aggaaaaaat 180 tgaatagtga gacgagttcc agcgcaaggg tttctggttt gccaagaaga aagtgaacat 240 tgaataggacag aacaacagcc tgccacctta cgctcagggc ttggcctcc ctcagggtgc 300 catgastccc agaataccta tctttaatcc aatgatacct tatgacacta gactgacccc 360
       taaaagtgtt gtttttctaa tttataactc ctaggggtta tttctgtgcc agacacattc 1740 cacctctcca gtattgcagg acggaatata tgtgttaatg aaaatgaatg gctgtacata 1800 tttttttctt tcttcagagt actctgtaca ataaatgcag tttataaaag tgttaaaaaa 1860
              aaaaaaaaa aaaaaa
```

<210>

<211>

6633

```
<212> DNA
 <213> Homo sapiens
 <400> 337
 ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc ccctgattgc 60
gtaagagcaa aaagcgaagg cgcaatctgg acactgggag attcggagcg cagggagttt 120 gagagaaact tttatttga agagaccaag gttgaggggg ggcttatttc ctgacagcta 180 tttacttaga gcaaatgatt agttttagaa ggatggacta taacattgaa tcaattacaa 240
attracttaga gcaaatgatt agttttagaa ggatggacta taacattgaa tcaattacaa 240 aacgcggttt ttgagcccat tactgttgga gctacaggga gagaaacagg aggagactgc 300 aagagatcat ttgggaaggc cgtgggcacg ctctttactc catgtgtggg acattcattg 360 cggaataaca tcggaggaga agtttcccag agctatgggg acttcccatc cggcgttcct 420 ggtcttaggc tgtcttcta cagggctgag cctaatctct tgccagcttt cattacctc 480 cttggggag agtgaaatg gcagctgat tcatcctttt ctctgagatg 540 cttggggag agtgaagtga gctggcagta ccccatgtct gaagaagaga gctccgatgt 600 ggaaatcaga aatgaagaaa acaacagcgg cctttttgtg acggtcttgg aagtgagcag 660 tgcctcggcg gcccacacag ggttgtacac ttgctattac aaccacactc agacagaaga 720 gaatgaggtt gaaggcagga acatttacat ctatgtcca gacccagatg tagcctttgt 780
 gaatgagctt gaaggcaggc acatttacat ctatgtgcca gacccagatg tagcctttgt 780 acctctagga atgacggatt atttagtcat cgtggaggat gatgatctg ccattatacc 840 ttgtcgcaca actgatcccg agactcctgt aaccttacac aacagtgagg gggtggtacc 900 tgcctcctac gacagcagac agggctttaa tggcactct actgtagggc cctatatctg 960
  tgaggccacc gtcaaaggaa agaagttcca gaccatccca tttaatgttt atgctttaaa 1020
 agcaacatca gagctggatc tagaaatgga agctcttaaa accgtgtata agtcagggga 1080 aacgattgtg gtcacctgtg ctgttttaa caatgaggtg gttgaccttc aatggactta 1140 ccctggagaa gtgaaaggca aaggcatcac aatgctggaa gaaatcaaag tcccatccat 1200
caaattggtg tacactttga cggtccccga ggccacggtg aaagacagtg gagattacga 1260 atgtgctgcc cgccaggcta ccagggaggt caaagaaatg aagaaagtca ctattctgt 1320 ccatgagaaa ggtttcattg aaatcaaacc caccttcagc cagttggaag ctgtcaacct 1380 gcatgaagtc aaacattttg ttgtagaggt gcgggcctac ccacctccca ggatatcctg 1440 gctgaaaaac aatctgact tgattgaaaa tctcactgag atcaccactg atgtggaaaa 1500 gattcaggaa ataaggtatc gaagcaaatt aaagctgatc cgtgctaagg aagaagacag 1560 tggccattat actattgtag ctcaaaaatga agatgctgtg aagagccatta cttttgaact 1620 gttsaactaa gttcctcat ccattctga ctttggtgaat gatcaccatt gctcaactga 1680
  gttaactcaa gttccttcat ccattctgga cttggtcgat gatcaccatg gctcaactgg 1680 gggacagacg gtgaggtgca cagctgaagg cacgccgctt cctgatattg agtggatgat 1740 atgcaaagat attaagaaat gtaataatga aacttcctgg actattttgg ccaacaatgt 1800 ctcaaacatc atcacggaga tccactcccg agacaggagt accgtggagg gccgtgtgac 1860
  tttcgccaaa gtggaggaga ccatcgccgt gcgatgcctg gctaagaatc tccttggagc 1920 tgagaaccga gagctgaagc tggtggctcc caccctgcgt tctgaactca cggtggctgc 1980 tgcagtcctg gtgctgttgg tgattgtgat catctcactt attgtcctgg ttgtcatttg 2040 gaaacagaaa ccgaggtatg aaattcgctg gcgatgcatt gagtgataatca gcccggatgg 2100
  acatgaatat atttatgtgg acccgatgca gctgccttat gactcaagat gggagtttcc 2160 aagagatgga ctagtgcttg gtcgggtctt ggggtctgga gcgtttggga aggtggttga 2220 aggaacagcc tatggattaa gccggtcca acctgtcatg aaagttgcag tgaagatgct 2280 aaaacccacg gccagatcca gtgaaaaaca agctctcatg tctgaactga agataatgac 2340
  tcacctgggg ccacatttga acattgtaaa cttgctggga gcctgcacca agtcaggccc catttacatc atcacagagt attgcttcta tggagatttg gtcaactatt tgcataagaa tagggatagc ttcctgagcc accacccaga gaagccaaag aaagagctgg atatctttgg
                                                                                                                                                                                                                             2460
  attgaaccct gctgatgaaa gcacacggag ctatgttatt ttatcttttg aaaacaatgg 2580 tgactacatg gacatgaagc aggctgatac tacacagtat gtccccatgc tagaaaggaa 2640 agagggttct aaatattccg acatccagag atcactctat gatcgtccag cctcatataa 2700 gaaggaagtcaatct atgttagact tagaaggcaa actcagatgata actcagaagg 2760
   čctťacttta ttggatťtgt tgágcťtcac ctatcaagtt gcccgaggaa tggagttttt
  ggcttcaaaa aattgtgtcc accgtgatct ggctgctcgc aacgtcctcc tggcacaagg 2880 aaaaattgtg aagatctgtg actttggcct ggccagagac atcatgcatg attcgaacta 2940 tgtgtcgaaa ggcagtacct ttctgcccgt gaagtggatg gctcctgaa gcaatctttga 3000
   caacetetac accacactga gtgatgtetg gtettatgge attetgetet gggagatett 3060 ttecettggt ggcacecett acceeggcat gatggtggat tetaettet acaataagat 3120 caagagtggg taceggatgg ceaageetga ecaegetace agtgaagtet acgagateat 3180 ggtgaaatge tggaacagtg ageeggagaa gagaceetee tettaecace tggagagat 3240
    tgtggagaat ctgctgcctg gacaatataa aaagagttat gaaaaaattc acctggactt
   cctgaagagt gaccatcctg ctgtggcacg catgcgtgtg gactcagaca atgcatacat
tggtgtcacc tacaaaaacg aggaagacaa gctgaaggac tgggagggtg gtctggatga
   gcagagactg agcgctgaca gtggctacat cattcctctg cctgacattg accctgtccc
                                                                                                                                                                                                                              3480
   tgaggaggag gacctgggca agaggaacag acacagctcg cagacctctg aagagagtgc 3540 cattgagacg ggttccagca gttccacctt catcaagaga gaggacgaga ccattgaaga 3600 catcgacatg atggacgaca tcggcataga ctcttcagac ctggtggaag acagcttcct 3660
                                                                                                                              Page 80
```

```
gtaactggcg gattcgaggg gttccttcca cttctggggc cacctctgga tcccgttcag 3720 aaaaccactt tattgcaatg cggaggttga gaggaggact tggttgatgt ttaaagagaa 3780 gttcccagcc aagggcctcg gggagcgttc taaatatgaa tgaatgggat attttgaaat 3840 gaactttgtc agtgttgcct ctcgcaatgc ctcagtagca tctcagtggt gtgtgaagtt 3900 gaactttgtc agtgttgcct ctcgcaatgc cacagaaggt gaactttgtg cttcaaggac 3960 tggagataga gtccaacaga cacaatttat actgcgacag aacttcagca ttgtaattat 4020 gtaaataact ctaaccaaga cacaatttat actgcgacag ctatcttctt togacttcta 4080
                                                                                                     39740-0001PCT.txt
 gtaaataact ctaaccaagg ctgtgtttag attgtattaa ctatcttctt tggacttctg 4080 aagagaccac tcaatccatc catgtacttc cctcttgaaa cctgatgtca gctgctgttg 4140 aactttttaa agaagtgcat gaaaaaccat ttttgaacct taaaaggtac tggtactata 4200 aactttttaa
```

```
39740-0001PCT.txt
cggggcaggg cagggcggct aggccggcca gctcccctt gcccgccagc cagtggccga 600 acccccact ccctgccacc gtcacacagt atttattgtt cccacaatgg ctgggagggg 660 gcccttccag attggggcc ctggggtcc cactcctgt ccatcccag ttggggctgc 720 gaccgccaga ttctccctta aggaattgac ttcagcaggg gtgggaggct cccagaccca 780 gggcagtgtg gtgggaggg tgttccaaag agaaggcctg gtcagcagag ccgcccctgg 840 tcccccagg tgctggaggc agactcgagg gccgaattgt ttctagttag gccacgctc 900 tctgttcagt cgcaaaggtg aacactcatg cggcagcat gggccctctg agcaactgtg 960 g94
  <210> 339
<211> 772
   <212> DNA
    <213> Homo sapiens
 <400> 339
agctcgtgcc
gaattcggca cgagccgggt cggagccatg gcggtggcaa attcaagtcc 60
tgttaacccc gtggtgttct ttgatgtcag
gatcgagctc tttgcagacg ttgtgcctaa ggagagaagatg gggttccaat aggaaagatg gggttccaat aggaaacact tccacagggt 240
cataaaggat ttcatgattc agggtggaga ttttgttaat ggagatggta ctggagtgg 240
cataaaggat cgggggccat ttgcagatga aaattttaac cggggggccat ttgcagatga aaattttaac ctggagtggaaca gtggtccaag taaaatggc tgtcagtct ttatcacctg 420
ctctaagtgc gattggctgg agaaagattg agaaatgtcc cacaggcccc aacaataagc ccaagctacc 540
tcttgggtgatc tcgcagtgtg gggagatgta tcgcagaca agactgaatc aggccttccc 600
tcttcttgg tggtgtctt gagtaagata atctggactg gccccgtct ttgctccct 660
gcctgctgct gccccatttg atcaagagac catggaagtg tcagaagtt aggaatccaag 720
attgtctta agtttcaac tgtaaataaa gttttttgt atgcgtaaaa aa 772
    <400> 339
     <210> 340
<211> 919
      <212> DNA
       <213> Homo sapiens
     cgctcgctc cctcgctca cgcgcgccg gacgcggggg ccaggcttgc gcgtggttcc 60 cctcccggtg ggcggattcc tgggcaagat gaagtgggtg tgggcgctct tgctgttggc 120 ggcgtgggca gcggccgagc gcgactgcg agtgagcagc ttccgagtca aggaagaactt 180 cgacaaggct cgcttcttg ggacctggta cgccatggca aagaagagcac ccgaagggct 240 ctttctgcag gacaacacg tcgcggagtt ctcggtggac gagaccggcc agatgagcgc 300 cacagccaag ggccgagtc gtctttgaa taactgggac gtgtgcgcag acatggtggg 360 cacttcaca gacaccgagg accctgccaa gtcaagatg aagtactggg gcgtagcctc 420 ctttctgcag aagagaaatg atgaccactg gatcgcga acaggactacg acacgataga acacgataga
      <400> 340
     caccttcaca gacaccgagg accctgccaa gttcaagatg aagtactggg gcgtagcctc 420 cttctgcag aaaggaaatg atgaccactg gatcgtcgac acagactacg acacgtatgc 480 cgtacagtac tcctgcgcc tcctgaacct cgatggcacc tgtgctgaca gctactcctt 540 cgtgtttcc cggggacccaa acggcctgcc cccagaagcg cagaagattg taaggcagcg 660 gcaggaggag ctgtgcctgg ccaggcagta caggctgac ctttgagaacc ttttgtagca atatcaagaa tctagtttca tctgagaact 720 tctgattagc tctcagttcc ctcagttcc ataaaacctt cattacaca aaagatacac gtgggggtca 840 ggaacctgc ttgccttcc tgaaagttc tggggcttaa gattccagac tctgattcat 900 g19
        taaactatag tcacccgtg
        <210> 341
        <211> 7365
        <212> DNA
          <213> Homo sapiens
       ggagttgatc aaggaacctg tctccacaaa gtgtgaccac atattttgca aattttgcat 540 gctgaaactt ctcaaccaga agaaagggcc ttcacagtgt cctttatgta agaatgatat 600
                                                                                                                                                                                          Page 82
```

```
39740-0001PCT.txt
aaccaaaagg agcctacaag aaagtacgag atttagtcaa cttgttgaag agctattgaa 660 aatcatttgt gcttttcagc ttgacacagg tttggagtat gcaaacagct ataattttgc 720 aaaaaaggaa aataatctc ctgaacatct aaaagatgaa gttctatca tccaaagtat 780
```

```
39740-0001PCT.txt
 ctacccttcc atcataagtg actcttctgc ccttgaggac ctgcgaaatc cagaacaaag 4740
 cacatcagaa aaagcagtat taacttcaca gaaaagtagt gaatacccta taagccagaa 4800
tccagaaggc ctttctgctg acaagtttga ggtgtctgca gatagttcta ccagtaaaaa 4860 taaagaacca ggagtggaaa ggtcatcccc ttctaaatgc ccatcattag atgataggtg 4920 gtacatgcac agttgctctg ggagtcttca gaatagaaac tacccatctc aagaggagct 4980
cattaaggtt gttgatgtgg aggagcaaca gctggaagag tctgggccac acgatttgac 5040 ggaaacatct tacttgccaa ggcaagatct agagggaacc ccttacctgg aatctggaat 5100 cagcctcttc tctgatgacc ctgaatctga tccttctgaa gacagagccc cagagtcagc 5160 tcgtgttggc aacataccat cttcaacctc tgcattgaaa gttccccaat tgaaagttgc 5220 agaatctgcc cagagtccag agaagccag agaagcaga agaagcaga agaagcaga agaagcaga agaagcaga agaagcaga agaagcaga 5240
 ggaagaaagt gtgagcaggg agaagccaga attgacagct tcaacagaaa gggtcaacaa 5340 aagaatgtcc atggtggtgt ctggcctgac cccagaagaa tttatgctcg tgtacaagtt 5400 tgccagaaaa caccacatca ctttaactaa tctaattact gaagagacta ctcatgttgt 5400
tgccagaaaa caccacatca ctttaactaa tctaattact gaagagacta ctcatgttgt 5460 tatgaaaaca gatgctgagt ttgtgtgta acggacactg aaatatttc taggaattgc 5520 gggaggaaaa tgggtagtta gctatttctg ggtgacccag tctattaaag aaagaaaaat 5580 gctgaatgag catgattttg aagtcagagg agatgtggtc aatgggagaa accaccaagg 5640 tccaaagcga gcaagagaat cccaggacag aaagatcttc aggggggtag aacttgttg 5760 tgcttctgg gtgaaggagc tttcatcatt cacccttggc acaggtgtcc acccaattgt 5820 ggttgtgaag ccagatgcct ggacagagga caatggctc catgcaattg ggcagatgtg 5880 tgaggcacct gtggtgaccc gagagtgggt gttggacagt gtagcactct accaattgt 5840 ggagctggac acctacctga tacccagat ccccaaga gtagcactct accaattgt 5820 ggagctggac acctacctga tacccaaga ccccaaga gtagcactct accaattgt 5840 ggagctggac acctacctga tacccaaga ccccaaga cactactgac tgcagccagc 6000 cacaaggtaca gagccacaga accccaagaa tgagcttaca aaqtqqcctt tccaqqccct 6060
 cacaggtaca gagccacagg accccaagaa tgagcttaca aagtggcctt tccaggccct 6060 gggagctcct ctcactcttc agtccttcta ctgtcctggc tactaaatat tttatgtaca 6120 tcagcctgaa aaggacttct ggctatgcaa gggtccctta aagattttct gcttgaagtc 6180 tcccttggaa atctgccatg agcacaaaat tatggtaatt tttcacctga gaagatttta 6240 aaaccattta aacgccacca attgagcaag atgctgatca attattatc agccctattc 6300 tttctattca ggctgttgtt ggcttagggc tggaagcaca gagtggcttg gcctcaagag 6360 aatagctggt ttccctaagt tacttctct aaaaccctgt gtccacaaag gcagagagtc 6420 aacaccatta aagacgag agtgcttagg aacgctata taggataag tcagaatagt 6480
  agaccctica atggaaggag agtgcttggg atcgattatg tgacttaaag tcagaatagt 6480
  ccttgggcag ttctcaaatg ttggagtgga acattgggga ggaaattctg aggcaggtat 6540 tagaaatgaa aaggaaactt gaaacctggg catggtggct cacgcctgta atcccagcac 6600 tttgggaggc caaggtgggc agatcactgg aggtcaggag ttcgaaacca gcctggccaa 6660
  catggtgaaa ccccatctct actaaaaata cagaaattag ccggtcatgg tggtggacac 6720 ctgtaatccc agctactcag gtggctaagg caggagaatc acttcagccc gggaggtgga 6780 ggttgcagtg agccaagatc ataccacggc actccagcct gggtgacagt gagactgtgg 6840 ctcaaaaaaa aaaaaaaaaa aggaaaatga aactaggaaa ggtttcttaa agccagga 6900
 ctcaaaaaaa aaaaaaaaa aggaaaatga aactaggaaa ggtttcttaa agtctgagat 6900 atatttgcta gatttctaaa gaatgtgttc taaaacagca gaagattttc aagaaccggt 6960 ttccaaagac agtcttctaa ttcctcatta gtaataagta aaatgtttat tgttgtagct 7020 ctggtatata atccattcct cttaaaatat agacctctg gcatgaatat ttcatatcta 7080 taaaatgaca gatcccacca ggaaggaagc tgttgctttc tttgaggtga ttttttcct 7140 ttgctccctg ttgctgaaac catacagctt cataaataat tttgcttgct gaaggaagaa 7200 aaagtgttt tcataaaccc attatccagg actgttata gctgttggaa ggactaggtc 7260 ttccctagcc ccccagtgt gcaagggcag tgaagacttg attgtacaaa atacgttttg 7320 taaatgttgt gctgttaaca ctgcaaataa acttggtagc aaaca
   <210> 342
    <211> 10386
    <212> DNA
    <213> Homo sapiens
    <220>
   <221> unsure
<222> (0)...(0)
     <223> n = a, t, c or g
    attgaggact cggaaatgag gtccaagggt agccaaggat ggctgcagct tcatatgatc 60
  attgaggact cggaaatgag gtccaagggt agccaaggat ggctgcagct tcatatgatc 60 agttgttaaa gcaagttgag gcactgaaga tggagaactc aaatcttcga caagagctag 120 aagataattc caatcatctt acaaaactgg aaactgaggc atctaatatg aaggaagtac 180 ttaaacaact acaaggaagt attgaagatg aagctatggc ttcttctgga cagattgat 240 tattagagcg tcttaaagag cttaacttag atagcagtaa tttccctgga gtaaaactgc 300 ggtcaaaaat gtcctccgt tcttatggaa gccgggaagg atcttatca agccgttctg 360 gagagtgcag tcctgttcct atgggttcat ttccaagaag agggtttgta aatggaagca 420 gagaaagtac tggatattta gaagaacttg agaaagagag gtcattgctt cttgctgatc 480 ttgacaaaga agaaaaggaa aaagactggt attacgctca acttcagaat ctcactaaaa 540
                                                                                                                                                                  Page 84
```

```
39740-0001PCT.txt
gaatagatag tcttccttta actgaaaatt tttccttaca aacagatatg accagaaggc 600
Page 85
```

39740-0001PCT.txt ttcaggaaaa tgacaatggg aatgaaacag aatcagagca gcctaaagaa tcaaatgaaa 4680 aaccaagtca gctgcctgtg tacaaacttc taccatcaca aaacaggttg caaccccaaa 4920 gigtaagaaa aaatgcagac tcaaaaaata atttaaatgc tgagagagtt ttctcagaca 5460 acaaagattc aaagaaacag aatttgaaaa ataattccaa ggacttcaat gataagctcc 5520 caaataatga agatagagtc agagggaagtt ttgcttttga ttcacctcat cattacacgc 5580 ctattgaagg aactccttac tgttttcac gaaatgattc tttgagttct ctagattttg 5640 atgatgatga tgttgacctt tccagggaaa aggctgaatt aagaaaggca aaagaaaata 5700 atgatgatga tgttgacctt tccagggaaa aggctgaatt aagaaaggca aaagaaaata 5700 aggaatcaga ggctaaagtt accagccaca cagaactaac ctccaaccaa caatcagcta 5760 ataagacaca agctattgca aagcagccaa taaatcgagg tcagcctaaa cccatacttc 5820 agaaacaatc cacttttccc cagtcatcca aagacatacc agacagaggg gcagcaactg 5880 atgaaaagtt acagaatttt gctattgaaa atactccagt ttgcttttct cataattcct 5940 ctctgagttc tctcagtgac attgaccaag aaaacaacaa taaagaaaat gaacctatca 6000 aagagactga gccccctgac tcacagggag aaccaagtaa acctcaagca tcaggctatg 6060 ctcctaaatc atttcatgtt gaagataccc cagtttgttt ctcaagaaac agttctcta 6120 gattctctag tattgactct gaagatgacc tgttgcagga atgtataagc tccgcaatgc 6180 caaaaaagaa aaagccttca agactcaagg gtgataatga aaaacatagt cccagaaata 6240 tgggtggcat attaggtgaa gatctgacac ttgattgaa agataacag agaccagatt 6300 cagaacatgg tctatccct gattcagaaa attttgattg gaaagctatt caggaaggtg 6360 cagaacatgg tctatccct gattcagaaa attttgattg gaaagctatt caggaaggtg 6360 caaattccat agtaagtagt ttacatcaag ctgctgctgc tgcatgttta tctagacaag 6420 cttcgtctga ttcagattcc atcctttccc tgaaatcagg aatctctctg ggatcaccat 6480 ttcatcttac acctgatcaa gaagaaaaac cctttacaag taataaaggc ccacgaattc 6540 taaaaccagg ggagaaaagt acattggaaa ctaaaaggat agaatctgaa agtaaaggaa 6600 tcaaaggagg aaaaaaagtt tataaaagtt tgattactgg aaaagttcga tctaattcag 6620 aaattcagg ccaaatgaa cagccccttc aagcaaacat gccttcaatc tctcgaggca 6720 aaaaaaggccc accccttaag agttcaagccc taggagacaaggt ccagaacagcca 6840 ăăaaaggčcc accccttaag actccagcct ccaaaagccc tagtgaaggt caaacagcca 6840 ccacttctcc tagaggagcc aagccatctg tgaaatcaga attaagcct gttgccaggc 6900 agacatccca aataggtggg tcaagtaaag caccttctag atcaggatct agagattcga 6960 cccttcaag acctgcccag caaccattaa gtagacctat acagtctcct ggccgaaact 7020 caatttccc tggtagaaat ggaataagtc ctcctaacaa attatctcaa cttccaagga 7080 catcatcccc tagtactgct tcaactaagt cctccaggttc tggaaaaatg tcatatacat 7140 ctccaggtag acagaaggt caacagaacc taccaaaca aacaggtta tcaaagaacc 7260 ccagtagtat tccaagaagt gagtctgcct ccaaaggact aaatcagatg aataatggta 7260 atggagccaa taaaaaggta gaactttcta gaatgtcttc aactaaatca agtggaagtg 7320 aatctgatag atcagaaaga cctgtattag tacgccagtc aactttcatc aaagaagctc 7380 caagcccaac cttaagaaga aaattggagg aatctgcttc atttgaatct ctttctccat 7440 catctagacc agcttctcc actaggtccc agggcca tccagttta aggctctctcc 7500 ttcctgatat gtctctatcc acacattcgt ctgttcaggc tggtggatgg cgaaaactcc 7560 cacctaatct cagtcccact atagagtata atgatggaag accagcaaag cgccatgata 7620 ttgcacggtc tcattctgaa agtccttcta gacttccaat caataggtca ggaacctgga 7680 aacgtgagca cagcaaacat tcatcatccc ttcctcgagt aagcacttgg agaagaactg 7740 gaagticate ticaattett tetgetteat cagaateeag tgaaaaagea aaaagtgagg 7800 atgaaaaaca tgtgaactet attteaggaa ecaaacaaag taaagaaaac caagtateeg 7860 caaaaggaac atggagaaaa ataaaagaaa atgaattte teecaaaat agtaettete 7920 agaccgtttc ctcaggtgct acaaatggtg ctgaatcaaa gactctaatt tatcaaatgg 7980 cacctgctgt ttctaaaaca gaggatgttt gggtgagaat tgaggactgt cccattaaca 8040 atcctagatc tggaagatct cccacaggta atactcccc ggtgattgac agtgtttcag 8100 aaaaggcaaa tccaaacatt aaagattcaa aagataatca ggcaaaacaa aatgtgggta 8160 atggcagtgt tcccatgcgt accgtgggtt tggaaaatcg cctgaactcc tttattcagg 8220 tggatgccc tgaccaaaaa ggaactgaga taaaaccagg acaaaataat cctgtccctg 8280 tatcagagac taatgaaagt tctatagtgg aacgtaccc attcagttct agcagctcaa 8340 gcaaacacag ttcacctagt gggactgttg ctgccagagt gactcctttt aattacaacc 8400 caagccctag gaaaagcagc gcagatagca cttcagctcg gccatctcag atcccaactc 8460 cagtgaataa caacacaaag aagcgagatt ccaaaactga cagcacagaa tccagtggaa 8520 cccaaagtcc taagcgccat tctgggtctt accttgtgac atctgtttaa aagagagggaa 8580 gaatgaaacta aagaaaatta aagagactgaa aagttttaa aagagacttaa aagaacttta aagagacttaa aagagactgaa aagttttaa aagagacttta aagagacttta aagagacttaa aagagactta aagagacttaa aagagact tgaaacttta aaagactgaa aaattttgta aataggtttg attcttgtta gagggttttt 8700 Page 86

```
<210> 343
<211> 2191
<212> DNA
<213> Homo sapiens
```

```
tcatgactga acagtcaccg acgagagtgc tggggaataa aaaggggatc ttcactcggc 1860 agagacaacc aaaaagtgca gcgttccttt tgcgagagag atactggaag attgccaatg 1920 aaaccaggta tccccactca gtagccaagt cacaatgttt ggaaaacaagc ccgtttactt 1980 agagaagaca gtgccacct gcgtgtcct tcctcccga gtcagggcga cttccacagc 2040 agcagaacaa gtgcctctg gactgttcac ggcagaccag aacgtttctg gcctgggttt 2100 tgtggtcatc tattctagca gggaacacta aaggtggaaa taaaagattt tctattatgg 2160 aaataaagag ttggcatgaa agtcgctact g
 <210> 344
  <211> 2776
  <212> DNA
  <213> Homo sapiens
cagcccatct tcgcggtgac cagtaggatg gtgaagacct acgagaaact Caccgagatc 1080 atcccaagt cagccgtggg ggagctgtct gaggactcca gcaatgtggt ccatctcatt 1140 acgagaaggtgact tcacctacga ctcctccagg gtcttcctgg atcacaacgc cctccccgac 1200 agagggtgact gtgatggcgt gcagatcaat gtcccaggag tgacgcacag gaacgcacc 1260 agagggtgact gcatcagga gcagtcgttt gtcatccggc cgctgggctt cacggacata 1380 gtgaccgtgc aggttcttcc cagggtgag tgccggtggc gggaccagag cagagaccgc 1440 atggcaaggg cttcttggag tgccggacat gcagggtgga cactggctac 1500 attggaaga actggaagg ctccagacacag gcccagaaga actggaaga ccagaacaca 1560
   attgggaaaa actgtgagtg ccagacacag ggccggagca gccaggagct ggaaggaagc 1560 tgccggaagg acaacaactc catcatctgc tcagggctgg gggactgtgt ctgcgggcag 1620 tgcctgtgcc acaccagcga cgtccccggc aagctgatat acgggcagta ctgcgagtgt 1680
  gacaccatca actgtgagcg ctacaacggc caggtctgcg gcggcccggg gagggggctc
     tcagggtata aaatgacatc ccattaatta tattgttaat caatcacgtg tatagaaaaa 2760
     aaaataaaac ttcaat
     <210> 345
     <211> 3160
      <212> DNA
     <213> Homo sapiens
     <400> 345
```

```
acaagttcat gtactttgag ttccctcagc cgttacctgt gtgtggtgat atcaaagtag 1800 agttcttca caaacagaac aagatgctaa aaaaggacaa aatgtttcac ttttgggtaa 1860 attacttctt cataccaga ccaaacagaac acaaacagaac acaaacagaac aaaaggacaa aatgtttcac ttttgggtaa 1800
         activitical activitian activitical activitical activitical activitian activitical activitical activitian activitical activitian a
                  <210> 346
<211> 2629
                     <212> DNA
                     <213> Homo sapiens
                  acttgtcatg gcgactgtcc agctttgtgc caggagcctc gcaggggttg atgggattgg 60 ggttttcccc tcccatgtgc tcaagactgg cgctaaaagt tttgagcttc tcaaaagtct 120 agagccaccg tccaggagc aggtagctgc tgggctccgg ggacactttg cgttcgggct 180 gggagcgtgc tttccacgac ggtgacacgc ttccctggat tggcagccag actgccttcc 240 gggtcactgc catggaggag ccgcagtcag acctatgg tggagcccct ctgagtcagg 300 aaacatttc agacctatgg aaactacttc ctgaaaacaa cgttctgtcc cccttgccgt 360 cccaagcaat ggatgatttg atgctgtccc cogaggatat tggagcaatgg ttcactgaag 420
                     <400> 346
                     cccaagcaat ggatgatttg atgctgtccc cggacgatat tgaacaatgg ttcactgaag 420 acccaggtcc agatgaagct cccagaatgc cagaggctgc tccccgcgtg gcccctgcac 480
                                                                                                                                                                                                                                                                          Page 89
```

39740-0001PCT.txt cagcagetee tacaceggeg geeeetgeac cageeeecte etggeeeetg teatettetg 540 teeetteeca gaaaacetae cagggeaget aeggtteeg tetgggette ttgcattetg 600 ggacagccaa gtctgtgact tgcacgtact cccctgccct caacaagatg ttttgccaac 660 tggccaagac ctgcctgtg cagctgtggg ttgattcac accccgcc ggcacccgcg 720 tccgcgccat ggccatctac aagcagtcac agcacatgac ggaggttgtg aggcgctgcc 780 cccaccatga gcgctgctca gatagcgatg gtctggcccc tcctcagcat cttatccgag 840 tggaaggaaa tttgcgtgtg gagtattgg atgacagaaa cacttttcga catagtgtgg 900 tggtgccta tggacgccta gagggtggct aggacagtaa cacttttcac acaactaca 960 cacccatcc cacaccctg aggattcat ctcttgtata tgatgatct gatccacca 2160 gattgttt atgctcagg tcaattctt tttttttt tttttttt tttcttttt 2220 tttgagact tgctcccg gctgagcag tcctgccta gctgcggtga tcttggctta 2280 ctgcagcctt tgcctcccg gctcgagcag tcctgcctca gcctccggag tagctgggac 2340 cacaggttca tgccaccatg gccagccaac ttttgcatgt tttgtagaga tgggggtctca 2400 cagtgttgcc caggctggtc tcaaactcct gggctcaggc gatccacctg tctcagcctc 2460 ccagagtgct gggattacaa ttgtgagcca ccacgtggag ctggaagggt caacactctt 2520 tacattctgc aagcacatct gcatttcac cccacccttc ccctcttct ccctttttat 2580 atcccattt tatatcgatc tcttatttta caataaaact ttgctgcca 2629 <210> 347 <211> 3442 <212> DNA <213> Homo sapiens <400> 347 agccggtgcg ccgcagacta gggcgcctcg ggccagggag cgcggaggag ccatggccac 60 cgctaacggg gccgtggaaa acgggcagcc ggacgggaag ccgccggccc tgccgcgcc 120 catccgcaac ctggaggtca agttcaccaa gatatttatc aacaatgaat ggcacgaatc 180 caagagtggg aaaaagtttg ctacatgtaa cccttcaact cgggagcaaa tatgtgaagt 240 caagagtggg aaaaagtttg ctacatgtaa cccttcaact cgggagcaaa tatgtgaagt 240 ggaagaagga gataagcccg acgtggacaa ggctgtggag gctgcacagg ttgccttcca 300 gaggggctcg ccatggcgc ggctggatgc cctgagtcgt gggcggctgc tgcaccagct 360 ggctgacctg gtggagaggg accgcgcac cttggccgc ctggagacga tggatacagg 420 gaagccattt cttcatgctt tttcatcga cctggagggc tgtattagaa ccctcaagata 480 ctttgcaggg tgggcagaca aaatccaggg caagaccatc cccacagatg acaacgtcgt 540 actgctgatg ctggtgtgga agctggcacc cgccctctgc tgtgggaaca ccatggtcc 660 gaagcctgcg gagcagacac ctctcaccgc cctttacc ggctctctga tcaagaggc 720 cgggttcct ccaggagtgg tgaacattgt gccaggattc gggcccacag tgggagcagc 780 aatttcttct caccctcaga tcaacaagat ccccttaaccg ggctccacag aggttggaaa 840 actggtaaa gaagctgcgt cccggagcaa tctgaagcgg gtgaccq agctggggg 900 actggttaaa gaagctgcgt cccggagcaa tctgaagcgg gtgacgctgg agctgggggg 900 gaagaacccc tgcatcgtgt gtgcggacgc tgacttggac ttggcagtgg agtgtgccca 960 tcagggagtg ttcttcaacc aaggccagtg ttgcacggca gcctccaggg tgttcgtgga 1020 ggagcaggtc tactctgagt ttgcaggga gagcgtggag tatgccaaga aacggcccgt 1080 gggagacccc ttcgatgtca aaacagaaca ggggcctcag attgatcaaa agcagttcga 1140 caaaatctta gagctgatcg agagtgggaa gaaggaaggg gccaagctgg aatgcggggg 1200 ctcagccatg gaagacaagg ggctcttcat caaacccact gtcttctag aagtcacaga 1260 caacatgcgg attgccaaag aggagattt cgggccagtg caaccaatac tgaagttcaa 1320 aagtatcgaa gaagtgataa aaagagcgaa tagcaccgac tatggactca cagcagccgt 1380 gticacaaaa aatctcgaca aagccctgaa gttggcttct gccttagagt ctggaacggt 1440 ctggatcaac tgctacaacg ccctctatgc acaggctcca tttggtggct ttaaaatgtc 1500 Page 90

```
<210> 348
<211> 737
         <212> DNA
         <213> Homo sapiens
         ttcgaggccg ctgcgcgcc ctgcgcatgc tgctggcaga tcagggccag agctggaagg 120 aggaggtggt gaccgtggag gacggcagg agggctcact caaagcctcc tgcctatacg 180 agggctccc caagttccag gacggaagac tcaccctgta ccagtccaat accatcctgc 240 ggcaccttggggaggaggacctcc ggagaaggacca gcaggaggca gcctgggggggaggaacctac ggaaggaggaacca gcaggaggca gcctgggggggaggaacctggaaggacctcc acacctgct gagcaaggacctcc agggaaggacctcc agggaaggacctcc acacctgct gaccagaac cagggaggca aggcacttcat tgtgggaaggacctggaaggacca gcctggtgg 300 gcctatgagaaggacctggaaggacca gccctggtgg 300 gcctatgagaaggacca gagcactgaaccagacctgaaggaaggacca aggcactgac cagggaaggac caggaacctg aggcacttcat tgtgggaaggac cagaccttct 480 ggcctgaacta caacctgctg tgatccatga ggccctcagcc cctggctgc 540 tgatccatga ggccctccct gagtacgtga acctccccat caatggcaac gggaaacagt 660 agggcttggg gggactctga ggggaggca gagtttgcct tcctttctcc aggaccaata 720 aaatttctaa gagagct
            <210> 349
<211> 5189
            <212> DNA
             <213> Homo sapiens
            atggccaagt cgggtggctg cggcgggga gccggcgtgg gcggcggcaa cggggcactg acctgggtga acaatgctgc aaaaaaagaa gagtcagaaa ctgccaacaa aaatgattct
            acctgggtga acaatgctgc aaaaaaagaa gagtcagaaa clyccaacaa aaatgattt 120 tcaaagaagt tgtctgttga gagagtgtat cagaagaaga cacaacttga acacattctt 180 cttcgtctg atacatatat tgggtcagtg gagccattga cgcagttcat gtgggtgtat 240 gatgaagaag ttttggataa ttttggttaa tgctgctgac aataaacaga gggataagaa catgacttgt 360 tgaatctaac attaaagtt ctattgatcc tgaatctaac attataagca tttggaataa tgggaaaggc 420 attccagtag tagaacacaa ggtagagaaa gtttatgttc ctgctttaat ttttggacag 480
                                                                                                                                                  Page 91
```

39740-0001PCT.txt cttttaacat ccagtaacta tgatgatgat gagaaaaaag ttacaggtgg tcgtaatggt 540 tatggtgcaa aactttgtaa tattttcagt acaaagttta cagtagaaac agcttgcaaa 600 gaatacaaac acagtttaa gcagacatgg atgaataata tgatgaagac ttctgaagcc 660 aaaattaaga attttgatgg tgaagattac acatgcataa cattccaacc agatctgtcc 720 aaaattaaga tgacaaaact tgacaaggat attgtggccc tcatgactag aagggcatat 780 ctcttctaa actcagacaa tgaaagatct ataccatctc ttgttgatgg ctttaaacct 2220 ggccagcgga aagttttatt tacctgtttc aagaggaatg ataaacgtga agtaaaagtt 2280 gcccagttgg ctggctctgt tgctgagatg tcggcttatc atcatggaga acaagcattg 2340 atgatgacta ttgtgaattt ggctcagaac tttgtgggaa gtaacaacat taacttgctt 2460 cagcctattg gtcagtttgg aactcggctt catggtgga aagatgctgc aagcctcgt 2460 ctccttaagt tcctttatga cactttagca aggctacttt ttcctgctgt ggatgacaac 2520 ctccttaagt tcctttatga tgataatcaa cgtgtagagc ctgagtggta tattcctata 2580 attcccatgg ttttaataaa tggtgctgag ggaattggta ctggatggc ttgtaaacta 2640 cccaactatg atgctaggga aattgtgaac aattgtcagac gaatgctaga tggcctggat 2700 cctcatcca tgcttccaaa ctacaaaaac tttaaaagca cgattcaaaa acttggtcaa 2760 cctcatccca tgcttccaaa ctacaaaaac tttaaaggca cgattcaaga acttggtcaa 2760

```
tcagaatttg gcattccaaa gaagactaca acaccaaaag gtaaaggccg aggggcaaag 4620 aaaaggaaag catctggctc tgaaaatgaa ggcgattata accctggcag gaaaacatcc 4680 aaaacaacaa gcaagaaaca gaagaagaca tcttttgatc aggattcaga tgtggacatc 4740 gaagaagaaaa attttgcaga gtctgatgaa gaagaagatg atgttgattt tgcaatgttt 4860 gaagtaaaat attttgcaga gtctgatgaa gaagaagatg atgttgattt tgcaatgttt 4860 tctctgtct cagacttttg tacatctggc ttatttaat gtgatgatgt aattgacggt 4980 tcttttaattat tgtggtaggc cttttaacat tttgttctta cacatacagt tttatgcctc 5040 tttttactca ttgaaaatgtc acgtactgtc tgattggctt gtagaattgt tatagactgc 5100 cgtgcattag cacagatttt caataaaaat ggaactgtg gtacaaact tttttgaaca acagacctgc tttttgaaca acagacctgc ttttttgaaca acagacctgc ttttttgaaca acagacctgc ttttttgaaca acagacctgc ttttttgaaca 5160 5189
                                                                                                              39740-0001PCT.txt
  gaaatttaaa cattaaaaat ggaactgtg
   <210> 350
   <211> 1536
    <212> DNA
    <213> Homo sapiens
   <400> 350
ggggggggggg ggaccacttg gcctgcctcc gtcccgccgc gccacttggc ctgcctccgt 60
ccgccgcgc cacttcgcct gcctccgcc cccgccgcc gcgccatgcc tgtggccgcg 120
ccgcgcacg gggagctgc ctgccccc gccgcacagg agcgggacgc cgagccgcgt 180
ccgccgcacg gggagctgca gtacctgggg cagatccaac acatcctccg ctgcggcgt 240
aggaaggacg accgcacggg caccggcacc ctgtcggtat tcggcatgca ggcgcgctac 300
agcctgagag atgaattcc tctgctgaca accaaacgtg tgttctggaa gggtgttttg 360
gaggagttgc tgtggtttat caagggatcc acaaatgcta aagagctgtc ttccaaggga 420
gtgaaaatct gggatccaa tggatcccaa gactttttgg acaaccctggg attccacc 480
   <210> 351
<211> 2386
        <212> DNA
         <213> Homo sapiens
       gcatatcaga gctttgaaca ggatactttt gtggaactct atgggaacaa tgcagcagcc 780 gagagccgaa agggccagga acgcttcaac cgctggttcc tgacgggcat gactgtggcc 840 ggcgtggttc tgctgggctc actcttcagt cggaaatgac cagacactga ccatccactc 900
                                                                                                                                         Page 93
```

```
39740-0001PCT.txt
taccetecca ecceptete tgetecacca catectecgt ecageegeca ttgecaccag 960
taccetecca coccettete tgetecacea cateetegt ceageegeea ttgeeaceag 960 gagaaceact acatgeagee catgeecace tgeecateae agggttggge ceagatetgg 1020 tecettgeag ctagtttet agaatttate acaettetgt gagaceecea caceteagtt 1080 cettggeet cagaatteae aaaattteea caaaatetgt ceagaagggge ttgtggeetggg ggeaggaggg ceetacetga ttggtgeaae cettaceeet 1200 tageeteet gaaaatgtt ttetgeeagg gagettgaaa gtttteagaa eetetteee 1260 agaaaggaga ctagattgee tttgtttga tgtttgtgge etcagaattg ateatttee 1320 ceecactee eecacactaa eetgggttee ettteetee ateeetee ateeetae eetgggtee 1380 attagggge eacttttgae tagggattea ooctoettgg gataaaggat caaagacea 1440
<211> 1270
 <212> DNA
 <213> Homo sapiens
aaaaaaaaaa
   <210> 353
   <211> 1600
   <212> DNA
   <213> Homo sapiens
   tgacttetec ggggaaggga gecagggact tecegacect tegecagage ceaageaget
   cccggagctg atccgcatga agcgagacgg aggccgcctg agcgaagcgg acatcagggg
cttcgtggcc gctgtggtga atgggagcgc gcagggcgca cagatcgggg ccatgctgat
   ggccătccga cttcggggca tggatctgga ggagacctcg gtgctgaccc aggccctggc 420
                                                              Page 94
```

```
<210> 354
  <211> 1842
  <212> DNA
 <213> Homo sapiens
    ctttatagaa ggaatttgta cttcttattg caggcaagtc tctatattat gtcctctttt 1740 gtggtgtctt ccatgtgaac agcataagtt tggagcacta gtttgattat tatgtttatt 1800 acaatttta ataaattgaa taggtagtat catatatatg ga
    <210> 355
    <211> 4975
    <212> DNA
    <213> Homo sapiens
    ctctcacaca cacacaccc tccctgcca tccctcccg gactccggct ccggctccga 60 tctcacact cacactccgc tgccgtcgcc gcagcagcca ccaattcgcc agcggttcag 120 tccctcccc cacactccgc tgccgtcgcc gcagcagcca ccaattcgcc agcggttcag 120 tccctcccc
    gtggctcttg cctcgatgtc ctagcctagg ggcccccggg ccggacttgg ctgggctccc 180
Page 95
```

```
39740-0001PCT.txt
ttcaccctct gcggagtcat gagggcgaac gacgctctgc aggtgctggg cttgcttttc 240
gattatgcag ccatgggggc ctgcccagca tctgagcaag ggtatgaaga gatgagagct 4080 tttcaggggc ctggacatca ggcccccat gtccattatg cccgcctaaa aactctacgt 4140 agcttagagg ctacagactc tgcctttgat aaccctgatt actggcatag caggcttttc 4200
  cccaaggcta atgcccagag aacgtaactc ctgctccctg tggcactcag ggagcattta 4260
                                       Page 96
```

```
atggcagcta gtgcctttag agggtaccgt cttctccta ttccctagtc ctccaggtc 4320 ccagccctt ttccccagtc ccagacaatt ccattcaatc tttggaggct tttaaacatt 4380 ctggaaaggt ttccttattt tgtgtgctt cccagtcca ttcctcagct ttcctaatt tgtgtgctt cccagtcca ttcctcagct ttcttcacagg 4500 aggaaactag gatatgaagg attactctc tggaactagg ctcttatgt tgcctttgtt tcccatcaga ctgtcaagaa gaggaaaggg 4620 agaaggctaa aatctgtgaa aatctgtgaa gaagaggtt aatctggaa aggagttaa aatctgtgaa aggagttaactac tatgagccag ttaaaacaat tctgtgacat tctgtgacat tctgtgacat tctgtgacat tctgtaatct aacattatct cacttagtcc 4800 aggacttaac tatgagccag tggctcatgc tctgtaatct acattatct cacttagtcc 4800 acctgaggca aggagttga gaccagctta gccaacatag taagaccccc atccccc atccccc 4440 aacattaccc tacattaccc cactagacaggaag 4860 acctgaggca aggagttga gaccagctta gccaacatag taagaccccc atccccc 4950 acctgaggca aggagttga gaccagctta accatattacc tacattaccc cactagaccc 4800 acctgaggca aggagttga aggagttgagg cagaaggat 4920 acctgaggca aggagttga aggagtttga gaccagctta gccaacatag taagaccccc atccccc 4975
    <210> 356
<211> 4627
     <212> DNA
     <213> Homo sapiens
  tcacttgct gatatttcca gtgtcagagg gacacagcca acgtggggtc ccttctaggc 60 tgacagccgc tctccagcca ctgccgcgag cccgtctgct cccgccctgc ccgtgcactc 120
         gtcatttggt gctctgctaa ccatttatat aaaacttaaa aacaagagaa aagaaaaatc 2460
```

39740-0001PCT.txt

<210> 357 <211> 2634 <212> DNA <213> Homo sapiens

```
39740-0001PCT.txt
atgaattatg tgaatgcca gagttacttg gatcagcatt taggaaagta aaatatagtg 1980 gaagtaaaac tgactcatcc aactagacat tctacagaaa gaaaaatgca ttattgacga 2040 actggctaca gtaccatgcc tctcagcccg tgtgtataat atgaagacca aatgatagaa 2100 actggctata
actygical glaciatyce collapses tytgialaat algaayacta aatyalayaa 2100 ctgtactgtt ttctgggcca gtgagccaga aattgattaa ggctttcttt ggtaggtaaa 2160 tctagagttt atacagtgta catgtacata gtaaagtatt tttgattaac aatgtatttt 2220 caacacatat ctaaagtcat catgaactgg cttgtacatt tttaaattct tactctggag 2280 caacctactg tctaagcagt tttgtaaatg tactggtaat tgtacaatac ttgcattcca 2340 gagttaaaat gtttactgta aatttttgtt cttttaaaga ctacctggga cctgatttat 2400 gagaaatttt ctctttaaaa acattttctc tcgttaattt tcctttgtca tttcctttgt 2460 tgtctacatt aaatcactta aatccattaa aagtgcttca agggataatct tgggatagaa 2100
  tgtctacatt aaatcacttg aatccattga aagtgcttca agggtaatct tgggtttcta 2520 gcaccttatc tatgatgtt cttttgcaat tggaataatc acttggtcac cttgccccaa 2580
  <210> 358
    <211> 1246
    <212> DNA
     <213> Homo sapiens
   1080
                                                                                                                                                                                                                                                                                  1140
                                                                                                                                                                                                                                                                                 1200
                                                                                                                                                                                                                                                                                   1246
        ttgatacata ataaaaaatt atgacaatgt caaaaaaaaa aaaaaa
        <210> 359
<211> 2360
         <212> DNA
         <213> Homo sapiens
       tccgatggta tctgggtaag aagaaagcaa aagcaaggga ccttcatgcc cttctgattc 1140 cctccacca aaccccactt ccctccataa gtttgttaa acacttatct tctggattag 1200 cctccacta aaccccactt tctggattag 1200 cctccacta tctggattag 1200 cctccacta tctcgattag 1200 cctccacta tctcgattag 1200 cctccacta tcccacta tcccacta
            aatgccggtt aaattccata tgctccagga tctttgactg aaaaaaaaa agaagaagaa 1260
                                                                                                                                                                  Page 99
```

```
39740-0001PCT.txt
 gaaggagagc aagaaggaaa gatttgtgaa ctggaagaaa gcaacaaaga ttgagaagcc 1320 atgtactcaa gtaccacaa gggatctgcc attgggaccc tccagtgctg gatttgatga 1380 gttaactgtg aaataccaca agcctgagaa ctgaattttg ggacttctac ccagatggaa 1440 aaataacaac tattttgtt gttgttgttt gtaaatgcct cttaaattat atatttattt 1500
ataaaaaaaa aaaaaaaaaa
    <210> 360
<211> 1433
      <212> DNA
      <213> Homo sapiens
  <210> 361
         <211> 1632
         <212> DNA
         <213> Homo sapiens
        <400> 361
        gccggccgaa cccagacccg aggttttaga agcagagtca ggcgaagctg ggccagaacc 60 gcgacctccg caaccttgag cggcatccgt ggagtgcgcc tgcgcagcta cgaccgcagc 12
        aggaaagcgc cgccggccag gcccagctgt ggccggacag ggactggaag agaggacgcg 180 gtcgagtagg tgtgcaccag ccctggcaac gagagcgtct accccgaact ctgctggcct 240 tgaggtggg aagccgggga gggcagttga ggaccccggg gaggcgctg actggttgag 300 cgggcaggcc agcctcgag ccggggtggac acaggttta aacatgaat cctacactca 360 cggcaggcc cttttagg ccctaggcc caggttgac caggttgac acaggttta aacatgaat cctacactca 360 cgggcaggcc cttttaggc cctataggcc caggttgac cagg
        Page 100
```

```
39740-0001PCT.txt
tccaggaacc tctgtttat gaggccccca gatctgtga ttggagagag aaaggctacg 720 780 tgactcctgt gaagaatcag ggtcagtgtg gtctttgttg ggcttttagt gctactggtg 840 ctcttgaagg acagatgtc cggaaaactg ggaggcttat ctcactgagt gagcagaatc 840 tggtagactg ctctgggcc caaggcaatg aaggctgcaa tggtggccta atggattatg 900 ctttccagta tgttcaggat aatggaggcc tggactctga ggaatcctat caacagaaga atcctgtaag taacaatccca agtattctgt tgctaatgac accggctttg 1020 aaggcaagaat tgaaggaag tgaaggagg tgcaactgtg gggcccattt 1080 tggacacagactg tagcaggat aatgaggcc tcctgttcta taaagaaggc attattttg 1140 catgatgaga aatcagataa aataaatatt ggctggtgaa aagaccggag gacatgggt aagaacagctgg ggtgaagaat 1260 aagaaggcca tgcatggag ctaccccact ggtgtgagctg ggtgacggtg aagaccggag aaaccattgt ggaattgcct 1320 aagatggcca tcattgaaga tcattgaaga tcattgaaga tcattgaaga taccgagtgtg aattcatct tcagtctac agatgatc tccagattg aaataaattt taccgagttg aattgaatt tcacactggt 1500 aattgatgct ttattttaa ttactgctat aaaaaggtt aataaatttt aacctgttaa aataaattt aacctgttaa aaaaggtta attattttga aaaaggtt aataaattta acctgttaa aataaattta acctgttaa ataaaattta 1620 atttcaaatg ta
 tccaggaacc tctgttttat gaggccccca gatctgtgga ttggagagag aaaggctacg
   atttcaaatg ta
    <210> 362
<211> 2756
    <212> DNA
    <213> Homo sapiens
  tcatattgag gggcaactcc agaagtggag ttttctgtga gaataaagca tttcaccttt 2640
                                                                                                                        Page 101
```

```
39740-0001PCT.txt
<210> 363
<211> 2768
 <212> DNA
 <213> Homo sapiens
gatggctcta acaatgacat ttatatcaca tgttttctct ggagtattct ataagtttta 2040 tgttaaatca ataaagacca ctttacaaaa gtattacag atgctttcct gcacattaag 2100 gagaaatcta tagaactgaa tgagaaccaa caagtaaata tttttggtca ttgtaatcac 2160 tgttggcgtg gggcctttgt cagaactaga atttgattat taacataggt gaaagttaat 2220 cactgtgac tttgccatt gtttagaaag aatattcata gtttaattat gccttttttg 2280 cgcctgaggt caggagttca agacaagcct tagcagtttg ggaggctgag ccgggtggat 2340 cgcctgaggt caggagtca agacaagcct ggcctacatg gttgaaaccc catctctact 2400 aaaataacac aaattagcta ggcatgggg acctggctgtg aagttgaaccc 2520 actgcactcc agtctgggtg agagtgagac tcagtcttaa aaaaaatatgc ctttttgaag 2580 cacgtacatt ttgtaacaaa gaactgaagc tcttattata ttattagttt tgattaatg 2640 ttttcagccc atctccttc atattctgg gagacagaaa acacttaata aaaaacagtc 2760 gattggtc
   gattggtc
   <210> 364
<211> 2984
    <212> DNA
    <213> Homo sapiens
    <400> 364
   gaggaggaac agaaaagaaa agaaaagaaa aagtgggaaa caaataatct aagaatgagg 60
   agaaagcaag aagagtgacc cccttgtggg cactccattg gttttatggc gccttactt 120 tctggagttt gtgtaaaaca aaaatattat ggtctttgtg cacattaca tcaagctcag 180 cctgggggc acagccagat gcgagaatgcg tctttgtg cacattaca cctgcagcat 240
   ggacctgggt cttccctgaa gcatctccag ggctggaggg acgactgcca tgcaccgagg 300
                                                                             Page 102
```

```
39740-0001PCT.txt
 gctcatccat ccacagagca gggcagtggg aggagacgcc atgaccccca tcctcacggt 360
   <210> 365
<211> 3061
   <212> DNA
   <213> Homo sapiens
   cggcacgagg cgactttggt ggaggtagtt ctttggcagc gggcatggcg ggtaccgtgg 60 tgctggacga tgtggagctg cgggaggctc agaggagatta cctggacttc ctggacgacg 120 aggaagacca gggaatttat cagagcaaag ttcgggagct gatcagtgac aaccaatacc 180 ggctgattgt caatgtgaat gacctgcgca ggaaaaacga gaagagggct aaccggcttc 240 tgaacaatgc ctttgaggag ctggttgcct tccagcgggc cttaaaggat tttgtggcct 300 cgattgaatgc taccaatgc 2360
   <400> 365
   Page 103
```

```
39740-0001PCT.txt
     atcgcctcac agaatccatc agcacagaca gcgaagagcc cttctctca gttgagatcc 2400 aggctgctct gagcaagatg caggatgaca atcaggtcat ggtgtctgag ggcatcatct 2460 tcctcatctg aggaggcctc tctcccacc tctccctgac actgaaggcg aggaatgttg gtgatgaagc actgaggggaggat ttgttctgtg 2520 actgaaggcg aaggaatgttg gtgatgaagc agggttcagg actcggtgga ccctttagga 2580 attgggtcatg aaggctgca aggatgagg aggatgaggaga cagtggggaga aggaatgtg acttttgggg gcacaactgg ttttttttgttt ttttctcag agcactttgggg gcacaactgg tttttttgttg 2820 acttgtttttt gtttcttttt gtttcccatt gggagagaa actttgggg gcacaactgg ttttttttgggg gcacaactgg ttttttttggggg aggaagaa gcttttggggg acgcacactgg gctttgggtg 2880 acgtcatgca aggtagaaa acaaacccaa acaaacccaa tatccagatg 3000 acaactgg atgtgaata acttagcca atttcgtaca acaaacccaa acaaaacccaa acaaacccaa acaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaacccaaccaaccaaccaacccaaccaaccaaccaacccaaccaacccaaccaacccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaacccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaaccaacc
            <210> 366
           <211> 1360
<212> DNA
                                              1360
            <213> Homo sapiens
```

Page 104

<210> 367

39740-0001PCT.txt

```
<211> 1412
<212> DNA
 <213> Homo sapiens
cggggtcgtc cgcaaagcct gagtcctgtc ctttctctct ccccggacag catgagcttc 60 cggggtcgtc cgcaaagcct caccatcac cggtccctgg gctctgtcca ggcgcccagc 12 accactcgct ccaccatcac caccactac cggtccctgg gctctgtcca ggggctctggt 18 tacggcgccc ggccggtcag cagcgggcc agcgtctatg cagggggtc cgggggcctg 24 tcccggatct ccgtgtcccg ctccaccagc ttcaggggca tccagaacga gaaggagacc 30 atggaggac tcagaacga cctggagac cctggagac 36 atggagga cctggagac cctggagac cctggagac 36
                                                                                                                                              240
300
   <210> 368
   <211> 1075
   <212> DNA
    <213> Homo sapiens
   1020
                                                                                                                                                   1075
      <210> 369
      <211> 1127
      <212> DNA
      <213> Homo sapiens
      cacgggcggg gcggggcctg ggtccaccgg ggttctgagg ggagactgag gtcctgagcc 60 cacgggcctca gctccctgcc aggccagacc cggcagacag atgagggccc aggaggcctg 120 gacagcctca gctccctgc aggccagacc cggcagacag tacctacca tacctacag aggaggcct aggaggcct
      gacayetta getectige aggecayate eggeagacay atgagggeet aggaggeetg 120 gegggeetig gggegetacg gtgggagagg aagceagggg tacetgeete tgeettecag 180 ggccaecgtt ggccccaget gtgcettgae tacgtaacat ettgteetea cageccagag 240 catgttecag atcccagagt ttgageeggg tgageaggaa gaeteeaget etgeagagag 300 gggeetggge eccageeceg caggggaegg geeeteagge teeggeaage ateategeea 360 ggeeeceagge eteetgtggg aegeeagtea eegeaggag cagecaacea geageageea 420
                                                                                      Page 105
```

```
39740-0001PCT.txt
tcatggaggc gctggggctg tggagatccg gagtcgccac agctcctacc ccgcggggac 480
ggaggacgac gaagggatgg gggaggagcc cagccccttt cggggccgct cgcgctcggc 540
gcccccaac ctctgggcag cacagcgcta tggccgcgag ctccggagga tgagtgacga 600 gtttgtggac tcctttaaga agggacttcc tcgcccgaag agcgcgggca cagcaacgca 660 gatgcggcaa agctccagct ggacgcgagt cttccagtcc tggtgggatc ggaacttggg 720 caggggaagc tccgcccct cccagtgacc ttcgcccac atcccccgtt 780
caggggaage telefect telegrate telegrate actecyaaac telacegtt 7.80 cccactgcc tgggcagcca tettgaatat gggcggaagt acttecetea ggcetatgca 840 aaaagaggat ccgtgctgte teetttggag ggagggetga eccagattee etteeggtge 900 gtgtgaagee acggaagget tggteecate ggaagttttg ggtttteege eccaegeege 960 eggaagtgge teegtggee egeeteege eteeggget teegeege egeeteege 1020 agtegegge eaggtttaae egttgegtea ecgggaeege ageeeeege 1080 ggeegtgete actaccaaat gttaataaag eccgegtetg tgeegee 1127
<210> 370
<211> 1890
 <212> DNA
 <213> Homo sapiens
 <400> 370
 cttaataaga agagaaggct tcaatggaac cttttgtggt cctggtgctg tgtctctctt 60
 ttatgcttct cttttcactc tggagacaga gctgtaggag aaggaagctc cctcctggcc 120 ccactcctct tcctattatt ggaaatatgc tacagataga tgttaaggac atctgcaaat 180
 ctttcaccaa tttctcaaaa gtctatggtc ctgtgttcac cgtgtatttt ggcatgaatc 240 ccatagtggt gtttcatgga tatgaggcag tgaaggaagc cctgattgat aatggagagg 300 agttttctgg aagaggaaat tccccaatat ctcaaagaat tactaaagga cttggaatca 360 tttccagcaa tggaaagaga tggaaggaga tccggcgttt ctcctcaca aacttgcgga 420
 tttccagcaa tggaaagaga tggaaggaga tccggcgttt ctccctcaca aacttgcgga 420 attttgggat ggggaagagg agcattgagg accgtgttca agaggaagct cactgccttg 480 tggaggagtt gagaaaaacc aaggcttcac cctgtgatcc cactttcatc ctgggctgtg 540 ctccctgcaa tgtgatctgc tccgttgtt tccagaaacg atttgatat aaagatcaga 660 attttctcac cctgatgaaa agattcaatg aaaacttcag gattctgaac tcccatgga 660 tccaggtctg caataatttc cctctactca ttgattgtt cccaggaact cacaacaaag 720 tgcttaaaaa tgttgctctt acacgaagtt acattaggag gaaagtaaaa gaacaccaag 780 catcatgga tgttaacaat cctcgggact ttatggattg cttcctgatc aaaatggagc 840 aggaaaagga caaccaaaag tcagaattca atattgaaaa cttggttggc actgtagctg 900 attatttgt toctggaaca gagacaacaa gcaccactct gagaatatoaa ctcctoctcc 960
  atctatttgt tgctggaaca gagacaacaa gcaccactct gagatatgga ctcctgctcc 960 tgctgaagca cccagaggtc acagctaaag tccaggaaga gattgatcat gtaattggca 1020 gacacaggag cccctgcatg caggatagga gccacatgcc ttacactgat gctgtagtgc 1080
  ctgttgatga tttaaagaac ctcaatacta ctgcagttac caaagggatt gtttctctgc 1500 caccctcata ccagatctgc ttcatccctg tctgaagaat gctagcccat ctggctgctg 1560 atctgctatc acctgcaact cttttttat caaggacatt cccactatta tgtcttctct 1620
   gacctctcat caaatcttcc cattcactca atatcccata agcatccaaa ctccattaag 1680 gagagttgtt caggtcactg cacaaatata tctgcaatta ttcatactct gtaacacttg 1740 tattaattgc tgcatatgct aatactttc taatgctgac tttttaatat gttatcactg 1800
                                                                                                                                                                                             1860
   taaaacacag aaaagtgatt aatgaatgat aatttagtcc atttcttttg tgaatgtgct
                                                                                                                                                                                              1890
   aaataaaaag tgttattaat tgctggttca
   <210> 371
   <211> 4946
    <212> DNA
    <213> Homo sapiens
   agtcagcct gctgccagcc agtgccggt gctggggact caggggaggcc cgccgggacc 60 actgcgggac agtgagccga gcagaagctg gaacgcagga gaggaaggag agggggggggt 120 cagggctctc aggaggccggg tcctgggcaa ggcggaagccgg ttttcaaatt ttcaggaaag 180 cggtcggctc acactcgagc agtaaaaaga tgcctctggg gaggaggcc gtgcagctc 240 ccgggcaatg gtggtggct ggcctagaga ggcggtagtg gaacgcagac cctggtgggg 300 gaatgacatc aagggaggaa acggggggaa ccccagattt ctgcctgtgg gcgatggaag 360 tgagggtcac tggccagcgg agccggacac agaacgcgca aaacgccgtg taggcctgga 420
   <400> 371
    ggagccgaag agcaggcgga cccctccgc ggggggaacag tttccgccgg gagcacaaag caacggaccg gaagtggggg gcggaagtgc agtgggctca gcgccgactg cgcgcctctg
                                                                                                                                                                                               540
    cccgcgaaaa ctctgagctg gctgacagct ggggacgggt ggcggccctc gactggagtc 600
                                                                                                            Page 106
```

```
ggttgagttc ctgagggacc ccggttctgg aaggttcgcc gcggagacaa gtgagcagtc 660 tgtgccatag ggattctcga agagaacagc gttgtgtccc agtgcacatg ctcgcatcgc 720 ttaccaggag tgcccgagac cctaagatgt tcggagtggt tttttcgcac agacccgaat 780 taccaggag tgcccgaccc tctgtgccct tctgagaaca ggctgatatg cccaagatag 840 agcctgcccc tcagccata gacttccctt tccagcccta cagatagcca cagataga 840 agcctgacatag totgagacatag gacttccctt tccagcccta cagataga cagataga 840
                                                                                                                                                                               39740-0001PCT.txt
agcctgccc tcagccacgc tctgtgccct tctgagaaca ggctgatatg cccaagatag 840 tcctgaatgg tgtgaccgta gacttcctt tccagccta caaatgccaa caggagtaca 900 tgaccaaggt cctggaatgt ctgcagcaga aggtgaatgg catcctggag agccctacgg 960 tgacagggaa gacgctgtgc ctgctgtgca ccacgctggc ctggcgagaa cacctccgag 1020 acggcatct tgccgcaag attgccgaga gggcgcaagg agagctttc ccggatcggg 1080 ccttgtcatc ctgggagaac gcttccagga cccactcgca gattattac gcctccagga cccactcgca actcacacag gtcatcaacg 1200 agctccatca cacctcctac cggcctaagg gtaaccatct acagatcac tgggggaa aacaagaga gtaaccatct acagatcac ttgtgccgta 1320 gcatccatcc aggccccatc ctggacattg agaacttggt caagagaaaa agcctggagc 1380 aggagttgcc cagccccatc ctggacattg aggacttggt caagagcaga agccaacac 1440 aggagctgcc ttactacctg tcccggaacc gcaagacaca caacattgac ctgaaggga 1560 cgtacaatta cttgttggat gccaagagcc gcaagagcaca caacattgac ctgaagggga 1560
```

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/07713

| A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12Q 1/68; G01N 33/53 US CL : 435/6, 7.1 | | | |
|---|---|--|--|
| According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED | | | |
| Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/6, 7.1 | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | | |
| | | | |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
| Category * | Citation of document, with indication, where a | | |
| •• Y | US 6,316,208 B1 (ROBERTS et al.) 13 November : 43-47. | 2001 (13.11.2001), columns 18-20 and 18-24,32,37,38 | |
| A | | 1-17,25-31,33-36,39- 45 | |
| Α | US 6,180,333 B1 (GIORDANO) 30 January 2001 (| | |
| A | US 5,563,035 A (WEIGEL) 08 October 1996 (08.1) | 0.1996). | |
| | | | |
| , | | | |
| | | | |
| 1)(1 | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Further documents are listed in the continuation of Box C. See patent family annex. | | | |
| Sı | pecial categories of cited documents: | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the | |
| | defining the general state of the art which is not considered to be lar relevance | principle or theory underlying the invention | |
| "E" earlier application or patent published on or after the international filing date | | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is | |
| "O" document | referring to an oral disclosure, use, exhibition or other means | combined with one or more other such documents, such combination being obvious to a person skilled in the art | |
| "P" document published prior to the international filing date but later than the priority date claimed | | "&" document member of the same patent family | |
| Date of the actual completion of the international search | | Date of mailing of the international search report | |
| 10 June 2003 | · · · · · · · · · · · · · · · · · · · | 03 JUL 2003 | |
| Name and mailing address of the ISA/US Mail Stop PCT, Aun. ISA/US. Commissioner for Patents P.O. Box 1450 | | Kendelh R Horlick D. Roberts you | |
| Alexandria 22313-1450 Facsimile No. (703)305-3230 | | Telephone No. 703-308-0196 | |

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/07713

| Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet) | | | |
|---|--|--|--|
| This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: | | | |
| I. Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely: | | | |
| | | | |
| 2. Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: | | | |
| | | | |
| 3. Claim Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). | | | |
| Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet) | | | |
| This International Searching Authority found multiple inventions in this international application, as follows: Please See Continuation Sheet | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. | | | |
| 2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. | | | |
| As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: | | | |
| | | | |
| | | | |
| | | | |
| 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: | | | |
| Remark on Protest The additional search fees were accompanied by the applicant's protest. | | | |
| No protest accompanied the payment of additional search fees. | | | |
| | | | |

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

INTERNATIONAL SEARCH REPORT

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-17, drawn to a method for predicting clinical outcome for a patient diagnosed with cancer.

Group II, claim(s) 18-24, drawn to a method of predicting the likelihood of the recurrence of cancer following treatment in a cancer patient.

Group III, claim(s) 25-31, drawn to a method for classifying cancer.

Group IV, claim(s) 32-40, drawn to a method for predicting the likelihood of long-term survival of a breast cancer patient, and an array for use therein.

Group V, claim(s) 41 and 44, drawn to a method of predicting the likelihood of long-term survival of a patient diagnosed with invasive breast cancer, and an array for use therein.

Group VI, claim(s) 42, 43, and 45, drawn to a method of predicting the likelihood of long-term survival of a patient diagnosed with estrogen receptor-positive invasive breast cancer, and an array for use therein.

The inventions listed as Groups I-VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each of the groups corresponds to a specific relationship between a specific type of cancer and a specific set of genes; thus, there is clearly no special technical feature in common.

Continuation of B. FIELDS SEARCHED Item 3: USPAT, PGPUB, DERWENT, MEDLINE, BIOSIS search terms: cancer, tumor, prognosis, expression, p27, p53BP2, etc.

Form PCT/ISA/210 (second sheet) (July 1998)

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

| M BLACK BORDERS |
|---|
| ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES |
| ☐ FADED TEXT OR DRAWING |
| BLURRED OR ILLEGIBLE TEXT OR DRAWING |
| ☐ SKEWED/SLANTED IMAGES |
| COLOR OR BLACK AND WHITE PHOTOGRAPHS |
| ☐ GRAY SCALE DOCUMENTS |
| ☐ LINES OR MARKS ON ORIGINAL DOCUMENT |
| ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY |
| OTHER: |

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.